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All cells within an organism must respond to their environment. Responses are regu-
lated by intracellular signalling pathways and signalling molecules. One such molecule
is hydrogen peroxide (H2O2). H2O2 is required in many cell signalling pathways, how-
ever, too much H2O2 can be toxic. As a result, organisms have evolved various systems
to sense, and respond to, H2O2.
How H2O2 can act as a signalling molecule is paradoxical, as it is rapidly metabolised
to water by proteins called Peroxiredoxins (Prdxs). Prdxs—including mammalian
Prdx1—are proposed to act as mediators of H2O2 signalling by oxidising protein
targets—such as the protein kinase, apoptosis signal-regulating kinase 1 (ASK1)—
via disulfide-relays. The overall contribution of Prdxs in H2O2 signalling is unknown,
as there are few examples of Prdx disulfide-relays.
ASK1 is an apical protein kinase that is activated in response to stressors (including
H2O2), ultimately regulating responses such as apoptosis and inflammation. ASK1 is
a large (154 kDa) protein with extensive regulatory regions, both N- and C-terminal to
a central kinase domain. Domains within the ASK1 N terminus are known to regulate
ASK1, but the precise mechanisms remain unclear, as we lack molecular detail. The
oxidoreductase protein, Thioredoxin 1 (Trx1), is purported to directly inhibit ASK1 by
binding within an N-terminal regulatory region—described as the thioredoxin binding
domain (TBD). The release of Trx1 from ASK1 is required for H2O2-induced activation
of ASK1, but how this process is governed is inconclusive.
This Thesis explores various aspects of ASK1 regulation and H2O2 signalling using
in vitro methods and proteomics. Recombinant human ASK1 protein constructs were
used to investigate ASK1 regulation in vitro. Different domains within the N terminus
iii
of ASK1 were seen to be able to both inhibit, and enhance ASK1 kinase activity. A
model is proposed whereby conformational changes within the ASK1 TBD can regulate
access of substrate proteins to the catalytic kinase domain. Once bound to ASK1,
substrate proteins are proposed to undergo a conformational change, making them a
better substrate for phosphorylation.
Using recombinant human Trx1 and ASK1, it was seen that Trx1 can interact with
ASK1 in vitro. Trx1 and ASK1 are able to form an inter-molecular disulfide bond, for
which ASK1-Cys250—within the ASK1 TBD—is required. Surprisingly, Trx1 was not
able to inhibit ASK1 in vitro, suggesting that Trx1 is not a direct inhibitor of ASK1.
In order to examine the role of Prdx1 in H2O2 signalling, and identify potential
Prdx1 signalling-partners other than ASK1, a pilot quantitative proteomics method was
tested. Oxidised protein cysteine residues from cell lysates were labelled, and analysed
using mass spectrometry. Whilst labelled peptides were detected, the method requires
further work to investigate the full cellular contribution of Prdx1 in H2O2 signalling.
Overall, this work advances our knowledge of ASK1 regulation, highlighting mech-
anisms that are likely conserved throughout metazoa. The proteomics work provides
the foundations for further studies, that will advance our understanding of the role of
Prdx1 in H2O2 signalling.
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Cell signalling is a diverse process that requires accurate signal sensing and transduc-
tion. To facilitate cell signalling, numerous signalling molecules exist, including protein
kinases—such as apoptosis signal-regulating kinase (ASK)1—and hydrogen peroxide
(H2O2), both of which are explored within this Thesis. These areas have discrete
underlying properties that require different approaches to study. As such, this Chap-
ter introduces the general themes and concepts of protein kinases and H2O2 biology.
Further background information will be provided in individual Chapters.
1.2 Introduction to cell signalling
Throughout all forms of life, cells within an organism must respond to a range of cues
in order to maintain a healthy state. These cues may be extracellular in origin or be
found within the cell itself (Figure 1.1). Responses to cell signalling events are varied.
For example, a single-celled organism, such as a bacterium, needs to be able to identify
potential new food sources in order to take advantage of them. By comparison, a
multi-cellular organism, such as a human, may require a cell to die so the organism
as a whole, can grow. Without an efficient signalling system, neither the single-cell















Figure 1.1: General cell signalling. A cell can respond to signals from its environment,
but also within itself. Signalling pathways, such as a three-tiered protein kinase cascade can
lead to a variety of responses.
signal requires an effective signal reception and transduction. In order to achieve these
appropriate responses, a vast number of cellular signalling pathways have evolved.
Protein post-translational modification is a key aspect of cell signalling. Modifica-
tion of proteins alters various aspects of a protein, such as activity and localisation.
The sum output will be a change in state for the cell. Importantly, these modifications
are usually reversible, thereby enabling the cell to switch off the signal. Competing
on and off signals will determine the signal amplitude (how much), duration (how
long) and frequency (how often). Signalling might be considered as digital (on or off)
or analogue (a gradient). Consequently, cellular signalling pathways have numerous
regulatory mechanisms to ensure that the correct response is achieved.
1.3 Protein kinase signalling
1.3.1 Phosphorylation
Post-translational modification of proteins is a fundamental aspect of cell signalling. In
humans, phosphorylation is one of the most frequent forms of post-translational modi-
fication (Aebersold et al., 2018). Phosphorylation is the transfer of the γ-phosphate of
ATP to a hydroxyl group on a substrate (Kornev and Taylor, 2015). Phosphorylation
is a reversible process governed by kinases—enzymes that add phosphoryl groups—and
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phosphatases—enzymes that remove phosphoryl groups (Reactions 1.1 and 1.2; Chen















Protein phosphorylation can act as an allosteric regulator. That is to say that phospho-
rylation can induce a change in the overall three-dimensional shape of a protein, influencing
its properties (Kornev and Taylor, 2015). For example, in mitogen activated protein kinase
(MAPK) signalling, signal transduction occurs via sequential phosphorylation of several pro-
tein kinases (Figure 1.2a). Specifically, the MAPKs extracellular-regulated kinases (ERKs)
are phosphorylated by the MAPK kinases (MAP2K), MAPK/ERK kinases (MEKs). MEKs
are phosphorylated and activated by MAP2K kinases (MAP3K) RAFs. Phosphorylation of
MEK and ERK induces conformational changes within each protein, thereby activating them
(Lavoie and Therrien, 2015).
1.3.2 MAPK signalling
The human genome encodes for over 500 protein kinases (Manning et al., 2002). The remain-
der of this Thesis focuses on protein kinases within MAPK signalling pathways. MAPKs
work in a cascade whereby each protein is phosphorylated and activated by the protein in
the tier above (Figure 1.2a). In general, the cascade is controlled by activation of the apical
MAP3K (Johnson and Lapadat, 2002).
MAPK signalling can broadly be divided depending upon which MAPK family is acti-
vated; the ERKs, the c-Jun N-terminal kinases (JNKs) and the p38 family (Johnson and
Lapadat, 2002). In general, the ERKs regulate cell growth and proliferation whereas, the
p38s and JNKs regulate stress responses, including apoptosis and inflammation (Figure 1.2b;
Kyriakis and Avruch, 2012).
MAPKs and MAP3Ks are all serine-threonine protein kinases—they catalyse the phos-
phorylation of serine and threonine target residues (Kyriakis and Avruch, 2012). By com-







































Figure 1.2: MAPK Cascades. a) A MAPK cascade is activated by a signal, activating the
MAP3K. The MAP3K phosphorylates (indicated by ‘P’) the MAP2K. The MAP2K
phosphorylates the MAPK and finally, the MAPK phosphorylates a protein substrate
eliciting a downstream response. b) Examples of MAPK pathways. One of the best known
is the RAF-MEK-ERK pathway that is activated in response to growth factors such as
platelet-derived growth factor (PDGF) or epidermal growth factor (EGF). The ASK-family
of MAP3Ks (including ASK1, a focus of this Thesis), is activated in response to stressors
including lipopolysaccharide (LPS), tumour necrosis factor-alpha (TNFα) and H2O2.
Active ASKs activate MKK3 and 6, or MKK4 and 7, which in turn activate the p38 and
JNK MAPK families, regulating responses such as apoptosis and inflammation Avruch
(2007); Johnson and Lapadat (2002); Kyriakis and Avruch (2012).
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1998). MAP3Ks and MAP2Ks phosphorylate target residues within the activation loops of
their respective substrate proteins (Piala et al., 2014).
All MAPKs, MAP2Ks and MAP3Ks have a core ∼30 kDa protein kinase domain (Fig-
ure 1.3). The sizes of MAPKs and MAP3Ks is quite varied, with MAP3Ks being the most
diverse in terms of size (from 40 to 180 kDa for MAP3Ks). The difference in size distri-
bution highlights that MAP3Ks have diverse properties and need to be able to co-ordinate
with further upstream signalling mechanisms. MAP2Ks, on the other hand, do not feature
much beyond being a protein kinase, with a limited number of MAPK substrates. MAPKs
are more divergent in size, highlighting their need to recognise a broader range of substrates
than MAP2Ks.
Perhaps the best characterised MAPK pathway is the RAF-MEK-ERK pathway (Fig-
ure 1.2b). Within RAF, for example, regions outside the kinase domain are critical in the
effective signal transduction. For example, active RAF signalling requires binding to the small
GTPase, RAS, in order to correctly localise RAF to the plasma membrane (Lavoie and Ther-
rien, 2015). Binding to RAS by RAF requires a RAS binding domain (RBD) within the N
terminus of RAF (Lavoie and Therrien, 2015). For other MAP3Ks much less is known about
regions beyond their kinase domains. For all MAP3Ks, the kinase domain represents far less
than half of the total protein (Figure 1.3). It is more than likely that these regions have roles
in modulating the overall signalling response. A focus of this Thesis is in investigating how























 Core protein kinase domain
Figure 1.3: Sizes of human MAPKs,
MAP2Ks and MAP3Ks. Each point represents
one protein. The positions of the ASK and
RAF MAP3Ks are indicated. The mean
molecular weight of the core protein kinase
domain of each group is shown. Sizes were
calculated using Protparam




1.4.1 ASK-family of MAP3Ks
The ASK-family of MAP3Ks are activators of the p38 and JNK MAPK pathways (Fig-
ure 1.2b; Nishida et al., 2017). There are three ASK proteins: ASK1 (also known as MAP3K5;
Ichijo et al., 1997); ASK2 (also known as MAP3K6; Wang et al., 1998) and, ASK3 (also known
as MAP3K15; Kaji et al., 2010).
As an upstream regulator of pathways connected to cellular responses such as apoptosis
and inflammation, ASK proteins are important in various aspects of human health (Fujisawa,
2017; Kawarazaki et al., 2014; Matsuzawa, 2017a; Ryuno et al., 2017). For example, mutations
within ASK1 have been reported in melanomas and ASK1 inhibitors have shown promise in
treating gastric cancers (Hayakawa et al., 2011, 2012b; Prickett et al., 2014; Stark et al.,
2012). More recently, ASK1 has garnered attention for its role in regulating inflammation
within the context of nonalcoholic fatty liver disease (NAFLD; Fujisawa, 2017; Schuster et al.,
2018). Elucidation of how ASK-type proteins are regulated is essential in understanding the
underlying biochemistry of these diseases.
1.4.2 Architecture of ASK1
ASK1 (and all ASK-family proteins) has a conserved architecture of a central serine-threonine
protein kinase domain and large N-terminal and C-terminal regulatory regions (Figure 1.4a).
The N terminus of ASK1 contains a highly conserved (in metazoa) region, that in protein fam-
ily (Pfam) database (pfam.xfam.org; Finn et al., 2016) is referred to as ‘domain of unknown
function (DUF)4071’. In human ASK1, DU4071 spans residue 165 to 545 (Figure 1.4a). The
majority of ASK1, N-terminal to the kinase domain is predicted to be ordered, including
a region denoted as the ‘thioredoxin binding domain’ (TBD) (Figure 1.4a,b). In contrast,
the region C-terminal to the kinase domain is predicted to be much more disordered (Fig-
ure 1.4b), with a predicted coiled-coil and sterile alpha motif (SAM) domain (Schneider et al.,
2013).
High-resolution structural data of ASK1 has also been invaluable in understanding the
architecture of the protein. The crystal structure of the kinase domain was first solved in
2007 (Bunkoczi et al., 2007). The Mace laboratory recently published the first structure























Figure 1.4: Schematic of ASK1. a) Scale schematic of human ASK1. N—N terminus;
TBD—thioredoxin binding domain; 7× TPR—Seven tetratricopeptide repeat;
PH—pleckstrin homology; CC—coiled-coil; SAM—sterile alpha motif; C—C terminus.
Numbers above represent the amino acid position. The regions covered by the domain of
unknown function (DUF)4071 and crystal structures—depicted in c)—are indicated. T838
and S966 indicate phosphorylation sites discussed in 1.4.3. b) Disorder prediction of ASK1
using the RONN server (Yang et al., 2005). The prediction is aligned relative to a). c)
Crystal structures for human ASK1—PDB IDs: 5ULM (Weijman et al., 2017) and 2CLQ
(Bunkoczi et al., 2007).
crystal structure of ASK1269–658 revealed a surprisingly compact arrangement, featuring seven
tetratricopeptide repeats (7×TPR) and a pleckstrin homology (PH) domain (Figure 1.4c;
Weijman et al., 2017). Chapter 3 will investigate the importance of the N-terminal domains
(relative to the kinase domain, see Figure 1.4a) on ASK1 auto-regulation.
1.4.3 Regulation of ASK1
Phosphorylation is a major regulatory mechanism for eukaryotic proteins. ASK1 is no excep-
tion to this and can be phosphorylated at various sites (see www.phosphosite.org (Hornbeck
et al., 2015), Nishida et al. (2017) and, Betanzos et al. (2016)). Phosphorylation is associated
with both activation and inhibition of ASK1.
Phosphorylation at Thr838 (located on the activation loop, within the kinase domain,
Figure 1.4a), is regarded as representing active ASK1 (Tobiume et al., 2002). However,
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Bunkoczi et al. (2007) showed that a Thr838Ala mutant of ASK1 was still an active protein
kinase in vitro. But in cells, ASK1 Thr838Ala did not result in an active signalling response
(Bunkoczi et al., 2007). Precisely why Thr838 phosphorylation is required is unclear, but
possibly it is important in protein-recruitment (Bunkoczi et al., 2007).
C-terminal to the ASK1 kinase domain, Ser966 (Figure 1.4a) is another important phos-
phorylation site. Phosphorylated Ser966 can be bound, and inhibited, by 14-3-3 proteins
(Cockrell et al., 2010; Goldman et al., 2004; Petrvalska et al., 2016; Zhang et al., 1999, 2003).
The precise mechanism of how 14-3-3 proteins regulate ASK1 is not clear but biophysical
evidence suggested that it may act as a steric block, preventing access to the kinase domain
(Petrvalska et al., 2016). Stimulation of cells with either H2O2 or tumour necrosis factor-
alpha (TNFα) can trigger dephosphorylation of ASK1, resulting in dissociation of 14-3-3
and active ASK1 signalling (Goldman et al., 2004; Zhang et al., 2003). Phosphorylation of
ASK1 is a dynamic process that is important in both positively and negatively regulating
signalling. However, phosphorylation at Thr838 and withdrawal of 14-3-3 proteins do not
explicitly explain why these processes are able to modulate ASK1 signalling.
The regulation of ASK1 is heavily associated with the large protein complex—greater than
669 kDa in size—dubbed the ‘ASK1 signalosome’ (Noguchi et al., 2005). The composition of
the signalosome is contingent on cellular conditions and can dictate overall ASK1 signalling
(Nishida et al., 2017; Rusnak and Fu, 2017). Under resting conditions, the signalosome is
said to contain ASK1, ASK2, and the oxidoreductase, Thioredoxin 1 (Trx1) (Fujino et al.,
2007; Noguchi et al., 2005; Takeda et al., 2007). Stimulation of cells with TNFα or H2O2
triggers activation of ASK1 in a process that requires the association of ASK1 with TNF-
receptor associated factors (TRAF)2 and 6 (Fujino et al., 2007; Nishitoh et al., 1998; Noguchi
et al., 2005). TRAF recruitment requires the prior withdrawal of Trx1 (Fujino et al., 2007;
Liu et al., 2000). Both Trx1 and TRAF association with ASK1 requires regions within the
conserved N terminal region (i.e. within residues 88–658).
In 1998, Saitoh et al. proposed that Trx1 was a direct inhibitor of ASK1. ASK1 regulation
by Trx1 represents a link between protein kinase signalling and cellular H2O2 sensing. When
H2O2 levels become elevated, Trx1 was proposed to be directly oxidised by H2O2, resulting in
dissociation from ASK1 and allowing active ASK1 signalling (Fujino et al., 2007; Liu et al.,
2000; Saitoh et al., 1998). However, the precise nature of ASK1 regulation by Trx1 remains
unclear, and there are opposing views on whether or not there is a covalent interaction between
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ASK1 and Trx1 (Nadeau et al., 2007; Saitoh et al., 1998). Trx1 is thought to regulate ASK1
by binding to the ASK1-TBD, thereby preventing ASK1 oligomerisation (Fujino et al., 2007),
however, the evidence is not conclusive. Further molecular detail into the interaction between
Trx1 and ASK1 is required for a conclusive picture of ASK1 regulation by Trx1.
Chapter 3 will focus on how ASK1 is auto-regulated and the role the ASK1 N terminus
plays. Chapter 4 moves onto applying how auto-regulatory mechanisms of ASK1 can be
manipulated by Trx1 and investigate the nature of the interaction between ASK1 and Trx1.
One reason why ASK1 regulation by Trx1 remains unclear is that the underlying biology and
biochemistry of H2O2 have often been overlooked. Chapter 5 will focus on H2O2 and will
explore mechanisms of H2O2 signalling.
1.5 H2O2 and signalling
Over the last 20 years, our view of H2O2 has undergone a paradigm shift. H2O2 is now
regarded as an essential secondary messenger in many cell signalling pathways. For example,
H2O2 is now known to be essential in platelet-derived growth factor (PDGF) signalling (Sun-
daresan et al., 1995). Typically, H2O2 leads to protein oxidation, a type of post-translational
modification. Precisely why H2O2 is required in signalling is still being dissected, along with
the mechanism(s) of H2O2 signalling. The following sections will provide an overview of oxi-
dation and how proteins can be modified by oxidation. There will also be a brief commentary
on how H2O2 is produced in mammalian cells and what defences exist to fight it giving rise
to the paradoxical nature of H2O2 signalling.
1.5.1 What is oxidation?
Oxidation can be described as the loss of electrons from a species. The opposite of oxidation
is reduction, the gain of electrons by a species (Halliwell and Gutteridge, 2007). These two
terms are often expressed as a portmanteau, ‘redox’ (reduction, oxidation). A redox reaction
requires the oxidation of one species and concomitantly the reduction of another (Halliwell
and Gutteridge, 2007). The standard reduction potential (Eo′) can be used to describe the
ease of a species to take up electrons and is one of the thermodynamic parameters that govern
a redox reaction (Poole, 2015). For example, cysteine residues within proteins can be in either
a reduced or oxidised form and cysteine oxidation is critical in H2O2 signalling (see 1.5.5,
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below). The reduction of a cysteine thiol reaction can be written as a redox-half equation
(Reaction 1.3). The chemical reductant dithiothreitol (DTT) also exists in a reduced and
oxidised form, so a redox-half equation can be written (Reaction 1.4). The overall redox
reaction can be combined, with the protein becoming reduced, and DTT becoming oxidised
(Reaction 1.5). Under standard conditions, the reaction will proceed spontaneously providing
the difference between the individual standard reduction potentials (∆Eo′) is positive (Poole,
2015). For example (Reaction 1.5), DTT will be able to reduce a protein-disulfide, providing
that Eo′ > −0.33 V, for the protein-disulfide.
Protein−S2
Disulfide
+ 2 e− + 2 H+ −−⇀↽− Protein−(SH)2
Thiol
Eo′ = x V (1.3)
DTT−S2
Oxidised
+ 2 e− + 2 H+ −−⇀↽− DTT−(SH)2
Reduced
Eo′ = −0.33 V1 (1.4)
Protein−S2 + DTT−(SH)2 −−⇀↽− Protein−(SH)2 + DTT−S2 ∆Eo′ = x−−0.33 V (1.5)
1.5.2 Toxicity of H2O2
One complication of H2O2 signalling is that H2O2 can be generated as a by-product
of respiration (see below) and can be toxic. For example, the addition of between
1 and 100 µM H2O2 to cells in culture is sufficient to induce cell death (Halliwell
and Gutteridge, 2007). The potential danger of H2O2 stems from it being a powerful
oxidising agent (i.e. H2O2 causes other species to lose electrons). However, the reality
is that H2O2 has relatively low reactivity towards most biomolecules within a healthy
cell (see Chapter 5, (5.3.2), for more details; Winterbourn, 2015). On the other hand,
when H2O2 is able to react with free iron, for example, the Fenton reaction occurs
(Reaction 1.6; D’Autréaux and Toledano, 2007). The Fenton reaction yields the very
reactive hydroxyl radical (•OH) which can oxidise and damage DNA, lipids and other
biomolecules (D’Autréaux and Toledano, 2007; Sies, 2017).
Fe2+ + H2O2 −−→ Fe3+ + OH− + •OH (1.6)
1Value from Cleland (1964)
10
1.5.3 Defence from H2O2
To protect from any potential danger of H2O2, a large array of peroxidase proteins exist
to break down H2O2. These include glutathione peroxidases (Gpxs) and peroxiredoxins
(Prdxs), which use cysteine (or selenocysteine) based mechanisms and convert H2O2
to water (Flohé, 2015). More detail about defence from H2O2 is given in 5.3.2. In
order to effectively break down H2O2, Gpxs require the small molecule glutathione
(GSH), whilst Prdxs require the oxidoreductase protein Trx. GSH is subsequently re-
plenished by glutathione reductase and Trx by Trx Reductase (TrxR) with the ultimate
reducing power coming from nicotinamide adenine dinucleotide phosphate (NADPH;
Hanschmann et al., 2013; Lu and Holmgren, 2014). Collectively these systems are re-
ferred to as the glutathione and thioredoxin systems (Hanschmann et al., 2013; Lu and
Holmgren, 2014).
Gpxs and Prdxs are found in all domains of life. The human genome encodes for 8
Gpxs and 6 Prdxs (Brigelius-Flohé and Maiorino, 2013; Hanschmann et al., 2013), all
having high reactivities with H2O2 (second order rate constants in the order of between
107 and 109 M−1 s−1 (Winterbourn and Hampton, 2008)). Additionally, these proteins
are also very abundant, ∼20 µM for Prdx2 (Winterbourn and Hampton, 2008). The
question then arises of how is H2O2 signalling possible, given the large ordinance at a
cell’s disposal to breakdown H2O2?
1.5.4 Where, how and why is H2O2 generated?
H2O2 is primarily generated from detoxification of the radical superoxide (O2
•– ) by
superoxide dismutases (SODs) via a disproportionation2 reaction (Reaction 1.7; Holm-
ström and Finkel, 2014; Reczek and Chandel, 2015; Sies, 2014).
2 O2
•− + 2 H+
SOD
−−−−−−→H2O2 + O2 (1.7)
Superoxide can be produced by the electron transport chain within mitochondria, but also
by a family of protein complexes named NADPH oxidases (NOXs; Murphy, 2009; Reczek and
2Disproportionation refers to simultaneous reduction and oxidation of a species, yielding two
different products.
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Thiol Disulfide Sulfenic acid Sulfinic acid Sulfonic acid
Figure 1.5: Common cysteine oxidations. Structure and names of various oxidations
states of cysteine (only the side chain is shown). The numbers refer to the oxidation status
of the cysteine sulfur atom (Nagy and Winterbourn, 2010).
Chandel, 2015). NOXs are membrane-bound complexes that upon activation, use electrons
from intracellular NADPH in order to reduce extracellular oxygen to superoxide (Winter-
bourn, 2008). Extracellular superoxide is converted to H2O2 by SOD3 (Trachootham et al.,
2009). Extracellular H2O2 is able to diffuse across the plasma membrane in a concentration
gradient dependent manner, but the process is also facilitated by membrane channels such as
aquaporin-3 (Miller et al., 2010; Sies, 2017). The generation of superoxide (and consequently
H2O2) by NOXs is important in bacterial defences (Cross and Segal, 2004; Nauseef, 2007),
as well as in H2O2 signalling (Winterbourn, 2008; Winterbourn and Hampton, 2008).
1.5.5 Cysteine oxidation
The primary mode by which H2O2 signalling operates is via cysteine oxidation. Cysteine
thiols can be oxidised to numerous forms, including disulfide bonds, sulfenic, sulfinic and
sulfonic acids (Figure 1.5; Nagy and Winterbourn, 2010). Cysteines can become oxidised
following reaction with, for example, H2O2 (Winterbourn and Hampton, 2008). Cysteine
oxidation is required in the formation of disulfide bonds, serving a structural role (Azimi
et al., 2011). Cysteine oxidation can also act analogously to phosphorylation, as an allosteric
regulator of protein function (Azimi et al., 2011). Both disulfide bond formation and allosteric
regulation are important in cysteine-dependent H2O2 signalling (see 1.5.6 and Chapter 5).
1.5.6 H2O2 as a signalling molecule
Many mammalian signalling pathways use H2O2 as a secondary messenger. For example,
PDGF (Sundaresan et al., 1995), epidermal growth factor (EGF; Bae et al., 1997), and insulin
(Mahadev et al., 2001) signalling all require the generation of H2O2 for effective signalling.
Additionally, in pro-inflammatory signalling, TNFα can also stimulate the generation of H2O2
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(Kang et al., 1998; Kim et al., 2007; Meier et al., 1989). Activation of the relevant growth
factor receptor results in the activation of NOXs in a mechanism that is thought to require
phosphatidylinositol-4,5-bisphosphate 3-kinases (PI3Ks; Brandes et al., 2014; Holmström and
Finkel, 2014; Park et al., 2004).
Precisely why H2O2 is required for effective signalling has not been fully deduced. One
mechanism is that H2O2 inactivates protein phosphatases, thereby potentiating canonical
receptor tyrosine kinase signalling (Holmström and Finkel, 2014; Truong and Carroll, 2012).
For example, the active site cysteine residue in protein tyrosine phosphatase (PTP)1B is able
to be oxidised (to either a sulfenic, sulfinic or sulfonic acid, see Figure 1.5), inactivating the
protein (Lee et al., 1998; Meng et al., 2002; van Montfort et al., 2003). In contrast, the EGF
receptor can have its kinase activity enhanced by sulfenylation of a cysteine residue within
the active site (Paulsen et al., 2012).
TNFα signalling leads to the activation of JNK and p38 MAPKs (Kang et al., 2004),
as well as active nuclear factor (NF)-κB (Latimer and Veal, 2016; Oliveira-Marques et al.,
2009). Whilst TNFα can stimulate the generation of H2O2, the importance of H2O2 to
TNFα-signalling remains unclear. ASK1 can be regarded as a link between TNFα and H2O2
signalling (Gotoh and Cooper, 1998). ASK1 activation following TNFα stimulation requires
dissociation of Trx1 from ASK1 (see 1.4.3), which is thought to be stimulated by direct
oxidation of Trx1 by H2O2 (Liu et al., 2000; Saitoh et al., 1998). However, as will be discussed
in Chapter 5 (5.3.3), direct oxidation of proteins by H2O2 requires a protein to outcompete
peroxidase proteins (Prdxs and Gpxs) for H2O2. The problem of H2O2 competition is best
illustrated by comparing the rate constants for proteins reacting with H2O2. The second order
rate constants for Prdxs reacting with H2O2 is in the order of 10
7 M−1 s−1, by comparison,
Trx1 is 1.05 M−1 s−1 (Winterbourn and Hampton, 2008). The difference in the rate constants
illustrates that Trx1 is unlikely to be directly oxidised by H2O2 in vivo. Consideration of
kinetic and other parameters is essential in determining a feasible route for H2O2 to act as a
signalling molecule.
1.5.7 Models of H2O2 signalling
Within cells, many peroxidase proteins exist to break down H2O2, which should prevent
protein oxidation (see 1.5.3). However, as outlined in 1.5.6 above, H2O2 is an important
messenger molecule in signalling pathways. How then can H2O2 act as a signalling molecule
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Figure 1.6: Synopsis of H2O2 signalling models.
H2O2 signalling is proposed to act following either the
inactivation of Prdxs (left) or a disulfide-relay (right).
1) Production of H2O2 following a signal pathway
activation. 2) Prdxs are inactivated by oxidation to
sulfinic or sulfonic acids (see Figure 1.5). 3) H2O2
accumulates leading to target oxidation. 4) In the
disulfide relay, a Prdx is oxidised (to a sulfenic acid
(shown) or disulfide). 5) Oxidised Prdx1 directly
oxidises the target protein via an inter-molecular
disulfide bond (Jarvis et al., 2012; Wood et al., 2003b).


























if peroxidases will convert it into water?
Various models have been proposed to explain the paradox of H2O2 signalling (Figure 1.6,
further details will be given in Chapter 5 (5.3.3)). One model focuses on how Prdxs are able
to be inactivated. Inactivation can occur by oxidation of the active site cysteines to sulfinic
or sulfonic acids (see 1.5.5) (further details are given in Chapter 5; Wood et al., 2003b,c).
Alternatively, Prdxs can also be inactivated by phosphorylation (Chang et al., 2002; Rawat
et al., 2013; Woo et al., 2010). Once inactivated, H2O2 is able to directly oxidise target
proteins. One limitation of the inactivation model is that the Gpxs would still be present
(Forman et al., 2010). Lastly, the inactivation model does not explain how the accumulation
of H2O2 leads to a specific response.
An alternative model (the disulfide-relay model) proposes that Prdxs themselves can act
as direct mediators of H2O2 (Figure 1.6). Prdxs oxidised by H2O2 will in turn, oxidise a
target protein via a disulfide-relay (Jarvis et al., 2012). Under the disulfide-relay model,
H2O2 signalling specificity can be explained, as it will be dependant upon Prdx protein-
protein interactions.
Arguably, the best-known example of a signalling disulfide-relay is the yeast transcription
factor, Yap1, which is oxidised in response to H2O2 by the yeast Prdx, Gpx3 (also known
as Orp1; Delaunay et al., 2000, 2002). Oxidation of Yap1 leads to the formation of disulfide
bonds within Yap1 that promote translocation of the protein to the nucleus (Wood et al.,
2003a, 2004). A similar mechanism has been seen in a mammalian context with Prdx2 and
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the transcription factor signal transducer and activator of transcription (STAT)3 (Sobotta
et al., 2015). ASK1 and Prdx1 have also been proposed to form a disulfide relay (Jarvis et al.,
2012).
It is not known how common the disulfide-relay mechanism is because there are only
a few well-characterised examples. In order to determine how prevalent the mechanism
is or whether the inactivation model is more likely, Chapter 5 will look into developing
a methodology to determining the contribution of Prdx1 to protein oxidation and H2O2
signalling.
1.6 ASK1 and H2O2 signalling
Our understanding of H2O2 and its contribution to cellular signalling is ever increasing but
questions still remain over the mechanism(s) of H2O2 signal transduction. ASK1 represents
a link between H2O2 and protein kinase signalling, notable by activation of the p38 and
JNK MAPKs (Gotoh and Cooper, 1998; Ichijo et al., 1997). Work from the Ledgerwood lab
showed how Prdx1 is required for H2O2 induced p38 activation (Jarvis et al., 2012). Prdx1
was proposed to directly activate ASK1 in a disulfide-relay (Jarvis et al., 2012). Trx1 is
regarded to be a negative regulator of ASK1 (Liu et al., 2000; Saitoh et al., 1998), connecting
both positive and negative regulation of ASK1 to H2O2 metabolism. ASK1, Prdx1 and
Trx1, therefore, represent a potential model system that can be exploited to further our
understanding of H2O2 as a signalling molecule, and how it can alter protein activity.
1.6.1 Outstanding questions
Using ASK1, Trx1 and Prdx1 as a model system requires a detailed molecular understanding
of the intrinsic regulatory mechanisms of ASK1. To date, the majority of studies on ASK1
have used either immunoprecipitated ASK1 from cells or the recombinant isolated ASK1 ki-
nase domain. Whilst these methods have provided invaluable information into ASK1 regula-
tion and association with other proteins, they do not allow us to understand how non-catalytic
regions within ASK1 can directly regulate protein activity.
Specifically, it is not clear how the N-terminal region of ASK1 facilitates inhibition of
ASK1 signalling—does the ASK1 N terminus directly regulate kinase activity or regulate
protein-interactions? ASK1 is purported to be negatively regulated by Trx1, but precisely
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how Trx1 regulates ASK1 is unclear. Elucidation of the mechanism of Trx1 inhibition would
further inform as to the basis of ASK1 regulation and how H2O2 can regulate protein kinase
signalling. Lastly, Prdx1 is proposed as a signalling protein, acting to transmit oxidative
signals in order to regulate proteins. Jarvis et al. (2012) and Sobotta et al. (2015) used rela-
tively targeted methods to identify ASK1 and STAT3 (respectively) as signalling substrates
for Prdx1 and 2 (respectively). Developing a proteomic method to identify likely signalling
targets of Prdx1, would help to clarify the true contribution of Prdx1 to H2O2 signalling at
a cellular level.
1.7 Thesis aims
The aims of this Thesis are to:
Aim 1 Characterise ASK1 auto-regulatory mechanisms;
Aim 2 Characterise ASK1 regulation by Trx1;
Aim 3 Carry out a pilot study to investigate the contribution of Prdx1 to H2O2 sig-
nalling.
Chapter 3 will use recombinant ASK1 protein constructs and biochemical analyses in order
to investigate how ASK1 is self-regulated. It will be guided by structural and biophysical
work from the Mace laboratory and use a novel approach for monitoring ASK1 kinase activity
in vitro.
Chapter 4 will use recombinant ASK1 protein constructs to examine ASK1 regulation by
Trx1 in vitro. The interaction between ASK1 and Trx1 will be probed with biochemical and
biophysical methods.
Chapter 5 will look at whether a proteomics method is feasible for probing the contribution
of Prdx1 to H2O2 signalling in mammalian cells. Chemical labelling and mass spectrometry





This manuscript was written in LATEX using TEXstudio (texstudio.org) and the TEXLive
distribution (www.tug.org/texlive). Mendeley Desktop (www.mendeley.com) was used
for reference management. All figures were made using Inkscape: Open Source Scalable
Vector Graphics Editor (inkscape.org). Quantification of gels was carried out using
Image Studio Lite (LI-COR). Numeric processing was carried out using Microsoft Excel
and graphic representation on GraphPad Prism. Molecular modelling was performed
using both PyMol (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger,
LLC) and UCSF Chimera (Pettersen et al., 2004). All other specific software packages
are listed in relevant sections.
2.2 Reagents
Unless stated, all chemicals used were of analytical grade purchased from AppliChem,
BioFroxx, Merck or Scharlab. Unless stated otherwise, all solutions were prepared
using type I water (18.2 MΩ·cm) from either a Millipore Milli-Q or Elga PURELAB
Chorus 1 system.
17
2.3 Cloning and mutagenesis
2.3.1 General cloning and mutagenesis information
Unless stated, all reagents for cloning were purchased from New England Biolabs. A
C1000 Thermal Cycler (Bio-Rad) was used for all polymerase chain reactions (PCR)
and molecular biology incubations unless stated otherwise. UltraPure water (Invitro-
gen) was used in all cloning and molecular biology.
All primer and oligonucleotide sequences can be found in Appendix A. All primers
and oligonucleotides were purchased from either Sigma or Integrated DNA Technolo-
gies. Upon arrival primers were briefly centrifuged before the addition of UltraPure
water to reconstitute primer to a final concentration of 100 µM). Primers were hydrated
at room temperature for at least 10 minutes before vortexing and briefly centrifuging
before being stored at −20 °C.
All cloning used chemically competent Escherichia coli MC1061 cells. MC1061
cells were grown in lysogeny broth (LB) containing 10 g sodium chloride (NaCl), 10 g
peptone (from casein) and 5 g yeast extract made up to one litre with type I water.
LB was sterilised by autoclaving at 121 °C, 100 kPa for 20 minutes.
2.3.2 Vectors
A list of all protein expression vectors used in this work can be found in Table 2.1
2.3.3 Miniprep isolation of plasmid DNA from MC1061 cells
Plasmids were isolated from 3 mL LB culture that had been grown from a single
colony overnight with appropriate antibiotic (50 µg/mL for kanamycin, 100 µg/mL
for ampicillin, 34 µg/mL for chloramphenicol). A Zyppy plasmid miniprep kit (Zymo
Research) was used for all plasmid mini-preps. All steps were performed at room
temperature and all centrifugation steps were at 16,000 g unless stated otherwise.
Briefly, cells were transferred to a 1.7 mL tube and pelleted by centrifugation at
4,000 g for 2 minutes in two sequential rounds. The supernatant was discarded and
the cell pellet was re-suspended in 500 µL of type I water. One hundred microlitres of
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His6-3C-X E. coli pET28 Kanamycin LIC
T7/
T7 Term NKI




T7 Term Dr Peter Mace
His6-MBP-3C-X E. coli pMAL Ampicillin LIC
MalE/
T7 Term Dr Peter Mace
His6-3C-X (Trx1
co-expression) E. coli pET28 Kanamycin LIC
DuetUp2/
DuetDown Dr Peter Mace








DuetDown Dr Peter Mace
His6-3C-X (FB) Insect pFastBac Ampicillin LIC
Polyhedrin/
SV40 Dr Peter Mace
His6–Hexahistidine tag; 3C—protease cleavage site; X—DNA sequence of the protein to be
incorporated; MBP—maltose binding protein; Trx1—human Thioredoxin 1; LIC—ligation
independent cloning; Lys-His6—: C-terminal T4 lysozyme
R12G,C54T,C97A,I137R. Sequencing
primers—forward/reverse, sequences are given in Appendix Table A.1. The pET28,
His6-3C-X vector was a gift from the Netherlands Cancer Institute Protein Facility (NKI).
Zyppy lysis buffer was added to the cell suspension and mixed by inversion at least five
times, for no longer than two minutes. Zyppy Neutralisation buffer (350 µL) was added
to each tube and mixed by inverting tubes at least five times. The lysate was clarified by
centrifuging for two minutes at maximum speed. The supernatant was transferred to a
fresh DNA-binding column in a collection tube and centrifuged for 30 seconds. Bound
DNA was washed with 200 µL of endotoxin wash and 400 µL of DNA-wash buffer with
centrifugation in-between each wash. Trace ethanol was removed by centrifuging DNA
column for 2 minutes. The DNA-column was subsequently transferred to a fresh 1.7
mL microfuge tube and 40 µL of UltraPure water added directly to the membrane.
DNA was eluted by centrifugation for 30 seconds and concentration quantified (2.3.4).
Plasmids were stored at −20 °C.
2.3.4 DNA quantification
DNA concentration was quantified using a NanoDrop2000 (Thermo Scientific) to mea-
sure absorbance at 260 nm.
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2.3.5 Agarose gel electrophoresis
Agarose gels were made in TAE buffer consisting of 40 mM tris(hydroxymethyl)aminomethane
(Tris), 20 mM acetate and 1 mM ethylenediaminetetraacetic acid (EDTA).
Linearised vector and PCR products were resolved and visualised on agarose-TAE
gels. Agarose-TAE gels (0.5–2% (w/v) agarose, HydraGene) were poured in ∼1 cm
thick slabs. Ethidium bromide was added fresh to molten gel at a final concentration
of approximately 0.5–2.0 µg/mL. Samples were mixed with 6× agarose gel loading dye
(Thermo Scientific) and loaded into wells. Gels were resolved by electrophoresis at 120
V for 25 minutes and then visualised on UV transilluminator.
2.3.6 DNA Gel extraction and purification
Linearised vector and PCR products were routinely purified by extraction follow-
ing agarose gel electrophoresis using a ZymoClean gel recovery kit (Zymo Research).
Briefly, bands of interest were excised from agarose gel and transferred to a fresh 1.7
mL tube. Agarose dissolving buffer (ADB) was added (∼500 µL) to the same tube and
was incubated at 50 °C until agarose had melted. Melted agarose-gel was transferred
to a DNA-binding column and centrifuged at 16,000 g for 30 seconds. Bound DNA was
washed with an additional 200 µL ADB and centrifuged again at 16,000 g for 30 sec-
onds. The column was washed twice with 200 µL ethanol-containing wash buffer before
centrifugation for 30 seconds at 16,000 g. The column was dried by centrifugation at
16,000 g for 2 minutes to remove all ethanol. DNA was eluted by the addition of 14 µL
of UltraPure water directly to the centre of the column. Columns were incubated at
room temperate for 10 minutes. DNA was eluted with a final centrifugation at 16,000 g
for 30 seconds. Eluted DNA was quantified spectrophotometrically using a NanoDrop
(2.3.4). Eluted DNA was stored at −20 °C until use.
2.3.7 PCR of inserts
Inserts for ligation independent cloning (LIC) and ligation cloning utilised a PCR recipe
consisting of a 25 µL reaction containing 5 µL Q5 buffer, 0.28 mM dNTPs, between
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20 and 50 ng DNA template, 1 µM each primer and 0.5 units of Q5 DNA polymerase.
UltraPure water was added to adjust final volume to 25 µL. The PCR reaction was
incubated under the following conditions: 98 °C for 30 seconds, 55 °C for 30 seconds
72 °C for 2 minutes, 31 cycles of 98 °C for 10 seconds, 72 °C for 2 minutes, 72 °C for 2
minutes.
PCR products were resolved by electrophoresis agarose-TAE gels (2.3.5). DNA
bands were visualised under UV and bands excised using a clean razor blade and
transferred to a 1.7 mL microfuge tube. DNA was liberated from gel slabs using a
DNA-agarose extraction kit (2.3.6).
2.3.8 Isolation of ASK1 cDNA
Full-length (2–1374) human ASK1 cDNA was isolated by sequential PCR using hu-
man cDNA as a template. Reaction and PCR conditions were the same as in 2.3.7.
MegaMan cDNA (Agilent) was diluted 10-fold in UltraPure water and 0.25 µL of the
diluted cDNA was used as a template. Primers in one reaction corresponded to ASK1
residues 2–335 and in a second reaction, residues 325–1374 (primer sequences are given
as in A.2). These reactions were resolved on a 1% (w/v) agarose-TAE gel (2.3.5). A
pipette tip was stabbed into each band and placed into a fresh PCR reaction with
the same recipe as previous (2.3.7) with primers for ASK1 2-forward and ASK1 1374-
reverse. The primers for ASK1 325-forward and 335-reverse overlapped completely, so
for the first few stages of the PCR the previous bands acted as both template and
primer. The final PCR product then contained LIC-compatible ASK1 2–1374 cDNA,
which was processed and inserted into vectors as previous (2.3.10) before confirming
by colony PCR and sequencing.
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2.3.9 Restriction enzyme cloning of Trx1-Lysozyme fusion con-
struct
2.3.9.1 Linearisation of lysozyme-His6 fusion vector by XhoI and NdeI
restriction enzymes
Cloning for Trx1-Lysozyme fusion construct utilised XhoI and NdeI sites within the
X-T4 lysozyme-His6 vector (Table 2.3.2). Two micrograms of lysozyme-His6 fusion
vector were incubated with 40 units of both XhoI and NdeI, 5 µL CutSmart buffer and
the reaction was made to a final volume of 50 µL with UltraPure water. The vector
was digested for 1.5 hours at 37 °C. Linearised vector was resolved by agarose-TAE
electrophoresis (2.3.5) before gel purification and extraction (2.3.6).
2.3.9.2 PCR generation of ligation cloning inserts
The program and recipe for PCR of inserts for ligation cloning was identical to that
as for all PCR-insert generation (2.3.7) with the exception that primers featured ei-
ther a NdeI cut-site (5’-CATATG-3’) within the forward primer or XhoI cut-site (5’-
CTCGAG-3’) within the reverse primer. Primers for ligation-based PCR can be found
in Appendix A.3. Following PCR, inserts were resolved by TAE-agarose gel elec-
trophoresis (2.3.5), and bands were excised and purified (2.3.6).
2.3.9.3 Restriction digestion of insert
Inserts were made compatible with vector by restriction digest with XhoI and NdeI.
One microgram of gel-purified insert was incubated with 20 units of NdeI and XhoI and
2 µL of CutSmart buffer in a 20 µL reaction made up with UltraPure water. Digested
insert was heat-inactivated at 65 °C for 20 minutes.
2.3.9.4 Ligation of insert and vector
Vector and insert were mixed together in a 1:3 (vector:insert) molar ratio. DNA ligation
took place in a reaction containing 21 ng of insert DNA, 125 ng of vector, 1 µL of T4
DNA ligase buffer, 200 units of T4 DNA ligase and UltraPure water was added to 10
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µL final volume. The ligation reaction took place at room temperature for 10 minutes.
Three microlitres of the ligation reaction were used to transform competent MC1061
cells (2.3.11).
2.3.10 Ligation independent cloning (LIC)
2.3.10.1 PCR for generation of LIC inserts
All primers for LIC had previously been designed by Dr Peter Mace using the Pro-
teinCCD tool (Mooij et al., 2009). LIC primers featured either an overhang of 5’-
CAGGGACCCGGT-3’ for forward primers or 5’-CGAGGAGAAGCCCGGTTA-3’ for
reverse primers. The sequences for all LIC-primers can be found in Appendix A. PCR
for LIC-inserts was identical to ligation-based cloning (2.3.7).
2.3.10.2 Linearisation of LIC-vectors by KpnI
All LIC-compatible vectors in this work featured a KpnI site for linearisation. Two
micrograms of vector were incubated with 1 unit of KpnI-HF with 5 µL of CutSmart
buffer in a 25 µL reaction made up with UltraPure water. The KpnI digestion was
incubated at 37 °C for 2 hours. Linearised plasmid was separated and by TAE-agarose
electrophoresis (2.3.5) before purification by gel-extraction (2.3.6).
2.3.10.3 T4 DNA polymerase treatment of vector
Approximately 800 ng of KpnI-cut vector was treated in a 30 µL reaction consisting
of 3 µL NEB Buffer 2, 2.5 mM dTTP and 4.5 units of T4 DNA polymerase with the
remaining volume made up with UltraPure water. T4 DNA polymerase treatment
occurred in a thermal cycler at 25 °C for 30 minutes followed by heat-inactivation at
75 °C for 20 minutes. T4 DNA polymerase-treated vectors (denoted as ‘LIC-ready
vector’) were stored at −20 °C before use.
2.3.10.4 T4 DNA polymerase treatment of insert
Between 100 and 200 ng of insert DNA are added to a 10 µL reaction containing 1
µL NEB Buffer 2, 2.5 mM dATP and 1.5 units of T4 DNA polymerase with the final
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volume made up with UltraPure water. Where insert-DNA concentration was too low
to quantify or yield was too low UltraPure water was omitted and the volume made
up with as much insert-DNA as possible. Insert T4 DNA polymerase treatment was
incubated identically to vector T4 DNA polymerase treatment; 25 °C for 30 minutes
followed by heat-inactivation at 75 °C for 20 minutes. T4 DNA polymerase-treated
inserts (denoted as ‘LIC-ready insert’) were stored at −20 °C before use.
2.3.10.5 LIC Combination
In a 1.7 mL microfuge tube, 1.5 µL of LIC-ready insert and 0.5 µL LIC-ready vector
were combined and centrifuged briefly. Insert and vector were incubated room tem-
perature for 5 minutes during which complementary ends anneal. The entire reaction
was transformed into MC1061 cells (2.3.11).
2.3.11 DNA Transformation of E. coli
For each transformation, approximately 20–50 ng of DNA was incubated with 20 µL of
chemically competent E. coli MC1061 cells. Cells were incubated on ice for 10 minutes,
before being heat-shocked in a 42 °C water bath for 45 seconds. Cells were returned to
ice for two minutes before the addition of 350 µL of sterile, room temperature LB. Cells
were transferred to a 37 °C shaking incubator for 45 minutes for antibiotic resistance
gene(s) to be expressed. Transformed cells were aseptically spread onto 15 mm Petri
dishes (Thermo Scientific) with 0.5% (w/v) agar-LB medium supplemented with either
ampicillin or kanamycin at 100 or 50 µg/mL respectively. Plated cells were placed in
37 °C incubator overnight.
2.3.12 Screening by colony PCR
LIC and ligation cloning were screened by colony PCR. Single colonies were picked using
a sterile 20 µL tip and placed in a PCR-strip tube containing 10 µL of pre-aliquoted
PCR master mix. Colony PCR master mix contained 1 µL ThermoPol Reaction Buffer,
0.5 units of Taq DNA polymerase, 0.7 mM dNTPs, 1 µM of forward and reverse primer
(vector dependant, see 2.3.2) made up to 10 µL with UltraPure water. Picked colonies
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were incubated in PCR master mix for between 1 and 5 minutes at room temperature
before tip was removed. The reaction was incubated in thermal cycler under the
following conditions; 95 °C for 2 minutes, followed by 33 rounds of 95 °C for 30 seconds,
55 °C for 30 seconds, 72 °C for 4 minutes, and a final step of 72 °C for 6 minutes.
The entire reaction was analysed by TAE-agarose electrophoresis (2.3.5). Colonies
that had an insert of the correct size, as judged by the colony PCR, were used to
inoculate 3 mL of sterile LB with the appropriate antibiotic and incubated overnight
at 37 °C in a shaking incubator. Plasmids were extracted using a mini-prep kit (2.3.3).
2.3.13 Sequencing of plasmid DNA
Plasmid DNA was regularly sequenced by Sanger sequencing by either Genetic Analysis
Services (University of Otago) or Massey Genome Service (Massey University) as per
their recommended instructions. DNA sequencing was analysed using 4Peaks and
EnzymeX (both www.nucleobytes.com) with comparison alignments against expected
sequences made using ClustalOmega (Li et al., 2015).
2.3.14 Mutagenesis
Site-directed mutagenesis was carried out by QuickChange using overlapping primers
(sequences can found in Appendix A) with deliberate 3’ overhangs (Liu and Naismith,
2008). The desired mutation was included in the overlapping portion.
QuickChange PCR was carried out in a 12.5 µL reaction containing 2.5 µL Q5
reaction buffer, 0.2 mM dNTP, 0.4 µM of each primer, 20 ng of template DNA. The
reaction volume was made up using UltraPure water. QuickChange PCR reactions
were incubated at 98 °C for 1 minute before 19 rounds of 98 °C for 30 seconds, 55
degrees for 30 seconds, 72 °C for 5 minutes, before a final step of 72 °C for 7 minutes.
Once the PCR was complete, 3 µL of the reaction was removed for a no-DpnI treated
sample. Ten units of DpnI was added to the remainder (∼9.5 µL) of the reaction. DpnI
digestion of host methylated DNA took place overnight (∼16 hours) at 37 °C. Four
microlitres of the DpnI-treated reaction was used to transform 50 µL of MC1061 cells
in the same manner as described in 2.3.11. Cells were plated onto agar plates and
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allowed to grow overnight. Single colonies were picked with a sterile pipette tip and
used to inoculate 3 mL of LB (with the appropriate antibiotic) for mini-prep isolation
of plasmid DNA (2.3.3). Plasmids were screened by Sanger sequencing to confirm the
inclusion of desired mutation (2.3.13).
2.3.15 Constructs used in this study
A list of all wild-type (WT) protein constructs is given in Table 2.2.
The majority of constructs used in this study were expressed in E. coli BL21(DE3)
using a modified pET28 vector featuring a LIC-cloning site that introduced an N-
terminal-His6-tag and 3C-protease cleavage site (SAALEVLFQ GPG, where 3C cuts
at ).
2.4 Polyacrylamide gel electrophoresis (SDS-PAGE)
2.4.1 Preparation of acrylamide gels for SDS-PAGE
All SDS-PAGE (except Phos-Tag SDS-PAGE) was conducted using hand-poured, 15-
well, 1 mm × 80 mm × 100 mm, 10–20% acrylamide gradient gels with a discontinuous
stacker.
Gradient gels were hand-poured using a Model 385 gradient former (Bio-Rad), P-1
peristaltic pump (Pharmacia Fine Chemicals) and SE215 10-gel multi-caster (Hoeffer)
with polycarbonate sheets separating each gel. Table 2.3 gives the recipe used in
gradient SDS-PAGE. Once poured, the gels were gently tapped to dislodge any trapped
air, placed on a level surface and 150 µL of isopropanol was gently pipetted on top of
each gel. Gels were left to cure for between 30 minutes and one hour. Once the resolving
gel had set, isopropanol was poured off of gels and the stacking gel was poured on. The
combs were inserted and the stacking gel was left to cure for an additional hour. Once
the stacking gel had set the multi-caster was disassembled and gels stored in an airtight,
humidified, box at 4 °C until use.
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Table 2.2: Protein constructs used in this work




88–266 N-terminal-His6-3C His6-3C-X LIC
88–338 N-terminal-His6-3C His6-3C-X LIC
88–658
N-terminal-His6-3C His6-3C-X LIC
N-terminal-His6-3C, C-terminal StrepII His6-3C-X LIC/QC
269–658 N-terminal-His6-3C His6-3C-X LIC
669–941 N-terminal-His6-3C His6-3C-X LIC
88–941
N-terminal-His6-3C His6-3C-X LIC
N-terminal-His6-3C, C-terminal StrepII His6-3C-X, Trx1 co-expression LIC/QC
2–1374 N-terminal-His6-3C His6-3C-X (FB) LIC
MKK6 2–334 N-terminal-His6-3C His6-3C-X LIC
λPP 1–221 Untagged pACYC(No tag) RE
Trx1 2–105
N-terminal-His6-3C His6-3C-X LIC
C-terminal-Lys-His6 X-T4 Lysozyme-His6 RE
Untagged His6-3C-X RE
N-terminal-His6-MBP His6-MBP-3C-X LIC
Prdx1 2–199 N-terminal-His6-3C His6-3C-X LIC
All proteins sequences are human with the exception of T7 phage lysozyme and λ phage PP. Wild-type (WT) proteins were initially
isolated and any mutations were derived via QuickChange (see section 2.3.14). 1) Refers to vector description in Table 2.3.2.
λPP—Lambda phage protein phosphatase, QC—QuickChange, RE—Restriction enzyme.
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1.5 M Tris, pH 8.8 (mL): 7.5 7.5 0
0.5 M Tris, pH 6.8 (mL): 0 0 7.8
40% (w/v) Acrylamide (mL): 7.5 15 3.75
Type I water (mL): 14.5 1.82 18
10% (w/v) SDS (mL): 0.3 0.3 0.3
60% (v/v) Glycerol (mL): 0 5 0
0.5% (w/v) Bromophenol blue (µL): 0 210 10
TEMED (µL): 15 15 25
10% (w/v) APS (µL): 150 150 150
TEMED—N,N,N’,N’-tetramethylethane-1,2-diamine, APS—ammonium persulfide.
TEMED was from Sigma, APS and 40% acrylamide/bis-acrylamide 37.5:1 was from
Bio-Rad. TEMED and APS were added to gel solution immediately before pouring.
2.4.2 Preparation of samples for SDS-PAGE
Samples were mixed with either 2× or 4× SDS-PAGE sample buffer as required. Two
times SDS-PAGE reducing sample buffer contained 120 mM Tris pH 6.8, 16% (v/v)
glycerol, 100 mM DTT, 0.01% (w/v) bromophenol blue. Four times SDS-PAGE re-
ducing sample buffer contained 240 mM Tris pH 6.8, 32% (v/v) glycerol, 200 mM
DTT 0.02% (w/v) bromophenol blue. Non-reducing SDS-PAGE sample buffers were
of an identical recipe except for the omission of DTT. Samples containing whole-cell
mixtures were always boiled and briefly centrifuged before running. Samples for both
Phos-Tag SDS-PAGE and non-reducing SDS-PAGE were never boiled. Samples were
routinely stored at −20 °C, if not being processed immediately.
2.4.3 Running of SDS-PAGE
SDS-PAGE was run using a SE250 gel tank (Hoeffer). The back reservoir of the tank
was filled with SDS-running buffer (consisting of 25 mM Tris, 192 mM glycine, 0.1%
(w/v) SDS). The comb was gently removed and wells were rinsed with running buffer.
For SDS-PAGE, 3.5 µL of Precision Plus Protein Standards (Bio-Rad) were loaded
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into one well. Samples to be analysed on the gel were loaded and gels were run with
water-cooling at a constant voltage of 200 V for 55 minutes. Once gels had run, the
gels were carefully removed from the apparatus. The wells were cut off and the gel was
transferred to a container and rinsed briefly in distilled water.
2.4.4 Coomassie staining of SDS-PAGE
Gels were stained using Coomassie brilliant blue (R-250) in a solution of 10% (v/v)
acetic acid, 50% (v/v) methanol, 0.25% (w/v) R-250, in distilled water. Gels were
then placed on a ROCKit rocker (Select BioProducts) for between 10 and 30 minutes
until even stain was achieved. Gels were subsequently destained by removing staining
solution and rinsing with distilled water. Destaining solution (10% (v/v) acetic acid,
40% (v/v) methanol, in distilled water) was poured over to completely cover the gel.
A paper towel was added to accelerate the destaining process. Gels were left to destain
until a desired level of background was reached. Gels were subsequently imaged on a
gel imaging system (GE Healthcare) using Epson Scan (Epson).
2.4.5 Phos-Tag SDS-PAGE
Phos-Tag SDS-PAGE used hand-poured, 15-well, 1 mm × 80 mm × 100 mm, 10%
acrylamide gels, 20 µM Phos-Tag acrylamide, 100 µM MnCl2 with a discontinuous
stacking gel. Gels were cast in a 5-gel SE200 multi-caster (Hoeffer). The recipe for
Phos-Tag polyacrylamide gels is given in Table 2.4.
Phos-Tag acrylamide (AAL-107, Wako-Chem) solution (5 mM) was prepared by
dissolving 10 mg of Phos-Tag acrylamide in 100 µL analytical grade methanol. Once
dissolved, 3.2 mL of type I water was added. The Phos-Tag acrylamide solution was
aliquoted and stored at −20 °C in the dark. Once thawed, working aliquots were kept
protected from light at 4 °C.
Gels were poured, tapped to dislodge trapped air and 150 µL of isopropanol was
added to the top of each gel. Phos-Tag gels were covered with a cardboard box to
protect from light and left to set for one hour. Once gels were set, the isopropanol
was poured off and the tops of the gels were rinsed with distilled water. The resolving
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Table 2.4: Phos-Tag (20 µM) SDS-PAGE (10%) 5-gel recipe
Solution Resolving gel Stacking gel
1.5 M Tris, pH 8.8 (mL): 6.25 0
0.5 M Tris, pH 6.8 (mL): 0 4.175
40% (w/v) acrylamide (mL): 6.25 2.075
Type I water (mL): 12.0 9.425
10% (w/v) SDS (µL): 250 167.5
5 mM Phos-Tag acrylamide (µL): 100 0
10 mM MnCl2 · 4 H2O (µL): 250 0
0.5% (w/v) Bromophenol blue (µL): 0 10
TEMED (µL): 25 25
10 % (w/v) APS (µL): 125 125
MnCl2 · 4 H2O—manganese chloride tetrahydrate (Sigma). TEMED and APS were added to
gel solution immediately before pouring.
gel solution was poured on top of the gels and combs were inserted. The gels were
covered with the box and left to cure for an additional hour. Once fully set, the gels
were disassembled. and placed in an airtight, humidified, dark box and stored at 4 °C.
Phos-Tag gels were used within two weeks.
The running (2.4.3) and staining (2.4.4) of Phos-Tag SDS-PAGE was as per con-
ventional SDS-PAGE. Samples for analysis by Phos-Tag SDS-PAGE were never boiled
and always frozen at −20 °C and thawed before analysis. Coomassie stained Phos-Tag
acrylamide gels were imaged in the 700 nm channel of an Odyssey FC (LI-COR) and
processed using Image Studio (LI-COR).
2.5 Western blot analysis
Gels for western blotting were run as for normal SDS-PAGE. With the exception that
4 µL of prestained Precision Plus Protein Standards (Bio-Rad) (which were already
diluted four-fold in 4× reducing SDS-sample buffer) were loaded into one well.
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2.5.1 Antibodies
Working dilutions and other details of primary and secondary antibodies used in this
work are given in Tables 2.5 and 2.6, respectively.









α-p-p38 Monoclonal Mouse 1 in 1,000 BD Biosciences 612288
α-p-MKK6 Polyclonal Rabbit 1 in 2,500 SantaCruz sc-7994-R
α-ASK1 Monoclonal Rabbit 1 in 1,000 Abcam ab45178 [EP553Y]
α-Prdx1 Polyclonal Rabbit 1 in 2,000 Abcam ab41906
α-Trx1 Polyclonal Rabbit 1 in 1,000 Abcam ab133524 [EPR6110]
α-His6 Monoclonal Mouse 1 in 1,000 Abcam ab18184
α-StrepII Monoclonal Mouse 1 in 20,000 IBA Lifescience 2-1509-001
α-α-Tubulin Monoclonal Mouse 1 in 10,000 Millipore 05-829 (clone DM1A)
α—anti, p—phospho, p-MKK6—phosphorylated MKK6 (phosphorylated at S207,
numbering for human MKK6), p-p38—phosphorylated 38 (phosphorylated at T180 and
Y182 numbering for human p38α).









α-rabbit-680LT Polyclonal Goat 1 in 20,000 LI-COR 925-68021
α-rabbit-800CW Polyclonal Goat 1 in 20,000 LI-COR 925-32211
α-mouse-800CW Polyclonal Goat 1 in 20,000 LI-COR 925-32210
α-mouse-HRP Polyclonal Goat 1 in 20,000 BioRad 170-6516




For wet transfer, gels were run as in 2.4. Once run, gels were trimmed of stacking gel
and any remaining bromophenol blue containing gel. The gel was soaked in ice-cold
transfer buffer (25 mM Tris, 192 mM glycine, 10% (v/v) methanol) for 10 minutes.
Nitrocellulose membrane (0.2 µm, GE Healthcare) was cut to size and soaked in the
same buffer. Two pieces of 1.5 mm blotting paper (Whatman) were trimmed and
soaked along with sponges. The transfer cassette was assembled from the bottom-up—
sponge, two pieces of blotting paper, membrane, gel, two pieces of blotting and then
a final sponge. At each layer, the transfer-sandwich was rolled to remove air. The
gel sandwich was placed inside a plastic clamp and placed in a TE22 transfer tank
(Hoeffer). The tank was filled with ice-cold transfer buffer and run with water cooling
at 100 V, 300 mA for 2 hours.
2.5.3 Semi-dry transfer
Semi-dry transfer used a Trans-Blot Turbo Transfer system (Bio-Rad). Running and
preparation of the gel was the same as for wet transfer (2.5.2). From the bottom-up,
four pieces of pre-soaked blotting paper were topped with the membrane, the gel, and
another four pieces of blotting paper. At each stage, the sandwich was rolled to exclude
air. Semi-dry transfer was run at 2.5 A, 15 V for 30 minutes.
2.5.4 Ponceau S staining
After transfer to membrane, total protein was stained and visualised using Ponceau S.
In brief, the membrane was placed in a clean container and submerged with Ponceau
S staining solution (0.5% (w/v) Ponceau S (BDH Chemicals), 1% (v/v) acetic acid,
in type 1 water). The membrane in Ponceau S solution was incubated on a rocker
at room temperature for between 3 and 10 minutes before being rinsed three times in
distilled water. The membrane was left in distilled water for a further 3 to 5 minutes
to help ensure an even level of staining. The stained membrane was imaged in the 800
nm channel on an Odyssey FC (LI-COR) and Image Studio (LI-COR). Once imaged,
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membranes were rinsed with distilled water before being rolled and placed inside a
clean 50 mL tube.
2.5.5 Blocking and probing
Membranes already rolled in tubes were blocked in a solution of Tris-buffered saline
(TBS; 20 mM Tris pH 7.4, 150 mM NaCl) containing 5% (w/v) bovine serum albumin
(BSA; MP Biomedical). Membranes were blocked for one hour at room temperature
on a SRT1 roller (Stuart Scientific).
Primary antibodies were diluted as appropriate (Table 2.5) in TBS with 0.1% (v/v)
Tween-20 (Sigma) (TBST) with 1% (w/v) BSA. Membranes were incubated with pri-
mary antibodies overnight at 4 °C on a roller. Membranes were washed 4 × 5 minutes
in TBST with rolling at room temperature. Secondary antibodies (see Table 2.6) were
diluted in TBST with 1% BSA. Membranes were probed with LI-COR secondary anti-
bodies were wrapped in foil to protect them from the light. Membranes were incubated
with secondary antibodies for one hour at room temperature on a roller before being
washed 4 × 5 minutes in TBST with rolling at room temperature.
2.5.6 Western blot imaging
Membranes with LI-COR secondary antibodies were imaged using appropriate channels
on an Odyssey FC (LI-COR). HRP-conjugated secondary antibodies were detected
using Clarity western ECL Substrate (Bio-Rad), as per manufacturer’s instructions.
Briefly, the two solutions in the kit were mixed in a 1:1 ratio then applied over the
membrane and left to incubate for one minute before imaging on an Odyssey FC (LI-
COR).
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2.6 Protein expression and purification
2.6.1 Transformations
Transformations for protein expression were identical to that for molecular cloning
(2.3.11) with the exception that all transformations for protein expression utilised E.
coli BL21(DE3). All protein expression used freshly transformed BL21(DE3) cells.
2.6.2 Inoculation, growth and induction of cultures
All colonies from one petri dish were suspended in 3 mL sterile LB (formulation in
2.3.1). One millilitre of cell suspension was used to inoculate one litre of sterile LB.
Appropriate antibiotics were added to a final concentration of 50 µg/mL for kanamycin
or 100 µg/L for ampicillin.
Inoculated cultures were transferred to a 37 °C incubator shaking at 200 rpm (In-
nova 4300, New Brunswick Scientific). After two hours growing the optical density
(OD) of the culture was checked by aseptically aspirating one millilitre of culture and
measuring the absorbance at 600 nm in a Ultrospec 2000 spectrophotometer (Pharma-
cia Biotech). When the OD600 was between 0.6 and 0.8 the cultures were transferred to
an 18 °C shaking incubator and left to acclimatise for 45 minutes. After cultures had
cooled, isopropyl β-d-1-thiogalactopyranoside (IPTG) was added to a final concentra-
tion of 0.2 mM to induce protein expression. Cultures were left to express proteins
overnight (approximately 16 to 20 hours).
The next day, cultures were transferred to 1 L centrifuge bottles (Beckman Coulter)
for the harvesting of cells. Cells were pelleted by centrifugation at 4,000 g (JLA-9.100
rotor, Avanti JXN-26 centrifuge both Beckman Coulter), 4 °C for 30 minutes. The
supernatant was poured off of cell pellets and cells were resuspended (10 mL per litre
of culture) in freeze buffer (20 mM Tris pH 8.0, 300 mM NaCl). Resuspended cells
were transferred to a 50 mL tube and stored at −20 °C before downstream processing.
Protein expression cell pellets were always frozen before processing.
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2.6.3 Bacterial cell lysis
For bacterial cell lysis, frozen cell pellets were thawed and standard-purification buffer
(50 mM Tris pH 8.0, 300 mM NaCl, 10% (v/v) glycerol, 10% (w/v) sucrose, 10 mM
imidazole) was added to a final approximate volume of 30 mL. Hen-egg lysozyme
(Hampton Research) was added to the slurry at a final concentration of 166 µg per mL
of cell suspension. Cells were incubated on ice for at least 15 minutes.
Following incubation with lysozyme, cells were disrupted by repeated rounds of
sonication using a Sonifier Cell Disrupter (Bronson Sonic Power Co.), output 7, 70%
amplitude for one minute pulsed-sonication in an ice-bath, one minute sitting on ice
and a final minute of pulsed-sonication in ice-bath.
2.6.4 Clarification of bacterial homogenate
Following cell lysis, insoluble material was pelleted by centrifugation at 13,000 g, 4
°C, 30 minutes (JA-17 Rotor, Avanti JXN-26 centrifuge both Beckman Coulter). Five
microlitres of cell homogenate was removed and separately centrifuged at 13,000 g, for
15 minutes, 4 °C (F45-30-11 rotor 5417R centrifuge, both Eppendorf) for an insoluble
sample for SDS-PAGE analysis. Clarified lysate supernatant was carefully transferred
to a clean 50 mL tube. Five microlitres of the supernatant was removed for a soluble
sample for SDS-PAGE analysis.
2.6.5 HIS-Select nickel affinity purification
His6-tagged proteins were purified using HIS-Select nickel affinity gel (Sigma). Gen-
erally, one millilitre of HIS-Select resin-bed (pre-equilibrated in standard purification
buffer) was used per one litre of E. coli culture. Proteins were allowed to bind to resin
for 1 hour at 4 °C on a RATRSM7DC orbital rotator (Ratek) at 10 rpm. Resin was
substantially washed in batch by three rounds of centrifugation at 3,500 g for 5 min-
utes, 4 °C (SX4400 rotor, Allegra X-30R centrifuge, both Beckman Coulter). After the
initial pelleting of resin, 5 µL of supernatant was removed for a flow-through sample
for analysis by SDS-PAGE. Pelleted resin was washed after each centrifugation step by
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resuspension in between 30 and 40 mL of standard purification buffer. After the final
wash, the resin was pelleted as previously, before being resuspended in 10 mL of stan-
dard purification buffer and transferred to a Poly-Prep Chromatography hand-column
(Bio-Rad).
Proteins were eluted from resin using 300 mM imidazole diluted in standard purifi-
cation buffer. Typically 500 µL of elution buffer was applied to resin and allowed to
flow through the resin by gravity. This was repeated 4 times or until no further protein
eluted from the resin. Protein elutions were measured spectrophotometrically at 280
nm to determine protein concentration. Protein containing elutions were combined.
Depending on the downstream application, proteins were either cleaved using 3C-
protease (2.6.6), stored overnight at 4 °C before fast protein liquid chromatography
(FPLC; 2.6.8), or aliquoted and frozen (2.6.12) .
2.6.6 3C-protease cleavage of proteins
Where applicable, the N-terminal His6-tag was removed from proteins by recombinant
3C-protease (made by Sam Jamieson, Mace laboratory) in a 50:1 protein:protease ratio
(by mass) with the addition of 2 mM DTT. Cleavage took place overnight (∼16 to 20
hours) at 4 °C.
2.6.7 Ultrafiltration concentration of proteins
Proteins were concentrated using appropriate molecular weight cut-off ultrafiltration
centrifugal concentrators (Pall or Sartorius Stedim Biotech). Concentrators were used
according to manufacturer instructions and were always pre-equilibrated in equivalent
protein-containing buffer.
2.6.8 FPLC
All FPLC was performed using an ÄKTA Pure 150 Chromatography system (GE
Healthcare). Buffers were always freshly filtered through a 0.2 µm cellulose acetate
filter (Sartorius Stedim Biotech) before being degassed for at least 15 minutes.
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2.6.9 Anion-exchange chromatography (IEX)
IEX was performed using a home-packed 2 mL column with SOURCE 15Q Resin (GE
Healthcare). IEX was routinely carried out using a low-molarity salt buffer-‘A’ (10 mM
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) (pH 7.6), 10 mM NaCl)
and a high molarity salt buffer-‘B’ (10 mM HEPES (pH 7.6), 1 M NaCl). Reductant
(2 mM DTT) was added fresh to buffers when required. Proteins were diluted ten-fold
in the low-molarity salt buffer-A in order to decrease the starting salt concentration
before being loaded onto the column by way of a S9H sample pump (GE Healthcare).
Once bound, the column was washed using 10 column-volumes of buffer-A. Proteins
were eluted by a gradient of 0 to 50% buffer-B over 25 column volumes at a flow rate
of 4 mL/min.
2.6.10 Size-exclusion chromatography (SEC)
SEC was routinely performed using either a Superdex 75 10/300 (S75) or Superdex 200
Increase 10/300 (S200I) (both GE Healthcare). Proteins were typically concentrated
(2.6.7) to ∼0.5 mL before being centrifuged at 20,000 g 4 °C for 5 minutes to pellet
any particulate or insoluble material. Samples were injected onto the column by way
of a 2 mL sample loop. SEC was conducted at a flow rate of 0.8 mL/min (Superdex
75) or 0.5 mL/min (Superdex 200 Increase) in a buffer of 300 mM NaCl, 10 mM
HEPES pH 7.6 with the addition of fresh reductant (2 mM DTT or 0.5 mM tris(2-
carboxyethyl)phosphine (TCEP; Hampton Research), where appropriate.
2.6.11 Quantification of protein concentration
Proteins concentrations were quantified using a NanoDrop2000 and measuring their
absorbance at 280 nm. Concentration (in mg/mL) was adjusted using the calcu-
lated extinction coefficients from the ProtParam web tool (web.expasy.org/protparam,
Gasteiger et al., 2005).
37
2.6.12 Freezing of proteins
Proteins were routinely aliquoted into PCR-strip tubes (Axygen) in 30–200 µL volumes
before being snap-frozen in liquid nitrogen and stored at −80 °C.
2.6.13 Purification of His6-ASK188–941-StrepII from E. coli
A C-terminal StrepII tagged ASK188–941 construct enabled more efficient purification
compared to the equivalent construct without the C-terminal StrepII tag.
ASK188-941-StrepII was co-expressed with untagged -phage protein phosphatase
(λPP) (2.2) to dephosphorylate potential ASK1 auto-phosphorylation during expres-
sion. Transformations were the same as in 2.3.11 but ∼100 ng of each plasmid was
used to transform 75 µL of BL21(DE3) cells and left to incubate on ice for at least
30 minutes. Transformation proceeded as previous with cells being plated on agar-LB
with 50 µg/mL kanamycin and 34 µg/mL chloramphenicol. Cultures were inoculated
as for other constructs, with the exception of 50 µg/mL kanamycin and 34 µg/mL chlo-
ramphenicol both being added to the culture. Culture growth, induction by IPTG, and
harvesting were the same as previous (2.6.2).
Lysis was similar as in 2.6.3 with the exception that the cell pellets were resuspended
in strep-purification buffer (50 mM Tris pH 8.0, 300 mM NaCl, 10% (v/v) glycerol,
10% (w/v) sucrose). Cell homogenate was clarified as previous (2.6.4). Clarified lysates
were transferred to 50 mL tubes. StrepTactin XT SuperFlow resin (IBA-Lifesciences),
pre-equilibrated in strep-purification buffer was added to each tube for 1 mL of resin
bed per 1 L of original culture. The tubes were placed on an orbital rotator for 1 hour
at 4 °C. StrepTactin resin was washed in batch by three repeat rounds of pelleting
resin at 3,500 g for 5 minutes, 4 °C. Pelleted resin was washed after each centrifugation
step by resuspension in between 30 and 40 mL of strep-purification buffer. After the
final wash, the resin was pelleted as previously, before being resuspended in 10 mL of
strep-purification buffer and transferred to a Poly-Prep Chromatography hand-column.
Proteins were eluted from resin in 4 × 500 µL fractions in a buffer consisting of 5 mM
biotin (Sigma) dissolved in strep-purification buffer. Eluted fractions were pooled,
DTT was added to 2 mM and 3C-protease added as previous (2.6.6).
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Cleaved ASK188–941 proteins were concentrated to a total volume of less than 0.5
mL before SEC on S200I as described in 2.6.10. Eluted protein was aliquoted and
snap-frozen (2.6.12) as soon as possible, before storage at −80 °C.
2.6.14 Purification of full-length ASK1 from Sf 9 insect cells
All insect culture (bacmids, baculovirus production, cell culture, infection and harvest-
ing) was performed by Abigail Burgess and Jack Curry (both Mace laboratory). In
brief, Sf 9 cells were infected with an ASK1 2–1374 (full length) containing baculovirus
and grown for three days before harvesting by centrifugation. Cell pellets were stored
at −20 °C before processing.
Sf 9 cell pellets (equivalent to 20 mL of culture) were thawed and resuspended in 30
mL of insect-purification buffer. DTT was added to a concentration of 2 mM as was
40 µL of P8340 protease inhibitor cocktail (Sigma) and 15 µg of DNaseI. Cells were
immediately sonicated using a Sonifer Cell Disrupter, output 7, 70% amplitude, with
pulsing, for 2 minutes, on ice. Lysed cells were clarified by centrifugation as in 2.6.4.
Clarified insect lysate was transferred to a 50 mL tube with 600 µL of HIS-Select
resin bed (that had been pre-equilibrated in insect purification buffer). Protein was
allowed to bind to resin at 4 °C on an orbital rotator for 1 hour. The resin was washed
in batch with three rounds of sequential centrifugation (3,500 g, 5 minutes, 4 °C). The
supernatant was removed and resin resuspended in 30 mL of insect-purification buffer.
After the final wash, the resin was resuspended in 5 mL of insect purification buffer
and transferred to a hand-column. Resin was allowed to settle and protein was eluted
with 500 mM imidazole diluted in insect-purification buffer.
Eluted protein was analysed for presence of full-length (2–1374) ASK1 by SDS-
PAGE analysis (2.4). Protein containing fractions were aliquoted and snap frozen
(2.6.12) before being stored at −80 °C. An example gel is given in Appendix A.2g,
showing the 150 kDa full-length ASK1 with a partial degradation product (roughly
∼100 kDa in size).
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2.6.15 Summary of protein purification methodologies by con-
struct
Table 2.1 outlines which purification methodologies were applied to each protein con-
struct. In general, all proteins were treated with 3C-protease to cleave the His6-tag
except where the presence of His6-tag was required.
2.7 In vitro kinase assays
Purified recombinant human proteins were used in all kinase assays. Kinase dead
MKK6K82A, hereafter referred to as MKK6, was used as a substrate. Individual com-
ponents of kinases assays were kept on ice until use where they were allowed to warm
to room temperature. Kinase assays were carried out at room temperature in a buffer
containing a final concentration of 10 mM HEPES (pH 7.6), 100 mM NaCl, 25 mM
MgCl2. Reactions were set up as a master mix containing buffer and, where appropri-
ate, substrate and enzyme.
Reactions were always started with the addition of either 50 µM or 1 mM ATP. To
facilitate simultaneous starting and sample taking reactions were set up in PCR strip
tubes using a multichannel pipette. At each time point, 15 µL of each reaction was
removed, simultaneously and then mixed directly into 5 µL of a 4× SDS-sample buffer
(reducing) (2.4.2). Before the addition of ATP a sample was removed (denoted as ‘time
0’). ATP was added and the samples were mixed and briefly spun down and incubated
for the desired length of time. Once all time-point samples were taken, samples were
always frozen at −20 °C. Samples were thawed at room temperature before analysis by
either Phos-Tag SDS-PAGE (2.4.5 and 2.7.1.1) or western blotting for p-MKK6 (2.5
and 2.7.1.2).
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88–266 N-terminal-His6-3C E. coli Ni-A, SEC-75 20.3 App. Fig. A.2b
88–338 N-terminal-His6-3C E. coli Ni-A 28.6 App. Fig.A.2c
88–658
N-terminal-His6-3C E. coli Ni-A, IEX, SEC-200 65.5 App. Fig. A.2d
N-terminal-His6-3C,
C-terminal StrepII
E. coli Ni-A, IEX 66.3 App. Fig. A.2h
269–658 N-terminal-His6-3C E. coli Ni-A, IEX, SEC-75 45.3 App. Fig. A.2e





E. coli Streptactin, SEC 98.1 Appendix A.2g
2–1374 N-terminal-His6-3C Insect Ni-A 156.6 Appendix A.2i
MKK6 1–334 N-terminal-His6-3C E. coli Ni-A, SEC-200 37.6 App. Fig. A.2j
λPP 1–221 Untagged E. coli n/a 25.2 n/a
Trx1 2–105
N-terminal-His6-3C E. coli Ni-A, SEC-75 11.8 App. Fig. A.2k
C-terminal-Lys-His6 E. coli Ni-A, SEC-200 31.6 App. Fig. A.2m
Untagged E. coli n/a 11.7
N-terminal-His6-MBP E. coli Ni-A, IEX-200 55.1 App. Fig. A.2l
Prdx1 2–199 N-terminal-His6-3C E. coli Ni-A 24.2 App. Fig. A.2n
All proteins sequences are for human, with the exception of the T7 phage lysozyme and λPP. WT and relevant mutant protein constructs
had identical purification strategies. 1) Refers to 2.6. 2) Expected size is as calculated following cleavage (on constructs that were purified)
of tag with 3C protease, note His6-Prdx1 was never cleaved. 3) Construct used for SAXS and had the following mutations: Cys206Ser,
Cys225,226Ser (A C-terminal StrepII tag was also present, but this was not used for purification). Ni-A—HIS-Select nickel affinity;
IEX—anion exchange chromatography; SEC-200/75—SEC on either S200I or S75 column; n/a—not applicable, construct was not
purified; App. Fig.—Appendix Figure.
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2.7.1 Data analysis of kinase assays
2.7.1.1 Phos-Tag SDS-PAGE kinase analysis
For kinase assays analysed by Phos-Tag SDS-PAGE, Coomassie stained gels were im-
aged in the 700-channel on an Odyssey FC (LI-COR). From each lane, bands repre-
senting either the phosphorylated protein or unphosphorylated parent were quantified
using ImageStudio (LI-COR). The sum of the two bands was used to calculate the
total MKK6. Phosphorylated MKK6 was calculated as a percentage of the total and
converted to a concentration by multiplying by the concentration of MKK6 used in the
assays (3 µM).
2.7.1.2 Western blot kinase assay analysis
For kinase assays analysed by western blot, blots were imaged on an Odyssey FC (LI-
COR). For each lane, the phosphorylated MKK6 band was quantified using ImageS-
tudio (LI-COR). Band intensity for each lane was normalised by expressing individual
intensity as a percentage of the signal at the 10 minute time point.
2.8 Nickel affinity pull-down of ASK1 and Trx1 in
vitro
Bl21(DE3) cells expressing His-tagged ASK constructs and untagged Trx1 were grown,
induced and pelleted as before (2.6). Pellets (equivalent to 33 mL of culture) were
thawed and resuspended in 1 mL standard-purification buffer before being incubated
with 250 µg of hen-egg lysozyme and sonicated for one minute at 35% amplitude
with pulsing on a Vibra Cell (Sonics). HIS-Select resin, pre-equilibrated in standard-
purification buffer was added to the His6-tagged ASK1 constructs with 2 mM DTT.
Proteins were allowed to bind the resin at 4 °C on a rotator for 30 minutes. Bound
proteins on resin were subsequently washed with standard-purification buffer in three
repeated rounds of centrifugation (4,000 g at 4 °C for 5 minutes). The resin was
pelleted and resuspended in a buffer (containing 25 mM HEPES, pH 7.6, 150 mM
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NaCl) whereupon it was divided into two tubes per ASK1 construct. Untagged Trx1
containing E. coli clarified lysate (100 µL) was added to the tubes and the volume was
adjusted to 200 µL with buffer (25 mM HEPES (pH 7.6), 150 mM NaCl). Half of the
tubes had DTT added to a final concentration of 2 mM. The tubes were placed on a
rotator at 4 °C for 30 minutes before being centrifuged and washed three times with
25 mM HEPES, pH 7.6, 150 mM NaCl (either with or without 2 mM DTT) to remove
unbound Trx1. The resin was pelleted, resuspended in 25 µL of 2 × SDS buffer before
boiling and resolving by SDS-PAGE (2.4). Proteins were transferred to nitrocellulose
(2.5.2) before probing using antibodies against His6 and Trx1 (2.5).
2.9 Preparation of disulfide-linked ASK1-Trx1 com-
plex for SAXS
Nickel affinity purified ASK188–658
C206S,C225,226S with a C-terminal StepII tag and
Trx1C35S, C73S, C-terminal-Lys-His6 was prepared as in 2.6 (referred to as ASK1 and
Trx1-Lys for the remainder of this section). Both ASK1 and Trx1-Lys were reduced
for 1 hour on ice with 2 mM DTT before either IEX for ASK1 (as per 2.6.9) or SEC
for Trx1-Lys as per 2.6.10. ASK1 was aliquoted and snap-frozen (2.6.12) immediately
post SEC. Trx1 was allowed to sit at 4 °C for 5 days before aliquoting and freezing.
From 6 L of E. coli culture, approximately 10 mg of purified ASK1 was produced
versus 10 mg of Trx1-Lys from 1 L of culture. Proteins were thawed and mixed (at
roughly equimolar amounts—approximately 10 mg of ASK1 and 5 mg of Trx1-Lys) in
a total volume of 7.1 mL in a buffer containing 10 mM HEPES, pH 7.3, 300 mM NaCl.
The proteins were incubated in a 37 °C water bath for 4 hours. After incubation,
the proteins were alkylated by addition of iodoacetamide (IAM; Sigma) to a final
concentration of 10 mM. Alkylation occurred in the dark at room temperature for 30
minutes. Proteins were concentrated by ultrafiltration (2.6.7). Concentrated proteins
were separated by three rounds of SEC on a S200I column, running at a flow rate
of 0.5 mL/minute in a buffer consisting of 10 mM HEPES (pH 7.6), 300 mM NaCl.
Relevant fractions were pooled, concentrated by ultrafiltration (2.6.7), aliquoted and
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snap-frozen (2.6.12) ready for analysis.
2.10 SEC-Small-angle X-ray scattering
All SEC-small-angle X-ray scattering (SAXS) data collection was carried out at the
Australian Synchrotron SAXS/WAXS beamline under the guidance of Associate Pro-
fessor James Murphy (Walter and Eliza Hall Institute, Melbourne, Australia). Fifty
microlitres of purified recombinant protein was injected onto an in-line Superdex 200
5/150 column (GE Healthcare) by way of an auto-sampler. Proteins were eluted from
the column at 12 °C at a flow rate of 0.2 mL/min in a buffer consisting of 10 mM
HEPES pH 7.5, 500 mM NaCl, 5% (v/v) glycerol. Proteins eluted from the column
into a 1.5 mm glass-capillary positioned in the X-ray beam using co-flow to reduce
radiation damage to the sample (Kirby et al., 2016).
Initial data reduction and background subtraction were performed by Associate
Professor James Murphy (Walter and Eliza Hall Institute, Melbourne, Australia).
Briefly, scattering profiles of samples were collected in 2-second exposures during the
course of elution. 2D intensity plots were averaged radially and normalised to the sam-
ple transmission. Background scatter was assessed by Scatterbrain software (Stephen
Mudie, Australian Synchrotron). The background scatter was determined by compar-
ing the scattering profiles from before and after protein elution on SEC. Six profiles for
ASK188–658
C206S, C225,226S, six profiles for Trx1C35S-Lys and nine profiles for the ASK1-
Trx1 complex were averaged and background-subtracted using Scatterbrain to produce
the scatter patterns presented in this work.
2.10.1 Analysis of SAXS data
The majority of the software used for SAXS data analysis was carried out using the
ATSAS package (Franke et al., 2017) following the instructions for each individual pack-
age. Pair-distance distribution function (P(r)) and the maximum dimension (Dmax)
were determined using GNOM and adjusted manually (Svergun, 1992). The radius
of gyration (Rg) and was calculated by both Guinier analysis (within the program
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PRIMUS, Konarev et al. 2003) and by P(r) from GNOM.
2.10.1.1 Estimation of molecular weight
Molecular weights were estimated using the SAXS Molecular Weight server (SAXS-
MoW; saxs.ifsc.usp.br; Fischer et al. 2010) with q= 8/Rg used as the integration limit.
2.10.1.2 Rigid body modelling
Rigid body modelling was carried out using CORAL (Petoukhov et al., 2012) as per the
default user instructions. More details are given in Chapter 4. For each species to be
modelled a conditions file was written specifying the domains to model, extra residues
(N- and C-terminal as well as inter-domain linkers). Parameters for the conditions file
are given in Appendix A.6. ASK188–266 was modelled using the previously published
(Weijman et al., 2017) de novo constructed using the Robetta server (Kim et al., 2004).
For the ASK1-Trx1 complex species, a constraint was placed on the modelling
based on the disulfide linkage whereby the alpha-carbon (αC) atoms from the relevant
cysteine residues was constrained to be no more than 10 Å away. This was based
on observations by Schmidt et al. (2006) whereby the mean distance between the two
αC atoms in 6874 measured disulfide bonds was 5.63 Å. However, using a distance
of less than 10 Å resulted in overlapping protein structures from CORAL modelling.
CRYSOL (Svergun et al., 1995) was used to calculate theoretical scattering profiles of
the models to compare the data and generate goodness of fit (represented by the chi,
χ) values.
2.11 Mammalian cell culture
All mammalian cell culture was carried out in a Class II biological safety cabinet. Cells
were maintained in a 37 °C humidified incubator with 5% (v/v) CO2.
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2.11.1 Cell counting
All cell counting was done using a TC10 automated cell counter and disposable counting
slides (both Bio-Rad) as per the manufacturer’s instructions.
2.11.2 Culture of HAP1 cells
HAP1 WT cells (catalogue number: C859) and Prdx1 knock-out (KO) cells (catalogue
number: HZGHC002675c008) were purchased from Horizon Discovery. Background
information on HAP1 cells is given in 5.5.1. The Prdx1 KO cells contain a 172 base
pair deletion in exon 4 of the PRDX1 gene. HAP1 cells were maintained in Iscove’s
modified Dulbecco’s medium (IMDM) (Gibco and HyClone) supplemented with 10%
(v/v) fetal bovine serum (FBS; Sigma and Gibco), 100 µg/mL streptomycin sulfate
and 100 units/mL penicillin G (both Sigma).
Cells were passaged every 2 to 3 days by aspirating media from cells and washing
with 5 mL (for a T75 flask) of with pre-warmed sterile phosphate buffered saline (PBS;
one PBS tablet (Oxoid) was dissolved in 100 mL type I water and autoclaved at 121
°C, 100 kPa, for 20 minutes). PBS was aspirated and 3 mL of 0.05% (w/v) trypsin-
EDTA (Gibco) diluted in sterile-PBS was added. The flask was returned to 37 °C
incubator for 5 minutes before being firmly tapped to encourage detachment. Cells
were resuspended and trypsin was neutralised by the addition of 5 mL of pre-warmed
complete media. Cells were typically diluted 1 in 20 in fresh, pre-warmed, complete
media and returned to a flask.
2.11.3 HAP1 p38 response to H2O2 treatment
2.11.3.1 Suspension H2O2 treatment of HAP1 cells
For H2O2 treatment of HAP1 cells, cells were either treated in an adherent state, or in
a suspension state post-trypsinising. For cells treated in a suspension state, cells were
grown as in 2.11.2. On the day of the assay, cells were trypsinised (as in 2.11.2) and
counted. Cells were plated in a 6-well plate (Corning) with 2× 106 cells per well in 3
mL of complete pre-warmed media. Cells were allowed to rest for 30 minutes. After
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resting, H2O2 (100 µM in type I water, determined spectrophotometrically at A280
nm using the absorbance coefficient for H2O2 of 43.6 cm
–1 M –1; Noble and Gibson
1970) was added to the media in reverse time-course so each time point had a common
end-point. Cells were returned to the incubator between treatments.
At the end-point, the 6-well plate was transferred to a cold-stage consisting of an
aluminium sheet on ice. Ice-cold PBS containing bovine catalase (Sigma, 20 µg/mL,
referred to as PBS-catalase hereafter) was added (3 mL per well). Cells were trans-
ferred to 15 mL tubes containing 3 mL of PBS-catalase. Cells were pelleted at 800 g,
4 °C for 5 minutes. The supernatant was aspirated and cells were resuspended in 1
mL of ice-cold PBS-catalase and transferred to a 1.5 mL tube. Cells were pelleted by
centrifugation (800 g, 4 °C for 5 minutes). The supernatant was aspirated and the cells
were resuspended in 1 mL of ice-cold PBS and pelleted as before. The supernatant was
aspirated and the cells were resuspended in 40 µL of radioimmunoprecipitation assay
(RIPA) buffer (150 mM NaCl, 1% (v/v) Triton X-100, 0.5% (w/v) sodium deoxy-
cholate, 0.1% (w/v) SDS, 50 mM Tris (pH 8.0), 5 mM EDTA, 1 mM EGTA, cOmplete
protease inhibitor (Roche), 1 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM
sodium pyrophosphate). Cells in lysis buffer were incubated on ice for 20 minutes with
periodic vortexing. The cell lysate was clarified by centrifugation (15,000 g, 4 °C, 15
minutes). Soluble material was aliquoted and snap-frozen in liquid nitrogen. Clari-
fied lysate protein concentration was determined by bicinchoninic acid (BCA) assay
(2.11.4) and between 20 to 30 µg of lysate was analysed by western blot (2.5) following
SDS-PAGE and wet-transfer to nitrocellulose.
2.11.3.2 Adherent H2O2 treatment of HAP1 cells
For HAP1 cells treated in an adherent state, cells were grown as in 2.11.2. HAP1
cells were seeded in a 6-well plate at 1 × 106 cells/mL in 3 mL of complete media.
Twenty-four hours after plating, the media was aspirated and cells were washed with
pre-warmed sterile PBS. Fresh pre-warmed complete media (2 mL) was added to the
cells and the plate as returned to the incubator for cells to rest for 1 hour. H2O2 (100
µM) was added as in 2.11.3.1, above.
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At the end point, 6-well plates were placed on a cold-stage and 3 mL of ice-cold
PBS-catalase was added. The wells were aspirated and cells washed with an additional
3 mL of ice-cold PBS-catalase. The wells were aspirated and cells washed in 3 mL of ice-
cold PBS. The wells were aspirated and 0.5 mL of ice-cold 10% (v/v) (in type I water)
trichloroacetic acid (TCA: Sigma) was added to each well to lyse cells and precipitate
proteins (Jarvis et al., 2012; Lee and Esselman, 2002). Plates were incubated on the
cold stage for 10 minutes before cells were scraped off using either a 1 mL pipette tip
or the plunger from a 1 mL syringe. The precipitated cell lysate was transferred to a
1.5 mL tube and the well and scraper were rinsed with an additional 0.5 mL of ice-cold
10% (v/v) TCA, which was transferred to the same tube. Precipitated material was
pelleted by centrifugation (10,000 g, 10 minutes, 4 °C). After pelleting, the majority of
the TCA was removed and approximately 100 µL was left. Leaving a small amount of
TCA helped to fully resuspend the pellet. The pellet was resuspended in the remaining
TCA before the addition of 1 mL of ice-cold acetone and centrifugation (10,000 g, 10
minutes, 4 °C). The supernatant was aspirated (taking care not to touch the pellet as
it would block the pipette tip). The pellet was washed in acetone for a total of three
washes. For each resuspension step, the pellet was originally resuspended in 200 µL of
acetone, using a 200 µL pipette tip with the end cut off. An additional 500–800 µL of
acetone was then washed. After the final wash, acetone was removed and the pellet
left to dry in a 50 °C heat block for approximately 10–15 minutes until there was no
longer a smell of acetone. Dried cell-lysate pellets were stored at −80 °C.
For analysis, the pellets were resuspended in a buffer containing 200 mM Tris (pH
8.5), 5 mM EDTA, 0.05% (w/v) SDS and 8 M urea (urea was always added fresh).
To each dried pellet, 40 µL of buffer was added. Samples were vortexed for 5 minutes
before sonication in a water bath for 10 minutes and a further 5 minutes vortexing.
Insoluble material was removed by centrifugation (10,000 g, 4 °C, 5 minutes). Soluble
material was transferred to a fresh tube. Protein quantification was determined by a
BCA assay (2.11.4) and analysed by western blot (2.5).
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2.11.4 Protein quantification by BCA assay
Soluble protein from mammalian cell lysate was routinely quantified by BCA assay
(Thermo Scientific), as per kit instructions. In brief, a 0.5 mg/mL stock of BSA
(determined spectrophotometrically based on a 0.5 mg/ml solution having an A278
absorption value of 0.327 (Kirschenbaum, 1973)) was dissolved in type I water, stored
at −20 °C. A working BSA protein standard was made by two-fold serial-dilution of the
BSA stock in 1% (v/v) Triton-x-100. Protein samples were diluted (generally between
1 in 10 and 1 in 50) in 1% (v/v) Triton-x-100. A working BCA reagent was made by
combining 50 parts of reagent A to 1 part reagent B. Enough working reagent was made
for 200 µL per sample. Protein standards and samples were added to a 96-well plate
(between 10 and 20 µL per well) in triplicate. A buffer blank matching the buffer the
sample was in was also prepared and added to the 96-well plates before the addition
of 200 µL (per well) of working BCA reagent. Samples and standards were set up in
triplicate. The plate was covered with parafilm and incubated at 37 °C for 30 minutes
before reading in a Multiskan GO (Thermo Scientific) plate reader at 562 nm. The
BCA protein standard was used to generate a standard curve from which the sample
protein concentration was determined.
2.12 ICAT-labelling of reversibly oxidised protein
cysteines in HAP1 cells
ICAT-labelling was conducted following the instructions from the ICAT kit (Sciex,
product number: 4339036) with amendments based on Garćıa-Santamarina et al.
(2014) and Kumar et al. (2013b). The full method used is given below.
2.12.1 Cell treatment
HAP1 WT and Prdx1 KO cells were grown as in 2.11.2. 150 mm cell culture dishes
(Corning and Falcon) were seeded with 1× 106 cells/mL in 20 mL of complete media
24 hours prior to treatment. For each time point, one dish was prepared. Seeding at
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this density ensured that cells were fully confluent on day of treatment. On the day
of treatment (24 hours post-seeding), the media was aspirated and cells were washed
with 10 mL of pre-warmed PBS. PBS was aspirated and replaced with 10 mL of pre-
warmed complete media. Cells were returned to the 37 °C incubator and allowed to
rest for 1 hour. A 2 mM stock of H2O2 was prepared (in type I water; the concentration
determined as in 2.11.3.1). Cells were treated with 500 µL of the working H2O2 (100
µM final concentration) and returned to the 37 °C incubator for the duration of the
assay. Samples were set up in reverse order so they would have a common endpoint but
no more than three dishes were treated and harvested in one session. Untreated cells
had an equal volume of type I water added to them and were immediately harvested.
2.12.2 TCA harvesting
After cell treatments, dishes were placed on a cold stage (comprised of an aluminium
sheet on ice). Ten millilitres of ice-cold PBS—containing 20 µg/mL bovine liver cata-
lase (Sigma)—was added to the dishes. Media and PBS-catalase were aspirated and
replaced with an additional 10 mL of PBS-catalase. The PBS-catalase was aspirated
and the cells were rinsed with an additional 10 mL of PBS. The PBS wash was aspi-
rated before 10 mL of ice-cold 10% TCA (w/v) was added. Cells were allowed to lyse
in the dish on the cold-stage for 15 minutes. Cells were carefully scraped with a cell
scraper (Nunc). Cell homogenate was transferred to a 15 mL tube and precipitated
material collected by spinning at 4,500 g for 10 minutes at 4 °C. All but 1 mL of
the TCA-containing supernatant was aspirated from the pellet. The pellet was resus-
pended in the remaining supernatant and transferred to a 1.7 mL tube. The material
was pelleted again by spinning at 10,000 g for 5 minutes, 4 °C. The supernatant was
removed and 500 µL of cold acetone was added. Using a 200 µL tip (with the end
cut-off) the pellet was carefully resuspended in acetone to attempt to break it apart as
much as possible. An additional 500 µL of cold acetone was added to the sample and
it was vortexed for ∼30 seconds to dislodge the pellet from the bottom of the tube.
The material was centrifuged (10,000 g, 4 °C, 5 minutes) and the supernatant removed.
The cold acetone wash was repeated for a total of three washes. Residual acetone was
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removed by placing tube with the lid open in a 50 °C heat-block for approximately 20
minutes until pellet was dry. Pellets were stored at −80 °C until further processing.
2.12.3 Resuspension and alkylation of reduced cysteine thiols
Pellets (from 2.12.2) were removed from −80 °C and centrifuged at 10,000 g for 5
minutes at room temperature to ensure all material was at the bottom of the tubes.
The pelleted material was gently crushed to a dust-like appearance using a plastic
pestle. A 5 × ICAT resuspension buffer (containing 1 M Tris (pH 8.0), 0.25% (w/v)
SDS, 25 mM EDTA) was prepared and stored at 4 °C and diluted fresh with additional
components when required. Fresh ICAT-alkylating buffer (8 M urea, 200 mM Tris
(pH 8.0), 0.05% (w/v) SDS, 5 mM EDTA, 100 mM IAM) was prepared and kept
protected from light. Five hundred microlitres of ICAT-alkylating buffer was added to
each sample and an additional 500 µL was used to rinse any material off of the pestle
into the same tube. Samples were kept protected from light before being vortexed
for 5 minutes and sonicated in a water bath for 10 minutes before an additional 5
minutes of vortexing. Any insoluble material1 was pelleted by centrifugation at 10,000
g, 5 minutes, 4 °C and the supernatant was transferred to a fresh 1.7 mL tube. The
samples were incubated at room temperature in the dark for an additional 30 minutes
to ensure complete alkylation of protein thiols. Protein was subsequently precipitated
by the addition of cold TCA to a final concentration of 10% (w/v). TCA-precipitation
was allowed to incubate on ice for 10 minutes before being centrifuged (10,000 g, 4 °C, 5
minutes). The precipitated material was washed three times in cold acetone and dried,
identical to as described above (2.12.2). The dried, alkylated material was stored at
−80 °C.
2.12.4 Resuspension and reduction of oxidised cysteine thiols
Pellets (from 2.12.3) were resuspended in fresh ICAT-resuspension buffer (8 M urea,
200 mM Tris (pH 8.0), 0.05 % (w/v) SDS, 5 mM EDTA) identical to previous (2.12.3).
A BCA assay (2.11.4) was performed to quantify the protein amount in each sample.
1An insoluble, jelly-like pellet always formed at each resuspension step.
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From a fully confluent 150 mm dish, between 0.5 and 2 mg of lysate was achieved. The
relatively low-yield from was due to an insoluble pellet that formed after each resus-
pension step (see Footnote 1). Five hundred micrograms of material (as determined by
BCA assay) was transferred to a 1.7 mL tube. The volume of each tube was adjusted
to 384 µL with ICAT-resuspension buffer and 16 µL of 0.5 M TCEP was added (final
concentration of 20 mM). Reduction of protein thiols by TCEP took place at 30 °C for
30 minutes.
2.12.5 ICAT-labelling and trypsin digestion
The ICAT reagents (from the ICAT kit) were allowed to warm to room temperate
after being removed from −20 °C. The vials were briefly centrifuged before opening,
whereupon each vial of ICAT reagent had 200 µL of 100% acetonitrile added. The
ICAT-labelling reagent was vortexed for ∼30 seconds before being spun down again.
The alkylated and reduced cell lysates (from 2.12.4) to be labelled were briefly spun
down.
The entire sample was transferred to the resuspended vial of ICAT-labelling reagent
and volume adjusted with fresh ICAT-resuspension buffer for a final volume of 750 µL.
This was then further vortexed for 30 seconds before being briefly spun down again.
The tubes were wrapped in foil and placed in a shaking 37 °C incubator for 2 hours.
Any unreacted ICAT reagent was quenched by the addition of 1 µL of 1 M DTT
followed by incubation at room temperature for 5 minutes.
Relevant heavy- and light ICAT-labelled samples were combined into a fresh 15 mL
tube. Samples were diluted to 10 mL with type I water in order lower urea concentra-
tion to below 1 M, and CaCl2 was added to a final concentration of 10 mM. Trypsin
(Promega) was resuspended in trypsin resuspension buffer (Promega) for a final con-
centration of 0.5 µg trypsin per 1 µL. Trypsin was added in a 1:20 protease:protein
ratio—i.e. 50 µg trypsin per 1 mg of lysate. Tubes were wrapped in foil and lids were
wrapped in parafilm. Samples were placed in a shaking 37 °C incubator overnight (for
at least 16 hours).
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2.12.6 Desalting of ICAT-labelled samples
Digested samples (from 2.12.5) were removed and allowed to cool to room temperature.
The samples were acidified to between pH 2–3 with the addition of formic acid, this
was checked by pipetting 10 µL of the sample onto a pH indicator strip. Approximately
300 µL of 100% (v/v) formic acid was sufficient for pH adjustment.
The samples were desalted using Oasis HLB Plus LP extraction cartridges (Waters).
A 1 mL tip (with the end cut-off) was placed in the top of the cartridge and a pipette
used to push the solutions through. The cartridges were conditioned with 5 mL of
100% (v/v) acetonitrile before being equilibrated with 5 mL of 5% (v/v) formic acid
in type I water. The sample was slowly (dropwise) loaded into the cartridge. The
cartridge was washed with 5% (v/v) formic acid in type I water. Samples were eluted
from the columns by passing 5 mL of 70% (v/v) acetonitrile, 5% (v/v) formic acid
in water through and collecting the elution. The samples were dried in a centrifugal
vacuum concentrator (Savant) before storage at −80 °C.
2.12.7 Clean-up of ICAT-labelled samples using the ICAT-kit
ICAT-labelled samples were further processed as per the ICAT-kit instructions with
the notable difference that in-house solutions were used and not those supplied with the
kit (with the exception of the column storage buffers). The samples were each split into
four parts for processing through a strong-cation exchange and biotin affinity column.
The columns supplied with the ICAT kit required the use of a specialised adapter,
which was borrowed from the Otago Centre for Proteome Research. A blunt, ø 0.7
mm injection port needle was used alongside 1 mL plastic syringes to inject samples
and solutions. The needle was thoroughly washed with type I water between solution
changes and sample changes.
The dried, desalted, peptides (from 2.12.6) were resuspended in 2 mL of cation-load
buffer (10 mM KH2PO4, 25% (v/v) acetonitrile, pH 3.0). Tubes were vortexed for one
minute, heated at 50 °C for 5 minutes, vortexed for one minute, sonicated in a water
bath for one minute and vortexed for a further minute before being briefly centrifuged
to bring everything to the bottom.
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2.12.7.1 ICAT strong-cation exchange
The ICAT strong-cation exchange cartridge was washed with 2 mL of cation-clean
buffer (10 mM KH2PO4, 25% (v/v) acetonitrile, 1 M KCl, pH 3.0). The column was
equilibrated with 4 mL of cation-load buffer. One-quarter of the resuspended sample
(∼250 µL) was slowly applied (drop-wise) to the column. The column was washed
with 1 mL cation-load buffer. Peptides were eluted drop-wise with 0.5 mL of cation-
elute buffer (10 mM KH2PO4, 25% (v/v) acetonitrile, 350 mM KCl, pH 3.0). The
column was cleaned with 2 mL of cation-clean buffer then the steps were repeated,
from equilibration, until the entirety of one sample was processed. In between different
samples, the column was washed with an additional 2 mL of cation-storage buffer (10
mM KH2PO4, 25% (v/v) acetonitrile, 0.1% (w/v) NaN3, pH 3.0), after which all steps
were repeated for the next sample, from the first cation-clean buffer wash. Eluted
peptides were stored overnight at 4 °C.
2.12.7.2 ICAT biotin affinity
Eluted cation-exchange samples were pH adjusted with an equal volume of affinity-load
buffer (20 mM NaH2PO4 300 mM NaCl, pH 7.2)—i.e. 2 mL of total cation-exchange
elution was neutralised with 2 mL of affinity-load buffer. The pH of the sample was
checked with a pH indicator strip to check it was between pH 7.0–7.2. The affinity
column was washed with 2 mL of affinity-elution solution (30 % acetonitrile (v/v) 0.4
% (v/v) TFA) before being equilibrated with 2 ml of affinity-load buffer. One-quarter
of the sample (∼1 mL) was loaded drop-wise. The column was washed with 500 µL
of affinity-load buffer followed by 1 mL of affinity-wash(1) buffer (10 mM NaH2PO4
150 mM NaCl, pH 7.2). The column was washed further with 1 mL of affinity-wash(2)
buffer (50 mM NH4HCO3 20% (v/v) methanol, pH 8.3) followed by 1 mL of type I
water.
The sample was eluted drop-wise from the column with 800 µL of affinity-elution
solution. The first 50 µL of this (2 drops) was discarded. For processing the remainder
of the same sample, the process was repeated from the beginning. In between samples,
the column was washed additionally with 2 mL of affinity-elution solution and 2 mL
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of affinity-storage buffer (20 mM NaH2PO4 300 mM NaCl, 0.1% (w/v) NaN3, pH 7.2)
before repeating from the beginning for the next sample. Eluted peptides were dried
in a SpeedVac centrifugal evaporator (Savant) before being stored at −80 °C.
2.12.7.3 Cleavage of biotin-tag on ICAT-labelled samples
The biotin tag on the ICAT-labelled peptides is cleaved to help the LC-MS/MS. Cleav-
age required two proprietary reagents (Reagent A and B) supplied with the ICAT kit.
Cleavage reagent A and B were mixed in a 95:5 ratio. For cleavage, 150 µL of fresh
working cleavage reagent was added to the dried affinity-eluted peptides. The samples
were vortexed for one minute, sonicated in a water bath for one minute, before vor-
texing for a further minute. The tubes were placed in a 37 °C shaking incubator for 2
hours for cleavage to occur. Following cleavage, samples were allowed to cool to room
temperature, briefly centrifuged before drying peptides in a centrifugal evaporator and
stored at −80 °C.
2.12.7.4 Sep-Pak clean-up of ICAT-labelled samples post cleavage
Dried, cleaved, ICAT-labelled peptides (from 2.12.7.3) were further cleaned up by using
SepPak single-use cartridges (Waters). Peptides were resuspended in 2 mL of 2% (v/v)
acetonitrile, 0.2% (v/v) formic acid. The tubes were vortexed for one minute, heated
at 50 °C for 5 minutes, vortexed for one minute, sonicated in a water bath for 1
minute, before a final minute of vortexing. Samples were briefly centrifuged to collect
all solution at the bottom of the tube. A SepPak cartridge was conditioned with 5
mL 100% (v/v) methanol followed by 5 mL type I water. The column was washed
with 5 mL of 70% (v/v) acetonitrile, 0.2% (v/v) formic acid, before being equilibrated
with 5 mL of 2% (v/v) acetonitrile, 0.2% (v/v) formic acid. The sample was applied
drop-wise to the cartridge and flow-through re-applied. Cartridges were washed with
5 mL of 2% (v/v) acetonitrile, 0.2% (v/v) formic acid. Bound peptides were eluted
with 5 mL 70% (v/v) acetonitrile, 0.2% (v/v) formic acid. Eluted peptides were then
evaporated to dryness in a centrifugal evaporator and stored at −80 °C until analysis
by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
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2.12.7.5 LC-MS/MS analysis of ICAT-labelled peptides
All LC-MS/MS was performed by Dr Torsten Kleffmann and Dr Abhishek Kumar
(Otago Centre for Protein Research). LC-MS/MS-ready, ICAT-labelled peptides (from
2.12.7.4) were resuspended in 20 µL of 2% (v/v) acetonitrile, 0.2% (v/v) formic acid.
The tubes were vortexed for one minute, heated at 50 °C for 5 minutes, vortexed for
one minute, sonicated in a water bath for 1 minute before a final minute of vortexing.
Samples were briefly centrifuged to collect all solution at the bottom of the tube.
Samples were transferred to a snap top auto-sampler vials (Thermo Scientific) for
analysis.
Resolublised samples were analysed, in duplicate, using an Ultimate 3,000 Nano-
Flow LC System (Thermo Scientific) and LTQ-Orbitrap XL hybrid mass spectrometer
(Thermo Scientific). The sample (5 µL) was injected into the LC-system, by way
of an auto-sampler, and separated on an in-house packed emitter-tip column (ø 75
µm fused silica tubing containing C18 material, 8–9 cm in length). The sample was
eluted from a gradient of 2% (v/v) acetonitrile, 0.2% (v/v) formic acid to 90% (v/v)
acetonitrile, 0.2% (v/v) formic acid in water, over 105 minutes at a flow rate of 4
µL/min. Full MS (with a mass range between mass/charge (m/z ) 300 and m/z 2000)
was performed in the Orbitrap mass analyser with a resolution of 60,000 at m/z 400
and an automatic gain control (AGC) target of 1 × 106. The strongest ten signals
were selected for collision-induced dissociation (CID)-MS/MS in the LTQ ion trap at a
normalized collision energy of 35% using an AGC target of 2× 105 and one microscan.
Dynamic exclusion was enabled with two repeat counts during 90 seconds and an
exclusion period of 120 seconds.
2.12.7.6 Analysis of ICAT-labelled peptides
MS spectrum data (Thermo Scientific RAW files) were analysed using Proteome Dis-
cover v2.4 (Thermo Scientific). The ICAT method enables the relative abundance of
labelled-cysteine containing peptides to be determined, as pairs of heavy and light
ICAT-labelled peptides have a mass difference of 9 Da. Abundance quantification uses
the area of the precursor peaks of corresponding peptide pairs (labelled with either
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the light or heavy ICAT reagent). Peptides and proteins were identified using Sequest
(Eng et al., 1994), searching against the human SwissProt database (The UniProt
Consortium, 2017) containing 20,188 entries (downloaded 03/01/2018). The search
was for tryptic peptides with up to three missed cut-sites. The following dynamic
modifications were allowed: oxidised methionine; deamidated asparagine, glutamate
and arginine; acetylated N-termini. Cysteines were allowed to be modified with IAM,
ICAT-light and ICAT-heavy. The precursor mass tolerance was 10 ppm and the maxi-
mum fragment mass tolerance was 0.4 Da. Proteome Discover calculates the confidence
(a q value) of the peptide based on an estimated false discovery rate of below 1% by
the software. For all samples only proteins identified with a high confidence (q value
of 0.01) were used. The data was exported to Microsoft Excel for further processing






As a MAP3K, ASK1 lies atop of a signalling cascade that—in response to a range of
cues—is essential in controlling diverse cellular responses. Accordingly, ASK1 regula-
tion is multifaceted. In this Chapter, recombinant ASK1 is used to address the ability
of ASK1 to regulate its own activity in vitro. A kinase assay is developed with which
to assess ASK1 activity. Domains, N-terminal to the ASK1 kinase domain, are seen to
both inhibit, and enhance ASK1 kinase activity.
3.2 Publication outputs
• Weijman, J. F., Kumar, A., Jamieson, S. A., King, C. M., Caradoc-Davies, T. T.,
Ledgerwood, E. C., Murphy, J. M., and Mace, P. D. (2017). Structural basis of
autoregulatory scaffolding by apoptosis signal-regulating kinase 1. Proceedings of




ASK1 is regulated by an array of different mechanisms. ASK1 also experiences a high
degree of auto-regulation. For example, ASK1 signalling is not seen from cells over-
expressing ASK1 in culture until they are stimulated with ligands such as TNFα (Gotoh
and Cooper, 1998; Ichijo et al., 1997). Lack of activity from over-expressed ASK1 is
indicative that ASK1 exhibits a high degree of self-regulation—namely auto-inhibition.
3.3.1.1 ASK1 auto-regulation by its N terminus
The N terminus (residues 1 to 658) of ASK1 is important for regulation and has dual
roles in both inhibiting ASK1 and allowing activation. Many studies on ASK1 have
reported that the ASK1 N terminus is important for ASK1 inhibition (Figure 3.1a).
When over-expressed, ASK1 constructs lacking the N terminus (up to residue 649) and
lacking the far N terminus (the first 277 residues) are intrinsically active (Fujino et al.,
2007; Saitoh et al., 1998).
Precisely why the N terminus is inhibitory has not been completely deduced. The N
terminus is purported to homo-oligomerise, which is required for TRAF6-induced ASK1
signalling (Figure 3.1b; Fujino et al., 2007; Wang et al., 2017). How oligomerisation
occurs is not clear, but was thought to occur via a coiled-coil within the N terminus
(Fujino et al., 2007). The coiled-coil was predicted to be contained within residues 297
to 324 within the conserved DUF4071 region (see 1.4.2; Fujino et al. 2007). However,
the recent crystal structure from the Mace laboratory demonstrated that residues 269
to 658 of ASK1 instead formed a relatively compact arrangement putting doubt into
how N-terminal olgiomerisation is mediated (Obsil and Obsilova, 2017; Weijman et al.,
2017).
The small oxidoreductase, Trx1, is purported to be able to block ASK1 N-terminal
association, blocking activation (Figure 3.1b; Fujino et al., 2007; Saitoh et al., 1998).
Trx1 inhibition of ASK1 is one of the most commonly cited mechanisms of how ASK1
is regulated and Chapter 4 will go into this in more detail. Trx1 mediated inhibition of
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Figure 3.1: Regulatory mechanisms of ASK1. a) The N terminus of ASK1 (residues
1–658) is described as inhibitory to ASK1 signalling (Fujino et al., 2007; Saitoh et al.,
1998), but the mechanism as to how is unknown. b) Under resting conditions, ASK1 can
homo-oligomerise via its C-terminus (residues 950–1374) (Tobiume et al., 2002). When
stimulated, the N terminus is thought to also homo-oligomerise in a manner that is
regulated positively by TRAF proteins and negatively by Trx1 (Fujino et al., 2007; Noguchi
et al., 2005; Saitoh et al., 1998; Tobiume et al., 2002). c) Oligomerised ASK1 is thought to
trans-auto-phosphorylate to become fully active and initiate downstream signalling (Gotoh
and Cooper, 1998; Tobiume et al., 2002).
ASK1 does not explain how over-expression of ASK1 is not sufficient to induce ASK1
signalling. That is to say, that over-expression will perturb the cellular molar ratio of
ASK1 to Trx1. ASK1 auto-inhibition is, therefore, a critical regulatory mechanism of
ASK1. Investigating how the N terminus can regulate ASK1, is one goal of this Thesis.
3.3.1.2 ASK1 auto-regulation by its C terminus
Like the N terminus, the C terminus (residues 950 to 1374) of ASK1 is also important
in ASK1 regulation. Under resting conditions, ASK1 forms a homo-complex via its C
terminus (Figure 3.1b; Tobiume et al., 2002). Following activation (such as following
cellular stimulation with H2O2 or TNFα) a large (>669 kDa) complex forms—referred
to as the ‘ASK1 signalosome’ (Noguchi et al., 2005). The signalosome involves recruit-
ment of several other proteins, notably TRAF proteins (Nishida et al., 2017; Rusnak
and Fu, 2017). Signalosome formation is a pre-requisite for subsequent active ASK1
signalling (Fujino et al., 2007; Noguchi et al., 2005; Tobiume et al., 2002). However, as
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ASK1 signalling is dormant regardless of the in-cell oligomeric state, other regulatory
mechanisms must be important.
To date, most studies on ASK1 have focused on truncation and deletion over-
expression in a cell culture system. Whilst these studies have proved invaluable our
understanding of ASK1 signalling, we have lacked a molecular understanding. To this
end, it is crucial to develop tools to study ASK1 in vitro utilising kinase assays.
3.3.2 Types of in vitro kinase assay
The study of protein kinases requires an assay. Multiple types of kinase assay are
available with their own advantages and limitations. Details of a few assays are given
in Table 3.1 below, but it is not meant to provide a comprehensive guide.
Of the assay systems listed in Table 3.1, only two (western blotting and mass spec-
trometry) are able to be used with an unpurified sample. The majority are endpoint
assays—the reaction must be stopped in order to measure the assay. Real-time assay—
that continuously monitor the reaction (e.g., a fluorescence quenching assay)—are also
available, but most require a peptide substrate (Eglen et al., 2008).
The use of in vitro kinase assays facilitates investigation into the nature and reg-
ulatory mechanisms of protein kinases, such as ASK1. This Chapter uses Phos-Tag
SDS-PAGE and recombinant ASK1 constructs purified from E. coli.
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Table 3.1: Examples of in vitro kinase assays
Assay system Description Advantages Limitations
Radiolabelled-ATP Incorporated radiolabelled [γ32P]-ATP is
measured by autoradiography or scintillation
High sensitivity, the ‘gold
standard’ method
Hazardous
Western blot Use antibodies against phosphorylated proteins. Quite sensitive, can be





migrate at a slower rate. Total protein
visualised via protein stain or western blot
Simple Sensitivity is dependent upon
protein detection method
ADP-Glo Plate-based assay. ADP generated during kinase
reaction is converted back to ATP, which is
detected via a luciferase assay
High throughput Any contaminant ATPase
activity will be detected







Alpha screen Bead-based immunoassay. Phosphorylated protein
complexes two beads. Singlet oxygen from one
bead causes fluorescence at the second
High throughput
Requires reliable antibodies
to conjugate to beads
Fluorescence quen-
ching e.g., Trulight
Substrate peptide-based plate assay.






Useful references: General—Ma et al., 2008; Radiolabelled-ATP—Hastie et al., 2006; Phos-Tag SDS-PAGE—Kinoshita et al., 2009 and
Section 3.5.1; ADP-Glo—Li et al., 2009; Mass spectrometry—Huang et al., 2010; Alpha Screen—Eglen et al., 2008; Fluorescence
quenching—Rininsland et al., 2004.
63
3.4 Aims
Aim 1 Design in vitro kinase assay for ASK1 activity
Aim 2 Assess ASK1 N-terminal auto-regulation in vitro
Aim 3 Identify residues within ASK1 important in ASK1 auto-regulation
3.5 Results
3.5.1 In vitro kinase assays used in this work
A reproducible assay system by which to measure protein activity has great potential
for informing us how that protein works. With regards to ASK1 function, one accessible
readout is measuring ASK1-catalysed phosphorylation of a substrate protein.
The majority of studies looking at in vitro activity of the ASK1 kinase domain
(roughly residues 660–940) have used a peptide-based substrate (for example, Bunkoczi
et al., 2007). However, this approach loses the detail of how the enzyme (ASK1) and
substrate (MAP2K) may interact, and what non-catalytic properties of ASK1 may also
govern the reaction.
Multiple forms of kinase assay were outlined within 3.3.2. This work uses in vitro
kinase assays that have a kinase (two different recombinant ASK1 constructs) phospho-
rylating recombinant human MKK6. MKK6K82A, ‘kinase dead’ (referred to hereafter
as MKK6) is used as a substrate in all assays, as it is unable to auto-phosphorylate
(Figure 3.3 and 3.5). All assays are subsequently analysed by either western blot or
Phos-Tag SDS-PAGE (Figure 3.2).
Phos-Tag SDS-PAGE uses a compound, (Phos-TagTM from Wako Chem), that is
immobilised within the acrylamide matrix. The Phos-Tag reagent has an affinity for
phosphoryl groups and so slows the migration of phosphorylated proteins—relative to
their unphosphorylated form (Figure 3.2a, Kinoshita et al., 2009). For example, when
MKK6 is incubated with, and without the kinase domain of ASK1 (ASK1669–941) for 30
minutes at room temperature there is an observable shift of MKK6 when analysed by




























































Figure 3.2: Illustration of in vitro kinase assays used in this work. a) Cartoon
demonstrating the Phos-Tag SDS-PAGE principle. b) Illustrative example where a
substrate (in this case MKK6) was incubated with and without a protein kinase (in this
case ASK1669–941). c) Illustrative example showing detection of phosphorylated substrate
(p-MKK6) by either Phos-Tag SDS-PAGE or western blot.
be visualised by western blot, for example in Figure 3.2c, where MKK6 was incubated
with catalytically active ASK1 for up to 10 minutes and analysed by both Phos-Tag
SDS-PAGE and western blot.
3.5.2 The N terminus of ASK1 is auto-inhibitory in cis
Most studies using recombinant ASK1 activity have focused solely on the isolated
kinase domain. We were able to express in E. coli and purify a longer protein construct
containing the majority of the ASK1 N terminus and the kinase domain (residues 88
to 941; Figure 3.3a, see Methods for purification details). These two protein constructs
(ASK1669–941, and ASK188–941) enabled a direct comparison of protein kinase activity in
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vitro in order to assess what effect, if any, the N terminus may play in ASK1 regulation.
An in vitro kinase assay was performed with different concentrations of either
ASK1669–941 or ASK188–941 and 3 µM MKK6. MKK6 phosphorylation (visible by
the upwards shift on Phos-Tag SDS-PAGE) after 5 minutes with 0.1 µM ASK1669–941
(Figure 3.3b,c). Resolving the same samples on SDS-PAGE shows that there are no
contaminants within the assay so the shift seen on Phos-Tag SDS-PAGE does indeed
come from phosphorylation (Figure 3.3b). Without the addition of either ASK1 ki-
nase construct there is no appearance of p-MKK6 showing that the phosphorylation is
catalysed by ASK1 (Figure 3.3b, c).
No p-MKK6 was seen when incubated with either ASK1669–941 or ASK188–941 at
0.01 µM for 10 minutes (Appendix Figure B.1). Conversely, 0.1 µM ASK1669–941 (but
not ASK188–941), was sufficient to have detectable amounts of p-MKK6 after 5 minutes
(Figure 3.3b,c). When the concentration was increased to 1 µM, there was a complete
conversion of MKK6 to the phosphorylated form by ASK1669–941 within 5 minutes. By
comparison, 1 µM of ASK188–941 showed similar levels of activity as 0.1 µM ASK1669–941
(Figure 3.3), showing that ASK1669–941 is ∼10-fold more active than ASK188–941.
One caveat to these results is that to minimise auto-phosphorylation during expres-
sion, ASK188–941 was co-expressed with lambda protein phosphatase (λPP), whereas
ASK1669–941 was not. As auto-phosphorylation is a well-studied mechanism of pro-
tein kinase regulation it is possible, therefore, that the differences between ASK1669–941
and ASK188–941 are due to phosphorylation status. However, the comparison between
ASK188–941 that was or was not co-expressed with λPP showed little difference between
respective activities (Appendix Figure B.2). Taken together, these results suggest that
ASK1669–941 is at least 10-fold more active than ASK188–941 and that the N terminus
of ASK1 is somehow negatively regulating ASK1 kinase activity.
SAXS data from the Mace laboratory yielded further insight into how the ASK1
N-terminal may operate to regulate the kinase domain (Weijman et al., 2017). A
background to SAXS data will be provided in Chapter 4. Briefly, SAXS is a biophysical
technique where the scattering of X-rays by a molecule in solution is measured (Putnam
et al., 2007). SAXS data is useful to construct a model of a multi-domain protein when
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Figure 3.3: The N terminus of ASK1 is inhibitory to ASK1 kinase activity. In vitro
kinase assay of ASK1 phosphorylating MKK6. a) Schematic showing which protein
constructs are used in this assay. b) In vitro kinase assay with 3 µM MKK6 and a range of
ASK1 concentrations. The assay was conducted at room temperature with 2 mM DTT.
ATP was added (50 µM) to start the reaction. A Phos-Tag SDS-PAGE gel (top) and
SDS-PAGE gel (bottom) are shown to indicate the shift from phosphorylation. Note that
no protein marker is used in these gels so the shift is relative to the band position at 0
minutes. All proteins are visualised with Coomassie. c) Quantification of two separate
experiments. The phosphorylated and unphosphorylated bands were quantified using
ImageStudio. The percentage of total phosphorylated MKK6 was then converted to
concentration based on 3 µM MKK6 being used in the assay. Error bars represent standard
error of the mean (SEM). Gels used in quantification are shown in Appendix Figure B.1.
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Rigid body modelling (using a program called BUNCH) of scattering data from
ASK188–941 and ASK188–658 (a construct consisting of the TBD, the 7× TPR and PH
domains on a single polypeptide) showed distinct conformational differences between
the relative orientation of the ASK1-TBD within the N terminus (Figure 3.4; Weijman
et al., 2017). Within the context of ASK188–941, the TBD points towards the kinase
domain. By comparison, when ASK188–658 is analysed, the TBD points away. A ‘flip’
of the ASK1-TBD could, therefore, be sufficient to limit the availability of binding
proteins to the rest of ASK1, thereby altering the protein’s activity.























ASK188–658 (b) PH7× TPR TBD
a)
ASK188–941 (c)
Key:1 : 7× TPR
2 : PH domain
3 : F623 and D632
4 : W476
5 : TBD (88–658)
6 : TBD (88–941)
7 : Kinase domain
Figure 3.4: N-terminal regulation of ASK1 modelled using SAXS. a) Schematic of the
ASK1 constructs in this Figure. b) and c) SAXS BUNCH model from Weijman et al.
(2017) for either ASK188–658 (b) or ASK188–941 (c). The locations of the proposed substrate
docking site (F623 and D632; 3.5.4.2; Figure 3.8) is indicated along with W476 (from
3.5.4.1).
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3.5.3 ASK1 kinase activity is not inhibited by N-terminal re-
gions when added in trans
In order to investigate how the N terminus of ASK1 might be regulating the ASK1
kinase domain a slightly different approach was used. If the regulation was a direct
effect between the N terminus and the kinase domain then the addition of the N
terminus in trans (i.e. on separate polypeptide chains) would inhibit the activity of
ASK1669–941.
To test whether the ASK1 N terminus is inhibitory when added in trans, an in
vitro kinase assay was carried out (Figure 3.5). The assay contained ASK1669–941 (0.01
µM) and isolated regulatory regions—either ASK188–658 or ASK1269–658—were added
at concentrations 100-fold above (1 µM) or equal (0.01 µM) to the kinase domain
concentration. Due to the similar size of MKK6 and ASK1269–658 (∼37 and 45 kDa,
respectively) Phos-Tag SDS-PAGE was not a suitable way of analysing the assay (as
p-MKK6 runs at a similar size to ASK1269–658) so western blotting (for p-MKK6) had
to be used instead.
No change in MKK6 phosphorylation was observed from the addition of either
ASK188–658 or ASK1269–658 (Figure 3.5). The lack of inhibition from the addition of
N-terminal constructs suggests that the N terminus does not modulate the ASK1 ki-
nase domain directly. An alternative hypothesis is that the N terminus can somehow
modulate the substrate (MKK6).
3.5.3.1 Phosphorylation of MKK6 can be enhanced by ASK1269–658
No effect on MKK6 phosphorylation by ASK1669–941 was seen when the N-terminal
constructs were added to either 100-fold above or equal to the kinase concentration. In
order to determine if there was any effect on the substrate (MKK6), the same approach
was used; an in vitro kinase assay with 0.01 µM ASK1669–941 and adding in N-terminal
ASK1 constructs (ASK1269–658 or ASK188–658) to amounts 10-fold below (0.3 µM) or
above (30 µM), relative to the concentration of MKK6 (3 µM; Figure 3.6).
Addition of up to 30 µM ASK188–658 had no or little effect on MKK6 phosphorylation








































































Figure 3.5: Addition N-terminal ASK1 regions (up to 1 µM) in trans does not alter kinase
activity. a) Schematic showing which regions of ASK1 and other proteins are used in this
assay. b) Kinase assay conducted with 3 µM MKK6 and 0.01 µM ASK1669–941 performed at
room temperature. Both ASK1269–658 and ASK188–658 were added to the assay with
concentration up to 1 µM. The assay was started by the addition of 50 µM ATP. This assay
was analysed by western blot against p-MKK6 with Ponceau S stained membrane shown
below for loading control. c) Quantification of bands based on three separate experiments.
Quantification is relative to p-MKK6 at 10 minutes for the band with no additional
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Figure 3.6: Addition of excess ASK1269–658 enhances phosphorylation of MKK6. In vitro
kinase assay of ASK1 phosphorylating MKK6. a) Schematic indicating the protein
constructs in this assay. b-c) In vitro kinase assay using ASK1669–941 adding in increasing
amounts of either ASK188–658 (b) or ASK1269–658 (c). Assays were conducted with 3 µM
MKK6, 2 mM DTT and 0.01 µM ASK1669–941 performed at room temperature. Assays were
started by the addition of 50 µM ATP. Assays were analysed by western blot against
p-MKK6 with Ponceau S stained membrane shown below for loading control. d)
Quantification of three separate experiments. Quantification is relative to p-MKK6 at 10
minutes for the band with no additional regulatory domain. Error bars represent SEM.
Blots used in quantification are shown in Appendix Figure B.4. Note—for b) all lanes were
from the same blot but it was loaded in the wrong order, hence it has been cropped here for
the purposes of clarity.
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of kinase activity but actually enhanced phosphorylation by up to 4-fold (Figure 3.6c,d).
Conducting a similar assay, but adding in the ASK188–266 (the ASK1-TBD) up to 30
µM also had no effect on MKK6 phosphorylation (Appendix Figure B.5).
MEKK1 (another MAP3K) has a similar kinase domain to ASK1 (Appendix Fig-
ure B.6). Conducting a similar assay with a protein construct of rat MEKK1 (rMEKK1)
kinase domain (residues 1160–1493), adding in up to 30 µM MKK6 did not cause en-
hancement (Appendix Figure B.6). However, the rMEKK1 construct used has a short
N-terminal extension, so it is not directly comparable. Whilst it should be treated with
caution, no enhancement with rMEKK1 kinase perhaps indicates that ASK1269–658 is
a regulatory domain that works in synergy with other regions of ASK1 rather than in
isolation. Overall, these results suggest that ASK1269–658 acts as a recruitment site for
the substrate (MKK6), and that it might be a regulatory mechanism that is unique to
the ASK family of MAP3Ks.
3.5.4 Mutations within ASK1269–658 can alter the activity of
ASK188–941
The crystal structure of ASK1269–658, from the Mace laboratory (Weijman et al., 2017),
enabled further investigation into how ASK1269–658 regulates ASK188–941. ASK1269–658
is comprised of an extended bundle of helices (7×TPR) and a cryptic PH domain
(Weijman et al., 2017).
Given that ASK1269–658 is able to enhance phosphorylation of MKK6 (3.5.3.1) it
is hypothesised that there is a substrate recruitment site within the region. It was
not clear, however, whether ASK1269–658 exhibited any flexibility, which would regu-
late ASK1 activity by bringing distal N-terminal domains (such as the TBD) close to
the kinase domain. By looking at conserved residues within ASK1269–658 and mutat-
ing them we investigated whether there was flexibility within ASK1269–658 and what
residue(s) may be important in both auto-inhibition and substrate docking. Mutations
within ASK1269–658 were cloned and mutant ASK188–941 proteins were purified (by Sam
Jamieson, Mace laboratory). The mutations were all at residues conserved throughout
metazoa (see Appendix Figure B.7).
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3.5.4.1 ASK1269–658 is a rigid domain
If ASK1269–658 were flexible—and its main role was to bring ASK188–266 into close prox-
imity to the kinase domain—then mutations within the 7×TPR could increase the
activity of ASK188–941. Arg395, at the centre of the 7×TPR (Figure 3.7a,b) was mu-
tated to Glu—under the hypothesis that if ASK1269–658 were flexible, then Arg395Glu
would increase kinase activity. However, ASK188–941
R395E had a decrease in kinase
activity (Figure 3.7c,d), suggesting that ASK1269–658 is a rigid domain.
A further pair of mutations within the 7×TPR were made: Arg322Glu and Trp509Glu
(Figure 3.7a,b). If there were any flexibility within the 7×TPR, then Arg322Glu would
disrupt the protein, whereas Trp509Glu would likely stabilise the protein (by forming
a salt bridge with Arg322), thereby decreasing activity. However, neither of these
mutations had any effect on kinase activity (Figure 3.7c,d), again suggesting that
ASK1269–658 is a rigid domain.
Lastly, to investigate whether the 7×TPR may facilitate stabilising of the ASK1-
TBD, Trp476 was mutated (Figure 3.7a,b). Trp476 is a conserved (Appendix Fig-
ure B.7), surface exposed residue. We therefore, hypothesised if Trp476 was important
in ASK1 auto-regulation via influencing the relative position of the TBD. Mutating
Trp476 to Ser should not destabilise the ASK1 protein but if it were important in
stabilising the ASK1-TBD, then mutating it would increase kinase activity. Indeed,
an increase in kinase activity is what was seen (Figure 3.7c,d). Overall, the functional
data from mutations suggest that ASK1269–658 is a rigid domain, consistent with SAXS
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Figure 3.7: ASK1269–658 is a rigid domain In vitro kinase assay of ASK1 phosphorylating
MKK6. a) Schematic showing protein constructs used in this assay and mutations. b)
Crystal structure of ASK1269–658 showing the position of mutations within the 7×TPR
(PDB ID: 5ULM; Weijman et al., 2017). c) Kinase assay conducted with 3 µM MKK6 and
1 µM ASK188–941 and 2 mM DTT, performed at room temperature. 50 µM ATP was added
to start the reaction d) Quantification of c) based on three separate experiments (Note:
R322E and the 30 minute time points were not used in the quantification experiments).
MKK6 and p-MKK6 bands were quantified using ImageStudio. The percentage of total
phosphorylated MKK6 was then converted to µM based on 3 µM MKK6 being used in the
assay. Error bars represent SEM. A gel showing the purified ASK188–941 proteins and gels
used for quantification values can be found in Appendix Figure B.8.
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3.5.4.2 The ASK1 PH domain may be important for substrate docking
As ASK1269–658 increased activity of ASK1669–941 when added in trans (3.5.3.1), it
suggested that there is a substrate docking site within ASK1269–658. In order to inves-
tigate this, a further two mutations within the context of ASK188−941 were also made
at conserved, exposed residues within the PH domain—Phe623Glu, Asp632Arg (Fig-
ure 3.8a,b). The hypothesis was that if the PH domain acted as a substrate docking
site, mutating Phe623 and Asp632 would cause a decrease in protein activity. Both
mutations resulted in approximately a 2-fold decrease in activity of ASK188–941, com-
pared to WT (Figure 3.8c,d). An illustration of how the PH domain may serve to
regulate ASK1 activity was shown previously in Figure 3.4. Under resting conditions,
the TBD can prevent access of the substrate (MKK6) to the recruitment patch on the
PH domain. When activated, the TBD is re-positioned, allowing MKK6 to bind and
be phosphorylated by the kinase domain.
Overall, the results in this Chapter demonstrate that the N terminus of ASK1 is
inhibitory but that ASK1269–658 can enhance activity when added in trans. Addition-
ally, mutations at conserved residues within the 7×TPR and PH domains (contained
within ASK1269–658) can have inhibitory effects, but also enhance activity. Altogether
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Figure 3.8: The ASK1 PH domain is a substrate docking site. In vitro kinase assay of
ASK1 phosphorylating MKK6. a) Schematic showing protein constructs used in this assay
and mutations. b) Crystal structure of ASK1269–658 showing the position of mutations
within the PH domain (PDB ID: 5ULM; Weijman et al., 2017). c) Kinase assay conducted
with 3 µM MKK6 and 1 µM ASK188–941 and 2 mM DTT, performed at room temperature.
50 µM ATP was added to start the reaction. d) Quantification of c) based on three separate
experiments (Note: the WT sample shown is reproduced from Figure 3.7 and the 30 minute
time points were not used in the quantification experiments). Error bars represent SEM.
Quantification was identical as described in Figure 3.7. A gel showing the purified




3.6.1 General comments on in vitro assays in this work
The work in this Chapter has looked into auto-regulatory mechanisms of ASK1. In
order to examine ASK1 activity, an in vitro assay system was developed. The assay
system used both recombinant protein substrates (MKK6) and enzymes (ASK1669–941
and ASK188–941). The assays have been visualised on gels using both Phos-Tag SDS-
PAGE and western blotting. Both methods of visualisation were relatively simple and
reproducible.
The advantage of Phos-Tag SDS-PAGE, as it has been used in this work, is that
analysis is straightforward. To analyse the assay all that is required is SDS-PAGE
and Coomassie staining. By comparison, western blotting has several extra steps in-
troducing additional chance for variation. For example, the efficiency of transfer may
differ from blot to blot, or even within one blot (MacPhee, 2010). A linear response
range—i.e. that the signal is directly proportional to the amount of protein on the
blot—is also critical in accurate western blots (MacPhee, 2010).
One limitation of Phos-Tag SDS-PAGE is sensitivity. For example, with Phos-Tag
SDS-PAGE assays 0.1 µM ASK1669–941 was used in an assay (e.g., Figure 3.3). Con-
versely, the western blot method had increased sensitivity so 0.01 µM ASK1669–941 was
used (e.g., Figures 3.5 and 3.6). Lower sensitivity is not actually inbuilt to Phos-Tag
SDS-PAGE and more associated with the use of Coomassie for visualisation of protein.
If a more sensitive method—such as silver staining—was used there would be increased
detection sensitivity (Chevalier, 2010). However, the advantage of using Coomassie is
it is very simple and fast, hence why it was used for this work. Western blotting also
proved invaluable for the experiments where ASK1269–658 was added into the assays in
trans (for example, Figures 3.5 and 3.6). ASK1269–658 and MKK6 have similar molecu-
lar weights (45 and 37.8 kDa, respectively). On Phos-Tag SDS-PAGE (as it was used
in this work) ASK1269–658 and MKK6 (unphosphorylated and phosphorylated forms)
overlapped one another. Therefore, western blotting was used to analyse the assays
instead.
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The major benefit from Phos-Tag SDS-PAGE is that the method enables detection
of both the phosphorylated and unphosphorylated forms of a protein. Therefore, it is
possible to quantify the total fraction (and thereby an indication of the total amount)
of phosphorylation (as in Figures 3.7 and 3.8). Conversely, by western blot, one cannot
say how much of a protein is modified, but only how much relative to the control (as
in Figure 3.6). Accordingly, by using Phos-Tag SDS-PAGE we were able to measure
phosphorylated MKK6 and the total protein from the same method of visualisation
(Coomassie staining). Determining both constraints enabled us to quantify the total
proportion of MKK6 that was phosphorylated and to convert it to molarity based on
the concentration of MKK6 used in the assays (as in Figures 3.3, 3.7 and, 3.8). Quan-
tification offered a rapid way to compare the activities of different protein constructs
or different assay conditions. Overall, the assays work well, and the use of a full-length
substrate provided a useful assay for investigating ASK1 activity and regulation.
3.6.2 Inhibition of ASK1 by the ASK1 N terminus (residues
88–658)
Comparison of ASK1669–941 and ASK188–941 showed that ASK1669–941 is approximately
10-fold more active than ASK188–941 (Figure 3.3). The N terminus of ASK1 has long
been known to facilitate inhibition. For example, Saitoh et al. (1998) reported that
an N-terminal truncation (i.e. missing the first 648 residues) of ASK1 (that was over-
expressed in cells and immunoprecipitated) had ∼10-fold more activity compared to
WT. Additionally, over-expression of N-terminally truncated ASK1 is sufficient to in-
duce apoptosis indicating that it has a major role in regulating ASK1 activity (Hatai
et al., 2000; Saitoh et al., 1998).
Dimerisation is common to many protein kinases and is known to be an impor-
tant mode of regulation (Marianayagam et al., 2004). For example, EGFR and RAF1
dimerise before becoming fully active (Lavoie and Therrien, 2015; Lemmon et al., 2014).
Synthetic dimerisation of ASK1 is sufficient to activate ASK1 in HEK293 cells (Gotoh
and Cooper, 1998). The ASK1 kinase domain is known to be a dimer in solution (Ap-
pendix Figure A.2f and Bunkoczi et al., 2007). Conversely, ASK188–941 is monomeric in
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solution (Appendix Figure A.2g and Weijman et al. 2017). The N terminus of ASK1,
therefore, may play a role in regulation via interference with dimerisation of the kinase
domain.
The reported dissociation constant (Kd) of the ASK1 kinase domain homodimer
is 0.2 µM (Bunkoczi et al., 2007). In the in vitro kinase assays analysed by Phos-
Tag SDS-PAGE (such as in Figure 3.3), 0.1 µM ASK1669–941 was used. Under these
conditions, it would be expected that less than half of ASK1669–941 would be dimeric.
Analysing the effect of dimerisation on enzyme kinetics would help to delineate what
role dimerisation plays in regulating ASK1 kinase activity.
Lastly, N-terminal mediated inhibition of ASK1 is canonically explained via Trx1
binding and stopping N-terminal oligomerisation of ASK1 (see 3.3.1). The work pre-
sented here demonstrates that the N terminus is sufficient to inhibit ASK1 kinase
activity, providing it is on the same polypeptide (3.5.2). Trx1, therefore, may regu-
late ASK1 via altering N-terminal inhibition, instead of acting as a direct inhibitor.
Chapter 4 will explore Trx1 regulation of ASK1 in greater depth.
3.6.3 Addition of ASK1269–658 in trans can enhance
phosphorylation of MKK6
Addition of different ASK1 N-terminal constructs to in vitro kinase assays had intrigu-
ing results. Addition of either ASK1269–658 or ASK188–658 at concentrations equal to, or
exceeding the kinase, but under the concentration of the substrate had no effect (Fig-
ure 3.5). Conversely, when ASK1269–658 was added in trans, at concentrations exceeding
that of the substrate, there was an enhancement of kinase activity (Figure 3.6).
One explanation for this effect is that ASK1269–658 acts as a docking site for the sub-
strate. Comparison of the available crystal structures of full-length MKK6 reveals that
the N-terminal lobe and αC-helix can undergo a conformational shift of approximately
18 Å, depending upon the state of the protein (Appendix Figure B.9 and Weijman
et al. 2017).
Within MKK6, Ser207 and Thr211 (the two residues that are required to be phos-
phorylated for the protein to become active) are buried in the unphosphorylated form
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of the protein (Appendix Figure B.9; Matsumoto et al., 2012; Weijman et al., 2017).
MKK6 can, therefore, undergo a large conformational change and such a change is
required for phosphorylation to occur. ASK1269–658 could promote phosphorylation of
MKK6 by inducing a conformational change. A conformational change would subse-
quently expose the key phosphorylation targets and augment the suitability for MKK6
to be a substrate for ASK1669–941.
3.6.3.1 Mutations within ASK1269–658 can promote and inhibit ASK1 ki-
nase activity
The high degree of conservation of ASK1269–658 between ASK1, 2 and 3 (Appendix Fig-
ure B.7), and the recent crystal structure of ASK1269–658 (PDB ID: 5ULM; Weijman
et al., 2017) enabled structure-guided mutational and functional analysis (3.5.4). Mu-
tations within ASK1269–658 (Figure 3.7, alongside SAXS data (Weijman et al., 2017))
showed that region is not flexible. Mutations at conserved, surface-exposed residues
can alter activity, indicating that there are interactions with MKK6 that promote bind-
ing (Figure 3.8). The mutation and functional assays helped to develop a model for
ASK1 auto-regulation.
3.6.4 Model of ASK1 auto-regulation and scaffolding
Based upon the results in this Chapter, it is proposed that ASK1269–658 within ASK1
acts as a scaffold to recruit MAP2Ks and promote their phosphorylation.
3.6.4.1 MAP2K recruitment
The N-terminal extensions of MKKs are well-known to be important in binding to
respective MAPKs via kinase interaction motifs (KIMs), also known as D-motifs (Peti
and Page, 2013). D-motifs—alongside other MAPK-binding proteins (Peti and Page,
2013)—are responsible for high-affinity binding and specificity between MAPKs and
MAP2Ks (Bardwell et al., 2009; Ho et al., 2003, 2006). MKK7, for instance, contains
three D-motifs giving it a high affinity for JNK-MAPKs (Ho et al., 2006; Kragelj et al.,
2015). By comparison, recruitment of MAP2Ks by MAP3Ks is more obscure.
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The C terminus of several MAP2Ks (including MKK6) has been reported to contain
a ‘domain for versatile docking’ (DVD) motif that is integral to MAP2K-MAP3K
recruitment (Avruch, 2007; Takekawa et al., 2005). Whilst a DVD-motif within MKK6
has been shown to be necessary for interacting with the ASK1 kinase domain (Takekawa
et al., 2005) there are many exceptions to DVD-mediated MAP2K-MAP3K interaction
mechanisms (Gloeckner et al., 2009; Tatebayashi et al., 2003, 2006; Wengier et al.,
2018).
3.6.4.2 Signalling scaffolds
Scaffolding proteins represent another mechanism by which MAP2Ks and MAP3Ks
are able to co-localise. Scaffold proteins are common regulatory proteins in signalling
systems. Two of the best-known examples are that of Kinase Suppressor of Ras (KSR)1
and the analogous yeast protein, Ste5 (Chol et al., 1994; Good et al., 2011; Scott and
Pawson, 2009; Therrien et al., 1996).
Several scaffolding proteins have been described for ASK1 including the protein
kinase LRRK2 (Yoon et al., 2017), the phosphatase DUSP22 (Ju et al., 2016) and the
zinc finger protein ZNF622 (also known as ZPR9; Seong et al., 2011). Several other
scaffold proteins are highlighted in Rusnak and Fu (2017), Nishida et al. (2017) and,
Weijman et al. (2017).
Scaffolding proteins are able to act as communication hubs within a cell by facilitat-
ing co-localisation of functionally connected proteins. Ste5 contains various domains
that help it associate to the plasma membrane, and co-localise a MAPK cascade conse-
quently enhancing the signalling output (Good et al., 2009, 2011; McKay et al., 2009).
Ste5 has been shown to confer a conformational change within the yeast MAPK, Fus3
(Good et al., 2009). Fus3 binds to a von-Willebrand Type-A (VWA) domain within
Ste5, making Fus3 a better substrate for the yeast MAP2K, Ste7. (Good et al., 2009).
In this manner the ASK1 PH domain could serve analogously to the Ste5 VWA do-
main. Moreover, Ste5 also regulates the overall MAP3K pathway by directly inhibiting
Fus3 until the pathway becomes activated (Zalatan et al., 2012). Consequently, ASK1



























Figure 3.9: Model of ASK1 auto-regulation. Under resting conditions, access to the ASK1
kinase domain is limited by the TBD. Conformational change of the TBD position (a
‘swing’), allows MKK6 to be recruited to the ASK1 PH domain, causing a conformational
change within MKK6, making it a better substrate for phosphorylation. MKK6 is
phosphorylated by the ASK1 kinase domain. Phosphorylated MKK6 can continue with
downstream signalling. Control over ASK1 and the TBD is frequently associated with Trx1
and H2O2 (redox regulators, explored in Chapters 4 and 5), but the mechanism that
governs this is unclear and will be explored in Chapter 4.
regulate access of MKK6, helping to prevent unsolicited activation of the pathway.
3.6.4.3 Model of ASK1 auto-regulation and scaffolding
The ability of ASK1269–658 to enhance MKK6 phosphorylation in trans merits it being
more than just a recruitment site (such as DVD-motifs). In this manner, the PH domain
within ASK1269–658 is akin the yeast Ste5 scaffold protein. Therefore, it is proposed
that ASK1269–658 is a scaffolding-subunit within ASK1, able to promote docking of
MKK6 and induce a conformational change that primes MKK6 to be phosphorylated
(Figure 3.9).
Under the proposed model, the ASK1-TBD (ASK188–266) can inhibit ASK1 kinase
activity by restricting access to the substrate docking site. When the ASK1-TBD shifts
from the auto-inhibitory position, MKK6 can bind, inducing a conformational change
to allow for phosphorylation by ASK1. Phosphorylated MKK6 is then active and able
to transmit the signal downstream. Such a model of MAP2K recruitment and priming
by a MAP3K has not previously been described.
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The proposed model is compatible with previous models of ASK1 regulation where
that N-terminal oligomerisation (or inhibition) is regulated by Trx1 (see 3.3.1). One
caveat is that the observations made in this Chapter do not suggest that N-terminal
oligomerisation is required for ASK1 regulation. However, as this Chapter only uses
constructs lacking the C-terminal portion of ASK1 (which is critical to ASK1 oligomeri-
sation within cells) there is scope for N-terminal oligomerisation playing a role in the
context of full-length ASK1. Nonetheless, control of the ASK1-TBD by cellular stim-
uli, in particular, oxidation by H2O2 and reduction by Trx1 (Fujino et al., 2007; Saitoh
et al., 1998) provides a mechanism to modulate the N terminus of ASK1, thereby
controlling overall ASK1 activity (discussed further in Chapter 4).
3.7 Conclusions
This Chapter has looked into how the protein kinase, ASK1, regulates itself in vitro.
Understanding ASK1 auto-regulation is fundamental in understanding how ASK1 sig-
nalling is regulated within cells. Kinase assays have been used to analyse ASK1 activity
in vitro. The assays have shown that the N terminus (residues 88–658) of ASK1 is auto-
inhibitory to ASK1 kinase activity when on the same polypeptide chain. Curiously,
the addition of ASK1269–658 in trans to the kinase assays enhanced phosphorylation of
MKK6 by up to 4-fold. When conserved, surfaced exposed residues within ASK1269–658
are mutated (such as Phe623 and Asp632), there is a decrease in ASK1 kinase activity.
Taken together, and in conjunction with biophysical work from our group, the work
in this Chapter suggests that the N terminus of ASK1 is both auto-inhibitory but also
contains a substrate docking site within a PH domain. It is proposed that the PH
domain acts as a scaffolding protein. Under this model the PH domain not only serves
to recruit the substrate but also induce a conformational change within MKK6, making
it a better substrate. Moreover, biophysical data from the Mace laboratory suggests
that the ASK1-TBD can sit in different positions. The TBD therefore, is able to control
access to the docking site, controlling overall ASK1 activity.
Altogether this Chapter proposes that the N terminus facilitates both auto-inhibition
of ASK1, but also substrate docking and priming for signalling via a mechanism that
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is hitherto unseen in any other MAP3K. This Chapter highlights that non-catalytic re-
gions of signalling proteins merit investigation as much, as catalytic domains. Further
work into the ASK1 TBD will increase our overall understanding of ASK1 regulation.
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Chapter 4
ASK1 regulation by Trx1
4.1 Overview
ASK1 is purported to directly be inhibited by Trx1, with dissociation of Trx1 from
ASK1 being required for ASK1 to become active. However, the nature of the interaction
between ASK1 and Trx1 is ambiguous. Within this Chapter, the interaction between
ASK1 and Trx1 is examined in vitro. Trx1 can bind to ASK1 in vitro. ASK1-Cys250
is seen to be necessary, and sufficient for ASK1 and Trx1 to form an inter-molecular
disulfide bond. SAXS data is used to derive a model of how Trx1 may modulate
ASK1. However, functional data reveals that Trx1 does not directly inhibit ASK1
kinase activity in vitro.
4.2 Introduction
ASK1 is well known for becoming activated in response to cellular stressors, such as
H2O2. Chapter 3, outlined possible mechanisms of ASK1 auto-regulation. Modulation
of ASK1 auto-regulation provides a basis for how ASK1 activity can be altered in re-
sponse to H2O2. The oxidoreductase, Trx1, is commonly associated with H2O2-induced
ASK1 signalling. Precisely how ASK1 is regulated by Trx1 remains somewhat unclear
because a defined molecular picture of the interaction is lacking. Overall building upon
the ASK1-Trx1 picture not only helps to further our understanding of ASK1 regulation
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but also informs us fundamentally how H2O2 can regulate proteins within a cell.
4.2.1 General Trx substrate recognition
Trx is a 12 kDa protein found in all domains of life. Humans have two Trxs: Trx1,
which is primarily cytosolic; and Trx2, which is mitochondrial (Lu and Holmgren,
2014). All Trxs have a conserved overall structure and dithiol containing active site
motif of Cys-Gly-Pro-Cys (Figure 4.1a). Within a cell, Trxs have important roles in
reducing oxidised protein cysteine residues, becoming oxidised during the process. Trx
is subsequently reduced itself by TrxR with the ultimate reducing power coming from
NADPH (Figure 4.1; Collet and Messens 2010; Lu and Holmgren 2014).
The cellular role of Trxs as reducers of proteins is well understood. On the other
hand, Trx substrate specificity is less clear. In mammals, Trx1 has a wide range of sub-
strates, including ASK1 (for a review see Matsuzawa 2017b and Lee et al. 2013). One
of the best-known targets of Trx1 is the cytosolic peroxidase proteins, Prdxs, where
Trx1 is required for effective cellular protection from H2O2 (Chae et al., 1994, 1999).
Trx1 is also important in preventing the formation of non-native disulfide bonds that
can occur within cells (Linke and Jakob, 2003). Perhaps because of the need to be
able to act on any cytosolic or nucleic disulfide bond, there has been no universal mo-
tif or sequence that Trx1 (or any other Trx) recognises. One recent study postulated
that Trx-substrate recognition is driven not by a sequence specificity, but by entropy
(Palde and Carroll, 2015). That is to say, thermodynamically, the reduction reaction
is governed by Gibbs free energy—∆G=∆H–T∆S (where G is Gibbs free energy, H
is enthalpy, T is temperature and S is entropy)—and the reaction will proceed spon-
taneously providing ∆G < 0 (Voet and Voet, 2011). Palde and Carroll (2015) argue
that in the reduction of disulfide substrates by Trx, entropy is the biggest contributor
(i.e. T∆S > ∆H) to favourable thermodynamics and therefore driving the reaction to
completion (Voet and Voet, 2011). In more simplistic terms it could be thought of as a
disulfide-bond representing a more stable conformer of a protein, thus increasing order
and decreasing entropy. Therefore breaking the disulfide bond will allow a change in





























Figure 4.1: Thioredoxin, structure and mechanism. a) Crystal structure of reduced human
Trx1 (PDB ID: 1ERT; Weichsel et al. 1996) rendered in PyMol. The active site cysteines
(Cys32 and Cys365) are indicated as sticks. b) Schematic of Trx-mediated reduction of
proteins. Proteins can become oxidised (from a reaction with H2O2, for example) leading to
the formation of a disulfide bond. Reduced Trx can reduce the protein target—via an
intermediate disulfide-linked species (Wynn et al., 1995). Oxidised Trx (with a
Cys32-Cys35, intra-molecular disulfide bond) is subsequently reduced by thioredoxin
reductase (TrxR) and NADPH.
In addition to entropy, protein-protein interactions also contribute in Trx substrate
recognition. Structural studies by Palde and Carroll (2015) on E. coli Trx and a
substrate—phosphoadenosine phosphosulfate reductase (PAPR)—highlighted residues
within PAPR that interact with Trx. However, the binding interactions—modelled as
favourable changes in enthalpy (∆H)—whilst a contributor, were never able to out-
compete the entropic factor (Palde and Carroll, 2015). Therefore the conclusion was
reached that Trx substrate specificity is primarily driven by entropy (Palde and Carroll,
2015).
4.2.2 ASK1 regulation by Trx1
Originally, Trx1 was identified as an interactor with ASK1 via a yeast two-hybrid
screen (Saitoh et al., 1998). Saitoh et al. (1998) found that Trx1 interacted with the
N-terminal portion of ASK1 (residues 1 to 648), with later work identifying residues 46
to 277 being the core ‘TBD’ (thioredoxin binding domain; Fujino et al. 2007). Saitoh
et al. (1998) proposed that the interaction between ASK1 and Trx1 was dependent
upon the redox status of Trx1. That is to say, reduced Trx1 associates with ASK1 and
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oxidation of Trx1 leads to the dissociation of Trx1 from ASK1, which can be regarded as
the ‘Trx1 oxidation model’ (Figure 4.2a; Saitoh et al., 1998). Under the Trx1 oxidation
mechanism, the oxidoreductase ability of Trx1 is not involved in regulating ASK1, only
the physical association between the two proteins is required.
In contrast, in 2007, Nadeau et al. proposed the activity of Trx1 is required. Trx1
was proposed to maintain ASK1 in a reduced state in a model referred to here as
the ‘ASK1 oxidation model’ (Figure 4.2b). Oxidation of ASK1 results in reduction of
ASK1 by Trx1, and subsequent oxidation and withdrawal of Trx1 (Figure 4.2b; Nadeau
et al., 2009). Nadeau et al. (2007) was not the first study to propose that ASK1 was
actually a reductive-target of Trx1. Liu and Min (2002) observed that a mutant of Trx1
(with either Cys32 or Cys35 mutated to a serine) could not disassociate from ASK1.
Reduction of ASK1 by Trx1 was further developed by mutational studies, changing
some of the 23 cysteine residues within ASK1 to alanine (Nadeau et al., 2007). Several
cysteine residues (Figure 4.2c) were implicated as being important. Later work by
Nadeau et al. (2009) indicated that three cysteine residues within ASK1 were the most
important, with Cys250 being the principal site for Trx1 to act upon (Figure 4.2c).
Lastly, Nadeau et al. (2007) also suggested that an unknown component (referred to
as ‘Factor X’) was also important for modulating ASK1 activity, but the nature of this
component remains undetermined.
4.2.2.1 Why is ASK1-Trx1 inhibition important?
Currently, ASK1-Trx1 represents a signalling nexus that links the redox status of a cell
with cellular events such as inflammation and apoptosis (Fujisawa, 2017; Hayakawa
et al., 2012a). As inflammation and cell death have widespread implications for human
health and disease (Hayakawa et al., 2012a; Matsuzawa, 2017a; Ryuno et al., 2017),
understanding Trx1 regulation of ASK1 has translational benefits. For instance, the
nature of ASK1 regulation by Trx1 and H2O2 can provide a basis for targeted drug
development to regulate ASK1. The ASK1 inhibitor selonsertib is currently undergoing
clinical trials for several hepatic diseases including NAFLD (Fujisawa, 2017; Loomba
et al., 2018). However, selonsertib, alongside many other ASK1-inhibitors, targets the
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Figure 4.2: Models for ASK1 regulation by Trx1 and ASK1 cysteine residues. a) Trx1
oxidation model. Trx1 binds to the N terminus of ASK1 preventing N-terminal
oligomerisation. Oxidation of Trx1 (such as by H2O2 ‘?’) leads to dissociation of Trx1 and
an active ASK1 complex. b) ASK1 oxidation mechanism Trx1 binds to the N terminus of
ASK1, maintaining ASK1 in a reduced state (including the formation of a mixed-species
disulfide, see Figure 4.1). Oxidation of ASK1 (such as by H2O2 ‘?’) can lead to
intra-molecular or inter-molecular disulfide bonds within ASK1 (indicated by ‘?’). The
oxidised ASK1 complex can actively signal. c) Scale schematic of ASK1 indicating the
location of each of all 23 cysteine residues. The indicated residues on the bottom of the
schematic are residues implicated by Nadeau et al. 2007 and Nadeau et al. 2009.
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ASK1 kinase domain (Lovering et al., 2018). As Trx1 is proposed to regulate ASK1 via
its N terminus, there is a greater potential to identify additional drug target sites that
would offer increased ASK1-specificity and expand our fundamental understanding of
ASK1 regulation.
4.2.3 ASK1 and oxidation
The two models for Trx1-mediated regulation of ASK1 outlined in 4.2.2 (Figure 4.2)
highlight that protein oxidation is required to alleviate Trx1 inhibition, allowing ASK1
signalling. Within the ASK1-Trx1 models, exactly how either ASK1 or Trx1 become
oxidised has not been fully explained. As introduced in Chapter 1 (and will be discussed
in more depth in Chapter 5), H2O2 is an unlikely protein oxidant in vivo. The family
of peroxidase proteins, Prdxs (peroxiredoxins), are both very abundant and have high
reactivities with H2O2 (second-order rate constant on the order of 1× 107 M−1 s−1;
Winterbourn and Hampton 2008). By comparison, Trx1 has a fairly low reactivity
with H2O2 (second-order rate constant of 1.05 M
−1 s−1; Winterbourn and Hampton
2008) and therefore H2O2 will react preferentially with Prdxs. Consequently, Trx1,
will not be able to react with H2O2 within the cell. Likewise, whilst there has been no
published characterisation of the reactivity of ASK1 and H2O2, ASK1 would require an
extraordinary high reactivity be able to out-compete the specialist peroxidases (such
as Prdxs) for H2O2.
To overcome the Prdx problem, work from the Ledgerwood laboratory (Jarvis et al.,
2012) has suggested that Prdxs can act as conductors of H2O2 signalling, transmitting
oxidation via disulfide bonds (see Chapter 5 for more detail). Specifically, Jarvis et al.
(2012) postulate that Prdx1 can directly oxidise ASK1 via transient inter-molecular
disulfide bonds. However, understanding how ASK1 might become oxidised does not
inform as to why oxidation is able to alter ASK1 signalling. As regulation of ASK1
by oxidation and Trx1 are intrinsically linked, understanding how Trx1 can regulate
ASK1 will inform on how oxidation can also regulate ASK1. Structural and biophysical
information, such as from SAXS, can help us to greater understand ASK1 regulation.
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4.2.4 Overview of SAXS
In this Chapter, SAXS is used to gain information on the interaction between ASK1
and Trx1. A brief overview of SAXS is given below to help better interpret SAXS data.
Biological SAXS (small angle X-ray scattering) is a technique that measures the
ability of a molecule, in solution, to scatter X-rays. Scattering is proportional to the size
and concentration of the molecule in question. SAXS gives low-resolution data (in the
range of 10–20 Å) that can be used to inform us of the oligomeric and quaternary states
of proteins (Korasick and Tanner, 2018; Mertens and Svergun, 2010). In this way, when
coupled with a high-resolution structural data (such as from X-ray crystallography),
SAXS data gives a powerful way for understanding how a protein behaves in-solution.
As a molecule in solution can adopt multiple orientations, SAXS data represents the
average of all molecule orientations (in contrast to X-ray crystallography where the
molecule analysed is very ordered).
SAXS scattering data is recorded as a factor of the momentum transfer vector, q
which is related to both the angle of scattering and beamline wavelength (Figure 4.3
and Table 4.1). As scattering occurs in a circular pattern, q is averaged across the circle
and hence is often plotted as radial q (Figure 4.3a,b). From SAXS data, a number of
structural parameters can be determined (see Table 4.1 and Figure 4.3). The ‘radius
of gyration’ (Rg), is one parameter which represents the mean distance from the centre
of mass of a molecule to the perimeter. The scattering data can be transformed to
represent the total of inter-atomic vectors—i.e. the sum of distances between every
atom and every other atom within the molecule. The output, referred to as the P(r)
can inform of the Rg and also represents a histogram of the vectors, providing an
impression of the overall shape of a molecule. P(r) analysis generally requires a defined
value for the maximum dimension (Dmax) of a given molecule. The value of Dmax
can be estimated by programs (such as GNOM), but can also be adjusted manually,
meaning care is needed not to over or under-estimate the true value of Dmax.
SAXS data can be used to build three-dimensional representations of the molecule
in question. Rigid-body modelling is one such method that can be used to model a
multi-domain protein where there are high-resolution structures for individual domains,
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but not the molecule as a whole (Putnam et al., 2007). The model output can then
be used to generate a theoretical scattering plot which enables comparisons to the raw
data for user assessment. Such modelling can provide invaluable information to better
understand the overall arrangement of a molecule. However, dueful consideration must
be used so as to not over-interpret the data. Furthermore, additional experimental











































Figure 4.3: Illustration of SAXS. a) Beamline set up for SEC-SAXS. A solution exiting
the chromatography column enters a capillary and is irradiated with X-rays. The X-ray
scattering is detected. The momentum transfer vector, q is indicated with the dotted line
representing the circular scatter pattern. b) Example of a scatter plot indicating the
Guinier region. c) Pairwise distance distribution illustrating how a globular protein with a
single domain might be projected versus a two-domain, globular protein. The maximum
distance (Dmax) is indicated. See Table 4.1 for definitions.
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Table 4.1: Definition of SAXS terms
Term Definition
I Intensity of scattering, has arbitrary units
q Also called s, has units of Å−1. It is the momentum transfer vector
which is related to the angle of scattering (2θ) and the wavelength
(λ) as follows: q=(4π·sinθ)/λ
Guinier Region of scattering at low q that is used for data quality control and
(region) to calculate Rg and I(0). Values should agree with P(r)
P(r) Pair-distance distribution function. Fourier transformation of SAXS
curve into real space. Produces a histogram of inter-atomic vectors.
Used to calculate Rg and I(0), the values should agree with the
Guinier region. Uses all data points but requires a value for Dmax
Rg Radius of gyration, has units of Å. The mean distance from the centre
of mass for a given molecule
I(0) The forward scattering at q=0, has units of cm−1. It is proportional to
molecular mass and protein concentration
Dmax Maximum dimension, has units of Å. The longest dimension for the
measured molecule
See Figure 4.3, also. Useful references: Jacques et al. 2012; Jacques and Trewhella 2010;
Kikhney and Svergun 2015; Korasick and Tanner 2018; Liu and Zwart 2012; Mertens and
Svergun 2010; Putnam et al. 2007; Rambo and Tainer 2011.
4.3 Aims
Aim 1 Characterise ASK1 and Trx1 binding and identify key cysteine residue(s)
Aim 2 Generate an in solution model of ASK1 and Trx1
Aim 3 Determine the effect of Trx1 and H2O2 on ASK1 kinase activity in vitro
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4.4 Results
4.4.1 Trx1 and ASK1 interact in vitro
Whilst a lot is known about ASK1 signalling and how Trx1 can modulate it, the
majority of data has come from cellular over-expression and immunoprecipitation based
methods. Accordingly, there is limited data from a molecular level informing us into
how ASK1 and Trx1 interact. The recombinant system used in Chapter 3 was used to
better understand the interaction between Trx1 and isolated regions of ASK1 in vitro.
A pull-down assay was initially performed to investigate ASK1-Trx1 binding in
vitro (Figure 4.4). His6-tagged ASK1 constructs (bound on HIS-Select nickel affinity
resin) were mixed with an E. coli clarified lysate containing untagged, human Trx1WT,1.
The resin was washed and the resultant bound proteins were analysed by western blot
(Figure 4.4). Due to the fact that the association between ASK1 and Trx1 is regarded
as being redox-regulated (Saitoh et al., 1998), the assay was washed either under non-
reducing conditions (no DTT), or reducing conditions (with 2 mM DTT).
Four ASK1 constructs (ASK188–266, ASK188–338, ASK188–658 and, ASK188–941) were
tested and all were able to pull-down Trx1 under non-reducing conditions (Figure 4.4c,
Figure 4.4: ASK1 and Trx1 interact in vitro. Pull-down of untagged Trx1WT (see
Footnote 1) by His6-tagged ASK1 constructs. a) Protein constructs used in this assay. b)
Illustration of pull down. ASK1 proteins on HIS-Select resin (bait) are incubated with a
clarified E. coli lysate containing untagged human Trx1WT (prey). The resin was washed
and analysed by western blot. c) Western blot of pull-down with anti-Trx1 in green and
anti-His6 in red. Ponceau S stained membrane is shown below for total protein. The
individual channels and a Coomassie stained SDS-PAGE gel are shown in the Appendix
Figure C.1.
1For the pull-down assay (Figure 4.4), WT Trx1 was used. Trx1 is also able to form a disulfide-
linked homodimer via Cys73 (Weichsel et al., 1996). However, the significance of Cys73 disulfide-linked
dimers, and whether they form in vivo, is unclear (Campos-Acevedo et al., 2017; Gronenborn et al.,
1999). To stop Cys73 disulfide bonds forming, Cys73 was mutated to serine. All further experiments
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Figure 4.4: ASK1 and Trx1 interact in vitro. Figure legend on previous page.
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left). The two shorter ASK1 constructs (ASK188–266 and ASK188–338) were able to pull
down a greater amount of Trx1 suggesting that these shorter constructs have a higher
affinity for Trx1.
When performed under reducing conditions (2 mM DTT was included in binding
and wash buffer), there was a decrease in the amount of Trx1 pulled-down by ASK1
(Figure 4.4c, right). Moreover, under reducing conditions, Trx1 was only detected via
antibody against Trx1. Indeed, when stained with Coomassie there is no noticeable
Trx1 band over the background (Appendix Figure C.1) Additionally, when looking at
the individual channels for α-Trx1, there appears to be non-specific binding to the resin.
Nonetheless, the western blot shows Trx1 remaining bound to ASK188–266, ASK188–338,
and ASK188–941, but not ASK188–658.
One caveat of the approach used for the pull-down is that it is purely qualitative
The different sizes of the ASK1 constructs used will result in different molar amounts
of each construct bound on the resin (as binding is relative to protein mass). Therefore
the stoichiometry of resin:ASK1:Trx1 is not consistent between each ASK1 construct.
Overall, the pull-down demonstrates ASK1-Trx1 binding to all tested ASK1 con-
structs under non-reducing conditions. However, ASK1-Trx1 binding is less definite
when performed under reducing conditions. The stark difference between the level of
Trx1 pulled-down by the shorter ASK1 constructs suggested that the interaction be-
tween ASK1 and Trx1 is (at least in part) sensitive to the redox status of one or both
of the proteins.
4.4.2 ASK1 can form a disulfide-linked species with Trx1
ASK1 regulation by Trx1 is viewed as being chiefly controlled by reduction and oxida-
tion (Saitoh et al., 1998). There have been contrasting reports suggesting that Trx1
oxidation is key to regulation vs ASK1 being the target of oxidation (see 4.2.2; Nadeau
et al., 2007; Saitoh et al., 1998).
The previous pull-down experiment above (4.4.1) indicated that the recombinant
ASK1 used in this work may also associate with Trx1 in a redox-sensitive manner.
To investigate this, ASK1 was incubated with purified Trx1 (see Methods, 2.6.15)
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under non-reducing conditions. A ‘kinetic trap’ mutant of Trx1 was used (Trx1C35S).
Trx1C35S is able to interact with disulfide bonds within protein substrates forming a
mixed-species disulfide via Trx1-Cys32 (see Figure 4.1). In the absence of the second
cysteine residue (Cys35), Trx1C35S is unable to break the inter-molecular disulfide bond,
forming a covalently-linked species (Schwertassek et al., 2007).
Following incubation and analysis by SDS-PAGE, a band at the approximate molec-
ular weight of ASK188–658 plus Trx1 appeared (∼75 kDa), but only when incubated
with Trx1C35S (Figure 4.5b, top). The 75 kDa band was no longer present when the
same samples were treated with DTT (Figure 4.5b, bottom). The disappearance of
the 75 kDa band is indicative of a disulfide bond between two species. The molecular
weight of the DTT-sensitive species suggested that ASK188–658 and Trx1
C35S are able
to form a complex with 1:1 stoichiometry containing an inter-molecular disulfide bond.
A similar assay using ASK188–338 also formed a DTT sensitive species, suggesting that
the cysteine residue(s) that are critical in the formation of this species are located
within ASK188–338 (Appendix Figure C.2).
Curiously, incubation of ASK188–658 on its own did not result in the formation of any
DTT-sensitive species (Figure 4.5b, left). For Trx1 to form a mixed-species with ASK1
it suggests that ASK1 contains an intra-molecular disulfide bond or other cysteine
oxidation product (discussed in 4.5.2.1).
The observation of ASK1 forming an inter-molecular disulfide bond with Trx1 reca-
pitulates the observations by Nadeau et al. (2007). The observations by Nadeau et al.
(2007) were based upon an over-expression and immunoprecipitation methodology.
The demonstration of similar results within this work—using purified, recombinant
proteins—demonstrates that ASK1 (residues 88–338) and Trx1 alone are sufficient to
form a covalent complex. The next question asked was which cysteine residue(s) within
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Figure 4.5: ASK1 forms an inter-molecular disulfide bond with Trx1. a) Schematic of
protein constructs in this assay. All proteins used for non-reducing experiments were
purified under reducing conditions then had a final SEC step without any reductant, after
which they were snap-frozen as soon as they had eluted from the column. b) ASK188–658
(20 µM) was incubated with equimolar amounts of either Trx1 or Trx1C35S (in a buffer
containing 10 mM HEPES, pH 7.6, 300 mM NaCl). The proteins were incubated for the
times indicated at 4 °C. At each time point (every 24 hours), a sample was removed and
placed into a non-reducing SDS-PAGE buffer, containing 10 mM IAM (to alkylate cysteine
thiols and stop potential disulfide-shuffling) and incubated in the dark for 30 minutes at
room temperature. Samples were resolved by non-reducing and reducing SDS-PAGE (for
reducing gels, the samples were incubated with 100 mM DTT for 5 minutes at RT before
loading). Proteins were visualised with Coomassie. Trx1 alone gels are given in Appendix
Figure C.4.
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4.4.3 ASK1-Cys250 is essential for ASK1 inter-molecular disul-
fide bond with Trx1
Full-length, human ASK1 contains 23 cysteine residues (Figure 4.6a). N-terminal to
the kinase domain (up to residue 669), there are 16 cysteine residues. Given that
ASK188–338 is sufficient to form an inter-molecular disulfide bond (4.4.2) and ASK188–266
and ASK188–338 have apparent higher binding affinities for Trx1 (4.4.1), it suggests
that the cysteine residue(s) required are within residues 88 to 338. Preliminary mass
spectrometry data (Jamieson and Mace, unpublished) indicated that Cys206, Cys225
or 226 and, Cys250 were the most likely candidates for forming the mixed-species
disulfide with Trx1. Therefore, these residues were mutated (to serine) and the mutant




Cys225,226Ser were all able to form
a DTT-sensitive species when incubated with Trx1C35S (Figure 4.6b). Western blotting
confirmed that the 75 kDa molecular weight species did contain Trx1 (Figure 4.6b).
ASK188–658
C250S did not form a 75 kDa species, indicating that ASK1 Cys250 is re-
quired for the formation of a mixed-disulfide with Trx1. When analysed in an identical
manner as in Figure 4.5, ASK188–658
C250S also did not form a mixed-species disulfide
(Appendix Figure C.4). Lastly, a variant of ASK188–266 that only has Cys250 (all
other cysteines are mutated to serine) is still able to form a mixed-disulfide species
with ASK1, demonstrating that Cys250 is sufficient to form the species (Appendix
Figure C.5).
During the course of this Thesis, Kylarova et al. (2016) also reported that ASK1
was able to form an inter-molecular disulfide bond with Trx1 in vitro. Kylarova et al.
(2016) incubated recombinant ASK1 (residues 88 to 302) with equimolar amounts
of recombinant Trx1 (Cys35Ser, Cys73Ser) and a 5-fold molar excess of H2O2 for 15
minutes and analysed the resulting species by non-reducing SDS-PAGE. Kylarova et al.
(2016) used mass spectrometry to determine that ASK1-Cys200 was in the mixed-
species disulfide with Trx1-Cys32. However, they did not carry out any validation
(such as using a Cys200 mutant). When ASK188–658
C200S was incubated with Trx1C35S,
as in Figure 4.5, a mixed-disulfide species was still able to form (Appendix Figure C.4).
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Nadeau et al. (2007) originally described that multiple cysteine residues were able to
form disulfide-linked species, so it is feasible that multiple cysteine residues within
ASK1 will be able to form a disulfide-linked species with Trx1. However, in this
Chapter, it is shown that Cys250 is sufficient and necessary for the formation of a mixed
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Figure 4.6: ASK1-Cys250 is essential in forming inter-molecular disulfide bond with Trx1.
a) Schematic of protein constructs used in this assay showing the location of all cysteine
residues in ASK1 and the residues mutated in this assay. b) ASK188–658 (2 µM) was
incubated with either Trx1 or Trx1C35S (20 µM), in PBS (pH 7.4) for 16 hours at 4 °C.
Samples were blocked with 10 mM IAM in SDS sample buffer and subjected to
non-reducing SDS-PAGE and western blot (against Trx1) and reducing SDS-PAGE. Full
gels and blots are shown in Appendix Figure C.3. Identical results were obtained when 20
µM H2O2 was added to the assay (Appendix Figure C.3).
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4.4.4 Biophysical analysis of ASK1 and Trx1
4.4.4.1 Trx1-fusion proteins are able to form a mixed-species disulfide with
ASK1
The desired method to study ASK1 and Trx1 by SAXS was via a stable covalent-
complex. To this end, and because previous work had indicated that a disulfide-linked
species forms between ASK188–658 and Trx1
C35S (4.4.2), a disulfide-linked species was
determined to be the best candidate for analysis by SAXS. However, the relatively small
size difference between ASK188–658 and ASK188–658-Trx1 (around 65 and 75 kDa, respec-
tively) made it challenging to isolate a native ASK1-Trx1 complex. To overcome this
limitation, two new Trx1 containing fusion-protein constructs were designed, cloned,
expressed and purified. The first construct was an N-terminal fusion with E. coli MBP,
the second construct was a C-terminal fusion T7 phage lysozyme (referred to as MBP-
Trx1C35S and Trx1C35S-Lys hereafter). Both of these fusion constructs contained no ad-
ditional cysteine residues (the amino acid sequences are given in Appendix Figure C.10)
helping to ensure only the desired disulfide-bond with ASK1 would form. Additionally,
a triple cysteine mutant of ASK188–658 was also used (ASK188–658
C206S, C225,226S).
Both Trx1C35S-Lys and MBP-Trx1C35S were able to form an inter-molecular disul-
fide bond with ASK188–658
C206S, C225,226S (Figure 4.7 for Trx1C35S-Lys and Appendix
Figure C.6 for MBP-Trx1C35S). When analysed by SEC, both species eluted at the
predicted molecular weight (before the 150 kDa marker; Figure 4.8 for Trx1-Lys and
Appendix Figure C.7 for Trx1-MBP). However, when analysed by non-reducing SDS-
PAGE, the species ran larger than expected, around the 250 kDa Mw marker for
MBP-Trx1C35S and 150 kDa for Trx1C35S-Lys (Appendix Figure C.6). However, when
the ASK1-MBP-Trx1C35S species was treated with 3C-protease (as MBP-Trx1C35S con-
tains a 3C-cleavage site between MBP and Trx1) the expected size for the complex
(∼75 kDa) was seen on non-reducing SDS-PAGE (Appendix Figure C.7).
Whilst both Trx1-fusion proteins were able to form a disulfide-linked species with
ASK188–658, the overall yield from using Trx1
C35S-Lys was greater. Additionally, the
similar molecular weights of MBP-Trx1C35S and ASK188–658 (Appendix Figure C.6)







































































































































Figure 4.7: Trx1-fusion proteins form a mixed-species disulfide with ASK1. a) Schematic
showing constructs used. C-terminal T7-Lysozyme fused to Trx1C35S, described in the
Figure as Trx1-Lys. An ASK1 cysteine mutant (ASK188–658
C206S, C225,226S) was also used
(referred to as ASK1 in the remainder of this legend). b) Trx1-Lys was purified by
nickel-affinity before being reduced, on ice, for 1 hour with 2 mM DTT and resolved by
non-reducing SEC. ASK1 was purified by nickel affinity chromatography and immediately
snap-frozen, whilst Trx1-Lys was stored at 4 °C for 4 days before being snap-frozen.
Thawed ASK1 and Trx1-Lys were combined (in a buffer containing 10 mM HEPES (pH
7.6), 300 mM NaCl) and at 37 °C with samples taken at the indicated times. At the
endpoint, samples were alkylated in non-reducing SDS sample buffer (50 mM IAM, 30
minutes at room temperature, in the dark) before analysis by SDS-PAGE. All gels were
stained with Coomassie. For reducing gels, samples were incubated with 100 mM DTT for
5 minutes at room temperature.
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single size-exclusion run. For these reasons, and due to impending synchrotron time,
Trx1C35S-Lys was taken forwards in order to isolate a stable disulfide-linked species
with ASK1.
4.4.4.2 Preparation of a disulfide-linked ASK1-Trx1 for SAXS analysis
Following on from the preliminary work using Trx1-fusion proteins (4.4.4.1), a large-
scale preparation of a disulfide-linked ASK1-Trx1 species was produced. Full details
are given in the methods (2.9). Briefly, ASK188–658
C206S, C225,226S and Trx1C35S-Lys were
incubated together at 37 °C for 4 hours. After incubation, the sample was alkylated
with IAM to block any potential disulfide-rearrangement. The entire sample was con-
centrated and individual species were separated via SEC (Figure 4.8). Performing
incubations with ASK188–658
WT yielded a similar complex (Appendix Figure C.8). By
comparison, incubation of ASK188–658
C250S with Trx1C35S-Lys resulted in no complex
(Appendix Figure C.8). These observations meant that a stable disulfide species had








































































































Figure 4.8: Preparation of ASK1-Trx1-Lys species for SAXS. a) Schematic showing
constructs used. Trx1C35S, C73S, C-terminally fused to T7-Lysozyme, described as Trx1-Lys.
An ASK1 cysteine mutant (ASK188–658
C206S, C225,226S), was also used (referred to as ASK1
in the remainder of this legend). For details on complex formation see methods (2.9).
Briefly, purified ASK1 and Trx1-Lys were mixed and incubated at 37 °C. Pre- and
post-incubation samples are shown on b) as input ‘pre’ and ‘post’. The sample was
alkylated with IAM before resolving by SEC (c). SEC fractions were analysed by
SDS-PAGE (b), and relevant fractions combined. Sample outputs are shown in (b).
Arrowheads below (c) indicate SEC molecular weight standards. A reducing gel of these
samples is shown in Appendix Figure C.8.
105
4.4.5 SEC-SAXS analysis of ASK1-Trx1 complex
The ASK1-Trx1 disulfide linked-complex from 4.4.4.2 was analysed by SEC-SAXS at
the Australian Synchrotron on the SAXS/WAXS beamline. Primary data reduction
and processing were performed by Associate Professor James Murphy (Walter and
Eliza Hall Institute, Melbourne, Australia). Data collection and analysis statistics are
shown in Table 4.2. Figure 4.9 shows the Rg from both Guinier analysis and P(r)
analysis, as well as the P(r) distribution curves. The scattering plots of the data are
shown (along with fits of rigid-body modelling) in Figure 4.10 (the scattering data on
their own can also be found in Appendix Figure C.9).
Guinier and P(r) analysis both give an approximation of the same structural values
(namely I(0) and Rg). In general, the values from either analysis should agree with one
another (Jacques et al., 2012). Overall the values for the analysed species show good
agreement (Table 4.2 and Figure 4.9). However, the Rg value for ASK188–658
C206S, C225,226S
differs by 1 Å. Differences between the P(r) and Guinier analyses can indicate aggrega-
tion within the sample (Putnam et al., 2007). However, the Guinier plot (Figure 4.10a-
c)iii) indicates that there is minimum contribution from aggregates to the scattering
data.
The experimental molecular weight (as calculated by SAXS-MoW (Fischer et al.,
2010), see Table 4.2) is within 5% of the predicted molecular weight for Trx1-Lys
(predicted: 31.58 kDa, experimental: 30.01 kDa). However, for ASK188–658 alone and
the ASK1-Trx1-Lys complex the values differ more from the predicted values (33.4 and
20.6% differences, respectively). Nonetheless, the sum of the determined molecular
weights for the individual ASK1 and Trx1-Lys species (88.4 and 30.0 kDa, respectively)
agree with the observed molecular weight for the ASK1-Trx1 complex (118.0 kDa),
agreeing with a 1:1 (ASK1:Trx1) stoichiometry for the complex.
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Table 4.2: SAXS data collection and analysis statistics
Variable ASK188–658(alone) Trx1-Lys (alone) ASK1-Trx1-Lys (complex)
Data collection parameters
Instrument Australian Synchrotron, SAXS/WAXS beamline
Beam geometry 120 µm point source
Wavelength (Å) 1.033
Exposure time (s) 2
Temperature (K) 285
q range (Å−1) 0.0057–0.334 0.0106–0.625 0.0057–0.334
Protein concentration1 50 µL of 12.5 mg/mL 50 µL of 7.5 mg/mL 50 µL of 8.5 mg/mL
Structural parameters
I(0) (cm−1), from P(r) 0.0692± 0.0002 0.0240± 0.0001 0.0497± 0.0002
Rg (Å), from P(r) 36.54± 0.12 24.00± 0.11 43.86± 0.18
Dmax (Å) 120 70 135
I(0) (cm−1), from Guinier 0.0690± 0.0002 0.0240± 0.0001 0.0500± 0.0003
Rg (Å), from Guinier 35.64± 0.18 23.98± 0.17 43.26± 0.35
Molecular mass (kDa), predicted 66.25 31.58 97.82
Molecular mass (kDa), experimental 88.35 30.01 118.00
Software used
Primary data reduction Scatterbrain (Australian Synchrotron)
Data processing PRIMUS, GNOM
Molecular weight estimation SAXS MoW
Computation of model intensities CRYSOL
Rigid-body modelling CORAL
3D graphical representations PyMol
1—The indicated volume and concentration of protein was analysed via inline SEC. ASK188–658(alone)—ASK188–658
C206S,C225,226S, Trx1-Lys
(alone)—Trx1C35S with C-terminal lysozyme, ASK1-Trx1-Lys (complex)—disulfide-linked species of the aforementioned ASK1 and Trx1-Lys proteins.
Full protein sequences are given in Appendix Figure C.10. For a definition of terms see Table 4.1.
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4.4.5.1 ASK1-Trx1 complex is relatively compact
The main conclusion from the SAXS data is that, overall, the ASK1-Trx1 complex
has a relatively compact arrangement. The argument for compactness comes from a
comparison of the Rg and Dmax values, as well as the overall P(r) distribution curves
(Table 4.2 and Figure 4.9). The Rg value represents the mean distance from the centre
of mass of a molecule and gives an estimation of the molecule size in solution (Putnam
et al., 2007). ASK188–658
C206S, C225,226S has an Rg value of ∼36 Å, and Trx1C35S-Lys
∼24 Å. The ASK1-Trx1 complex, by comparison, has an Rg value of ∼43.6 Å, which
is smaller than the sum of the two individual components.
The P(r) curve indicates the distribution of inter-atomic vectors, i.e. the sum of
distances between any two atoms within a molecule. The shape of the curve represents,
to some degree, the overall topology of a molecule in solution (Putnam et al., 2007).
The Dmax represents the point where P(r)=0 and is the maximum dimension for a given













































Figure 4.9: Comparison of Rg values and P(r) curves. Graphical representation of (a) Rg
values and (b) normalised P(r) distribution from P(r) and Guinier analysis (Table 4.2).
ASK1 alone—ASK188–658
C206S,C225,226S, Trx1-Lys—Trx1C35S with C-terminal lysozyme,
ASK1-Trx1-Lys—disulfide-linked species of the aforementioned ASK1 and Trx1-Lys
proteins. Normalised P(r) curves were generated by dividing the raw P(r) value by the
maximum P(r) value for a given curve. Raw P(r) curves are shown in Appendix
Figure C.9d.
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Dmax values for the individual ASK1 and Trx1-Lys species and the complex again
shows the same result as comparing the Rg values. The complex P(r) curve is not
drastically different from the curve of ASK1 alone (Figure 4.9b). Additionally, the
sum of the individual Dmax values (70 and 120 Å) is less than that for the complex
(135 Å). However, the Dmax value can be adjusted by the user and should not be taken
at face value. Nonetheless, overall the Rg values and P(r) distributions support the
notion that Trx1-Lys forms a compact unit with ASK1, which in turn suggests a change
in conformation of ASK1. Modelling of the complex and individual species can better
represent changes in conformation.
4.4.5.2 Rigid-body modelling of ASK1-Trx1 complex
SAXS data can be used to model a multi-domain protein when only structures of
individual domains are known (Putnam et al., 2007). For modelling the SAXS data
presented in 4.4.5, the program ‘complexes with random loops’ (CORAL, part of the
ATSAS package; Franke et al. 2017; Petoukhov et al. 2012) was used. The program
CRYSOL (also part of the ATSAS package; Franke et al. 2017; Svergun et al. 1995)
was used to generate theoretical scattering curves against which the goodness of fits
for the models—denoted by a chi (χ) value—is produced. In general, the lower the χ
value, the better the data agrees with the model. However, it should be noted that the
χ value is relative for a given data set, and therefore should not be used to compare
models for different data sets.
There is no current structure of the ASK1-TBD (88–269)2. Consequently, to model
ASK188–658, the recent crystal structure of ASK1269–658 (PDB ID: 5ULM; Weijman et al.
2017) along with a de novo model for ASK188–266 was used. The de novo ASK188–266
was generated using the Robetta server (Kim et al., 2004). It is the same de novo
model as used in Weijman et al. (2017). The model depicts a globular protein with
an α-β-sandwich (a core of β-sheets surrounded by α-helices, Appendix Figure C.11).
Five models were generated by the Robetta server (Kim et al., 2004) and a comparison
of all is shown in Appendix Figure C.11. For modelling using CORAL, the same
2Numerous attempts were made towards crystallising N-terminal ASK1 constructs (e.g., 88–266,
88–338 and 88–658, all with and without Trx1). However, no ASK1-containing crystals formed.
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Robetta model was used in this work as in Weijman et al. (2017). In this fashion,
there was some degree of freedom within where the ASK1-TBD could be placed by
CORAL relative to ASK1269–658.
For the ASK1-Trx1-Lys complex, ASK188–658 was allowed to be modelled as above
(i.e. allowing a positional change for the ASK1-TBD). Trx1-Lys was modelled indepen-
dently using the crystal structure of Trx1C35S in a mixed-disulfide with TrxR1 (PDB ID:
3QFB; Fritz-Wolf et al. 2011) and T4 lysozyme (PDB ID: 2I2L; Vetter et al. 1996). The
model output was then used as a rigid molecule in combination with ASK1269–658 and
the ASK1-TBD model. The disulfide-linkage between ASK1 and Trx1-Lys (Cys250–
Cys32) enabled the use of a distance restriction, where αC atoms from each cysteine
residue within the disulfide bond should be no more than 10Å apart). This distance
was based on observations by Schmidt et al. (2006), who analysed over 6,000 disulfide
bonds from the PDB and saw that the distance between the Cα from each cysteine
residue (within the disulfide bond) was between 5.61 and 5.65 Å. A distance of 10 Å
was used to prevent CORAL placing two molecules in overlapping space.
4.4.5.3 Proposed model for Trx1 mediated inhibition of ASK1
The models generated using CORAL showed a reasonable agreement with the experi-
mental data (Figure 4.10). Comparison with the CORAL models shown in this Chapter
with the previous BUNCH models (from Weijman et al. 2017 and presented in Chap-
ter 3) highlights two possible conformations for the ASK1-TBD which can explain how
ASK1 activity may be controlled (Figure 4.11).
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b) ASK1-Trx1-Lys


































































































































































Figure 4.10: CORAL rigid-body modelling of SAXS data. Figure legend on next page.
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Figure 4.10: CORAL rigid-body modelling of SAXS data. a) ASK188–658
C206S, C225,226S
(ASK1) alone. i. CORAL model. The fit of the model to experimental data was calculated
using CRYSOL ii. q vs Log(I) and iii. Guinier region (q2 vs Ln(I)). The agreement of the
model to experimental data is shown by the χ value. b) ASK1-Trx1C35S-Lys disulfide-linked
complex. i., ii., and iii. are as in a). The red patch within the PH domain and blue patch
within the 7×TPR denote the sites mutated in Chapter 3 (see Figure 3.8). c) Agreement
between the Trx1-Lys (alone) CORAL model that is used to generate b). i. and ii. are
theoretical scattering and Guinier regions for the model compared to the experimental data

















BUNCH model (Weijman et al., 2017)
CORAL model (This work)
1 : ASK1269–658
1': Proposed substrate docking site
2 : ASK1 kinase domain
3 and 4: TBD from ASK188–658
5 : TBD from ASK1-Trx1-Lys
6 : TBD from ASK188–941














Figure 4.11: Comparison of CORAL and BUNCH SAXS models. Overlay of the
ASK1-TBD positions in the CORAL models from Figure 4.10 and BUNCH models from
Weijman et al. (2017) (shown in Chapter 3, Figure 3.4) illustrating the proposed ‘open’ (a)
and ‘closed’ (b) forms. Positions are relative to ASK1269–658 (1) depending upon whether
they are from the BUNCH models (from Weijman et al., 2017) or CORAL models from this
work (note—lysozyme from the ASK1-Trx1-Lys complex is omitted for clarity). c) Overlay
of the CORAL models in this work (Figure 4.10) illustrating the relative change in position
of the TBD. Models were rendered in PyMol.
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The model (Figure 4.12) proposes that the TBD-switching mechanism (proposed in
Chapter 3) can be modulated by Trx1. Under this model, the disulfide-linked complex
represents an inhibitory, ‘closed’ state whereby MKK6 recruitment to the PH domain
within ASK1269–658 is blocked by the TBD. Consequently, the release of Trx1 from the
TBD would allow the TBD to change to the ‘open’ form, permitting MKK6 recruitment
and downstream signalling. The proposed model would mean that addition of Trx1 to
in vitro kinase assays would result in inhibition of ASK1 and addition of the ‘kinetic





































Figure 4.12: Model of ASK1 regulation by Trx1. a) Inactive ASK1. i. The ASK1-TBD
can block recruitment of MKK6 to the ASK1-PH domain. ii. Trx1 maintains the
ASK1-TBD in a reduced state, whilst also preventing of MKK6 to the ASK1-PH domain.
b) Active ASK1. i. When H2O2 levels become elevated ASK1 becomes oxidised, and the
TBD becomes ‘locked’ in a more rigid conformation, allowing MKK6 to be recruited and
phosphorylated. ii. Trx1 can reduce ASK1, returning ASK1 to an inactive state.
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4.4.6 Functional evaluation of ASK1 regulation by Trx1 in
vitro
In order to test the proposed model for Trx1-mediated inhibition of ASK1, in vitro
kinase assays were used, performed essentially identical to as in Chapter 3, but with
the notable difference that all proteins used in the assay were reduced with DTT,
before a final SEC step under non-reducing conditions. The proteins were aliquoted
and snap-frozen as soon as they eluted from the SEC column. This step was used in
order to minimise potential non-specific oxidation.
Many assays were performed and the consistent result was that Trx1 does not alter
ASK1 kinase activity. Whilst these assays were being carried out, full-length, recom-
binant, ASK1 (ASK12–1374) expressed and purified from insect cells became available
(see Methods, 2.6.14). Trx1 also did not alter ASK12–1374 kinase activity. However,
there was one exception where Trx1 did inhibit ASK1 kinase activity. Addition of both
Trx1 and H2O2 resulted in inhibition of MKK6 phosphorylation (4.4.7.2). Table 4.3
provides a summary of performed assays.








88–941 DTT No App. Fig. C.12
88–941 Trx1 (reducing) No App. Fig. C.13
88–941 Trx1 (non-reducing) No Figure 4.13
Full-length Trx1 (reducing) No App. Fig. C.15
Full-length Trx1 (non-reducing) No Figure 4.14
88–941 H2O2 No Figure 4.15
88–941 H2O2 and Prdx1 No Figure 4.16
Full-length H2O2 and Prdx1 No App. Fig. C.17
88–941 H2O2 and Trx1 Yes (inhibition) Figure 4.17
88–941 H2O2 and Trx1 Yes (inhibition) Figure 4.18
App. Fig.—Appendix Figure. Reducing—2 mM DTT in assay. Non-reducing—no DTT.
See specific Figures for details.
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4.4.6.1 Trx1 does not inhibit ASK188–941 under reducing or non-reducing
conditions
Initially, effects from non-specific protein oxidation—that could have occurred during
protein preparation—were assessed. DTT was added into kinase assays (from 0 to 100
mM) performed with two different (2 and 6 µM) concentrations of ASK188–941. No
change (increase or decrease) in kinase activity was detected (Appendix Figure C.12).
Consequently, it could be assumed that any potential effect on activity from addi-
tion of Trx1 would be because of a specific Trx1-ASK1 interaction rather than the
oxidoreductase activity of Trx1 (which would be mimicked by DTT).
Next, Trx1 was added to the kinase assay (with ASK188–941) under both non-
reducing (Figure 4.13) and reducing (Appendix Figure C.13) conditions. Neither con-
dition affected the rate of MKK6 phosphorylation. Under non-reducing conditions, an
ASK1-Trx1 disulfide-linked species still formed as previously (Figure 4.13d). In order
to try to promote the formation of a disulfide-linked species, ASK188–941 and Trx1 were
incubated together overnight at 4 °C. The longer incubation of 1 µM ASK188–941 (in
the presence of 100 µM Trx1C35S) resulted in the majority of ASK1 forming a disulfide-
linked species with Trx1C35S (Appendix Figure C.14). However, despite the increased
amount of the disulfide-linked ASK1-Trx1 species, no effect on kinase activity was seen.
Figure 4.13: Trx1 does not inhibit ASK188–941 activity in vitro under non-reducing
conditions. a) Schematic of proteins in this assay. b) Flow diagram showing order of
incubations. c) Trx1 and d) Trx1C35S were incubated (at the concentrations indicated) with
ASK188–941 (1 µM) as indicated. ATP (50 µM) was added to start the reaction. At each
time point, a sample was removed and added to a non-reducing SDS-PAGE buffer
(containing 10 mM IAM). Samples were resolved by either Phos-Tag SDS-PAGE (for which
sample was reduced with the addition of 100 mM DTT for 5 minutes) or non-reducing
































































Figure 4.13: Trx1 does not inhibit ASK188–941 activity in vitro under non-reducing
conditions. Figure legend on previous page.
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4.4.6.2 Full-length ASK1 is not inhibited by Trx1 in vitro
As previously mentioned, full-length recombinant ASK1 (ASK12–1374) from insect cul-
ture (Sf 9 cells) became available during the course of this Thesis. The cultures were
supplied by Abigail Burgess and Jack Curry (both Mace laboratory) and subsequently
purified via nickel affinity chromatography (Figure 4.14c). The purified ASK12–1374 was
active and could phosphorylate MKK6 in vitro (Figure 4.14d). It should be noted, how-
ever, that the full-length recombinant ASK1 prepared in this manner always had either
contaminant proteins and/or degradation products present (Figure 4.14c). Therefore,
it is not conclusive whether the apparent kinase activity is from true full-length ASK1
or from a degradative species.
ASK12–1374 was incubated with Trx1 under non-reducing conditions and subjected
to an in vitro kinase assay (Figure 4.14). Phos-Tag SDS-PAGE, as well as western blot-
ting for p-MKK6, were used to monitor MKK6 phosphorylation in case the increased
sensitivity of western blotting would reveal a more subtle change. In agreement with
the Phos-Tag SDS-PAGE analysis, no change in activity was detected by western blot
(Figure 4.14c).
Overall, the addition of Trx1 did not alter ASK1 activity under reducing or non-
reducing conditions. All of the conditions tested thus far can be considered ‘reductive’
as they have contained DTT (a chemical reductant), Trx1 (normally a cellular reduc-
tant), or both DTT and Trx1. To further assess the implications of a lack of change
of activity, the effect of ‘oxidising’ agents on ASK1 was next considered.
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Figure 4.14: Trx1 does not inhibit full-length ASK1 in vitro. a) Schematic of proteins in
this assay. b) Flow-diagram showing order of addition of proteins. c) SDS-PAGE gel
showing elution from nickel affinity purification of ASK12–1374 from Sf 9 cells. The
arrowhead indicates the position of ASK12–1374. d) In vitro kinase assay conducted under
non-reducing conditions (no DTT) with addition of indicated amounts of Trx1 or Trx1C35S.
The assay was started with addition of 1 mM ATP. Note—the actual concentration of
ASK12–1374 in the assay was not quantifiable by A280 nm but based on the band from
purification (c), it was estimated to be at 0.1–0.5 µM. The assay was analysed by both
Phos-Tag SDS-PAGE and western blot (for p-MKK6), both under reducing conditions. An
equivalent assay under reducing conditions (2 mM DTT) was also performed with identical
results (Appendix Figure C.15).
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4.4.7 Functional evaluation of ASK1-Trx1 under oxidising con-
ditions
4.4.7.1 Addition of H2O2 or Prdx1 does not change ASK1 activity in vitro
Treatment of many human cell lines with H2O2 is sufficient to activate ASK1 and down-
stream signalling pathways (Jarvis et al., 2012; Nadeau et al., 2009, 2007; Saitoh et al.,
1998). In combination with these observations—and owing to the lack of inhibition
from addition of Trx1 (or DTT)—H2O2 was added to in vitro kinase assays. Addition
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Figure 4.15: ASK1 kinase activity is not changed by H2O2. a) Schematic of proteins in
this assay. b) Flow diagram showing how proteins were incubated. c) ASK188–941 (1 µM)
was incubated with up to a 10-fold molar excess of H2O2 for 30 minutes at room
temperature before being added to MKK6 (3 µM) and the kinase assay starting. The
reaction was started with the addition of 50 µM ATP. The assay was analysed with
Phos-Tag SDS-PAGE and proteins were visualised with Coomassie.
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The thiol peroxidase protein, Prdx1, has been postulated to be able to oxidise ASK1
in human U937 cells, thereby altering ASK1 activity (Jarvis et al., 2012). To this end,
recombinant human Prdx1 was added to in vitro kinase assays with both ASK188–941
and ASK12–1374. Prdxs are well-known for being sensitive to oxidation in vitro, causing
Prdx1 to run as a disulfide-linked dimer on non-reducing SDS-PAGE (Winterbourn and
Peskin, 2016). To compensate, the Prdx1 used in assays was first reduced with DTT,
before subsequent desalting through a spin-column (Appendix Figure C.16a). Under
these conditions, reduced, monomeric Prdx1 could be maintained and was sensitive to
H2O2 induced dimerisation (Appendix Figure C.16b). When Prdx1 was added (either
1 or 10 µM) to an in vitro kinase assay with ASK188–941 and H2O2 was added (10 µM),
there was no change in MKK6 phosphorylation (Figure 4.16). A similar experiment
was also performed using ASK12–1374 and Prdx1 with no detectable change in the
appearance of p-MKK6 (Appendix Figure C.17).
Overall, the addition of H2O2 did not change the rate of MKK6 phosphorylation
by ASK1. As ASK1 regulation by H2O2 and Trx1 in vivo can be regarded as being
opposites, with H2O2 activating and Trx1 inhibiting ASK1, a final set of assays was
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Figure 4.16: ASK1 kinase activity is not changed by Prdx1. a) Schematic of proteins in
this assay. b) Flow diagram showing the order proteins and H2O2 were combined. c)
Recombinant, human Prdx1 was reduced and desalted before being added (at the
concentrations indicated) to ASK188–941 (1 µM) and H2O2 (either 0, 1 or 10 µM). The
proteins were incubated together for 15 minutes at room temperature before MKK6 was
added. The reaction was started with the addition of 50 µM ATP and analysed via
Phos-Tag SDS-PAGE. Proteins were visualised with Coomassie. The reduction and
desalting conditions for Prdx1 were sufficient to produce a predominately monomeric
species (on non-reducing SDS-PAGE that dimerised in response to treatment with H2O2
(Appendix C.16).
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4.4.7.2 Addition of H2O2 and Trx1 results in inhibition of MKK6 phos-
phorylation
As a final attempt to see whether any reductive or oxidative treatment could alter
MKK6 phosphorylation by ASK1, both H2O2 and Trx1 were included in the kinase
assay system. ASK188–941, Trx1 (Trx1 or Trx1
C35S) and H2O2 (up to 100 µMsee footnote 3)
were incubated together overnight (Figure 4.17a,b). The incubated proteins were then
used in an in vitro kinase assay with MKK6. No change in activity was seen with
either ASK1 alone (Appendix Figure C.18) or with Trx1 (Figure 4.17c). In contrast,
with Trx1C35S and 100 µM H2O2, there was a decrease in the appearance of p-MKK6
(Figure 4.17d).
A follow-up assay (Figure 4.18) was performed to better understand what the pre-
cise cause of MKK6 phosphorylation inhibition was. The previous assay (as in Fig-
ure 4.17) used a combination of ASK1, Trx1 and H2O2 that were incubated together
for 15 minutes before addition of MKK6. The kinase assay performed used the same
stopping method as in Chapter 3—a reducing (including DTT) SDS-PAGE buffer.
Therefore, any information into the possible oxidation status of MKK6 was lost.
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Figure 4.17: Inhibition of MKK6 phosphorylation following incubation with Trx1 and
H2O2. Figure legend on next page.
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Figure 4.17: Inhibition of MKK6 phosphorylation following incubation with Trx1 and
H2O2. a) Schematic of proteins in this assay. b) Flow diagram showing the order of
addition of proteins and incubations. c) and d) ASK188–941 (1 µM) was incubated with
either 100 µM of Trx1 (c) or Trx1C35S (d) in addition to the indicated concentration of
H2O2 (see Footnote 3). ASK1, Trx1 and H2O2 were incubated together for 15 minutes at
room temperature, before which a sample was taken for analysis by non-reducing
SDS-PAGE (ii). The remainder had MKK6 added (3 µM) and an in vitro kinase assay was
performed. ATP (50 µM) was added to start the reaction. The assay was monitored by
Phos-Tag SDS-PAGE. All gels (i and ii) were stained with Coomassie. For non-reducing
SDS-PAGE (i), the sample was alkylated with 10 mM IAM. The arrowheads under d)ii.
indicate decreased levels of p-MKK6. An equivalent assay was also performed without the
addition of any Trx1, with no change in ASK1 activity detected (Appendix Figure C.18).
The follow-up assay deviated in two ways. Firstly, the pre-incubation was omitted.
Instead ASK1, Trx1 and MKK6 were combined before the simultaneous addition of
H2O2 (100 µM) and ATP (Figure 4.18b). Secondly, the kinase reaction was stopped
by placing the sample into a non-reducing sample buffer, supplemented with IAM (to
stop potential thiol-rearrangements). The results of performing the kinase assay this
way broadly mimicked those seen previously in Figure 4.17. The addition of H2O2 to
only ASK188–941 and MKK6 did not inhibit MKK6 phosphorylation, neither did the
addition of Trx1 (Figure 4.18c i.). By comparison, the addition of both H2O2 and
Trx1C35S resulted in less p-MKK6 forming (compared to the same assay set-up without
H2O2, Figure 4.18c i.). When the same samples were resolved by non-reducing SDS-
PAGE (Figure 4.18c ii.), several bands appeared when both Trx1C35S and H2O2 were
added. Most notably, the parent MKK6 band decreased and bands of an approximate
molecular weight of MKK6 in a disulfide-linked state with Trx1 appeared (which was
not present under any other condition). The occurrence of Trx1-MKK6 species likely
means that the observed inhibition of MKK6 phosphorylation (as in Figure 4.17) is
not due to modulation of ASK1, but oxidation from H2O2 followed with reduction by
Trx1C35S, which was unable to detach from MKK6. The implication of MKK6-Trx1
disulfide-linked species formation will be discussed in 4.5.4.
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Figure 4.18: Formation of MKK6-Trx1 species causes inhibition of MKK6
phosphorylation. a) Schematic showing which proteins are used in this assay. b) Flow
diagram illustrating the order proteins were combined. c) Kinase assay with ASK188–941 (1
µM) alone or with 100 µM Trx1 or Trx1C35S. The proteins were mixed with ATP (50 µM)
and H2O2 (either none or 100 µM) were simultaneously added before incubation at room
temperature. i. Samples were taken at the times indicated for the kinase assay resolved by
Phos-TagSDS-PAGE. ii. A separate sample was taken at 10 minutes and alkylated with 10
mM IAM for non-reducing SDS-PAGE.
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4.5 Discussion
4.5.1 ASK1 and Trx1 interact in vitro
To date, the majority of published studies on ASK1 and Trx1 have been from co-
immunoprecipitation following overexpression in cells. Across multiple studies, ASK1
and Trx1 (both endogenously and when over-expressed) have been seen to associate
via pull-downs (Cho et al., 2012; Fujino et al., 2007; Liu et al., 2000; Liu and Min,
2002; Nadeau et al., 2009, 2007; Saitoh et al., 1998). Two notable reports have instead
used a recombinant system which also showed an interaction between the ASK1-TBD
and Trx1 (Kosek et al., 2014; Kylarova et al., 2016).
In this work, an interaction between ASK1 and Trx1 is seen (Figure 4.4). The
interaction is stronger with shorter constructs of ASK1, agreeing with the notion that
residues 88–266 represent (or form the majority of) the core binding region for Trx1 by
ASK1. The fact that less Trx1 is pulled down by the longer ASK1 constructs (88–658
and 88–941) suggests that the interaction between ASK1 and Trx1 is antagonised by
regions outside the core binding domain.
Kosek et al. (2014) reported the binding affinity (Kd) for ASK188–302 and Trx1
as 0.3 µM. The observations in this work that longer ASK1 constructs (88–658 and
88–941) appear to have a decreased affinity for ASK1 (Figure 4.4), means that the
Kd reported by Kosek et al. (2014) should be interpreted with the understanding
that it may not accurately reflect the true ASK1-Trx1 interaction in vivo. When the
ASK1-Trx1 pull-down was performed under reducing conditions (with 2 mM DTT),
a decreased amount of Trx1 was pulled-down by all but the longest (88–941) ASK1
construct (Figure 4.4). This result is in contrast to the observation by Kosek et al.
(2014), where their observed Kd of 0.3 µM was under reducing conditions (2 mM
β-mercaptoethanol). Kosek et al. (2014) also used oxidised Trx1 (where Trx1 was
incubated with a 100-fold molar excess of H2O2 for 15 minutes), which caused the Kd
to increase to 6 µM, indicating a weaker affinity. When Kosek et al. (2014) mutated
both Trx1 active site cysteine residues to serine (Trx1C32S,C35S), the Kd increased to
900 µM. It is clear from the results by Kosek et al. (2014) (and a follow-up study by
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Kylarova et al. 2016), that the association between ASK1 and Trx1 is stronger under
reducing conditions. Therefore, without further follow-up work, the differences seen in
this work of a pull-down under reducing conditions (Figure 4.4) should be interpreted
with caution. It is clear, however, that the redox-status of cysteine residues, within
both Trx1 and ASK1, is important to the ASK1-Trx1 interaction.
4.5.2 Importance of Cys250 in ASK1 for ASK1 interaction
with Trx1
There are two proposed models for the interaction between ASK1 and Trx1 (see 4.2.2
and Figure 4.2). One model purports that the oxidoreductase activity of Trx1 is not
required, instead, oxidation of Trx1 causes Trx1 to disassociate from ASK1. The
other model states that Trx1 maintains ASK1 in a reduced state and therefore ASK1
oxidation can regulate ASK1 activity.
In this work, ASK1 and Trx1 were seen to interact in vitro allowing the formation
of an inter-molecular disulfide bond between ASK1 and Trx1 (Figure 4.6). Moreover,
when ASK1-Cys250 was mutated to Ser, the disulfide-linked species did not form (Fig-
ure 4.6 and Appendix Figure C.4c). The necessity of Cys250 was previously reported
by Nadeau et al. (2009), whereby Cys250 was described as being necessary for down-
stream signalling from ASK1, but not for activation (i.e. phosphorylation at ASK1
T838, see 1.4.3) of ASK1. On the contrary, Kylarova et al. (2016) described ASK1-
Cys200 as being able to form a mixed-species disulfide with Trx1. However, Kylarova
et al. (2016) did not validate the role of ASK1-Cys200 in the ASK1-Trx1 interaction.
In this work, when ASK1C200S was incubated with Trx1C35S, a mixed-disulfide species
between ASK1 and Trx1 still formed (Appendix Figure C.4d). Lastly, a variant of
ASK188–266 that only has Cys250 (the other 6 cysteine residues in the construct were
mutated to serine), was still able to form a mixed-species disulfide with Trx1 (Appendix
Figure C.5). The more important question, perhaps, is not which cysteine residue(s)
are important but rather how does Trx1 form a mixed-species disulfide with ASK1?
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4.5.2.1 Mechanism of ASK1-Trx1 mixed-species disulfide bond formation
Trx1, and other Trxs, have essential roles in all known forms of life. The primary role
of Trxs—as part of the ‘thioredoxin system’—is in the maintenance of the oxidation
status of a cell by reducing disulfide bonds (Linke and Jakob, 2003). The mechanism
occurs via two cysteines in the active site of Trx. One cysteine (Cys32 in human Trx1)
can attack a disulfide bond, forming an inter-molecular disulfide with the protein target
and Trx itself (Wynn et al., 1995). The second cysteine in the active site (Cys35 in
human Trx1) breaks the mixed-species disulfide, releasing oxidised Trx (containing an
intra-molecular disulfide bond between the two active site cysteines) and the reduced
substrate (see 4.2.1 and Figure 4.1b).
Following the system outlined above, ASK1 should contain an intra-molecular
disulfide-bond for Trx1 to break, allowing the inter-molecular disulfide bond to form.
However, as an ASK1 construct with only ASK1-Cys250 is still able to form a mixed-
species disulfide (Appendix Figure C.5) it suggests that perhaps a disulfide-bond within
ASK1 is not required. Trx-mediated reduction of non-disulfide, oxidised cysteines
(namely sulfenic acid and sulfenyl amide) has previously been reported in vitro (Fig-
ure 4.19; Kim and Kim, 2008; Schwertassek et al., 2014).
Sulfenic acid and sulfenyl amide require only a single cysteine residue and there-
fore make an enticing hypothesis for how ASK1 and Trx1 might form a disulfide-
linked species. Experimental evidence to investigate whether ASK1-Cys250 can form
a sulfenic acid or sulfenyl amide could come from chemical labelling and mass spec-
trometry. For example, the chemical 5,5-dimethylcyclohexane-1,3-dione, better known
as dimedone, has been used to identify sulfenic acids both from live cells and in vitro
(Nelson et al., 2010; Reddie et al., 2008). More recently, it has been suggested that
dimedone is not specific for sulfenic acids but rather sulfenyl amide, (Forman et al.,
2017). However, as sulfenic acid is able to act as a precursor to the formation of sulfenyl
amides, labelling with dimedone would prove invaluable regardless of the exact species
it reacts with (Defelipe et al., 2015; Forman et al., 2017; Salmeen et al., 2003; van
Montfort et al., 2003).
















Figure 4.19: Reduction of sulfenic acid and sulfenyl amides by Trx. Depicted is a cysteine
residue in a polypeptide chain. Shown is the cysteine side chain (SH) and the amide (NH)
from the adjacent C-terminal amino acid. 1) Cysteine thiols can be oxidised to sulfenic acid
by H2O2. 2) Sulfenic acids can condense on the amide from the polypeptide backbone to
form a cyclic sulfenyl amide. 3) Reduced Trxs (TrxRed)—and other thiol-containing
reductants, such as GSH)—are proposed to reduce both sulfenyl amides and sulfenic acids
via the formation of a mixed-species disulfide. 4) The second active site cysteine within Trx
can break the intermediate yielding oxidised Trx (TrxOx) and the reduced cysteine thiol.
formation of a sulfenic acid or sulfenyl amide would require Cys250 to be relatively
reactive. One aspect that controls the reactivity of cysteine residues within proteins is
the deprotonation of the thiol group, to form a thiolate (R-S−), which depends on the
pKa of the side chain (Poole, 2015). Cysteines at the N terminus of a helix are more
prone to being reactive owing to the electron withdrawing effect of the helix (Iqbalsyah
et al., 2006; Kortemme and Creighton, 1995; Paulsen and Carroll, 2013). Secondary
structure predictions for ASK1 show that Cys250 is predicted to be N-terminal to a
helix (Appendix Figure C.19), meaning it would be more likely to deprotonate. Other
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cysteine residues within the ASK1-TBD are not predicted to occur N-terminal to a
helix (Appendix Figure C.19). A high-resolution structure would be vital to confirm the
secondary structural prediction. During this Thesis, attempts were made to crystallise
the ASK1-TBD, but no ASK1-containing crystals formed. Potential strategies for
achieving a structure of full-length ASK1 will be outlined in the final Discussion (6.3.1).
4.5.3 Observation of multiple Trx1 species on non-reducing
SDS-PAGE
In this work, use of the ‘kinetic trap mutant’ version of Trx1 (Trx1C35S) facilitated
the formation of several Trx1-containing species (for example in Figure 4.7c and Ap-
pendix Figure C.4b). These bands are likely the result of oxidation of Trx1 cysteine
residues. Human Trx1 contains five cysteine residues—at positions 32, 35, 62, 69 and
73 (Figure 4.20a).
Trx1 Cys32 and Cys35 form the active site of the protein. Cys73, for example, is
well-noted as being able to form a disulfide-linked homo-dimer, which is why Trx1-
Cys73 is generally mutated to a serine (Weichsel et al., 1996). Nitrosylation of Cys62
and Cys73 is proposed to have a regulatory role for Trx1 (Haendeler et al., 2002;
Hashemy and Holmgren, 2008). Moreover, Cys62 and Cys69 have also been proposed
to form an additional intra-molecular disulfide bond within Trx1 (Cheng et al., 2011;
Watson et al., 2003). Intra-molecular disulfide bonds are well-known to increase the
mobility of a denatured protein on SDS-PAGE (Pollitt and Zalkin, 1983; Wells and
Powers, 1986). Cys62 has also been reported to form inter-molecular disulfide bonds,
forming homo-dimers (Hall et al., 2010; Weichsel et al., 2010). All of these modifications
can result in multiple Trx1-containing species that have different mobilities on non-
reducing SDS-PAGE.
A combination of all of the aforementioned disulfide bonds is likely the cause of
the multiple Trx1 bands, which possible specific species indicated in Figure 4.20. Ad-
ditionally, the samples were alkylated (with IAM) before running on SDS-PAGE. The
additional mass from alkylation could result in different sized products depending on






















































Figure 4.20: Multiple Trx1 species. a) Location of cysteine residues on reduced Trx1
(PDB ID: 1ERT; Weichsel et al. 1996) and a ‘fully-oxidised’ Trx1 (PDB ID: 5DQY; Hwang
et al. 2015). The oxidised form depicts intra-molecular Cys32-Cys35 and Cys62-Cys69
disulfide bonds. Structures were rendered in UCSF Chimera (Pettersen et al., 2004). b–d)
Examples of multiple Trx1-species on non-reducing SDS-PAGE seen in this work.
Postulated explanations are annotated. C62-C69—intra-molecular disulfide bond between
Cys62 and Cy69; Dimer ‡—unknown disulfide-linked dimer; R—reducing (+DTT),
NR—non-reducing (–DTT). See Figure sources for details on individual experiments. b)
from Appendix Figure C.4b; c) from Figure 4.7c; d) from Figure 4.17di.
bands only occur with the Cys35Ser mutant, and under conditions of long incubations,
or exposure to relatively high concentrations of H2O2, so are unlikely to be of any true
biological importance. In the context of this work, the multiple species do raise a point
of concern for the SAXS-analysis, as it will mean that the samples analysed were a
mixture of oxidised (containing an intra-molecular disulfide bond) and reduced Trx1.
Whilst it will not affect the quality of data, it will mean that the data is representative
of a heterogeneous population making accurate interpretation harder. To avoid this
in the future, the use of a Trx1 variant with all non-active site cysteines mutated to
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serine (i.e. Trx1C35S,C62S,C69S,C73S) should be considered.
4.5.4 H2O2 and Trx1 mediated inhibition of MKK6 phospho-
rylation
In addition to the multiple Trx1-only containing disulfide-linked species, the use of
Trx1C35S and H2O2 also caused the formation of Trx1-MKK6 disulfide-linked species
(Figure 4.18). The occurrence of Trx1-MKK6 species likely means that the observed
inhibition of MKK6 phosphorylation (as in Figure 4.17) is not due to alteration of
ASK1, but oxidation from H2O2 followed with reduction by Trx1
C35S, which was un-
able to detach from MKK6. MKK6 has previously described as being sensitive to
oxidation in vitro (Diao et al., 2010; Sturchler et al., 2010). Human MKK6 contains 6
cysteine residues, including one cysteine, Cys216 on the activation loop—near Ser207
and Thr211—the residues that are phosphorylated by ASK1, Appendix Figure C.20).
A formation of a Trx1-linked species at Cys216 therefore, would provide enough of a
steric hindrance to block access of ASK1 to MKK6-Ser207/Thr211, thereby stopping
phosphorylation without direct inhibition of ASK1 itself. Alternatively, Trx1-linkage
at other cysteine residues could also promote an unfavourable MKK6-conformation for
ASK1 to phosphorylate.
Ultimately, it is difficult to argue that the observed inhibition is anything other than
an in vitro artefact given that the inhibition was only seen from dual treatment with
Trx1C35S and higher levels of H2O2. Future work should either use enzymatic (such as
catalase) or physical (such as desalting) removal of excess H2O2 prior to the addition
of MKK6. Alternatively, mutagenesis of MKK6 to substitute the cysteine residues is
also possible.
4.5.5 In-solution SAXS model of ASK1 and Trx1
Use of a Trx1-lysozyme fusion protein construct enabled the isolation of a disulfide-
linked ASK1-Trx1 species. The isolated species was analysed using SAXS to determine
structural parameters and rigid body modelling to illustrate how the species may be
arranged (4.4.5). As previously discussed (4.5.3), the data needs to be interpreted in
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light of a likely heterogeneous population of oxidised and reduced (relative to Trx1-
Cys62 and Cys69) Trx1. Notwithstanding, the model can be of use to inform as to
the relative arrangement of ASK1 and Trx1. From the structural parameters—Rg and
P(r) (Figure 4.9)—it can be argued that the ASK1-Trx1 complex has a fairly compact
arrangement (for instance the sum of the Rg values for ASK1 and Trx1-Lys alone is
greater than actually observed for the ASK1-Trx1 complex). The compact arrangement
for the ASK1-Trx1 disulfide-linked complex was subsequently visualised by rigid body
modelling.
4.5.5.1 Comparison with published ASK1-Trx1 SAXS models
A SAXS model of ASK1 in complex with Trx1 was previously reported by Kosek et al.
(2014). As in the work presented in this Chapter, Kosek et al. (2014) used a de novo
model of the ASK1-TBD (corresponding to residues 88–302). The overall ASK1-TBD
model used by Kosek et al. (2014) is broadly similar to the de novo model used in this
work (4.4.5, and in Weijman et al., 2017)—a globular protein with an α-β-sandwich.
Kosek et al. (2014) proposed, based on SAXS and other biophysical analyses, that the
ASK1-TBD is a fairly rigid domain, and does not drastically change in shape upon
binding with Trx1 (forming a non-covalent complex). Furthermore, the complex is
proposed to be fairly compact. However, the model presented by Kosek et al. (2014)
also assumes that ASK1 contains a coiled-coil within its N terminus (residues 272 to
302). From the crystal structure of ASK1269–658 it is clear that within there is no coiled-
coil and instead this portion of ASK1 has a closely-packed arrangement (Weijman et al.,
2017).
On the whole, the model proposed by (Kosek et al., 2014) is useful as it analysed
the more isolated ASK1-TBD as opposed to the longer N-terminal region used in this
work (ASK188–658). The data agree with the TBD being a relatively compact, globular
domain (as assumed by the Robetta models; 4.4.5.2 and Appendix Figure C.11). Be-
yond this, it is difficult to extrapolate. Kylarova et al. (2016) refined the model with
their observations that Cys200 can form a disulfide bond, therefore, adjusting their de
novo model so that ASK1-Cys200 and Trx1-Cys32 are relatively close. As they saw an
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ASK1-Cys200–Trx1-Cys32 linkage, the model proposed by Kylarova et al. (2016) places
Cys250 on a loop far away from the active site of Trx1. Ultimately, the low-resolution
data that SAXS is capable of is useful for informing of the general relative arrange-
ment of ASK1 and Trx1. Understanding how and why specific residues within either
protein can control the protein-protein interaction requires higher resolution data from
methods such as X-ray crystallography and this will be explored further in the final
Discussion (6.3.1).
4.5.6 Trx1 does not inhibit ASK1 in vitro
Within cells, Trx1 has long been regarded as a direct inhibitor of ASK1 signalling
(Saitoh et al., 1998). The general viewpoint has been that Trx1 associates with the N
terminus of ASK1, blocking ASK1 N-terminal oligomerisation. Disassociation of Trx1
is required to allow for the formation of a fully active ASK1 complex (see 4.2.2; Fujino
et al., 2007; Saitoh et al., 1998). Exactly how Trx1 inhibits ASK1 has remained elusive
(see 4.2.2) hence in this work a biophysical model of ASK1-Trx1 was developed (4.4.5)
and in vitro kinase assays were performed (4.4.6).
Whilst in vitro kinase assays have been performed on ASK1 previously, the approach
used has generally been to over-express and immunoprecipitate ASK1 from cells. For
example, Saitoh et al. (1998) over-expressed ASK1 in HEK293 cells, immunoprecipi-
tated ASK1 and used the subsequent material in an in vitro kinase assay to monitor
ASK1 activity directly. From this approach, Saitoh et al. (1998) reported roughly
two-fold less ASK1 activity when ASK1 was co-expressed with Trx1 and then ASK1
was immunoprecipitated. One major caveat of this approach is that other molecules
may be co-purified and it is impossible to know with any certainty what they may
be. Co-purification of non-ASK1 molecules is even more likely in light of observations
that when purified in this manner, ASK1 forms a large complex (Noguchi et al., 2005).
Additionally, Saitoh et al. (1998) produced ASK1 via an in vitro (eukaryotic cell-free)
translation system alongside recombinant GST-tagged Trx1 from E. coli. However,
Saitoh et al. (1998) did not show any kinase assays with the in vitro translated ASK1,
nor did they add any form of Trx1 directly to their kinase assays with immunoprecip-
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itated ASK1.
The assays presented in this Chapter (4.4.6) have used recombinant ASK1, sub-
strate and regulatory proteins, purified to homogeneity from E. coli. Throughout the
in vitro kinase assays performed addition of Trx1 has shown no inhibition regardless of
the conditions tried. These assays have included up to a 100-fold molar excess of Trx1.
Based on these observations it has to be assumed that either Trx1 does not inhibit
ASK1 directly or the system used in this work is not complete enough to emulate the
exact conditions required for Trx1-inhibition.
Saitoh et al. (1998) show quite conclusively that the association between ASK1
and Trx1 can be modulated by, for example, treating cells with H2O2. However, the
assumption is made that Trx1 no longer associates with ASK1 because Trx1 becomes
oxidised, yet the actual oxidation status of Trx1 following these treatments is never
directly assessed. Moreover, whilst Saitoh et al. (1998) do state that the oxidation
mechanism is unclear and is a proposed hypothesis, it is widely accepted in the lit-
erature. The work done by Nadeau et al. (2009) goes some-way in improving the
model, with the inclusion that an unknown contributor (dubbed “Factor X”) is likely
required for Trx1 to control ASK1 signalling. However, the missing element suggested
by Nadeau et al. (2009) is generally omitted and the model of direct Trx1-inhibition of
ASK1 still predominates in the literature.
Jarvis et al. (2012) proposed that Prdx1 activates ASK1 via an inter-molecular
disulfide bond. In this fashion, Prdx1 may act as the “Factor X”. However, in this
work, the addition of Prdx1 to kinase assays did not change the activity of ASK1
(Figure 4.16 and Appendix Figure C.17). Whilst not conclusive, it does imply that
oxidative regulation of ASK1 requires more than the presence of Trx1, H2O2 or Prdx1.
One aspect that is not recapitulated by the methodology used in this work is ASK1
N-terminal homo-oligomerisation. Of the constructs used in this work, only the ASK1
kinase domain (ASK1669–941) behaves as a dimer in solution (Appendix Figure A.2f).
ASK188–266 is monomeric, as is ASK188–658, and ASK188–941 (Appendix Figure A.2b,d,
Table 4.2; Bunkoczi et al., 2007; Kosek et al., 2014; Kylarova et al., 2016; Weijman
et al., 2017). Whether Trx1 would inhibit an oligomeric form of ASK1 in vitro re-
mains to be seen. ASK12–1374 (as used in 4.4.6.2) will likely be oligomeric owing to the
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presence of the C-terminal coiled-coil and SAM domain (Trevelyan, 2017). However,
experiments using ASK12–1374 purified from insect cells also did not show any inhibi-
tion by Trx1 (4.4.6.2). On the other hand, the ASK12–1374 species used exhibited many
degradation products (or other contaminants) and therefore there can be no certainty
that the activity seen is from ASK12–1374. Further experiments with a homogeneous
ASK12–1374 sample is required to say for certain. Use of full-length ASK1 would also
be very telling for the true oligomeric nature of ASK1. As was discussed in Chapter 3
(3.6.2), dimerisation, and further oligomerisation are also viewed as important regula-
tory mechanisms of ASK1. It follows, therefore, that Trx1 regulation may only occur
on an oligomeric form of ASK1.
As mentioned in the introduction (4.2.1), Palde and Carroll (2015) proposed that
the biggest driver towards E. coli Trx substrate recognition is entropy. Palde and
Carroll (2015) used isothermal titration calorimetry (ITC) to reach their conclusions.
Similar ITC-based experiments between ASK1 and Trx1 would help towards investi-
gating what, thermodynamically speaking, drives ASK1 and human Trx1 association.
Such ITC-based experiments would thoroughly benefit from a high-resolution struc-
ture of ASK1 and Trx1 in order to probe the interaction interface with mutagenesis.
Moreover, experiments such as these would also have broader conclusions as to the
nature of human Trx1 substrate recognition.
Altogether, this Chapter highlights that ASK1 regulation by Trx1 requires more
than an interaction between the two proteins. It is highly probable that other regula-
tory mechanisms of ASK1 signalling are required in order for Trx1 to have a regulatory
role.
4.6 Conclusions
The work in this Chapter has shown that ASK1 and Trx1 do interact in vitro. Moreover,
residues within the N terminus of ASK1 (88–266) are sufficient for binding between
ASK1 and Trx1. Trx1 can form a disulfide-linked species with ASK1 forming a 1:1
complex. ASK1-Cys250 is necessary and sufficient for formation of the disulfide-linked
species. The precise mechanism leading to the formation of the species is unclear. The
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formation of a disulfide-linked ASK1-Trx1 species allowed for the isolation of a stable
protein complex to be analysed via SAXS. Rigid body modelling of the SAXS data
indicated that Trx1 could influence the relative conformation of the ASK1 TBD, regu-
lating overall ASK1 activity. However, functional analysis has shown that ASK188–941
is not inhibited by Trx1 under any condition tested. Altogether, further work is re-
quired to understand the true nature of Trx1 regulation of ASK1 and identify missing
regulatory features of Trx1-regulated ASK1 signalling.
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Chapter 5
A pilot study into the contribution
of Prdx1 to H2O2 signalling
5.1 Overview
H2O2 is a molecule that is required in many cell signalling pathways, but how H2O2
signalling is possible is paradoxical, as in vivo, H2O2 will be rapidly converted to water
by Prdxs. Prdxs, such as Prdx1, are proposed to facilitate H2O2 signalling by forming
inter-molecular disulfide bonds with signalling-substrates, such as ASK1. However, it
is unclear how universal disulfide bond transmission is, as there are limited examples.
The focus of this Chapter is to test a redox proteomics approach for investigating the
hypothesis that Prdx1 is a bona fide signalling protein. A pilot study is performed
using isotopic-labelling of cysteine residues from a cell lysate. Whilst the method is
able to identify differentially oxidised proteins, it is not sufficiently optimised to address
the hypothesis.
5.2 Publication outputs
• Ledgerwood, E. C., Marshall, J. W., and Weijman, J. F. (2017). The role of




5.3.1 Background on H2O2 signalling
Since the discovery of H2O2 in the early 1800s, our view of H2O2 has progressed from
it being a dangerous, reactive molecule that has to be controlled, to being essential for
healthy homoeostasis (Holmström and Finkel, 2014; Ledgerwood et al., 2017; Reczek
and Chandel, 2015; Sies et al., 2017).
The discovery that growth factor signalling could stimulate the production of H2O2
by NOXs represented a paradigm shift in our fundamental understanding of H2O2
biology (Bae et al., 1997, 2000; Lassègue et al., 2001; Park et al., 2004; Sundaresan et al.,
1995). When stimulated, growth factor receptors (such as the PDGF receptor) not
only initiate canonical receptor tyrosine kinase signalling, but there is also activation
of NOXs (Holmström and Finkel, 2014). NOXs produce superoxide (extracellularly)
which is subsequently converted (by SODs, see 1.5.4) to H2O2 (Winterbourn, 2008).
The nascent H2O2 can subsequently freely diffuse across the plasma membrane. Whilst
the generation of H2O2 is quite well understood, how and why H2O2 is then important
for downstream receptor signalling is more enigmatic.
Our understanding of precisely how such a small and simple molecule could influence
the cellular environment continues to gather interest. Much of this interest is because
eukaryotes express an armament of proteins named Prdxs (Peroxiredoxins) whose chief
role is to break down H2O2 to water.
5.3.2 Peroxiredoxins
Prdxs are abundant proteins found in every domain of life. Within mammalian cells,
peroxiredoxins (and Gpxs) make up the majority of our anti-peroxide defences1 (Cox
et al., 2010; Rhee et al., 2012; Winterbourn, 2008).
Mammals have 6 Prdxs: Prdx1–4 are very similar and use a two cysteine (2-Cys)
1Catalase is an abundant peroxidase protein with a very fast reaction rate with H2O2 (see Ta-
ble 5.1). However, catalase is primarily in peroxisomes and so does not greatly contribute to the
breakdown of cytosolic H2O2 (Schrader and Fahimi, 2006).
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Peroxiredoxins 1–4×107 a 20 a
Glutathione peroxidases 6×107 b 2 a
Catalase 2–3×107 a,b 1,000 e,h
Thioredoxin 1 1.05 a 1–10 c
Antioxidant small molecules
Glutathione (reduced) 0.89 b 2,000 a
Cysteine 2.9 a 30–200 f
N -acetylcysteine 0.16 a n/a
Non-antioxidant proteins
PTPs 9–20 b,e 0.01–0.1 a,e
PTEN 14 c < 0.002 g
KEAP1 140 d 1 e
GAPDH 100–500 a,b 50 a
Cdc25s 120–164 b 0.1 a
PTPs—Protein tyrosine phosphatases, PTEN—Phosphatase and tensin homologue,
KEAP1—Kelch-like ECH-associated protein 1, GAPDH—Glyceraldehyde 3-phosphate
dehydrogenase, Cdc25s—Cell division cycle 25 dual-specificity phosphatases. References:
a—Winterbourn and Hampton (2008); b—Stone (2004); c—Holmgren and Luthman (1978)
and Schwertassek et al. (2014); d—Marinho et al. (2014); e—Antunes and Brito (2017);
f—Tian et al. (2014); g—Johnston and Raines (2015). h—Catalase, though abundant, is
primarily located within peroxisomes (see Footnote 1).
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mechanism (see Figure 5.1a) whereas Prdx5 uses an atypical 2-Cys mechanism and
Prdx6 uses a 1-Cys mechanism (Nelson et al., 2011). The main difference between
Prdx1–4 is in their primary sub-cellular locations: Prdx1 and 2 are cytosolic; Prdx3
is mitochondrial and, Prdx4 is in the ER. All Prdxs have high rate constants (in the
order of 107 M−1 s−1) with H2O2 (Table 5.1; Winterbourn and Hampton 2008).
Eukaryotic 2-Cys Prdxs exhibit a paradoxical characteristic whereby they can be
inactivated by their substrate, H2O2 (Rabilloud et al., 2002; Rhee et al., 2012). Inacti-
vation occurs via ‘over-oxidation’ (also referred to as hyper-oxidation) of the peroxidatic
cysteine (CP) residue (Figure 5.1a). Over-oxidised Prdx involves the formation of a
sulfinic (R–SO2H) or sulfonic (R–SO3H) acid at the peroxidatic cysteine. Whereas
the sulfenic acid and disulfide bond forms are reversible via the Trx/TrxR system (Fig-
ure 5.1a), the sulfinic acid form requires an ATP dependent process with the protein
sulfiredoxin (Biteau et al., 2003; Woo et al., 2003). By comparison, there is no known
process by which the sulfonic acid form can be reduced.
Figure 5.1: Prdx mechanism, structure, and comparison of Prdx1 and 2. a) Peroxidase
cycle of eukaryotic 2-Cys Prdxs. 1: The peroxidatic cysteine (CP, drawn as the more
reactive thiolate, S– ) reacts with H2O2 forming a sulfenic acid (R-SOH). 2: The resolving
cysteine (CP, on the second subunit) and sulfenic-CP condense to form a disulfide bond. 3:
The Prdx is regenerated via the Trx/TrxR/NADPH system. 4) When concentrations of
H2O2 are high, the peroxidatic cysteine can become over-oxidised to sulfinic (R–SO2H) or
sulfonic (R–SO3H) acids which is irreversible by the Trx/TrxR system (Karplus, 2015) (see
5.3.2). b) Structure of human Prdx1 showing the peroxidatic cysteine (Cys52) and resolving
cysteine (Cys172). Left: reduced (PDB ID: 1QQ2; Hirotsu et al. 1999), right: oxidised
showing the protein surface (PDB ID: 2RII; Jönsson et al. 2008). The inset shows the
inter-subunit disulfide bond. c) Amino acid alignment of Prdx1 and 2 showing 77.4%
identity. The position of the peroxidatic and resolving cysteines are indicated. *—identical,
:—strongly similar, .—weakly similar. The alignment was generated using ClustalOmega





















































Figure 5.1: Prdx mechanism, structure, and comparison of Prdx1 and 2. Figure legend on
previous page.
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5.3.2.1 Why do mammals have two cytosolic Prdxs?
The existence of both Prdx1 and 2 has continued to gather interest amongst researchers.
Are the two proteins redundant, or do they each serve a different process? The primary
sequence is very similar but there is approximately a 20% difference in the primary
amino acid sequence (Figure 5.1c). Evidence that Prdx1 and 2 are not functionally
redundant can come from kinetic data. For example, Lee et al. (2007) compared the
relative reactivity of Prdx1 and 2, finding that Prdx2 was approximately 3-fold more
active than Prdx1. More recently, Carvalho et al. (2017) published a second-order
rate constant for Prdx1 with H2O2 as 3.8 × 107 M−1 s−1, which is higher than the
reported value for Prdx2—1.3 × 107 M−1 s−1 (Peskin et al., 2007). A side-by-side
determination of rate constants would be required for a more accurate comparison.
Nonetheless, Lee et al. (2007) also observed that Prdx1 was markedly more sensitive
to over-oxidation than Prdx2, with Prdx1 being over-oxidised by exposure to 0.2 mM
H2O2, whereas Prdx2 was not over-oxidised until exposure to 1 mM H2O2. Other dif-
ferences between Prdx1 and 2 have been seen in their interactions with other proteins.
For example, Prdx1 can bind to the protein kinase MST1, but Prdx2 cannot (Morinaka
et al., 2011). Additionally, Prdx1-KO (knock-out) and Prdx2-KO mouse models have
different cancer phenotypes (Hampton et al., 2017), suggesting the two proteins serve
different purposes. Overall, the differences between Prdx1 and 2 (and other Prdxs)
may be important in regards to H2O2 signalling.
5.3.3 Models of H2O2 signalling
As eluded to in 5.3.1, H2O2 signalling is somewhat paradoxical. H2O2 is a reactive
molecule capable of damage and thus is kept under tight control by various peroxidases.
However, H2O2 production is required for many cell signalling events. How then is H2O2
able to react with any targets and how does it do so with any specificity?
Several models (Figure 5.2) have been postulated to explain the discrepancy:
• Direct oxidation
• The floodgate model
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• The disulfide relay model
5.3.3.1 Direct oxidation as a model for H2O2 signalling
Direct oxidation is the simplest explanation for how H2O2 can modulate protein sig-
nalling (Figure 5.2a). H2O2 reacts with cysteine residues in a protein, altering that
protein’s activity.
Specificity from direct oxidation can be achieved owing to the chemistry of cysteine.
The most reactive form of cysteine comes from the deprotonated thiolate (Reaction 5.1).
The degree of deprotonation is dependent upon the pK a of cysteine thiol which is
influenced by the localised environment of the cysteine residue (Bulaj et al., 1998;
Poole, 2015). The pK a of a thiol in free cysteine is ∼8.3 meaning it will be protonated
at physiological pH (∼7.4). Conversely, the peroxidatic cysteines of human Prdxs have
a pK a of ∼5–6 meaning the thiolate is more likely to form, making the cysteine more
reactive (Winterbourn and Hampton, 2008). Therefore, a cysteine residue’s milieu can






The notion of direct oxidation is a simple idea, H2O2 produced on demand (e.g.,
from NOXs, see 5.3.1), can find and react with cysteine residues that are ‘ready’ (i.e.
thiolates). Additionally, H2O2 being a small molecule will allow it to permeate into
regions of proteins and other macromolecules. The major problem with this simple
model of direct oxidation is it cannot explain how H2O2 could escape being converted
to water by abundant and fast peroxidases. Peroxidases, such as Prdx1, would out-
compete any non-peroxidase protein (see Table 5.1). Even non-peroxidase proteins
(such as GAPDH or Cdc25 phosphatases, Table 5.1) that have a relatively fast rate
constant (∼100–500 M−1 s−1) with H2O2 are several orders of magnitude below that
of Prdxs (second-order rate constants of ∼107 M−1 s−1). One model put forward to
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Reduced Prdx Oxidised Prdx
Figure 5.2: H2O2 signalling models. a) Direct oxidation model. H2O2 reacts with protein
targets, oxidising cysteine thiols (“Cys–Sox”). The oxidised and reduced protein will have a
different output from either a direct effect on protein activity or a change in localisation,
stability or interaction partners. b) The floodgate model. High concentrations of H2O2 will
over-oxidise and inactivate Prdxs (see 5.3.2). Inactive Prdxs will no longer be able to break
down H2O2 allowing H2O2 to oxidise protein targets as in a). c) The disulfide relay model.
1) Prdxs act as sensors of H2O2 becoming oxidised during the breakdown (see Figure 5.1a).
2) Oxidised Prdx (either as a disulfide or a sulfenic acid) will oxidise a protein target
forming an intermediate mixed-species disulfide bond. 3) The mixed-species disulfide bond
collapses resulting in an oxidised protein target (likely containing a disulfide bond) and
reduced Prdx.
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5.3.3.2 The floodgate model of H2O2 signalling
Eukaryotic Prdxs are able to be inactivated by H2O2 via over-oxidation of the peroxi-
datic cysteine residues (see 5.3.2 and Figure 5.1a). The phenomenon of over-oxidation
has been used to explain how H2O2 could react with non-peroxidase thiols (Wood
et al., 2003a). When the concentration of H2O2 is high enough, over-oxidation of Prdxs
occurs allowing H2O2 to signal to targets as in the direct oxidation model above (Fig-
ure 5.2a,b). Furthermore, phosphorylation has also been seen as a way of inactivating
Prdx1, which would also facilitate the floodgate model (Woo et al., 2010).
Whilst the floodgate model does explain how H2O2 may be able to overcome Prdxs
it does have two problems. Firstly, even if Prdxs were inactivated, other peroxidases
(namely glutathione peroxidases, Gpxs) are still quite abundant and have high rate
constants with H2O2 (Table 5.1). Secondly, there is the problem of H2O2 specificity.
Even if a target cysteine thiol had a relatively low pK a, H2O2 cannot delineate between
different targets therefore not allowing for signalling specificity. The disulfide relay
model attempts to overcome the limitations above by viewing Prdxs not simply as
peroxidases, but as playing an active role in signal transduction.
5.3.3.3 Disulfide relay of H2O2 signalling
The disulfide relay is another model for H2O2 signalling. In this model, peroxiredoxins
will ‘sense’ H2O2, becoming oxidised, and in turn oxidise a signalling substrate (Fig-
ure 5.2c). This model explains how there can be specificity within the system and how
abundant and fast peroxidase do not compromise the system. Specificity is allowed by
protein-protein interactions by the Prdx, and the peroxidase activity is a requirement
(Rhee et al., 2018).
The biggest drawback of the disulfide relay model of H2O2 signalling is that whereas
there are many proteins known to be modulated by oxidation (e.g., the non-peroxidase
proteins in Table 5.1), there is only a handful of disulfide-relay examples from yeast
and mammalian systems.
Arguably, the best-characterised relay, comes from yeast, between the transcription
factor, Yap1, and the peroxiredoxin, Gpx3 (also called Orp1) (Marinho et al., 2014).
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Gpx3 becomes oxidised in response to H2O2. Oxidised Gpx3 oxidises Yap1 via the
formation of a transient mixed-species disulfide bond. Gpx3 disassociates from Yap1,
leaving a disulfide bond within Yap1. The nascent Yap1 disulfide bond causes a change
in the protein, secluding a nuclear export sequence allowing the protein to localise to
the nucleus and initiate transcription (Delaunay et al., 2000, 2002; Wood et al., 2004,
2003b). Examples from mammalian systems include Prdx1 and ASK1, and Prdx2
and the transcription factor signal transducer and activator of transcription (STAT)3
(Jarvis et al., 2012; Sobotta et al., 2015).
Further evidence that Prdxs have a role in signalling comes from a yeast transcrip-
tion study. Saccharomyces cerevisiae that had all Prdxs and Gpxs genetically deleted
were unable to transcriptionally respond to H2O2 treatment (Fomenko et al., 2011).
WT yeast under the same conditions had ∼1500 genes that were differentially regulated
by H2O2 treatment (Fomenko et al., 2011). The absence of a transcriptional response
without expression of Prdxs and Gpxs is strongly indicative that, in S. cerevisiae at
least, Prdxs/Gpxs are responsible for signalling from H2O2 to transcription factors.
The requirement of Prdxs and Gpxs for H2O2 transcriptional response in yeast
would not be compatible with the floodgate model pointing towards the disulfide relay
model. Examples such as the Gpx3-Yap1 relay provide evidence towards the disulfide-
relay, however, without more examples and a broader study from a mammalian setting
it is difficult to assess whether a disulfide-relay is the major signalling mechanism or
simply one part of many.
5.3.4 Prdx1 as a disulfide-relay partner
Previous work from the Ledgerwood laboratory showed that Prdx1 and the protein
kinase ASK1 were involved in a disulfide-relay (Jarvis et al., 2012). When treated
with exogenous H2O2, U937 cells responded with the phosphorylation of p38 MAPK.
Knock-down of Prdx1 ablated the p38 response. Interestingly, over-expression of Prdx2
in U937 cells also inhibited the H2O2-p38 response suggesting that the two cytosolic
Prdxs have contrasting roles.
Studies such as by Jarvis et al. (2012) provide great power in terms of our mecha-
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nistic understanding. Very recently, Stöcker et al. (2018a) published a study suggesting
that Prdxs do contribute to H2O2 signalling and this will be expanded upon in the final
Discussion (6.4). However, more examples and other evidence from a more system-wide
approach is required to inform us into the greater role a disulfide-relay model plays in
H2O2 signalling.
5.3.5 Redox proteomics
A holistic study of cellular proteins—proteomics—allows for a picture of a cell on the
whole rather than a brief snapshot. Such a method is useful for questions such as
investigating the signalling role of Prdx1, as it does not assume what may or not be
targets.
One method that has been devised for redox proteomics is isotope-coded affinity
tag (ICAT) (for a more comprehensive view of the redox proteomics landscape, see
Bachi et al. 2013 and Yang et al. 2016). ICAT was originally developed as a tool for
quantitative proteomics (Shiio and Aebersold, 2006). The ICAT reagent features an
IAM-based thiol-modifying group, an isotopic tag and an acid-cleavable biotin moiety
(Figure 5.3a; Hägglund et al. 2008; Shiio and Aebersold 2006). The original use of
ICAT is based on the principle that despite only ∼25% of human tryptic peptides
contain cysteines, this pool will represent over 95% of the human proteome (Shiio and
Aebersold, 2006). Therefore, by labelling peptides from two different samples (one
with the light reagent and the other with heavy) and analysing it by LC-MS/MS, a
ratio can be calculated for the relative abundance of proteins from the two samples.
Redox proteomics using ICAT takes advantage of the thiol-reactive group in order
to label cysteines (Leichert et al., 2008). Sequential labelling, reduction and alkylation
then informs us not of the abundance of a protein, but rather its oxidation status.
This Chapter seeks to address whether an ICAT-proteomics approach would work and
whether a cell line that is deficient for Prdx1 has a different protein oxidation profile
to the WT cell line. An ICAT-based method is used for several reasons. Firstly, the
ICAT method is a kit-based system lowering the methodological development time.
Secondly, the ICAT method uses a biotin-enrichment step which allows for enrichment
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of lower abundant ICAT-labelled proteins.
The ICAT method can be used in a monoplexed (Figure 5.3b) or duplexed approach
(Figure 5.3c). For the monoplexed version, two samples are combined with analysis
of either oxidised or reduced cysteines (Figure 5.3b). By comparison, the duplexed
approach enables the user to label an entire proteome (reduced and oxidised cysteines)
from one sample Figure 5.3c).
There are advantages and disadvantages for opting for a monoplexed or duplex ap-
proach. The duplexing approach captures a broader image (reduced and oxidised) of
one cellular population. By contrast, the monoplexed version allows for the comparison
between two cell treatments, decreasing the overall monetary cost of the total experi-
ment. Additionally, the monoplexed version can label either reduced protein thiols or
reversibly oxidised thiols, depending upon the aim of the experiment. Lastly, as the
duplexed approach compares proteins within the same sample there is consistency for
the total protein amount. By comparison the monoplexed version is dependant upon
accurate protein quantification for the individual populations to be analysed.
Figure 5.3: Overview of ICAT redox proteomic experiments. a) The ICAT reagent consists
of the thiol-reactive component, based on IAM (iodoacetamide), an isotopic tag containing
either 9× Carbon-12 (12C, light) or Carbon-13 (13C, heavy) and a biotin moiety. The biotin
group enables enrichment and is cleavable under acidic conditions (Hägglund et al., 2008;
Shiio and Aebersold, 2006). b) Monoplexed version. Cells from two different conditions
processed in tandem. The cells are lysed and proteins are denatured. The proteins will
contain a mixture of reduced cysteines and oxidised cysteines. Reduced cysteines are
alkylated with IAM. Reversibly oxidised cysteines (such as disulfide bonds and sulfenic
acids) are reduced with TCEP. Liberated reduced cysteine thiols are labelled with either
the light (ICATL) or heavy (ICATH) ICAT reagent. The two samples are combined and
digested with trypsin. Digested peptides are enriched using a biotin affinity column. The
samples are cleaned up and analysed by LC-MS/MS. The order of alkylation and
ICAT-labelling can be inverted to analyse reduced cysteine thiols. c) Duplexed version. As
with the monoplexed version except only one condition is analysed and the sample is























Oxidised cysteine (reversible)  :
Oxidised cysteine (irreversible):
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linker
Biotin
a) The ICAT reagent
ICATH
Figure 5.3: Overview of ICAT redox proteomic experiments. Figure legend on previous
page.
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5.3.6 Redox proteomics to investigate a signalling role for
Prdx1
This Chapter will look into whether an ICAT-proteomics approach can be used to
investigate the role of Prdx1 in H2O2 signalling. The overall hypothesis is presented
in Figure 5.4. If Prdx1 does not contribute to H2O2 metabolism, then Prdx1 KO cells
should show no change in overall protein oxidation. In contrast, if Prdx1 inactivation
is required for signalling (the floodgate model), the loss of Prdx1 should lead to an
increase overall protein oxidation. On the other hand, if Prdx1 actively transmits a
signalling from H2O2 (the disulfide-relay model), the loss of Prdx1 will result in an
overall decrease in protein oxidation.


















Figure 5.4: Hypotheses of consequences of Prdx1 KO on protein oxidation. In the direct
oxidation model, Prdx1 would play no major role in altering a protein’s oxidation status,
therefore there will be no change in protein oxidation. In the floodgate model, the loss of
Prdx1 will lower the required H2O2 concentration to elicit a response, thus protein
oxidation will increase. In the disulfide relay model, Prdx1 is actively oxidising proteins so
the loss of Prdx1 will result in decreased protein oxidation.
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5.4 Aims
Aim 1 Characterise HAP1 p38 response to H2O2
Aim 2 Perform a pilot proteomic study to determine if WT and Prdx1 KO HAP1
cells are similar
Aim 3 Determine the feasibility of a larger ICAT based study to investigate the
role of Prdx1 in response to H2O2
5.5 Results
5.5.1 Prdx1 is required for p38 activation in HAP1 cells fol-
lowing H2O2 treatment
5.5.1.1 HAP1 cells respond to H2O2 treatment with p38 phosphorylation
In order to carry out a proteomic method, a cell line is required to generate a sample
for analysis. In this work, the human HAP1 cell line was chosen. HAP1 cells are a
near-haploid cell line, originally derived from the chronic myelogenous leukaemia cell
line—KBM-7 (Carette et al., 2011; Essletzbichler et al., 2014). Initially, we wanted
to investigate how HAP1 cells respond to H2O2 by monitoring phosphorylation of the
stress-responsive MAPK, p38.
Treatment of HAP1 cells with 100 µM H2O2 produced a similar p38 response as
previously reported in U937 cells (Figure 5.5a). There is a fast initial response (at 2.5–5
minutes), with an increase in p-p38. Over time, p-p38 decreases and by 30 minutes is
no longer present.
5.5.1.2 HAP1 Prdx1 KO cells do not express Prdx1
Jarvis et al. (2012) reported that knock-down of Prdx1 in U937 cells ablated the H2O2
response. In order to look further into the role Prdx1 may play in such a response,









































Figure 5.5: H2O2 induces p38 activation in HAP1 cells. a) Flow diagram of the assay in
this Figure. b) HAP1 cells (2 × 106 cells in 3 mL, in a suspension state, 30 minutes
post-trypsinising see Methods (2.11.3.1) for details) were treated with H2O2 (100 µM) for
the times indicated. The cells were lysed in RIPA buffer and subjected to western blot.
Phosphorylated-p38 (p-p38) was probed for (α-p-p38) and visualised with ECL. As a
loading control, α-tubulin was probed for (α-α-tubulin). Note—a blot for total p38 (the
alpha isoform) is shown in Appendix Figure D.2a, but the antibody used resulted in
unspecific bands so α-tubulin was the only loading control used. Performing a similar assay
on adherent cells, lysed using 10% (w/v) TCA gave similar results (Figure 5.6).
details see Methods (2.11.2)). The absence of Prdx1 expression at a protein level was
confirmed by western blot (Figure 5.6b).
5.5.1.3 Prdx1 is required for H2O2 induced p38 response in HAP1 cells
Next, WT and Prdx1 KO HAP1 cells were treated with H2O2 before analysing p38
phosphorylation. For these assays, the cells were grown and treated in an adherent
state and lysed using TCA. Phosphorylated p38 was visualised by western blot. For
the WT HAP1 cells the same trend was seen in the fast response in p38 phospho-
rylation (2.5 minutes) but by 30 minutes post-treatment p-p38 is no longer detected
(Figure 5.6). By comparison, the Prdx1 KO cells showed a lower response (Figure 5.6)
indicating that, like U937 cells (Jarvis et al., 2012), HAP1 cells require Prdx1 to ac-
tivate the p38 pathway in response to H2O2. In order to validate that Prdx1 was

























































Figure 5.6: Prdx1 is required for H2O2 induced p38 response in HAP1 cells. a) Flow
diagram of the assay in this Figure. b) HAP1 cells (seeded 24-hours previously at 1 × 106
cells in 3 mL) were treated with 100 µM H2O2 (or an equivalent volume of water for 0
minutes) for the times indicated before lysis with TCA and subsequently western blotting
for p-p38 (see methods for details). Prdx1 and α-tubulin were subsequently probed against
and visualised. c) Quantification of three experimental replicates. Bands (both the higher
and lower p-p38 bands) were quantified using Image Studio and normalised to tubulin and
the WT p-p38 band at 2.5 minutes. Error bars represent SEM. Full blots are given in
Appendix Figure D.1.
cells were made. However, attempts at transient over-expression of Prdx1 failed to
result in Prdx1 expression levels that were comparable with endogenous WT HAP1
cells (Appendix Figure D.2b). Nonetheless, Prdx1 has previously been reported to
be integral to exogenous H2O2 activated p38 (Conway and Kinter, 2006; Jarvis et al.,
2012). Observations such as these lend support to the notion that Prdx1 (and other
mammalian Prdxs) may be more than a peroxidase protein (see 5.3.3). However, the
hypothesis has been hampered by a limited number of identified signalling-substrates
for mammalian Prdxs. In order to further investigate what role Prdx1 may have as a
signalling protein, we moved onto the pilot redox proteomics study.
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5.5.2 Using ICAT redox proteomics to investigate the role of
Prdx1 in cellular thiol status—a pilot study
The main aim of this Chapter is to determine the feasibility of an ICAT-based pro-
teomics experiment for investigating the role Prdx1 may have as a signalling protein.
To achieve this aim a pilot ICAT study was performed using a monoplexed ICAT
method (as illustrated in Figure 5.3a), based on a protocol by Garćıa-Santamarina
et al. (2014) for analysing a yeast thiol proteome. The method, as trialled in this
Thesis, has several key features:
1. TCA (trichloroacetic acid) is used to protonate cysteine thiols, keeping them
reduced and less sensitive to oxidation during sample preparation.
2. IAM (iodoacetamide) is used to alkylate reduced thiols, preventing oxidation
during sample preparation
3. TCEP (tris(2-carboxyethyl)phosphine) is used to reduce any previously-oxidised
thiols enabling labelling of only thiols that were oxidised.
4. A biotin-enrichment step enriches for ICAT-labelled peptides
An outline of the approach used is shown in Figure 5.7, the full experimental method
is given in the Methods (2.12). An in-gel fluorescence method (similar to that of Baty
et al. 2002) was used to confirm that reduced cysteine thiols could be blocked and
reversibly oxidised thiols could be labelled (Appendix Figure D.3).
Observations from the Ledgerwood laboratory showed that Prdx1 KO HAP1 cells
have similar characteristics (such as cell proliferation and H2O2-induced apoptosis) to
WT HAP1 cell line (Carrad, 2017). With no overt differences in phenotypes and, as re-
introduction of Prdx1 had proved ineffective (see 5.5.1.3 and Appendix Figure D.2b),
it was decided to directly compare the HAP1 WT and Prdx1 KO cell lines.
This was a pilot study to determine whether the method works as intended and,
more importantly, whether the HAP1 WT and Prdx1 KO cells have comparable basal
levels of protein oxidation. As such the initial pilot consists of a direct comparison
















Figure 5.7: ICAT pilot study overview. WT and Prdx1 KO HAP1 cells were grown and
processed using a monoplexed ICAT method (see Figure 5.3a) where both samples were
alkylated with IAM. The samples were subsequently reduced before labelling with the ICAT
reagent. WT cells were labelled with the light ICAT reagent (ICATL) and Prdx1 KO cells
were labelled with the heavy ICAT reagent (ICATH). The data is expressed as a ratio of
heavy over light (Prdx1 KO/WT) indicating the relative abundance of a given protein
modification in the starting material.
carried out three times (three experimental replicates). An additional preliminary
experiment was also performed, treating both WT and Prdx1 KO HAP1 cells with
H2O2 and comparing them to the respective untreated cell line.
5.5.2.1 Evaluation of the ICAT pilot study
The pilot study (a direct comparison of WT and Prdx1 KO HAP1 cells as in illustrated
in Figure 5.7) was completed three times (for three experimental replicates). Within
these, the samples were analysed by LC-MS/MS either once (for replicate 1) or in
duplicate (for replicates 2 and 3).
The data output is expressed in terms of an ‘ICAT ratio’. The ratio is calculated
by the Proteome Discoverer software (see Methods (2.12), for details), which calculates
the abundances of light and heavy ICAT-labelled peptides relative to the entire peptide
pool for a given protein. The ICAT ratio displayed in this pilot study is expressed in
terms of heavy ICAT (peptides from Prdx1 KO cells) divided by light ICAT (peptides
from the WT cells). The data can also be expressed as a binomial log (Log2). The
advantage of Log2 is that the data, when displayed graphically, is symmetrical about
0. The data is also referred to in the ratio form as the less transformed state can make
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it easier to understand that there was x -fold more or less of one peptide in one sample
than the other.
The evaluation of the pilot study is divided into the following areas:
1. Coverage—how many proteins (and peptides) were identified?
2. What is the ICAT-labelling efficiency (out of total detected proteins)?
3. How close are the duplicate LC-MS/MS runs on the same sample(s)?
4. Do WT and Prdx1 KO HAP1 cells have a similar basal oxidation level?
5.5.2.2 Protein and peptide coverage
Table 5.2 shows the break down for how many peptides were identified in the ICAT
pilot study. Between 2000 and 3500 individual peptides were identified per LC-MS
run representing between 224 and 559 proteins (with either more than one peptide or
identified in two LC-MS/MS runs, Figure 5.8a). Only a relatively small proportion of
these proteins were labelled with the ICAT reagent (∼40%) in replicate 1, and ∼10%
in replicates 2 and 3, Figure 5.8a and c. A number of proteins were only found either
labelled as heavy or light only. As such, an ICAT ratio cannot be calculated for these
proteins. Whilst incomplete labelling could indicate that for a certain protein it was
only found in an oxidised state in either the WT or Prdx1 KO cell line, there was
inconsistency in this (e.g., even within a technical replicate some proteins, such as
calnexin (see Appendix Table D.1), had a ratio of 0.93 in one LC-MS/MS run but was
only found in the heavy channel for the duplicate run2.
2Missing light or heavy channels. Proteome Discovery the ICAT ratio by taking the sum of
all labelled-peptides (for a given protein) as representing 100%. The specific abundance for a heavy
or light labelled peptide is set relative to this 100% value. The ratio is determined by the division of
one channel over the other. Therefore, if a protein is only identified in one channel (heavy or light)
the ratio will be either 100 or 0.01 (1/100).
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Table 5.2: Identified peptide numbers for the ICAT pilot study (comparison of HAP1 WT
and Prdx1 KO cells)
Rep 1 Rep 2 Rep 3
Run 1 Run 2 Run 1 Run 2
All peptides 2574 3473 3417 2077 2082
ICAT-labelled peptides
Light 490 199 207 141 156
Heavy 427 136 136 147 141
Total (H+L) 917 335 343 288 297
Total ICAT-labelled
(% of all peptides)
35.63 9.65 10.04 13.87 14.27
Rep—Experimental replicate.
The duplicate LC-MS runs for replicates 2 and 3 showed reasonable replication of
one another (ranging between 0 and 0.56 SD units) with the mean and median SD
being 0.09 and 0.06 respectively (Figure 5.8c). All of the ICAT ratio values (regardless
of SD variation) were taken forward as long as they were found in both of the duplicate
LC-MS/MS runs. In total this meant that there were 90 proteins from replicate 1, 55
from replicate 2 and 46 from replicate 3.
5.5.2.3 Enrichment of ICAT-labelled proteins
The ICAT reagent features a biotin tag for enrichment purposes. Even though the
biotin-enrichment was used (see Figure 5.3 and Methods; 2.12) there is a remarkably
high number of non ICAT-labelled peptides identified in the LC-MS (Table 5.2 and
Figure 5.8). More concerning is that the number of ICAT-labelled peptides (and pro-
teins) decreases between replicate 1 and replicates 2 and 3 (Table 5.2 and Figure 5.8).
Concomitant to the overall decrease in ICAT-labelling, there is also a decrease in the





























































































Rep 3 Rep 2 Rep 3
Figure 5.8: Pilot ICAT study: replicate protein numbers. a) Venn diagrams for the three
experimental replicates (Rep 1, 2 and 3). Only proteins that were identified with high
confidence by Proteome Discoverer were used. The top panel shows the total number of
proteins identified in each run and either how many had more than 1 peptide identified
(Rep 1) or the overlap between the duplicate LC-MS runs for replicates 2 and 3. The
bottom panel shows how many peptides were identified being ICAT-labelled. Numbers in
parentheses indicate additional proteins that were identified as ICAT-labelled, but only in
either the heavy or light channel. b) Percentage of identified protein that were labelled by
the ICAT reagent. The total value is as per the eligible identified proteins—more than 1
peptide for replicate 1 or found in both LC-MS/MS runs for replicates 2 and 3. c) Standard
deviation (SD) of ICAT-ratios for the two LC-MS runs for replicates 2 and 3.
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35% of all peptides were ICAT-labelled, but in the subsequent replicates only 9 to 14%
were labelled (Table 5.2). The method used was the same, but there was a tempo-
ral gap of approximately 3 months between replicate 1 and replicates 2 and 3. The
assumption for loss of efficiency (in labelling and enrichment) is due to reduced per-
formance in the streptavidin column (that comes with the ICAT kit) or degradation of
the ICAT reagent.
5.5.2.4 Comparison of WT and Prdx1 HAP1 cell basal oxidation levels
Across the three experimental replicates (comparing WT and Prdx1 KO HAP1 cells), a
total of 23 proteins were identified in all three replicates (of these, 4 were incompletely
labelled, see Footnote 2). Thirty eight proteins were identified as ICAT-labelled in
both heavy and light channels and found in at least two replicates (Figure 5.9a, c and
Table 5.3). Several proteins were identified labelled only in the heavy or light channel.
As such a true ratio is not generated therefore only proteins that have a ‘complete’
ratio are shown (incompletely labelled proteins are given in Appendix Table D.1).
A histogram can be used to look at the data as a whole, showing the spread of
ICAT ratios. Looking at the data as a whole illustrates whether the WT and Prdx1
KO are similar, independent of individual proteins. Figure 5.9b shows a histogram as


























































ICAT Ratio (WT/Prdx1 KO) Log2 (ICAT Ratio(WT/Prdx1 KO))
Figure 5.9: Distribution of protein ICAT ratios from untreated WT and Prdx1 KO HAP1
cells. HAP1 cells were lysed and ICAT-labelled as per in Figure 5.3. a) Venn diagram
showing from the three experimental replicates which identified proteins were also found in
the other replicates (reps). A protein that was identified in at least two of these replicates
was carried forwards. Numbers in parenthesis represent proteins that were identified, but
only as labelled with either the light or heavy ICAT reagent. b) and c) Histograms of ICAT
ratios (b) or Log2(ratio) (c). The grey line represents a non-linear regression fit of the
distribution data generated using GraphPad Prism (outputs can be found in Appendix
Table D.6), with an R2 value representing the fit of the curve to the data. Median and
mean positions of the data are indicated. The bin widths were 0.1 for b) and 0.2 for c).
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The spread of the data (assessed by both the raw ratios and as Log2) shows a near-
normal distribution (Figure 5.9b). A normal distribution indicates there is not a large
difference between either the WT or Prdx1 KO HAP1 cells.
When looking at the individual values assigned to each identified protein (for the 37
proteins that were labelled with both heavy and light reagent), the average ratios for
all proteins falls between 0.53 and 1.53 (Figure 5.10 and Table 5.3). The data is also
shown graphically as a ratio with SEM or as a Log2 scale with error bars representing
a 95% confidence interval. By showing the data in both layouts the spread of the
replicates can be seen with the confidence intervals, but the differences between the
mean values are not scaled down by the error bars.
Three proteins are statistically different from a ratio value of 1 (or Log2 value of 0):
IGF2R, CCDC58 and COXB6B1 (Figure 5.10). The remaining 34 proteins (92%) do
not significantly differ from a ratio value of 1 (or Log2 value of 0). However, the spread
of the experimental replicates appears to be quite large (especially when looking at the
error in terms of a confidence interval, Figure 5.10).
Taken together, the data does provide a starting point that shows there is no
difference in the basal oxidation between the WT or Prdx1 KO HAP1 cells. A more

































































































































Rep 1 Rep 2 Rep 3
* * *
* * *
Figure 5.10: ICAT-labelled proteins from untreated WT and Prdx1 KO HAP1 cells. Figure legend on next page.
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Figure 5.10: ICAT-labelled proteins from untreated WT and Prdx1 KO HAP1 cells. Each graph is displaying the same data ranged by
the mean for each protein. Only proteins that were identified in two or more replicates with a complete ICAT ratio (WT/Prdx1 KO) are
plotted. Different symbols represent each experimental replicate (rep). Top: ICAT ratios are plotted and error bars represent SEM.
Arbitrary lines have been drawn representing an ICAT ratio of 0.93 and 1.07. Bottom: Log2 scale of the ICAT ratio (WT/Prdx1 KO).
Error bars represent a 95% confidence interval. Arbitrary lines have been drawn for a Log2 ratio value of 0.1 or -0.1 (equivalent to the
lines in the top graph). ∗ represents statistical significant (P < 0.05) difference from an ICAT ratio of 1 or a Log2 value of 0 as determined
by a one-sample t-test. This data is also displayed in Table 5.3










Rep 1 Rep 2 Rep 3 Mean




IGF2R Cation-independent P11717 0.60 0.62 0.61 731 Yes (760)
mannose-6-phosphate receptor
NPC2 Epididymal secretory protein E1 P61916 0.51 0.74 0.63 27 Yes (140)
99 Yes (93)
CCDC58 Coiled-coil Q4VC31 0.63 0.63 0.63 53 No
domain-containing protein 58 74 No
Continued on next page
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Rep 1 Rep 2 Rep 3 Mean
FAM136A Protein FAM136A Q96C01 0.25 1.11 0.74 0.70 53 No
57 No
NDUFA8 NADH dehydrogenase 1 P51970 0.25 1.20 0.72 0.72 36 Yes (66)
alpha subcomplex subunit 8 66 Yes (36)
110 Yes (78)
TIMM13 Mitochondrial import inner Q9Y5L4 0.17 1.30 0.81 0.76 50 Yes (65)
membrane translocase subunit Tim13
MIF Macrophage migration inhibitory factor P14174 0.74 0.80 0.77 81 No
TXNDC5 Thioredoxin Q8NBS9 0.99 0.71 0.69 0.79 121 Yes (128)
domain-containing protein 5 128 Yes (121)
247 Yes (253)
381 Yes (388)
SOD1 Superoxide dismutase P00441 0.75 0.94 0.78 0.83 58 Yes (147)
BSG Basigin P35613 0.75 0.93 0.84 242 Yes (301)
FKBP10 Peptidyl-prolyl cis-trans Q96AY3 0.66 1.09 0.88 110 No
isomerase FKBP10 222 No
GLG1 Golgi apparatus protein 1 Q92896 0.70 1.09 0.93 0.90 269 Yes
ACTB Actin, cytoplasmic 1 P60709 1.08 0.76 0.92 285 No
NPTN Neuroplastin Q9Y639 0.78 1.06 0.92 218 Yes (170)
CHCHD6 MICOS complex subunit MIC25 Q9BRQ6 1.06 0.80 0.93 218 Yes (197)
1079 Yes
SDF2L1 Stromal cell-derived factor 2-like protein 1 Q9HCN8 0.90 0.98 0.93 0.93 38 No
100 No
Continued on next page
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Rep 1 Rep 2 Rep 3 Mean
CHCHD3 MICOS complex subunit MIC19 Q9NX63 1.35 0.73 0.74 0.94 183 Yes (214)
193 Yes (204)
PPIA Peptidyl-prolyl cis-trans isomerase A P62937 1.26 0.69 0.90 0.95 62 No
ERP44 Endoplasmic reticulum resident Q9BS26 1.17 0.93 0.81 0.97 189 Yes (241)
protein 44 301 Yes (318)
318 Yes (301)
PRKCSH Glucosidase 2 subunit beta P14314 0.98 0.96 0.97 471 No
TIMM10 Mitochondrial import inner P62072 1.14 0.82 0.98 29 Yes (54)
membrane translocase subunit Tim10 50 Yes (33)
CD59 CD59 glycoprotein P13987 1.13 0.85 0.99 70 Yes (88)
AK2 Adenylate kinase 2 P54819 1.16 1.11 0.70 0.99 42 Yes (92)
92 Yes (42)
SDF2 Stromal cell-derived factor 2 Q99470 0.99 0.98 1.01 0.99 80 No
88 No
LMAN2 Vesicular integral-membrane Q12907 1.11 0.91 0.98 1.00 202 Yes (239)
protein VIP36 239 Yes (202)
CD276 CD276 antigen Q5ZPR3 0.75 1.32 1.03 383 Yes (438)
122/340a Yes (50/340)
CTSB Cathepsin B P07858 1.01 1.16 1.09 211 Yes (179)
CALR Calreticulin P27797 0.91 1.41 1.00 1.11 105 Yes (137)
218 No
AHSG Alpha-2-HS-glycoprotein P02765 1.05 0.81 1.50 1.12 132 Yes (114)
219 Yes (208)
Continued on next page
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Rep 1 Rep 2 Rep 3 Mean
ERGIC1 Endoplasmic reticulum-Golgi Q969X5 1.19 1.06 1.12 115 No
intermediate compartment protein 1
NDUFB7 NADH dehydrogenase 1 P17568 1.49 0.85 1.17 59 Yes (90)
beta subcomplex subunit 7 90 Yes (59)
LTF Lactotransferrin P02788 1.54 0.79 1.18 1.17 424 Yes (705)
478 Yes (553)
GPC4 Glypican-4 O75487 1.09 1.60 1.34 344 No
341 No
PRDX4 Peroxiredoxin-4 Q13162 1.71 1.25 1.23 1.40 51b No
P4HA1 Prolyl 4-hydroxylase subunit alpha-1 P13674 1.78 1.16 1.49 1.47 503 No
COX6B1 Cytochrome c oxidase subunit 6B1 P14854 1.58 1.51 1.55 30 Yes (65)
54 Yes (40)
This data is plotted graphically in Figure 5.10. Proteins shown here were detected in both heavy and light channels for at least two
experimental replicates. Proteins are arranged by ascending mean ICAT ratio. The table was annotated manually using UniProt
(www.uniprot.org; The UniProt Consortium, 2017) as a reference. a—There is an identical peptide repeat within the protein so either
cysteine could have been identified; b—Cys51 of Prdx4 is in the N-terminal signal peptide.
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5.5.3 Preliminary data into H2O2 response for WT and Prdx1
KO HAP1 cells
The previous ICAT pilot study (the comparison between WT and Prdx1 KO HAP1
cells) was focused on establishing whether the WT and Prdx1 KO HAP1 cell lines
would be directly comparable. Whilst not conclusive, there was some evidence to
suggest that the two cell lines have similar basal levels of protein oxidation. Following
on from this a preliminary study of two single experiments was conducted, looking at
how WT and Prdx1 KO HAP1 cells respond to H2O2 treatment (Figure 5.11). The
same ICAT-labelling strategy was employed as for the untreated direct cell comparison.
The difference being here that either cell line was treated with 100 µM H2O2 for 2.5
minutes (this treatment had previously shown to induce p38-MAPK activation, see
5.6). In addition to the overall Chapter aim of determining the feasibility of using
ICAT to investigate H2O2 signalling, the aim of these preliminary experiments was to

































Figure 5.11: Overview of H2O2 treated HAP1 ICAT experiments. HAP1 cells (seeded
24-hours previously at 1 × 106 cells per mL in 20 mL)—WT in a) or Prdx1 KO in b)—were
grown and either treated with 100 µM H2O2 (for 2.5 minutes) or an equivalent volume of
water (untreated). The cells were processed as previously (as outlined in Figure 5.3) and
analysed by LC-MS/MS. The data is expressed as an ICAT ratio of +H2O2 over untreated.
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WT HAP1 Prdx1 KO HAP1
Log2 (ICAT Ratio(+H2O2/untreated))
Figure 5.12: ICAT ratio distribution for H2O2 treated WT and Prdx1 KO HAP1 cells.
HAP1 cells treated with H2O2 compared to untreated cells (refer to Figure 5.11 for an
overview of the experiment). Shown are histograms of Log2(ICAT ratio) frequencies with
0.2 bin widths. Curves are a non-linear regression fit (calculated using GraphPad Prism) of
the distribution data (the output from GraphPad Prism is shown in Appendix Table D.6).
The mean and median ICAT ratios for the data as a whole is indicated. a) HAP1 WT cells
treated with 100 µM H2O2 for 2.5 minutes compared to untreated WT cells. b) Prdx1 KO
HAP1 cells treated with 100 µM H2O2 for 2.5 minutes compared to untreated Prdx1 KO
cells.
Each of these experiments (comparison of H2O2 treated and untreated WT or Prdx1
KO cells) was only carried out once, so is shown for purely demonstrative purposes. The
majority of the data is shown in Appendix Figure D.5 and Appendix Tables D.2–D.5.
The labelling efficiency and replication of the duplicate LC-MS runs were similar
to that seen in the untreated pilot study (Appendix Figure D.4). Overall, proteins
from both WT and Prdx1 KO cells had a higher mean and median ICAT ratio than
compared untreated pilot (Figure 5.12). The Prdx1 KO cells had a slightly higher
average ICAT ratio overall. In terms of the distribution, whilst the WT cells had a
normal distribution (Figure 5.12a) the Prdx1 KO cells are less normally distributed
(Figure 5.12b).
A total of 38 proteins were labelled (with both the heavy and light ICAT reagent)























Figure 5.13: Comparison of H2O2 treated WT and Prdx1 KO HAP1 cells. a) Venn
diagram showing overlap of identified ICAT-labelled proteins in the two H2O2 treatment
experiments (as outlined in Figure 5.11). Numbers in parenthesis indicate proteins that
were identified but only in either the light or heavy ICAT channels. b) Heat-map of the
ICAT-labelled proteins that were found in both experiments (the overlap in a) Proteins that
have different oxidation levels are indicated (1—P4HA1, 2—CMC2, 3—CNPY2), but as
these experiments was only conducted once they are only indicated for illustrative purposes.
Comparing the proteins that were in each experiment, there are a few (such as P4HA1,
CMC2, CNPY2), appear to behave differently between the two cell lines (Figure 5.13b).
As these experiments only have a single replicate these subtle differences should be
treated with caution, but they do suggest that the two cell lines have a different response
to H2O2.
5.5.4 Comparison of all ICAT experiments: sub-cellular lo-
calisation and cysteine origins
As a final evaluation of the ICAT method used in this work, the sub-cellular localisation
and cysteine origins of ICAT-labelled proteins were analysed. All data (from the WT-
Prdx1 KO comparison and H2O2 treated WT or Prdx1 KO cells) were combined for
this purpose in order to determine what proteins were being represented in the data
set. The individual data sets are also shown separately in Appendix Figure D.6.
Looking at which cysteine within the identified protein was labelled (across all data
















































Figure 5.14: ICAT-labelled cysteine origins and protein localisation. Qualitative
comparison of all ICAT experiments (as illustrated in Figures 5.7 and 5.11) a) Proportion of
ICAT-labelled proteins identified where the labelled cysteine residue is predicted or known
to be in a structural disulfide bond (as per UniProt annotations) for all ICAT experiments.
The individual experimental breakdown is given in Appendix Figure D.6. b) Sub-cellular
origins of ICAT-labelled proteins for all ICAT experiments, manually annotation as
according to UniProt (www.uniprot.org; The UniProt Consortium, 2017).
ER—endoplasmic reticulum
to be) in disulfide bonds (Table 5.3, Figure 5.14b). Disulfide bonds represent one
form of cysteine oxidation, therefore it was expected that disulfide-containing proteins
would be identified. That more than half of all proteins identified would come from
disulfide-bonds was unexpected, but was consistently seen across the three experiments
performed (Appendix Figure D.6a).
When the sub-cellular origins of the proteins were looked at, the majority of proteins
originated from the ER/Golgi, mitochondria or the plasma membrane (Figure 5.14b).
Moreover, only a relatively small fraction (about 10%) were cytosolic in origin. Given
the majority of proteins identify could form a disulfide bond (Figure 5.14a) it follows
that the proteins should originate from these locations, as they are more oxidative cellu-
lar environments (Cook and Hogg, 2013). The implication of disulfide bond enrichment
and sub-cellular location will be explored in the discussion (5.6.2.4)
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5.6 Discussion
This Chapter looks at the possible role Prdxs have beyond being a cysteine-peroxidase—
e.g., Prdxs using H2O2 to oxidise specific targets thus altering downstream signalling
(Figure 5.3.3). A redox proteomics approach was outlined that could provide exper-
imental evidence, for or against, the hypothesis that mammalian Prdxs are bona fide
mammalian signalling proteins.
5.6.1 Prdx1 is required for H2O2-induced p38 response
Phosphorylated p38 is frequently used to monitor oxidative stress in cells. Addition
of exogenous H2O2 to media is also very commonplace as it is simple and affordable.
Whilst the physiological relevance of a bolus H2O2 treatment can be debated, H2O2 is
able to cross the plasma membrane (Antunes and Cadenas, 2000; Winterbourn, 2008).
NOX complexes that are known to generate H2O2 (via superoxide, see 1.5.4) do so on
the extracellular side of the cell (Holmström and Finkel, 2014). Addition of exogenous
H2O2 can, therefore, be thought of as a user-controlled way of emulating the activation
of NOXs.
HAP1 cells responded with p38 phosphorylation when treated with H2O2 (Fig-
ures 5.5 and 5.6). Conversely, in HAP1 cells without Prdx1 there was an ablated p38
response upon H2O2 treatment (Figure 5.6). The Prdx1 KO HAP1 cells were developed
using CRISPR/Cas9 which is known to have off-target effects (Zhang et al., 2015). In
order to rule out that loss of Prdx1 is the reason behind the ablated p38 H2O2 response,
ideally, Prdx1 would be re-introduced to the cells.
Unfortunately, difficulty in transient transfection of the HAP1 cells meant that
Prdx1 was never re-introduced to anything near endogenous levels (Appendix Fig-
ure D.2b). However, the Prdx1-required p38 response emulates the finding by Jarvis
et al. (2012) where U937 cells also required Prdx1 to respond to H2O2. Thus, whilst
there are possible caveats, the broad conclusion is HAP1 cells do respond to exoge-
nous H2O2 treatment and that Prdx1 is essential for the H2O2 response. Jarvis et al.
(2012) saw that Prdx1 was able to form a transient, inter-molecular disulfide bond
with ASK1. In this manner, it has been postulated that Prdx1 is required for H2O2
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induced activation of ASK1 via a disulfide-relay (Jarvis et al., 2012). As ASK1 is the
only (purportedly) known Prdx1 disulfide-relay signalling partner, more examples are
required in order to fully appreciate the signalling role of Prdx1 and other Prdxs in
H2O2 signalling.
5.6.2 ICAT proteomics to investigate the role of Prdx1 as a
signalling protein
The main aim of this Chapter was to perform a pilot study in order to determine
whether the ICAT method would be a suitable approach for investigating the contribu-
tion of Prdx1 to protein oxidation. This work was designed to feed into the hypothesis
that Prdx1 acts as a signalling protein, and identify potential signalling-substrates of
Prdx1. The ICAT method—as deployed in this Chapter—used the ICAT method to
label oxidised cysteine residues within a cell lysate.
5.6.2.1 How different does a ratio need to be?
One concept that needs to be addressed for analysing a differential analysis is how
different do to two samples need to be (i.e. the ICAT ratio) for the samples to be
considered discrete. Several of the studies using an ICAT-based method to look at
redox-proteomics have a ratio between 1.2 and 1.5 as ‘different’ from their respective
controls, for example, Garćıa-Santamarina et al. (2011); Hägglund et al. (2008) and
Leichert and Jakob (2004). However, the ratio readouts from these studies cannot
necessarily be directly compared owing to key experimental differences.
Figure 5.10 gave an arbitrary cut-off value (roughly a 10% change—an ICAT ratio
value between 0.93 and 1.07 or Log2 value range of -0.1 and 0.1) that is used to indicate
a range for an ‘unchanged’ value. Whether a 10% change or an ICAT ratio of between
1.5 and 2 are biologically relevant is another question. For example, in protein kinase
signalling, a residue on a protein may need to be phosphorylated for a pathway to
be activated. However, less than 5% of the total protein in question may actually be
phosphorylated, which may be sufficient to activate a downstream pathway (Jensen,
2006). Accordingly, a relatively small change (∼5%) in the total oxidation status of a
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protein pool may be sufficient to alter cellular signalling. Furthermore, it is also possible
that multiple proteins within a pathway could be oxidised, having a synergistic effect
on the signalling system.
Follow up validation experiments are critical to accurately evaluate ICAT-based
results. For example, if known protein kinases were identified as differentially oxidised
between WT and Prdx1 KO HAP1 cells, genetic editing could be used to mutate the
ICAT-labelled cysteine for the protein in question. The Prdx1-dependant effects on
oxidation on protein signalling could then be assessed by western blotting for a phospho-
target (akin to the p38 phosphorylation monitoring in this work, 5.5.1). Alternatively,
targeted MS-based experiments, such as by selected reaction monitoring (SRM), could
be used (Held et al., 2010). SRM is a quantitative method where only pre-determined
peptide masses are analysed by the mass spectrometer (Picotti and Aebersold, 2012).
However, for an SRM method to be used, the precise cysteine modification would need
to be determined. There are over a dozen different known forms of cysteine oxidation
so determining a modification is not a trivial task (Devarie Baez et al., 2015). Lastly,
whilst SRM would confirm the oxidation of a target protein, it does not confirm it being
biologically relevant to cellular signalling so other methods would still be required.
5.6.2.2 WT and Prdx1 have equivalent basal oxidation levels
In this work, WT and Prdx1 KO HAP1 cells were directly compared with the ICAT
method. A lysate from each cell type was labelled with one of the ICAT reagents and
the samples were combined for analysis by LC-MS/MS (5.5.2 and Figure 5.7). The
overall question for this pilot study being ‘do Prdx1 KO cells have a different basal
oxidation state from WT’?
Broadly, the data collected can be used to argue that the two cell lines do not differ
from one another, agreeing with the observations from within the Ledgerwood lab
(Carrad, 2017). The distribution of the identified ICAT-labelled peptides (Figure 5.9)
and only three proteins having an ICAT ratio that is statistically different from 1
(Figure 5.10) indicates that there are no major differences between the cell lines and
that they can be considered to be equivalent. There are a few caveats to this conclusion
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which will be outlined shortly.
It may be surprising that a complete loss of Prdx1 from the HAP1 cells does not
cause an overall increase in protein oxidation. After all, Prdx1 is an abundant cytosolic
peroxidase (see 5.3.2). However, Prdx1 is not the only cytosolic Prdx, with Prdx2 also
being cytosolic, alongside Gpxs (Winterbourn, 2018). Furthermore, an absence in
increased protein oxidation also supports the notion that proteins have a relatively low
reactivity with H2O2 (see 5.3.3 and Table 5.1) and, therefore, will not become oxidised
under basal conditions.
There are two main problems with the broad conclusion that the WT and Prdx1
KO cell lines do not have different basal oxidation statuses. Firstly, only a relatively
small number of proteins were identified (37; Figure 5.9) in at least two experimental
replicates. Therefore, the question can be raised as to whether the analysed pool
is representative of the proteome and cellular state. Secondly, the lack of statistical
significance could be representing the true state—that both cell lines have similar
distributions of oxidised proteins. Alternatively, it could be viewed that the variation
between individual experimental replicates is too great, as could be concluded from the
95% confidence intervals (Figure 5.10, bottom). However, the wider error bars (from
either SEM and 95% confidence intervals) are also due to most of the analysed proteins
only being detected in two replicates. Further work could not only increase the overall
proteome coverage (helping with the first problem) and give greater statistical power.
Other problems with any potential conclusions from the ICAT data could come from
potential off-target effects of the CRISPR/Cas9 KO system (as mentioned in 5.6.1)
used to generate the Prdx1 KO HAP1 cells. Re-introduction of Prdx1 may alleviate
any potential off-target effects of the KO system (as discussed in 5.6.1), however, the
method of re-introduction needs to be carefully determined. Transient transfection to
a level that is similar to the endogenous protein could be effective, depending on how
robust the transfection system used is. By comparison, re-introduction by a lentiviral
vector would achieve a stable system, however, the random nature of lentiviral genome-
integration could result in similar problems (Sakuma et al., 2012).
A more effective control would be a comparison between WT and Prdx1 KO, and,
WT and a Prdx1-overexpression system. An alternative approach would be to genet-
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ically edit Prdx1. An strategy similar to that of Gaudelli et al. (2017) could be used
make an active site mutant—Prdx1C52S, C173S—that is unable to break down H2O2.
This method has reportedly far fewer off-target effects. The other advantage of mutat-
ing Prdx1 compared to deleting it is any non-peroxidase function will be preserved.
The ICAT proteomic method used in this thesis uses an equal amount of a cell
lysate determined by a BCA assay (or similar). Whilst this way of controlling protein
levels has been used in several redox-proteomic studies (e.g., Araki et al., 2016; Kumar
et al., 2013a), and does ensure that the total protein levels used are comparable it
does not mean that individual proteins will be expressed at similar levels. The ICAT
method, as used in this work, examines changes in the labelling of cysteine-containing
proteins. Therefore, if a protein is 2-fold increased in one cell-line (relative to control)
the ICAT ratio will also show a 2-fold difference despite there not necessarily being
any difference in the actual oxidation status of the labelled cysteine residue. Genes
that are known to be under transcriptional control by redox-regulated transcription
factors (such as NRF2) may possibly be expressed at different levels in Prdx1 KO cells
(Marinho et al., 2014). A better way to compensate for differential protein expression
would be to perform quantitative proteomics alongside the quantitative ICAT redox
proteomics. Quantitative proteomic methods, such as isobaric tag for relative and
absolute quantification (iTRAQ) or dimethyl labelling have been used for this purpose
(for example, Fu et al. 2009 and Garćıa-Santamarina et al. 2014). Whilst additional
quantitative methods would make the ICAT method used in this work more robust,
there would also be the added cost of reagents and time to perform and analyse the
second labelling method.
5.6.2.3 HAP1 cellular response to H2O2 treatment
In addition to the pilot study, comparing WT and Prdx1 KO HAP1 cells, HAP1
cells (WT and Prdx1) were also treated with H2O2 and analysed (relative to a vehicle
control, 5.5.3 and Figure 5.11). One of the advantages of looking at changes in response
to H2O2 is that as a cell line is essentially compared to itself, the problem of differing
protein levels between cell lines (as discussed above, 5.6.2.2) is alleviated.
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In this work, when HAP1 cells were treated with H2O2 (5.5.3), there were differ-
ences (between WT and Prdx1 KO cells) in the ICAT ratio distribution (Figure 5.12).
Whilst the number of proteins common to the two cell lines was still relatively low
(42; Figure 5.13), a small pool is more informative for inferring about cellular response
to H2O2. Experimental replication of H2O2 treated cells and ICAT-labelling would
be essential in order to draw any specific conclusions. Additionally, any results would
also require validation (as discussed previously, 5.6.2.1) to draw a strong biological
conclusion.
5.6.2.4 Enrichment of disulfide-bond proteins by the ICAT method
An advantage of using a MS-based method is that in addition to differential analysis,
information is also gained about the protein itself, namely the residue that is labelled.
The majority (∼60%) of proteins that were identified as ICAT-labelled in this study
contained, or are predicted to contain, a structural disulfide bond (5.5.4). The method
used in this work is primarily based on a protocol by Garćıa-Santamarina et al. (2014).
The method is designed to label only oxidised cysteine residues (see Figure 5.3). Given
the method is designed to label oxidised cysteine residues, and disulfide bonds will
form a portion of that pool, it is to be expected that disulfide bond containing proteins
were identified. Additionally, cysteine residues involved in structural disulfide bonds
are unlikely to have a great change in their own oxidation status.
Garćıa-Santamarina et al. (2011) used the oxidised cysteine labelling method to
analyse a yeast (Schizosaccharomyces pombe) proteome and the response to treatment
with 0.2 mM H2O2. Garćıa-Santamarina et al. (2011) divided their data into structural
disulfide bonds (that have a constant ICAT ratio upon H2O2 treatment), and redox-
sensitive disulfide bonds (that have an ICAT ratio that changes upon H2O2 treatment,
and this will be further discussed below). For the pilot study in this work (the compari-
son between basal WT and Prdx1 KO HAP1 cells, 5.7) seeing a high degree of labelling
of known (or predicted) structural disulfide bond containing-proteins was, therefore,
anticipated. In the same vein, the sub-cellular localisation also fits with these re-
sults. The majority of labelled proteins originated from the ER, Golgi, mitochondria
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or plasma membrane (Figure 5.5.4). In eukaryotes, disulfide bonds are formed within
the ER, Golgi apparatus or the mitochondrial intermembrane space (Cook and Hogg,
2013). Therefore it fits for the identified proteins to originate within these locations.
In this work, HAP1 cells were also treated with H2O2 and analysed via the ICAT-
method (5.5.3). Whilst only one single experiment was conducted, there were few
proteins that had an ICAT ratio above 1.5 (5 and 6 proteins for WT and Prdx1 KO
HAP1 cells, respectively; Appendix Figure D.5 and Appendix Tables D.2 and D.4). By
comparison, Garćıa-Santamarina et al. (2011) detected over 40 proteins that had an
ICAT ratio of 1.5 from H2O2 treated S. pombe cells. Garćıa-Santamarina et al. (2011)
based their observations on 1195 identified peptides, but there is no comment as to
how many proteins this represents or how many proteins did not have an ICAT ratio
of over 1.5. However, from their responses, Garćıa-Santamarina et al. (2011) do see an
increase in proteins that would be expected to be oxidised under H2O2 treatment, such
as the yeast Prdx, Tpx1, and yeast Trx1. Overall, whilst Garćıa-Santamarina et al.
(2011) do not identify an especially large number of differentially oxidised proteins
there is still 10-fold more than was detected in this work.
5.6.2.5 Closing remarks regarding ICAT experiments
The observation that Prdx1 is required for p38 phosphorylation in response to H2O2
as seen by Jarvis et al. (2012) has been replicated here in the HAP1 cell line. These
experiments highlight that Prdx1 is important in translating an oxidative signal to
a protein kinase cascade. An ICAT proteomics approach may be appropriate to in-
vestigating the role of Prdx1 as a signalling protein, but further optimisation will be
required to ensure reliable results. For example, a cytosolic sub-cellular fraction could
be isolated in order to minimise the structural disulfide-bond rich cellular components
(such as the ER). However, this makes it more difficult for accurate comparisons be-
tween two different conditions (as it increases the number of handling steps for the
proteome to be labelled). Secondly, it would also be incompatible with the TCA lysis
method and an alternative thiol-preservation step would be required. However, these
approaches would not help with the relatively low number of proteins identified nor
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the poor biotin-enrichment (see Figure 5.8b). The use of a different enrichment step,
such as loose streptavadin-conjugated resin, may be useful. Other methods could be
used to address the role that Prdx1 plays in cell signalling and a few examples will be
outlined in the final Discussion (Chapter 6).
5.6.3 Conclusions
The work in this Chapter has shown that human cell HAP1 cell line responds to
H2O2 treatment. Upon addition of bolus H2O2 to cells, phosphorylated p38 can be
detected by western blot. Prdx1 is essential for this p38 response, as has been seen
previously in the U937 cell line (Jarvis et al., 2012). In order to determine whether
Prdx1 was acting as a signalling protein under these conditions, a redox-proteomics
method was established. The proteomics method used the ICAT reagent to isotopically
label oxidised protein thiols so two cell states can be directly compared. A pilot study
was carried out to determine whether HAP1 cells that have had Prdx1 genetically
deleted exhibit a different basal oxidation level. Whilst the ICAT method successfully
labelled and identified proteins from WT and Prdx1 KO HAP1 cells, there was a poor
coverage of the overall proteome. The low coverage means further work is required
to draw any biological conclusion about the basal oxidation status of WT and Prdx1





This Thesis has explored regulatory mechanisms of ASK1 and the general principle of
H2O2 signalling using in vitro and proteomic methods. This Chapter serves to connect
the individual results Chapters, putting them into the perspective of the wider biolog-
ical field. Outstanding questions will be raised and possible methods for addressing
them will be highlighted.
6.2 Summary of results Chapters
The overall aims of this Thesis were to investigate the regulatory mechanisms of ASK1
and assess whether a proteomics method would be feasible for exploring the role of
Prdx1 in H2O2 signalling.
Chapter 3 used recombinant ASK1 protein and in vitro kinase assays to look at
ASK1 auto-regulation. The ASK1 N terminus was seen to be auto-inhibitory on ASK1
kinase activity. The ASK1 PH domain, within the N terminus, was postulated to act
as a scaffold by recruiting MKK6, priming it for phosphorylation.
Chapter 4 used recombinant ASK1, Trx1 and SAXS data to investigate ASK1
regulation by Trx1. Trx1 was found able to bind to ASK1. Trx1 and ASK1 could form
an inter-molecular disulfide bond for which ASK1-Cys250 was required. Somewhat
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surprisingly, no Trx1 mediated inhibition of ASK1 kinase activity was observed in
vitro.
Chapter 5 was a pilot study in order to determine whether a redox proteomics
method would be suitable for understanding the role Prdx1 plays in H2O2 signalling.
The ICAT method was used in conjunction with a Prdx1 KO cell line. The data
suggested, that there are no differences in basal protein oxidation levels between WT
and Prdx1 KO cell lines. Preliminary data indicates that WT and Prdx1 KO HAP1
cells do respond differently to H2O2. However, further work is required to identify a
greater number of proteins.
6.3 ASK1 regulation
In cells, ASK1 is activated in response to a myriad of factors, including H2O2, but little
is known about how this process is governed at a molecular level. MAP3Ks contain
large extra-kinase regions (see Figure 1.3 on page 5), but the role of these regions in
regulating protein catalytic activity often goes overlooked. Concordantly, as a MAP3K,
ASK1 contains a serine/threonine protein kinase domain, and large regulatory regions,
both N- and C-terminal to the kinase domain (see Figure 1.4 on page 7). The work
within this Thesis has allowed for an in vitro investigation into N terminal regulation
of ASK1, to a level hitherto not possible.
6.3.1 Auto-regulation of ASK1
In Chapter 3, it was seen that the N terminus (residues 88–658) of ASK1 is directly
inhibitory on ASK1 kinase activity. A model was proposed that the ASK1 PH domain,
N terminal to the kinase domain, could act as a docking site for MKK6. Overall control
of access to the PH domain could be regulated by the TBD (see Figure 3.9 on page 82).
This model is attractive, as it allows for the TBD to be the redox sensor of ASK1,
regulating ASK1 in response to H2O2.
The high degree of conservation within ASK1269–658 (see Appendix Figure B.7;
Weijman et al., 2017), means it is probable that the model will also be true for both
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ASK2 and ASK3. Replicating the work within Chapter 3 with the other ASKs would
be needed to confirm whether the model is true for all ASKs. It remains to be seen
whether other MAP2Ks would behave similarly to MKK6. Extending the work within
Chapter 3 with other MAP2Ks (e.g., MKK3, 4 and 7), would help to inform how
universal the proposed model is. Lastly, in order to confirm an affinity between the non-
catalytic regions of ASK1 and MAP2Ks, it would be worthwhile to characterise binding
affinities—by methods such as such as ITC or surface plasmon resonance (SPR)—
between ASK1 domains and different MAP2Ks.
The model of TBD-mediated regulation of ASK1 is based on comparisons of SAXS
data from two protein constructs: ASK188–658 and ASK188–941. However, in light of
the observations in Chapter 4 that ASK188–941 is not inhibited by Trx1 (despite ASK1
and Trx1 being able to interact), it is worth reconsidering the model. The model for
ASK1 auto-inhibition was based on rigid-body modelling of the constitutive domains
within ASK188–658 and ASK188–941. However, the direct comparison of ASK188–658 and
ASK188–941 rigid-body models cannot account for any potential flexibility between the
ASK1 kinase domain and ASK1269–658. The relative positions of ASK1269–658 and the
ASK1-TBD will be quite constrained, by comparison, there will be a greater degree of
freedom in the position of the kinase domain (there is a linker, 16 amino acids in length,
between ASK1269–658 and the kinase domain). Whilst ensemble rigid-body modelling
of SAXS data could be used to give a series of most probable conformers (Tria et al.,
2015), kinetic data may be more informative.
Fluorescence (or Förster) resonance energy transfer (FRET) could be used to under-
stand how dynamic the constitutive domains within ASK188–941 are. FRET is a tech-
nique that allows for the inferences of distances (∼20–60 Å) between two fluorophores:
a donor and acceptor (Ma et al., 2014). When excited, a donor will transfer energy
to the acceptor causing the acceptor molecule to fluoresce (Ma et al., 2014). A donor-
acceptor pair could be covalently conjugated to the N- and C-termini of ASK188–941,
and the FRET signal measured under different conditions, such as when MKK6 or
Trx1 are present. A FRET approach would help to show how dynamic ASK188–941 is,
as movements at either the N or C terminus of the construct could alter the FRET
signal. Correctly interpreting any FRET signal from ASK188–941 would benefit from
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higher-resolution structural data on which to model any perceived movement.
To date, there are published crystal structures of the ASK1 kinase domain (Bunkoczi
et al., 2007) and ASK1269–658 (Weijman et al., 2017). During this Thesis, attempts were
made to crystallise various N-terminal ASK1 constructs (e.g., 88–266 and 88–658) to
no avail. Other efforts within the Mace laboratory have been made at crystallising
ASK188–941, also with no success. Other ASK1 constructs, such as full-length ASK1
(ASK12–1374) from Sf 9 cells could be more useful. As ASK12–1374 is expected to form
a large oligomer (Federspiel et al., 2016; Noguchi et al., 2005), it may be possible to
use cryo-electron microscopy (cryo-EM) to determine a structure for ASK1. Cryo-EM
requires relatively small amounts (∼5 µL) of low concentration (less than 2 mg/mL)
protein (Murata and Wolf, 2018). Critically, cryo-EM does not require a crystal, yet
can be used to achieve a high-resolution (below 4 Å) structure (Cheng, 2015). Apply-
ing cryo-EM to ASK12–1374 would give a detailed picture of how domains within ASK1
are arranged, and how they interact with each other in the context of the full-length
protein. It would then be beneficial to revisit the ASK1 constructs used in this Thesis
(88–266, 88–658 and 88–941), and re-evaluate the data in light of a cryo-EM structure.
6.3.2 ASK1 N-terminal mutations in health and disease
The importance of the N-terminal domains in ASK1 regulation can be further illus-
trated by looking at known mutations within the MAP3K5 gene. The cBioPortal for
Cancer Genomics (www.cbioportal.org; Cerami et al., 2012) lists ∼600 missense mu-
tations within the MAP3K5 gene. Within N-terminal ASK1 domains, two mutations
stand out in context of this work: Arg395Gln and Arg256Cys.
In Chapter 3, Arg395 was mutated to Glu to investigate whether ASK1269–658 was
a flexible or rigid domain. If there were flexibility, Arg395Glu would increase ac-
tivity, whereas if it were a rigid domain, Arg395Glu would decrease activity (3.5.4).
ASK188–941
R395E was approximately 50% less active than WT (3.5.4.1). An Arg395Gln
mutation will likely not be as detrimental as Arg395Glu, but based on this work it goes
towards explaining how mutations within ASK1269–658 could be pathogenic.
Prickett et al. (2014) identified ASK1 Arg256Cys mutations in human melanomas.
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When ASK1R256C was over-expressed in HEK293T cells, Prickett et al. (2014) observed
lower levels of p38 and JNK phosphorylation (Prickett et al., 2014). Prickett et al.
(2014) saw, by co-immunoprecipitation, that ASK1R256C associated with Trx1 to a
greater degree than ASK1WT. Based on these observations, Prickett et al. (2014)
hypothesised that ASK1R256C had increased inhibition by Trx1, resulting in decreased
p38 and JNK activation and lower levels of cell death, which would contribute to cancer
progression. However, the work in Chapter 4 argues that association between ASK1
and Trx1 is not sufficient to directly alter ASK1 kinase activity in vitro, bringing in to
question the true nature of the association between ASK1 and Trx1.
6.3.3 Is Trx1 a bona fide inhibitor of ASK1?
In Chapter 4, the interaction between Trx1 and ASK1 was investigated. Trx1 is gen-
erally regarded to bind to the ASK1-TBD, directly inhibiting ASK1 kinase activity
(Fujino et al., 2007; Saitoh et al., 1998). However, there are conflicting opinions as
to whether Trx1 only binds to ASK1 or whether the oxidoreductase activity of Trx1
(on ASK1) is required (see Figure 4.2 on page 89; Nadeau et al., 2009, 2007; Saitoh
et al., 1998). Whilst ASK1 and Trx1 were seen to interact in vitro (agreeing with
observations by Kosek et al. (2014) and Kylarova et al. (2016)), Trx1 mediated inhibi-
tion of ASK1 kinase activity was not observed. Lack of ASK1 inhibition by Trx1 was
rather surprising given the prevalence of the direct-binding and inhibitor model in the
literature. It is worth considering what is known about Trx1 interactions in vivo.
The ubiquity of Trx (and Trx like proteins) has led to much interest in identifying
interacting partners and substrates of Trxs in different systems. To this end studies
have been conducted on identifying Trx targets from bacteria (Arts et al., 2016; Kumar
et al., 2004), yeast (Vignols et al., 2005), plants (Hägglund et al., 2008; Maeda et al.,
2005; Yano et al., 2001), mammalian cells (Benhar et al., 2010; Engelhard et al., 2011;
Nakao et al., 2015; Schwertassek et al., 2007) and mouse tissue (Booze et al., 2016;
Fu et al., 2009). These studies have used various approaches, including methodologies
similar to the ICAT method that was deployed in Chapter 5.
Focusing on studies that have looked at Trx1 substrates and interacting partners
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from mammalian material (in particular: Benhar et al. (2010); Booze et al. (2016);
Fu et al. (2009) and Nakao et al. (2015)), ASK1 has not been reported as either a
substrate nor interactor with Trx1. However, one of the limitations of studies such as
these (that use shotgun-MS based methods) is that the relative abundances of proteins
may skew the results. For example, highly abundant proteins, such as Prdxs and
protein translation factors, are frequently reported as Trx1 interacting partners, making
it difficult to identify lower-abundant proteins, including ASK1 (Benhar et al., 2010;
Booze et al., 2016; Fu et al., 2009; Mellacheruvu et al., 2013).
Most of the studies reporting an association between ASK1 and Trx1 demonstrate
the association by co-immunoprecipitation from cell over-expression systems. Feder-
spiel et al. (2016) used a targeted (SRM) mass spectrometry method to look at ASK1
interacting partners. When ASK1 was over-expressed in HEK293, less than 0.5% of
ASK1 was associated with Trx1. When Federspiel et al. (2016) looked instead at en-
dogenous levels, 5% of ASK1 was associated with Trx1 and did decrease when they
treated cells with 4-hydroxynonenal (a lipid electrophile that can be used to activate
JNKs and ASK1 (Federspiel et al., 2016; Soh et al., 2000)). By comparison, 70–80% of
endogenous ASK1 was found to associate with ASK2 and ∼40% with 14-3-3 proteins
(Federspiel et al., 2016). Therefore, the interaction between ASK1 and Trx1 may be a
lot more transient than first assumed, or, dependent upon other cellular conditions.
In Chapter 4, ASK1 and Trx1 were seen to associate and were able to form an inter-
molecular disulfide-linked species. Whilst the mechanism of how ASK1 and Trx1 were
able to form a cross-linked species is unclear (see 4.5.6), it was seen that ASK1-Cys250
was necessary and sufficient to allow the formation of the species. One possibility that
has not previously been explored is a disulfide-linked ASK1 homo-dimer (i.e. Cys250-
Cys250). Such a species would have to be present at low levels, as there was no clear
evidence to support a homo-dimer forming. For instance, in Figure 4.5 (page 98), where
ASK188–658 was incubated with Trx1 or Trx1
C35S and analysed by non-reducing SDS-
PAGE, there were several bands—greater than 100 kDa in size—that could indicate a
disulfide-linked dimer (or oligomer) of ASK188–658. However, these bands are present at
the beginning of the assay, do not substantially change over time, and critically, are still
present on reducing SDS-PAGE. These observations were identical when ASK188–658-
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Cys250Ser was incubated with Trx1 (or Trx1C35S) in the same manner (Appendix
Figure C.4c). Nonetheless, in cells, ASK1 is known to form high molecular weight,
disulfide-linked species in response to H2O2 (Jarvis et al., 2012; Nadeau et al., 2009,
2007). Prdx1 is required for ASK1 to form these disulfide-linked species (Jarvis et al.,
2012; Stöcker et al., 2018a). Nadeau et al. (2007) proposed that Trx1 acted as an
oxidoreductase, reducing the ASK1 disulfide-linked species, thereby regulating ASK1
activity. The work in Chapter 4 would indicate that Trx1 can indeed serve to reduce
ASK1, but Trx1 itself does not directly inhibit ASK1 activity. Taken together with
the work by Federspiel et al. (2016), Trx1 may not be a specific regulator of ASK1,
but rather a non-discriminant reducer of cysteine residues within ASK1.
6.3.4 Missing components of ASK1 regulation?
Whilst this Thesis points towards Trx1 not being a direct inhibitor of ASK1, there
are several caveats to consider. The strength of the recombinant model system used
in this work is that we are able to know the concentration and condition of proteins
in an assay. However, the weakness of the system is that it will be impossible to ever
recapitulate the true complexity of a cellular environment. Thus whilst Trx1 is not
seen to inhibit ASK1 in this work, it cannot be extrapolated to Trx1 not being an
inhibitor in vivo as other factors need to be considered.
6.3.4.1 Post-translational modification of ASK1
One aspect of native ASK1 that will not be recapitulated with bacterial expression
system used in this work, is post-translational modifications of ASK1. Modifications
of ASK1 could result in different behaviours, explaining the discrepancy between the
work in this Thesis and in the literature. ASK1 can be phosphorylated (see Chapter 1)
and methylated (Nishida et al., 2017). ASK1 can be methylated by protein arginine
methyltransferases (PRMT) 1 and 5 (Chen et al., 2016; Cho et al., 2012). Methylation
within the ASK1 N terminus, at Arg78 and Arg80, has been seen to increase binding of
Trx1 to ASK1 (Cho et al., 2012). Arg78 and Arg80 fall outside of the regions covered
by any ASK1 protein construct used in this Thesis. Therefore, it would be informa-
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tive to repeat some of the experiments within this Thesis with an ASK1 construct
that includes Arg78 and Arg80 (perhaps residues 2–266, providing that they do not
cause instability or decreased protein solubility) and confirm whether there are differ-
ences in ASK1 activity or Trx1 binding. Recombinant rat PRMT1 has been purified
from E. coli (Zhang and Cheng, 2003). It is, therefore, feasible to use recombinant
PRMT1 to methylate ASK1 in vitro, and determine the effect of methylation on Trx1
binding and inhibition. Arg to Phe mutants could also be used to mimic the methyl
group (Mostaqul Huq et al., 2006) allowing any effect on Trx1 binding to be deter-
mined. Understanding how ASK1 and Trx1 associate would still greatly benefit from a
high-resolution structure. If a longer N-terminal ASK1 construct (residues 2–266) did
increase ASK1’s affinity for Trx1, it would be worthwhile to attempt to co-crystallise
the proteins in a complex for structure determination by X-ray crystallography.
ASK1 can also be ubiquitylated. It has been suggested that one of the mechanisms
by which Trx1 can regulate ASK1 is not via directly altering ASK1 activity but rather
by binding to the ASK1-TBD, promoting ubiquitylation and consequent degradation
(Liu and Min, 2002). Polyubiquitylation of ASK1 within its C terminus (at six lysine
residues between 946 and 957) has been shown to be required for active ASK1 sig-
nalling in response to viral infection (Yu et al., 2016). Whilst polyubiquitylation of the
ASK1 C terminus may not directly modulate the interaction between ASK1 and Trx1,
polyubiquitylation could affect localisation or recruitment of other factors, all of which
would affect the overall signalling system.
6.3.4.2 The ASK1 signalosome
ASK1 is known to form a complex that has been termed the ‘ASK1 signalosome’
(Noguchi et al., 2005). Under resting conditions, the signalosome is at least 669 kDa in
size (Federspiel et al., 2016; Noguchi et al., 2005). Using a target mass spectrometry
approach, Federspiel et al. (2016) deduced that the ASK1 signalosome likely consists
of two copies each of ASK1 and ASK2 and one copy of a 14-3-3 protein. ASK1 and
ASK2 have repeatedly been seen to associate (Ortner and Moelling, 2007; Takeda
et al., 2007; Wang et al., 1998). Perhaps then Trx1 only regulates ASK1 in context of
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the full signalosome. Reconstituting the signalosome (at least ASK1 and ASK2) with
recombinant protein would allow for Trx1 regulation to be tested this way.
6.3.5 ASK1 and activation by H2O2
Trx1 is widely purported as a constitutive binder of ASK1, and only when Trx1 is
released, is ASK1 fully active (Fujino et al., 2007; Liu et al., 2000; Liu and Min, 2002;
Saitoh et al., 1998). Trx1 is generally regarded to be released from ASK1 when Trx1
becomes oxidised by H2O2 (Saitoh et al., 1998). However, as covered in Chapter 5,
the most likely target of H2O2 in vivo will be Prdxs. It is highly probable, therefore,
that the interaction between ASK1 and Trx1 is much more transient, with Trx1 only
associating with ASK1 to reduce oxidised-ASK1. Prdx1 would then serve to act as an
activator of ASK1 by facilitating oxidation of ASK1 (Jarvis et al., 2012). In Chapter 4,
ASK1 and Prdx1 were combined in an assay (4.4.7.1) with no change in ASK1 activity.
However, as discussed above (6.3.4.2) perhaps ASK1 and ASK2 need to be in a complex.
Prdxs are purported to serve as mediators of disulfide relays in order to facili-
tate H2O2 signalling (Stöcker et al., 2018b). One of the best-known examples of a
disulfide-relay is from yeast, between the peroxiredoxin Gpx3 and transcription factor
Yap1 (Winterbourn, 2018). Gpx3 is required to transmit the oxidative signal from
H2O2 to Yap1 but Yap1 and Gpx3 alone are not sufficient for proper transmission of
the signal in vivo (Veal et al., 2003). An interacting protein—Yap1 binding protein,
Ybp1—is required (Veal et al., 2003). Bersweiler et al. (2017) described Ybp1 as a
sulfenic acid chaperone, explaining why Ybp1 is required. Ybp1 brings Yap1 together
with the sulfenylated peroxidatic cysteine residue (i.e. Cp-SOH) of Gpx3, preventing
disulfide bond formation within Gpx3 and promoting the formation of a Gpx-Yap1
inter-molecular disulfide bond (Bersweiler et al., 2017). In the Pfam database, Ybp1
belongs to the ‘Kinetochore Ybp2 (PF08568)’ family of which the human protein glo-
mulin is also a member (pfam.xfam.org; Finn et al., 2016). Glomulin may act as a sim-
ilar sulfenic acid chaperone in a mammalian system (although not necessarily between
ASK1 and Prdx1). TRAF proteins and polyubiquitlayion have well-characterised roles
as protein adaptors (Rusnak and Fu, 2017; Swatek and Komander, 2016) and there-
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fore could act orthogonally to Ybp1 in regulating Prdx1 and ASK1. Additionally, we
may yet identify other proteins that have equivalent roles as mammalian sulfenic acid
chaperones.
6.4 Prdx1 and H2O2 signalling
In this Thesis, ASK1 has been used as a model system for investigating how factors
associated with oxidation (i.e., Trx1, H2O2 and Prdx1) can regulate protein activity in
vitro. The broader question is, how do proteins get oxidised within a cellular environ-
ment? Prdxs are proposed to act as mediators of H2O2 signalling, becoming oxidised
by H2O2 themselves then transmitting the signal to target proteins via inter-molecular
disulfide bonds (see Figure 5.2 on page 146; Stöcker et al., 2018b).
The cytosolic mammalian Prdx, Prdx1 has been seen to be required for H2O2
induced activation of p38 MAPK within human myeloid leukemia U937 cells (Jarvis
et al., 2012), the J774A.1 mouse macrophage cell line (Conway and Kinter, 2006) and,
in this work, human myelogenous leukaemia HAP1 cells (5.5.1). In yeast (S. pombe)
the Prdx, Tpx1, is required for activation of Sty1—a yeast MAPK that is orthologous
to p38 and JNK—via a disulfide-relay (Day and Veal, 2010; Veal et al., 2004). In the
case of Tpx1 and Sty1, the Prdx is directly activating the MAPK. In the case of Prdx1
and p38, it is thought that Prdx1 instead activates the pathway at the MAP3K level,
by directly activating ASK1 (Jarvis et al., 2012). It suggests, perhaps, that Prdx-
mediated activation of MAPKs is an evolutionarily conserved process, but the precise
signalling partners are divergent.
Chapter 5 tested a redox proteomics approach to identify proteins that are differ-
entially oxidised depending upon Prdx1 expression. Accordingly, it was hypothesised
that additional H2O2 signalling substrates (including ASK1) of Prdx1 might be identi-
fied by the redox proteomics approach. Whilst the method did identify proteins, there
were only ∼40–80 ICAT-labelled proteins that were identified per experiment. Fur-
thermore, as the majority (more than 60%) of labelled cysteine residues originate from
structural disulfide bonds (see 5.6.2.4), there is not enough to data to make any conclu-
sions about Prdx1 as a signalling protein. The ICAT method—as deployed within this
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Thesis—could be further refined, however, alternate techniques should be considered
in order to investigate the role of Prdx1 in H2O2 signalling.
6.4.1 Alternative methods to investigate Prdx1 contribution
to H2O2 signalling
Other approaches could be used to investigate the role of Prdx1 in H2O2 signalling.
For example, van der Reest et al. (2018) used a redox proteomics approach to look at
protein cysteine oxidation in response to metabolic perturbation. A differential alky-
lation strategy was used, similar to that used in Chapter 5. There were a few major
differences that van der Reest et al. (2018) used, chiefly that they used a combination
of N-ethylmaleimide (NEM) and isotopically labelled IAM. Reduced cysteines were
firstly labelled with their IAM reagent followed by reduction and labelling of all other
cysteines with NEM—an approach van der Reest et al. (2018) dubbed “stable isotope
cysteine labelling with iodoacetamide (SICyLIA)”. Importantly, this approach does
not feature an enrichment step. Instead, there is complete fractionation of an entire
lysate—from cell lines and mouse tissue—using HPLC before subsequent LC-MS/MS
analysis of individual fractions. As the SICyLIA method does not rely on enrichment
it can give a much better overview of the whole proteome. Van der Reest et al. (2018)
were able to identify on the order of 105 peptides, representing 2,000–3,500 cysteine-
containing proteins—one of the most in-depth redox proteomics studies that has been
published. The main drawback of the SICyLIA method is the total fractionation ap-
proach requires extensive LC-MS/MS time. Nonetheless, the SICyLIA approach would
also increase the coverage of lower-abundance proteins—proteins that are more likely
to represent signalling proteins—offering a marked increase in the coverage that was
achieved using the ICAT method as in Chapter 5. The experimental aspect is relatively
straightforward and would be easily translatable to another biological question, such
as with the contribution of Prdx1 to H2O2 signalling.
An alternative to looking at protein oxidation is instead to monitor other aspects
of cell signalling. For example, as Prdxs are linked to regulation of protein kinase
signalling—either by activating kinases or inactivating phosphatases (Holmström and
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Finkel, 2014)—loss of Prdx1 may alter cellular phosphorylation levels, ‘the phospho-
proteome’. The use of mass spectrometry to look at the phosphoproteome (phospho-
proteomics) has provided an in-depth view of phosphorylation during the cell cycle
(Olsen et al., 2006, 2010). Comparing the phosphoproteomes of WT and Prdx1 KO
cells in response to H2O2 would inform as to whether protein kinase signalling is altered
by Prdx1 expression.
Moving away from a proteomics approach, determining changes in gene expression
(transcriptomics) in response to H2O2 could be an alternative approach. Fomenko
et al. (2011) compared the transcription responses of S. cerevisiae in response to H2O2
in WT strains and strains that had all Prdxs and Gpxs genetically deleted. Strikingly,
Fomenko et al. (2011) saw that without Prdxs and Gpxs, there was almost no tran-
scriptional response to H2O2, indicating that the peroxidases are required to regulate
the yeast H2O2 adaptation response. A similar approach could be taken in mammalian
cells, comparing the transcriptional response to H2O2 in WT and Prdx1 KO cells. An
advantage of looking at responses in transcription—or even phosphorylation—rather
than protein oxidation, is that it may no longer be necessary to protect the native
oxidation status of the proteome (such as with thiol blocking using IAM). However, it
would still be an important control to ensure that there is minimal effect of artefactual
oxidation on transcription during sample preparation.
Stöcker et al. (2018a) used a novel approach to investigate the effect of Prdx1 and
2 expression on protein oxidation within HAP1 and HEK293T cells. They treated
cells—that were either KO or knock-down for Prdx1 and 2—with H2O2 and analysed
changes in protein oxidation by a combination of Trx1 substrate trapping, western blot
and mass spectrometry. Overall their approach demonstrated that Prdx1 and 2 are
required for proteins to become oxidised in vivo. A limitation of the work by Stöcker
et al. (2018a), is that it does not directly link protein oxidation with signalling events
(i.e. protein phosphorylation). Additionally, as proteins were identified by shotgun
MS, there is less sensitivity than a direct MS-method. Nonetheless, there is a clear
demonstration that Prdx1 and 2 are important in protein oxidation, highlighting that
both Prdx1 and 2 act as more than a peroxidase.
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6.4.2 Do Prdxs contribute to H2O2 signalling?
In Chapter 5, several models were outlined concerning the mechanisms of how Prdxs
may contribute to H2O2 signalling—that they did not and H2O2 directly oxidises targets
(the null hypothesis); that inactivation is required (the floodgate hypothesis); or that
Prdxs actively directly transmit a signal from H2O2 (the disulfide-relay model). It will
likely never be possible to completely rule out direct oxidation, as the small size of
H2O2 makes it ideal to oxidise relatively inaccessible cysteine residues, such as with
the EGF receptor (Paulsen et al., 2012). More broadly, there is sufficient evidence to
show that Prdxs to contribute to H2O2 signalling. As exemplified by Stöcker et al.
(2018a) and Fomenko et al. (2011), loss of Prdxs results in less protein oxidation and
a lack of a transcriptional response. The work by Stöcker et al. (2018a) and Fomenko
et al. (2011) also strongly suggests that Prdxs are direct mediators of H2O2 signalling.
However, Stöcker et al. (2018a) do not have a signalling read-out of the importance of
Prdx-mediated protein oxidation and Fomenko et al. (2011) do not demonstrate that
Prdxs are directly transmitting H2O2 signals. Ultimately, a combination of methods—
such as outlined above (6.4.1)—are needed to link protein oxidation with Prdxs and a
downstream consequence. Furthermore, using a recombinant in vitro system, such as
was done in this Thesis with ASK1, would allow for a powerful validation of any effects
seen from these wider studies.
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6.5 Thesis Conclusions
This Thesis sought to investigate the regulatory mechanisms of the protein kinase,
ASK1, and determine whether the ICAT proteomics method would be feasible for
examining the role of the cytosolic peroxidase, Prdx1, in H2O2 signalling.
Prdx1 is required for H2O2 induced activation of the MAPK, p38, in HAP1 cells. A
redox proteomics method was tested, using ICAT-labelling to monitor protein oxida-
tion in HAP1 cells. Whilst ICAT-labelled proteins were detected, the deployed ICAT
method was not sensitive enough to identify sufficient numbers of differentially oxidised
proteins, and an alternative method is recommended for future studies.
The N terminus (residues 88–658) of ASK1 is directly inhibitory of ASK1 kinase
activity. Inhibition can be regulated by the TBD within the ASK1 N terminus. The
TBD can regulate access of the substrate, MKK6, to a postulated scaffolding region
within the N-terminal PH domain. The PH domain may be able to promote a confor-
mational change within MKK6, making it a better substrate for phosphorylation by
the ASK1 kinase domain.
ASK1 is widely thought to be directly inhibited by the oxidoreductase, Trx1. The
ASK1-TBD is able to interact with Trx1 and Trx1 and ASK1 are able to form an
inter-molecular disulfide bond. ASK1-Cys250 is necessary and sufficient for the mixed-
species disulfide to form between ASK1 and Trx1. However, Trx1 was not seen to
inhibit ASK1 in vitro.
Overall this work has used both top-down and bottom-up approaches to build
upon our knowledge of how MAP3Ks—such as ASK1—are regulated, and H2O2 as a
signalling molecule. Higher resolution techniques—cyro-EM and mass spectrometry,
for example—are required to understand the true nature of Trx1 in ASK1 regulation
and the contribution of Prdx1 in H2O2 signalling.
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Table A.1: Primers used in colony PCR and sequencing










1—Also called pET Upstream, 2—For sequencing pcDNA3 mammalian expression vector (see A.1).
Table A.2: Primers used to generate LIC-PCR inserts and ASK1 cDNA
Primer Sequence (5’ to 3’)
ASK1 2 FW CAGGGACCCGGTAGCACGGAGGCGGACGAG
ASK1 88 FW CAGGGACCCGGTAGCCGACGGACCACGGTGG
ASK1 269 FW CAGGGACCCGGTAGCCAGTACTTCCGGGAATCTATACTC
ASK1 266 RV CGAGGAGAAGCCCGGTTATGCTTGTGCCACCTTCAAAAGTTGAATAAAACG
ASK1 338 RV CGAGGAGAAGCCCGGTTATTCTAAAGTCTCTACCAGCTTCACAATAGAATC
ASK1 658 RV CGAGGAGAAGCCCGGTTACCCCTTCTCTTCGGTAATGGTGTTC
ASK1 941 RV CGAGGAGAAGCCCGGTTATGAAACTTTTAAAAACTCATCAACAAGCAAGTCGTTAG
ASK1 1374 RV CGAGGAGAAGCCCGGTTAAGTCTGTTTGTTTCGAAAGTCAATGATAGCCTTC
ASK1 325 FW CAGGACTATGATTCTATTGTGAAGCTGGTAGAGAC
ASK1 335 RV GTCTCTACCAGCTTCACAATAGAATCATAGTCCTG
MKK6 1 FW CAGGGACCCGGTATGTCTCAGTCGAAAGGCAAGAAGCGAAACC
MKK6 334 RV CGAGGAGAAGCCCGGTTAGTCTCCAAGAATCAGTTTTACAAAAGATGCCACATCTG
Trx1 2 FW CAGGGACCCGGTGTGAAGCAGATCGAGAGCAAGACTG
Trx1 105 RV CGAGGAGAAGCCCGGTTAGACTAATTCATTAATGGTGGCTTCAAGCTTTTC
Prdx1 2 FW CAGGGACCCGGTTCTTCAGGAAATGCTAAAATTGGGCACCC
Prdx1 199 RV CGAGGAGAAGCCCGGTTACTTCTGCTTGGAGAAATATTCTTTGCTCTTTTG
All sequences are for human. FW—forward, RV—reverse. Numbers denote residue in the
protein product. Underlined nucleotides denote LIC overhangs.
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Table A.3: Primers used to generate restriction enzyme inserts
Primer Sequence (5’ to 3’)
Trx1 2 FW NdeI GAATTTTCCATATGGTGAAGCAGATCGAGAGCAAGACTG
Trx1 105 RV XhoI GTGGTCTCGAGGACTAATTCATTAATGGTGGCTTCAAGCTTTTC
All sequences are for human. Numbers denote residue in the protein product. Underlined
nucleotides relevant restriction enzyme site.
Table A.4: Primers used for introduction of mutations in protein sequences
Primer Sequence (5’ to 3’)
StrepII Generic FW TCAGCATGGAGCCACCCGCAGTTCGAAAAGTAACCGGGCTTCTCCTCG
ASK1 658 StrepII RV CTGCGGGTGGCTCCATGCTGACCCCTTCTCTTCGGTAATGGTGTTCAC
ASK1 940 StrepII RV CTGCGGGTGGCTCCATGCTGAAACTTTTAAAAACTCATCAACAAGC
ASK1 R322E FW CTTTCCTACGAAGATATCCAGGACTATGATTCT
ASK1 R322E RV CCTGGATATCTTCGTAGGAAAGTAACAGATTTAT
ASK1 R395E FW CCTAGTTGGTGAAATCTACAAAGATATGTTTTTG
ASK1 R395E RV TTTGTAGATTTCACCAACTAGGCAATACATATC
ASK1 W476S FW CTCCAGAGCTACTCAGAAGTTGGATTTTTTCTGGGGGCCAGCGTC
ASK1 W476S RV GAAAAAATCCAACTTCTGAGTAGCTCTGGAGTTTTTCCAAG
ASK1 W509E FW GACACCAGCAGAGTACCTCAAGTCTATTGTAGAG
ASK1 W509E RV CTTGAGGTACTCTGCTGGTGTCTTCAGTTTAAA
ASK1 F623E FW GAAAGATGCTGCGAGCTTTATGTGCTTCACAATTCT
ASK1 F623E RV CACATAAAGCTCGCAGCATCTTTCTTCAAATTT
ASK1 D632R FW CAATTCTGATCGTTTCCAAATCTATTTCTGTACA
ASK1 D632R RV GATTTGGAAACGATCAGAATTGTGAAGCACATA
ASK1 C200S FW GAAATAATTAGCCAGAAGAATACTATGTGCACTGGG
ASK1 C200S RV ATTCTTCTGGCTAATTATTTCCTTCAGTGACTGCAG
ASK1 C206S FW GAATACTATGTCCACTGGGAACTACACCTTTGTTCCTTACATG
ASK1 C206S RV CAAAGGTGTAGTTCCCAGTGGACATAGTATTCTTCTGGCAAATTATTTCC
ASK1 C225,226S FW AAAGTCTACTCCTCTGACAGCAGCTTCATGAAGGGGTTG
ASK1 C225,226S RV GCTGCTGTCAGAGGAGTAGACTTTGTTATGTGGAGTTATCATG
ASK1 C250S FW GGACCCATCTCCTTACCTCTTGTGGATCGTTTTATTC
ASK1 C250S RV CAAGAGGTAAGGAGATGGGTCCAAGAAGCAGCTCGAAG
Trx1 C35S FW GCCACGTGGTGTGGGCCTAGCAAAATGATCA
Trx1 C35S RV TGATCATTTTGCTAGGCCCACACCACGTGGC
Trx1 C73S FW CTTCAGAGTGTGAAGTCAAAAGCATGCCAACATTC
Trx1 C73S RV GAATGTTGGCATGCTTTTGACTTCACACTCTGAAG
Numbers denote residue in the protein product. Underlined nucleotides denote substitution
sites. Italicised nucleotides denote StrepII tag.
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Table A.5: Oligonucleotides used in cloning mammalian LIC expression vector





FW-forward, RV-reverse. Start site (ATG) is in bold. KpnI sites are underlined. EcoRI
sites are italicised. HindIII sites are italicised and underlined.
b)a)
Figure A.1: SEC molecular weight standards. SEC protein standards run on either a S200I
(a) or S75 (b) column. Protein standards: 1) Thyroglobulin, 669 kDa, 0.32 mg/mL. 2)
Apoferritin, 400 kDa, 0.4 mg/mL. 3) Alcohol dehydrogenase (ADH) 150 kDa, 0.2 mg/mL.
4) BSA, 66 kDa, 0.4 mg/mL. 5) Carbonic anhydrase, 29 kDa, 0.12 mg/mL. 6) Ubiquitin,
8.9 kDa, 0.4 mg/mL. 250 µL of the protein standards mix, at the indicated concentration,
was injected and run at a flow rate of 0.5 mL/minute in a buffer containing 300 mM NaCl,
10 mM HEPES (pH 7.6). All standards were from Sigma (catalogue number MWGF1000)





















































































































































































i) ASK12–1374 Kinase SAMPHTBD CC
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Prdx1
Trx1 C35S
Figure A.2: Example protein purifications. Relates to main Table 2.7. a) Schematic
showing order of samples shown on SDS-PAGE gels and schematic of full-length ASK1 for
reference. b-n) Purifications of indicated protein constructs listed in main Table 2.7. For an
explanation of SDS-PAGE samples see a). IEX—anion exchange chromatography
(ResourceQ); SEC—size exclusion chromatography on either Superdex 75 (S75) or 200
Increase (S200Inc) columns. For IEX traces, the conductivity trace is shown in yellow.
Chromatogram traces for SEC molecular weight marker protein standards are shown in
Appendix Figure A.1.
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Table A.6: Configuration and contact files for CORAL modelling
ASK1 alone Trx1-Lys ASK1-Trx1
Configuration NTER 4 Trx1.pdb Trx-Lys.pdb
file (.con :) TBD-Robetta.pdb LINK 2 NTER 4
LINK 4 Lys.pdb TBD-Robetta.pdb
ASK-269-658.pdb CTER 8 269-658.pdb





1 32 32 2 166 166
NTER and CTER define the number of extra N- and C-terminal residues in the protein
sample not in the respective PDB file, LINK defines residues between linked proteins in a
given PDB file. TBD-Robetta is the Robetta model used in this work (see Appendix
Figure C.11). ASK-269-658 is from PDB ID: 5ULM (Weijman et al., 2017). Trx1 is from
PDB ID: 3QFB (Fritz-Wolf et al., 2011). Lys (lysozyme) is from PDB ID: 2I2L (Vetter
et al., 1996). Trx-Lys.pdb is the output from Trx1-Lys. For the contacts, ‘dist’ defines the
distance (in Å) between two atoms (defined in the row below). Refer to the CORAL
manual (www.embl-hamburg.de/biosaxs/manuals/coral; Petoukhov et al. 2012) for further
information.
A.1 Cloning of LIC-compatible mammalian expres-
sion vector
A LIC-compatible mammalian expression vector was designed to feature an N-terminal
StrepII (WSHPQFEK) tag, and 3C-protease cleavage site (SAALEVLFQGPG) within
a pcDNA3 vector backbone. In this manner, any inserts generated for E. coli protein
expression could also be inserted into pcDNA3. Oliogonucleotides were designed and
ordered from Sigma (the sequences are listed in Appendix A.5).
Linearisation of pcDNA3 vector Two and a half micrograms of pcDNA3 (Invit-
rogen) was linearised with 10 units of EcoRI and HindIII in SuRE/Cut Buffer B (all
Roche) in a 50 µL reaction. DNA digest occurred for 4 hours at 37 °C. The restriction
enzymes heat inactivated at 65 °C for 15 minutes. Linearised DNA was purified by
agarose electrophoresis (2.3.5) and gel extraction (2.3.6).
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Annealing of oligonucleotides to form LIC cassette Oligonucleotides (sequences
are listed in Appendix A.5) were designed and ordered from Sigma. Oligonucleotides
were resuspended in UltaPure water to a final concentration of 100 µM (2.3.1). The
oligonucleotides were designed so that when annealed, they would have sticky-ends
that were compatible with EcoRI–HindIII linearised DNA.
Each stock oligonucleotide was diluted 10-fold in UltraPure water. Oligonucleotides
were annealed in a reaction consisting of 1 µL of each diluted oligonucleotide, 5 µL of
T4 DNA ligase buffer, made up to a final volume of 50 µL with UltraPure water. The
reaction was mixed by pipetting before being centrifuged briefly and placed in a pre-
heated 90 °C heat block (Select Bio-Products). The oligonucleotides were incubated
for two minutes before the heat block was switched off and allowed to cool, slowly, to
room temperature. Annealed oligonucleotides were further diluted 10-fold in UltraPure
water before quantification by NanoDrop (2.3.4).
Ligation of linearised vector and LIC cassette The LIC-cassette (insert) and
linearised vector were mixed in a 1:3 vector:insert molar ratio. The ligation reaction
contained 100 units of T4 DNA ligase, 2 µL of T4 DNA ligase buffer, 2.5 ng of insert
and 25 ng of linearised pcDNA3 in a 20 µL reaction made up to volume with UltraPure
water.
The ligation reaction was incubated at room temperature for 10 minutes. Ini-
tial ligations yielded no successful incorporation of the LIC-cassette insert. In order
to circumvent this problem, the ligation reaction was repeated and subsequently di-
gested with BamHI (as successfully EcoRI–HindIII digested and ligated vector would
no longer contain a BamHI site). The ligation reaction (∼8 µL) was incubated in a
reaction with 2.5 units BamHI, 2 µL, SuRE/Cut Buffer B made up to 20 µL total
volume with UltaPure water. BamHI digest was incubated at 37 °C for 2 hours before
heat inactivation at 65 °C for 20 minutes. Four microlitres of the digested ligation
reaction was transformed into chemically competent MC1061 cells (2.3.11). Colonies
were screened by colony PCR (2.3.12) using SP6/T7 Term primers (Appendix A.1).
A single positive colony was used to inoculate 3 mL of sterile LB with ampicillin (100
µg/mL) for mini-prep isolation (2.3.3) and subsequent sequencing.
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A.2 Transient transfection of HAP1 cells
All DNA transfections were performed using Lipofectamine2000 (Invitrogen). Cells
were grown as in 2.11.2. The day before transfection, cells were seeded in a six-well
plate 5 × 105 cells per well in 3 mL of complete media. On the day of transfection,
the media was removed and cells gently washed with PBS followed by the addition
of 1 mL of pre-warmed IMDM base media (i.e. media with no FBS or antibiotic).
The plate was returned to the 37 °C incubator for 30 minutes. During this time, the
DNA-Lipofectamine mix was set up. For every well to be transfected, 150 µL of base
IMDM were added to a sterile tube, followed by 9 µL of Lipofectamine2000. Plasmid
DNA (2.5 µg per well) and 150 µL of base media were added to a separate tube. The
DNA-media mix was filter-sterilised using a 0.2 µm filter-syringe. The DNA-media
and Lipofectamine-media were then added in together in equal volume (150:150 µL
per well). The mixture was vortexted briefly before incubating at room temperature
for 10 minutes. 250 µL of the complete DNA-Lipofectamine complex was added to each
well (equivalent to 2 µg of DNA per well). The cells were returned to the incubator
for 6 hours. After incubation, an additional 2 mL of complete pre-warmed media was
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Figure B.1: The N terminus of ASK1 is
inhibitory to ASK1 kinase activity.
Replicate assay used for quantification in
addition to main Figure 3.3. The assay was
performed identically to main Figure 3.3
except a lower concentration (0.01 µM) of
















Figure B.2: Effect of phosphatase co-expression on ASK188–941 activity. ASK188–941 with and
without lambda phage protein phosphatase (λPP) co-expression. The assays were carried out at
room temperature with 3 µM MKK6, 2 mM DTT, the indicated amounts of ASK188–941, started
with the addition of 50 µM ATP. Assays were analysed by Phos-Tag SDS-PAGE and visualised with
Coomassie. High-contrast of the no co-expression gel shows ASK188–941 (which is
auto-phosphorylated during expression) as multiple bands on Phos-Tag SDS-PAGE. The λPP


















































Figure B.3: Addition N-terminal ASK1 regions (up to 1 µM) does not alter kinase activity. Blots














































Figure B.4: Addition of excess ASK1269–658 enhances phosphorylation of MKK6. Three replicate
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Figure B.5: Addition of excess of ASK188–266 has no effect on ASK1 kinase activity. a)
Schematic of protein constructs used in this assay. b) Kinase assay conducted with 3 µM MKK6 and
0.01 µM ASK1669–941 and 2 mM DTT and was performed at room temperature. ASK188–266 was
added to the assay with concentration up to 30 µM. The assay was started by the addition of 50 µM
ATP. This assay was analysed by western blot against p-MKK6 with Ponceau S stained membrane
shown for loading control.
Figure B.6: Addition of ASK1269–658 does not change MKK6 phosphorylation by rMEKK1. a)
ClustalOmega alignment (Li et al., 2015) of the kinase domains of human ASK1, human MEKK1
and rat MEKK1 (rMEKK1). Identity=31.8%; *—identical; :—strongly similar; .—weakly similar.
b) Schematic of protein constructs in the assay. MEKK1 annotated according to UniProt
(www.uniprot.org; The UniProt Consortium, 2017): S—SWIM-type zinc finger; R—RING-type zinc
finger. c) rMEKK1 (residues 1160–1493) used in this assay (purified from Sf 9 cells), provided by
Abigail Burgess (Mace laboratory). d) In vitro kinase assay conducted with 3 µM MKK6, 2 mM
DTT and rMEKK11160-1493 (at indicated concentrations), performed at room temperature. ATP (50
µM) was added to start the reaction. The assay was analysed by western blot against p-MKK6.
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Figure B.6: Addition of excess of ASK1269–658 does not change phosphorylation of MKK6 by rat
MEKK1. Figure legend on previous page.
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S R P L S V V Y V L T R E P Q P G L E P R E G T E A E P L P L R C L R E A C A Q V P R P R P P P Q L R S
L P F G T L E . . . . L G D T A A L D A F Y N A D V V V L E V S S S L V Q P S L F Y H L G V R E S F S M
T N N V L L C S Q A D L P D L Q A L R E D V F Q K N S D C V G S Y T L I P Y V V T A T G R V L C G D A G
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M A G
P C P R A . . . G V L E R A G S CWQ D P L A E A L S R G R S S P . . . . . . . A . . . V T G R G C A R
S R P L S V V Y V L T R E P G P G V E P G S G T E A E P L P L R C L R E A C A Q L QG T R P P P Q L R S
L P F A T L A . . . . L G D T A A L D S F Y N A D V V V L E V S S S L A Q P S L F Y H L G V R E S F S M
T N N V L L C S Q A E L P D L Q A L R E D V F Q K N S D C V G S Y T L I P Y V V T A T G R V L C G D A G
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M A G
P S P R S . . . G A L E R A G S CWQ D P L A E A L S R G R P L A . . . . . . . A . . . S P G R G C A R
S R P L S V V Y V L T R E P L P E V E P E T G A E A E P L P L R C L R E A C A Q L P G P R P R P Q L L P
L KWP T T G S R L G V Q A E L R A S T C V S T DM V V L E V S S S L A Q P S L F Y H L G V R E S F S M
T N N V L L C S Q A D L P D L Q A L R E D I F Q K N S D C I G S Y T L I P Y V V T A T G R V L C G D A G
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M A G
P S P R S . . . G A L E R A G S CWQ D P L A E A L S R G R P L A . . . . . . . A . . . S P G R G C A R
S R P L S V V Y V L T R E P L P E V E P E T G A E A E P L P L R C L R E A C A Q L P G P R P R P Q L H S
L P F G T L A . . L G . . D T A A L D S F Y N A D V V V L E V S S S L A Q P S L F Y H L G V R E S F S M
T N N V L L C S Q A D L P D L Q A L R E D I F Q K N S D C I G S Y T L I P Y V V T A T G R V L C G D A G
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M E S GGG N A P A G A L G A A S E S
P Q C P P . . . P P G V E G A A . . . . . . . . G P A . . . E P D G A A E G A A GG S G E G E S GGG P
R R A L R A V Y V R S E S S QGG A . . . A . G G P E A G A R Q C L L R A C E A E G . . . . . A H L T S
V P F G E L D . . . . F G E T A V L D A F Y D A D V A V V DM S D V S R Q P S L F Y H L G V R E S F DM
A N N V I L Y H D T D A D T A L S L K DM V T Q K N T A S S G N Y Y F I P Y I V T P C A D Y F C C E S D
. . . . . . . . . . . . . . . . . . . . . . . . . . . M E G G GG S GGGGG P V P A E A P E E A G E P
P QG R L . . . P P G P E G A A . . . . . . . . G L A . . . E P E S T G D A A . . . G G E A E GG R G P
R R A L R A V Y V R S E S S QG A A . . . A G GG P E A G A L K C L L R A C E A E G . . . . . A H L T S
V P F G E L D . . . . F G E T A V L D A F Y D A D V A I V DM S D I S R Q P S L F Y H L G V R E S F DM
A N N V I L Y Y D T D A D T A L S L K DM V T Q K N T A S S G N Y Y F I P Y T V T P C A D Y F C C E S D
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . M
E T A M D V V C V M D T A V G D H L . . . . . . E D R Q C A L E E I K Q A V Q S A G . . . . . A N F Q R
V Q F E R L D . . . . F G E T N V L E T F Y N A D V A I I D L S I L T QQ R P L S Y H Y G V R E S F GM
K E N I L T Y N D I D S K Q T L S L K L . . . . . . . . S C A N Y L F L S Y K R N A E T N S C H L T S Q
. . . . . . . . . . . . . . . . . . . . . . . . . . . M S Q . . . . . . . . N N K R Q V Q H N H E M S N
D V C P L P L P P R G A P P P T A Y H A S RM A . . . . . . A T S S S T N G S F . . . . E K S A I P G N
A R K L H V V I V I D Q K V Q K N L . . . . . . R V R E M A L K D V Q K V A D T L N . . . . . V N L T R
I D F D K L D . . . . F G E T E T L D L F Y N A D V A L V D V T V T H QQ P S L C Y H I G V R E S MGQ
S Y NM I L T YWS P D P E Y H I M D A L . . . . . K K T H A H L P M I V Y I H H Q D S N Q L Q S Y D .
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F MK G L T E L MQ P N F E L L L G P I C L P L V D R F I Q L L K V A Q A S S S Q Y F R E S I L N D I R
K A R N L Y T . . G K E L A A E L A R I R Q R V D N I E V L T A D I V I N L L L S Y R D I Q D Y D S I V
K L V E T L E K L P T F . D L A S H H H V K F H Y A F A L N R R N L P G D R A K A L D I M I P M V Q . .
. . . . . S E GQ V A S DM Y C L V G R I Y K DM F L D S N F T D T E S R D H G A SWF K K A F E S E P
T L Q S G I N Y A V L L L A A G H Q F E S S F E L R K V G V K L S S L L G K K G N L E K L Q S YWE V G
F MK G L T E L MQ P N F E L L L G P I C L P L V D R F I Q L L K V A Q A S S S Q Y F R E S I L N D I R
K A R N L Y T . . G K E L A A E L A R I R Q R V D N I E V L T A D I V I N L L L S Y R D I Q D Y D S I V
K L V E T L E K L P T F . D L A S H H H V K F H Y A F A L N R R N L P G D R A K A L D I M I P M V Q . .
. . . . . S E GQ V A S DM Y C L V G R I Y K DM F L D S N F T D T E S R D H G A SWF K K A F E S E P
T L Q S G I N Y A V L L L A A G H Q F E S S F E L R K V G V K L S S L L G K K G N L E K L Q S YWE V G
F MK G L T E L MQ P N F E L L L G P I C L P L V D R F V Q L L K V A Q A S S S Q Y F R E S I L S D I R
K A R N L Y T . . G K E L A A E L A R I R Q R V D N I E V L T A D I V I N L L L S Y R D I Q D Y D S I V
K L V E T L E K L P T F . D L A S H H H V K F H Y A F A L N R R N L P G D R A K A L D I M I P M V Q . .
. . . . . S E E Q V A S DM Y C L V G R I Y K DM F L D S N F T D T E S R D H G A SWF K K A F E S E P
T L Q S G I N Y A V L L L A A G H Q F E S S F E L R K V G V K L S S L L G K K G N L E K L Q S YWE V G
F MK G L T E L MQ P N F E L L L G P I C L P L V D R F V Q L L K V A Q A S S S Q Y F R E S I L N D I R
K A R N L Y T . . G K E L A A E L A R I R Q R V D N I E V L T A D I V I N L L L S Y R D I Q D Y D S I V
K L V E T L E K L P T F . D L A S H H H V K F H Y A F A L N R R N L P G D R A K A L D I M I P M V Q . .
. . . . . S E E Q V A S DM Y C L V G R I Y K DM F L D S N F T D T E S R D H G A SWF K K A F E S E P
T L Q S G I N Y A V L L L A A G H Q F E S S F E L R K V G V K L S S L L G K K G N L E K L Q S YWE V G
F MK G L T E L MQ P N F E L L L G P I C L P L V D R F I Q L L K V A Q A S S S Q Y F R E S I L N D I R
K A R N L Y T . . G K E L A A E L A R I R Q R V D N I E V L T A D I V I N L L L S Y R D I Q D Y D S I V
K L V E T L E K L P T F . D L A S H H H V K F H Y A F A L N R R N L P G D R A K A L D I M I P L V Q . .
. . . . . N E E Q V A S DM Y C L V G R I Y K DM F L D S N F M D T E S R D H G A SWF K K A F E S E P
T L Q S G I N Y A V L L L A S G H Q F E S S F E L R K V G V K L S S L L G K K G N L E K L Q S YWE V G
F MR GM T E L M P S N F E L L L G P I C L P L V D R F V Q I L K V A Q A T S C Q Y F R E A I L N D I R
R A R N Q Y T . . G K D L A A E L I R I R Q R V D S I E L L S P D I I I N L L L S Y R D I Q D Y D S V V
T L V E I L E K L P T F . N L S S N H H I K F H Y A F A L N R R N H P G D R V K A L E I M L P L V Q . .
. . . . . L E D Q V A S D I Y C I V G R I Y K DM F L D S N F M D T E S R D N A I HWY R K A F E S E P
T L H S G I N Y A V L L L A A G H Q F E T S L E L R K I G V K L S S L L G K K G N L E K L Q S YWD V G
L MK G L S E L MQ P S F E A L L G P I CM P L L D R L T Q L L T G C K S N T C Q Y F R E T V L N E I R
K A R E L Y T . . G A E L A A E L R R I QQ R L D N V E C L S A D V V I N L L L S Y R D I Q D Y E S I V
K L V E T L E K L P T F . D P V A H P H I K F H Y A F A L N R R N L P G D R Q K A L D I M L P L V N . .
. . . . . S D E Q V A S D I Y C L V G R I Y K DM F L D S H F T D T N S R D QG I HWF R R G F E S E P
T L H S G I N Y A V L L L A A G H Q F D S S F E L R K V G V K L S S L L G K K G S L D R L Q S YWD V G
L L R G L A D G L V Q A . G V G T E A L L T P L V G R L A R L L E A T P T D S C G Y F R E T I R R D I R
Q A R E R F S . . G P Q L R Q E L A R L Q R R L D S V E L L S P D I I M N L L L S Y R D V Q D Y S A I I
E L V E T L Q A L P T C . D V A E Q H N V C F H Y T F A L N R R N R P G D R A K A L S V L L P L V Q . .
. . . . . L E G S V A P D L Y CM C G R I Y K DM F F S S G F Q D A G H R E Q A Y HWY R K A F D V E P
S L H S G I N A A V L L I A A GQ H F E D S K E L R L I GM K L G C L L A R K G C V E KMQ Y YWD V G
L L R G L A D G L V Q A . G V G T E A L L T P L V G R L A R L L E A T P T D S C G Y F R E T I R R D I R
Q A R E R F S . . G P Q L R Q E L A R L Q R R L D S V E L L S P D I I M N L L L S Y R D V Q D Y S A I I
E L V E T L Q A L P T C . D V A E Q H N V C F H Y T F A L N R R N R P G D R A K A L S V L L P L V Q . .
. . . . . L E G S V A P D L Y CM C G R I Y K DM F F S S G F Q D A G H R E Q A Y HWY R K A F D V E P
S L H S G I N A A V L L I A A GQ H F E D S K E L R L I GM K L G C L L A R K G C V E KMQ Y YWD V G
L L R G I A D G L V Q A . G A G T E A L L T P L V G R L V R L L E A T P T D S C G Y F R E T I R Q D I R
Q A R E R F S . . GQQ L R Q E L A R L Q R R L D S V E L L S P D I V M N L L L S Y R D V Q D Y S A I I
E L V E T L Q A L P T C . D V A E Q H N V C F H Y T F A L N R R N R P G D R E K A L A V L L P L V K . .
. . . . . Y E G P V A P D L Y CM C G R I Y K DM F F T S G F Q N A G H L E Q A Y HWY R K A F D V E P
S L H S G I N A A V L L I A A GQ H F E D S E E L R L I GM K L A C L L A R K G C V E KMQ Y YWD V G
L L R G L A D G L L Q A . G V G T E A L L T P L V G R L A R L L E A T P T D S C G Y F R E T I R Q D I R
R A R E R F S . . G P Q L R Q E L A R L Q R R L D S V E L L S P D I I M N L L L S Y R D V Q D Y S A I I
D L V E T L Q A L P T C . D V A E Q H N V C F H Y T F A L N R R N R P G D R E K A L A V L L P L V Q . .
. . . . . V E G P V A P D L Y CM C G R I Y K DM F F S S G F Q D A G H R E Q A Y HWY R K A F D I E P
S L H S G I N A A V L L I A D GQ R F E D S E E L R L I GM K L G C L L A R K G C V E KMQ Y YWD V G
L L R G L A D G L L Q A . G V G T E A L L T P L V G R L A H L L E A T P T D S C G Y F R E T I R Q D I R
R A R E R F S . . G L Q L R Q E L A R L Q R R L D S V E L L S P D I I M N L L L S Y R D V Q D Y S A I I
D L V E T L Q A L P T C . D V A E Q H N V C F H Y T F A L N R R N R P G D R E K A L A V L L P L V Q . .
. . . . . V E G P V A P D L Y CM C G R I Y K DM F F S S R F Q D A G H R E Q A Y HWY R K A F D I E P
S L H S G I N A A V L L I A D GQ R F E D S E E L R L I GM K L G C L L A R K G C V E KMQ Y YWD V G
A Q R R A S E Y MQ P NWD N I L G P L CM P L V D R F I S L L K D I H V T S C V Y Y K E T L L N D I R
K A R E K Y Q . . G E E L A K E L A R I K L RMD N T E V L T S D I I I N L L L S Y R D I Q D Y D A M V
K L V E T L E M L P T C . D L A D Q H N I K F H Y A F A L N R R N S T G D R E K A L Q I M L Q V L Q . .
. . . . . S C D H P G P DM F C L C G R I Y K D I F L D S D C K D D T S R D S A I EWY R K G F E L Q S
S L Y S G I N L A V L L I V A GQQ F E T S L E L R K I G V R L N S L L G R K G S L E KM N N YWD V G
A Q R R A S E Y MQ P NWD T I L G P L CM P L V D R F T S L L K D I R V T S C A Y Y K E T L L N D I R
K A R E K Y Q . . G D E L A K E L T R I K F RMD N I E V L T S D I I I N L L L S Y R D I Q D Y D A M V
K L V E T L K M L P T C . D L A D Q H N I K F H Y A F A L N R R N S T G D R E K A L Q V M L Q V L Q . .
. . . . . S C D H P A P DM F C L C G R I Y K D I F L D S G C E E D A S R D S A I EWY R K G F E L Q S
S L Y S G I N L A V L L I V S GQQ F E T S M E L R K I G V R L N S L L G R K G S L E KM N N YWD V G
P N S G N . N S K E P N . . . . A E G R V P T L QWR L K R K L Q D V E I Q S K A HM R E K F L S DMR
T A R D T Y A T N G A K L Q S I L H E MR K R L D D P H V L S G E V V H S F M C S L R D V Q D Y D A M V
R L V N D L K N I P N T R K Y V E T G NM S F L Y A F A L N R R N R K G D R E K A L E S S L K A L E . .
. . . . . K K E N H F P DM L C L C G R I Y K D I F V E S D Y T D A T S L A H A I KWY R Q S F E V Q P
N E Y A G I N L A T L L V I E G K E F T N T E E L Q H I GM T L N N L I G K K G S L S S L S E YWD V A
K N N N D D D S K P P F A R T N V P A K T I T F Q H RM K Q V L K S V Q V E A S A H S R E K F M S D L R
K A R E I T D . . G D Q K N D Y L D KMR T R L D N P D V L H P D T V S L MM L S Y R D N Q N Y GGM I
R L V D D L K R I P D C L K V V D T P V I R Y Q Y A F A L N R R N K D G D R D L A L N T V L S L V E G T
T E N E E K N G P L S P D V V C L A G R I Y K D K F I A S N Y E D R E S L N S A I EWY R R A F E M S P
L E Y S G I N L T T L L R A S G E H F E N N L E MQQ I A V V L N S L L G R K G A L Q N L M E YWD V A
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F F L G A S V L A N D HM R V I Q A S E K L F K L K T P AWY L K S I V E T I L I Y K H F V K L T T EQ
P V A . K Q E L V D FWMD F L V E A T K T . . D . . V T V V R F P V L I L E P T K I Y Q P S Y L S I N
N E V E E K T I S I WH V L . . . . . . . . . P D D K K G I H EWN F S A S S V R G V S I S K F E E R C
C F L Y V L H N S D D F Q I Y F C T E L H C K K F F E M V N T I T E E K G R . . . S . . . . . . . . . .
F F L G A S V L A N D HM R V I Q A S E K L F K L K T P AWY L K S I V E T I L I Y K H F V K L T T EQ
P V A . K Q E L V D FWMD F L V E A T K T . . D . . V T V V R F P V L I L E P T K I Y Q P S Y L S I N
N E V E E K T I S I WH V L . . . . . . . . . P D D K K G I H EWN F S A S S V R G V S I S K F E E R C
C F L Y V L H N S D D F Q I Y F C T E L H C K K F F E M V N T I T E E K G R . . . S . . . . . . . . . .
F F L G A S V L A N D H L R V I Q A S E K L F R L K T P AWY L K S I V E T I L I Y K H F V K L T T EQ
P S A . K Q E L V D FWMD F L V E A T K T . . D . . V T V V R F P V L I L E P T K I Y Q P S Y L S I N
N E V E E K T I S I WH V L . . . . . . . . . P D D K K G I H EWN F G A S S V R G V S I S K F E E R C
C F L Y V L H N S D D F Q I Y F C T E L H C K R F F E M V N T I T E E K G R . . . G . . . . . . . . . .
F F L G A S V L A N D H L R V I Q A S E K L F R L K T P AWY L K S I V E T I L I Y K H F V K L T T EQ
P T A . K Q E L V D FWMD F L V E A T K T . . D . . V T V V R F P V L I L E P T K I Y Q P S Y L S I N
N E V E E K T I S I WH V L . . . . . . . . . P D D K K G I H EWN F N A S S V R G V S I S K F E E R .
L F P Y V L H N S D D F P L H F C S E V H L G R F F E M V N T I T E E K G R . . . G . . . . . . . . . .
F F L G A S V L A N D H L R V I Q A S E K L F K L K T P AWY L K S I V E T I L I Y K H F V K L T S EQ
P V A . K Q E L V D FWMD F L V E A T K T . . D . . V T V V R F P V L I L E P T K I Y Q P S Y L S I N
N E V E E K T I S I WH V L . . . . . . . . . P D D K K G I H EWN F S A S S V R G V S I S K F E E R C
C F L Y V L H N S D D F Q I Y F C T E L H C K K F F E M V N T I T E E K G K . . . N . . . . . . . . . .
F Y L G A C I L A N D S S K V I H A A E K L F K L K T P AWF L N S V V E T I L I Y Q H F K T P N Q EQ
H V T . N H E L V D FWMD F L V E S T S S . . N . . V S V L R F P V L I L E P T K I Y Q P S Y L S I N
S E A E V Q T I S I WH V L . . . . . . . . . P G D K K G I H EWN F P A D S I R G V S I S K F E E R C
C F L Y V L N N S D D F Q I Y F C T E L H C K K F F D K V N R I K E E N G K . . . N . . . . . . . . . .
F F L G A S I L A C D N T R V I Q A S E K L F K I K A P I WY L R S L V E T I L I Y K H F T K V S T D P
Q A P . K Q E L V D FWMD F M V E A T N K D K D . . V T S V R F P V L I L E P T K V Y Q P S Y L S I N
K D A E E N T L S I WH V T . . . . . . . . . P D D K K G I H EWN F S A A S V R G V S I S K F D E R S
C F L Y V V N N S E D F Q I Y F C T E M H C K R F C D L V N T V T E E AWK . . . G . . . . . . . . . .
F Y L G A Q I L A N D P T Q V V L A A E Q L Y K L N A P I WY L V S V M E T F L L Y Q H F R P T P . E P
P GG . P P R R A H FW L H F L L Q S C Q P F K T A C A QG D Q C L V L V L E MN K V L L P A K L E V R
G T D P V S T V T L S L L E . . . . . . . . . P E T Q D I P S SW T F P V A S I C G V S A S K R D E R C
C F L Y A L P P A Q D V Q L C F P S V G H C QW F C G L I Q AWV T N P D S T . A P . . . . . . . . . .
F Y L G A Q I L A N D P T Q V V L A A E Q L Y K L N A P I WY L V S V M E T F L L Y Q H F R P T P . E P
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Figure B.7: Alignment of ASK proteins. a) Schematic showing overview of human ASK1.
b) Alignment of ASK1, 2 and 3. Numbering denotes human ASK1. Position of mutations in
Chapter 3 are denoted by a blue circle, cysteine residues are denoted by a red triangle.
Alignment made using ClustalOmega and displayed using ALINE (Bond and Schüttelkopf,




























































Figure B.8: Gels used for quantification in for Figures 3.7 and 3.8. a) Purified ASK188–941

















Figure B.9: Comparison of MKK6 structures. Three structures of MKK6 are available in
the PDB: 3VN9 (in red); 3ENM (in orange) and 3FME (in green). 3VN9 is
unphosphorylated and the only structure where the activation-loop is visible (Matsumoto
et al., 2012). 3ENM is a phosphomimetic (Ser207Asp, Thr211Asp), in an ‘inhibited’ state
(Min et al., 2009). 3FME is a phosphomimetic (Ser207Asp, Thr211Asp) in an ‘active’ state.
An overlay (based on the C-terminal lobes) of all three structures is shown below, with all
three structures in grey. The phosphorylation sites (Ser207 and Thr211) from 3VN9 are





























































































Figure C.1: ASK1 and Trx1 interact in vitro. Relates to main Figure 4.4. a) His6-tagged ASK1
constructs bound on resin resolved by SDS-PAGE. b) (Top) Full Coomassie stained gel of pull-down.



























































Figure C.2: ASK1 and Trx1 can form an inter-molecular disulfide bond. a) Schematic
showing protein constructs used in this assay. Trx1 and ASK188–338 were purified using only
nickel-affinity. b) 5 µM ASK188–338 was incubated with Trx1C35S (5 µM) in PBS (pH 7.4) at
4 °C for the times indicated. At each time point, a sample was removed and added to a
non-reducing SDS-PAGE buffer containing 20 mM NEM. Samples were analysed by
SDS-PAGE. For reducing SDS-PAGE, the samples were incubated with 100 mM DTT for 5



























































Coomassie, non-reducing (– DTT)
Coomassie, non-reducing (– DTT)
b)
a)
Figure C.3: ASK1-Cys250 is essential in forming an inter-molecular disulfide bond with
Trx1. Relates to main Figure 4.6. a) Full blots and gels for main Figure 4.6. b) Trx1 and
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Figure C.4: ASK1-Cys250 is required to form an inter-molecular disulfide bond with Trx1.
Figure legend on next page.
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Figure C.4: ASK1-Cys250 is required to form an inter-molecular disulfide bond with Trx1.
Relates to 4.4.2 and 4.5. a) Schematic of proteins in this Figure. b) Trx1 alone gels for
main Figure 4.5. c) and d) Identical to main Figure 4.5, except either Cys250Ser (c) or
Cys200Ser (d) was used. Cys200Ser formed a DTT-sensitive species, but Cys250Ser did
not. For further details see main Figure 4.5.
a)
























Figure C.5: ASK188–266 Cys250-only can form a disulfide-linked species with Trx1. a)
Schematic showing proteins b) ASK188–266 with only C250 (all other cysteines are mutated
to Ser) was co-expressed with (untagged) human Trx1C35S in E. coli. Shown is purified
proteins after nickel affinity purification and IEX. On non-reducing SDS-PAGE (-DTT), the
proteins run predominately as a single ∼30 kDa species and as two bands on reducing



























































































































Figure C.6: Trx1-fusion proteins can form a mixed-species disulfide bond with ASK1.
Relates to 4.4.4.1. a) Schematic showing constructs in this Figure. N-terminal-MBP fused
to Trx1C35S, described in the Figure as MBP-Trx1. An ASK1 triple cysteine mutant
(ASK188–658
C206S, C225,226S), with a C-terminal StrepII-tag, was also used (referred to as
ASK1 in the remainder of this legend). b) Nickel-purified ASK1 and MBP-Trx1 were
reduced with 2 mM DTT for one hour, on ice, before being purified by IEX in non-reducing
conditions. IEX purified ASK1 and MBP-Trx1 were combined at roughly equimolar
amounts (in a buffer containing 10 mM HEPES (pH 7.4), 300 mM NaCl) before being
incubated at either 10 or 30 minutes at room temperature, or for 16 hours at 4 °C. At the
endpoint, samples were alkylated and denatured (in SDS sample buffer containing 50 mM
IAM) for 30 minutes at room temperature, in the dark, before analysis by SDS-PAGE.
Proteins were visualised with Coomassie. For reducing gels, samples were incubated with






















































































Figure C.7: SEC and cleavage of MBP-Trx1C35S. Relates to 4.4.4.1. a) MBP-Trx1C35S
was incubated with ASK188–658
C206S, C225,226S (see Figure 4.7 for details), and subjected to
SEC on an S200I column (running at 0.5 mL/min, in a buffer of 10 mM HEPES (pH 7.6),
300 mM NaCl). Arrowheads indicate molecular weight standards. The ASK1-Trx1-MBP
complex eluted before the 150 kDa marker. b) Elution fractions from (a) were subjected to
non-reducing and reducing SDS-PAGE. c) Elution fractions from (a) were incubated with
an excess of 3C-protease—which cleaves the MBP-tag from Trx1 (see Methods (2.3.15) and
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Figure C.8: Preparation of ASK1-Trx1-Lys species for SAXS and comparison of
ASK188–658 WT and Cys250Ser. a) Reducing (+ DTT) gels for main Figure 4.8. Samples
were incubated with 100 mM DTT at room temperature for 5 minutes before SDS-PAGE.
b) and c) ASK188–658 WT (b) or Cys250Ser (c) was incubated with Trx1
C35S-Lys at 37 °C
for the times indicated and analysed by SDS-PAGE, see main Figure 4.7 for methods.
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Figure C.9: SAXS scattering and Guinier plots. Relates to 4.4.5. i) Scattering plots of
Log(I) vs q, ii. Ln(I) vs q2 for a) ASK1 (ASK188–658
C206S, C225,226S) alone, b) Trx-Lys




































Figure C.10: Protein sequences for SAXS constructs. a) ASK188–658 construct used for
SAXS. Lower case, underlined ‘gpg’ denotes the residues left from the His6-tag after 3C
cleavage, bold and underlined residues denote Cys to Ser mutations, letters in italic
represent the (unused) C-terminal Strep-II tag. b) Trx1-Lys construct used for SAXS. Bold
and underlined residues denote Cys to Ser mutations, the underlined ‘le’ represents the
linker between the C terminus of Trx1 and N terminus of T4 phage lysozyme. Letters in
italics denote the C-terminal His6-tag. c) MBP-Trx1 fusion protein. Letters in italics
denote the N-terminal His6-tag, the underlined ‘LEVLFQgpg’ indicates the 3C cleavage site




















Figure C.11: De novo ASK188–266 Robetta models. The Robetta server (Kim et al., 2004)
was used to generate a de novo model for ASK188–266. Five models were generated. a) The
model used in the SAXS CORAL modelling. b) Overlay of the three most similar models
(including a). All models feature a globular protein with an α-β-sandwich. Cys250 is
located N-terminal to the final α-helix within the models. c) Shows the last two generated
models (i. and ii.), which are, overall, more extended and disordered. Models were rendered













































ASK1 + DTT Add MKK6,
begin assay
Figure C.12: Addition of DTT does not alter ASK188–941 kinase activity. a) Schematic of
proteins in this assay. b) Flow-diagram showing the order of addition of proteins. c) and d)
Kinase assay, performed at room temperature, with ASK188–941—2 µM in c) and 6 µM in
d)—and MKK6 (3 µM) and the addition of indicated amounts of DTT. The assay was
started with the addition of 50 µM ATP and analysed via Phos-Tag SDS-PAGE. Proteins











































Figure C.13: Trx1 does not inhibit ASK188–941 activity in vitro under reducing conditions.
a) Schematic of proteins in this assay. b) and c) Kinase assay (performed at room
temperature) with 2 mM DTT and titrating in Trx1 (b) or Trx1C35S (c). The assay was
started with the addition of 50 µM ATP and analysed via Phos-Tag SDS-PAGE. Proteins
were visualised with Coomassie. Note—Under the conditions used, Trx1 migrates off the















































































Pre-incubation Kinase assay with pre-incubated ASK1 + Trx1
 
(kDa)
b) ASK1 + Trx1 Incubate,






Figure C.14: Pre-incubation of ASK1 and Trx1 does not inhibit ASK1 kinase activity.
Figure legend on next page.
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Figure C.14: Pre-incubation of ASK1 and Trx1 does not inhibit ASK1 kinase activity. a)
Schematic showing protein constructs used in the assay. b) Flow diagram showing the order
proteins were combined. c) and d) Kinase assay, similar main Figure 4.13 except with
ASK188–941 (1 µM) and indicated concentrations of Trx1 (c), or Trx1C35S (d), incubated
together under non-reducing conditions for 16 hours at 4 °C. After the incubation, a sample
was taken and alkylated with 10 mM IAM before running on non-reducing SDS-PAGE (i).
The remaining sample was used for an in vitro kinase assay with MKK6 (3 µM). The assay
performed at room temperature and started with the addition of ATP (50 µM). The kinase































Figure C.15: Trx1 does not inhibit full-length ASK1 in vitro. Relates to main Figure 4.14.
Assay is identical to Figure 4.14 except for the inclusion of the indicated amount of DTT.
a) Flow-diagram showing order proteins were combined. b) Phos-Tag SDS-PAGE and
western blot (probing for p-MKK6) of the same samples.
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 Prdx1 + DTT
(10 mM),
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Figure C.16: Prdx1 reduction and desalting. a) Prdx1 reduction and desalting. i.
Schematic of protocol and samples shown on SDS-PAGE in ii. Prdx1 was reduced with 10
mM DTT (in a buffer containing 10 mM HEPES (pH 7.6), 300 mM NaCl) for 16 hours at 4
°C before being desalted twice through a 0.5 mL Zeba Spin column (Thermo Scientific).
The spin column was pre-equilibrated in 10 mM HEPES (pH 7.6) 300 mM NaCl (that had
been dialysed against the same buffer containing 10 µg/mL bovine catalase (Sigma)). b)
Treatment of 10 µM Prdx1 with the indicated concentration of H2O2 for the times
indicated. At each time point, a sample was removed and the reaction was stopped by
plunging it directly into SDS sample buffer with 10 mM IAM. Disulfide-linked dimerisation
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ASK12–1374 Kinase SAMPH7x TPR TBD CC
c)
Figure C.17: ASK12–1374 kinase activity is not changed by addition of Prdx1 and H2O2.
a) Schematic of proteins used in this assay. b) Flow diagram showing order proteins were
combined. c) Prdx1 was reduced and desalted (as in Appendix C.16) and added (at the
concentrations shown) to ASK12–1374 (approximately 0.1 to 0.5 µM, see main Figure 4.14).
The proteins were incubated with the indicated amounts of H2O2 for 5 minutes at room
temperature, before being added to MKK6 to perform the in vitro kinase assay, with 3 µM
MKK6, started with the addition of 1 mM ATP. The assay was visualised by western blot,
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Figure C.18: Inhibition of MKK6 phosphorylation following incubation with Trx1 and
H2O2. ASK188–941 alone for main Figure 4.17. a) Flow diagram of assay. ASK188–941 was
incubated with the indicated concentrations of H2O2 for 15 minutes at room temperature.
A sample was taken for non-reducing SDS-PAGE shown in b). The remainder used in a
kinase assay with MKK6 and analysed by Phos-Tag SDS-PAGE, shown in c). For further
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Figure C.19: ASK1 secondary structure prediction. Secondary structure prediction for
human ASK188–266 numbers refer to the position in the protein sequence. e—extended;
h—helix; t—turn. The stars indicate the position of the cysteine residues. Cys250 is the
only cysteine predicted to be N-terminal to a helix. The prediction was generated using the
ProteinCCD webtool (https://ccd.rhpc.nki.nl/; Mooij et al., 2009) with the HNN
(Guermeur, 1997), DPM (Deleage and Roux, 1987) and Predator (Frishman and Argos,
1996) prediction servers. The figure was generated using Aline (Bond and Schüttelkopf,











































































Figure C.20: MKK6 cysteine residues. a) ClustalOmega (Li et al., 2015) alignment of
human MKK6 and the related MAP2K, MKK3. The cysteine residues in MKK6 are
indicated by a yellow dot. The activation loop (AL) is indicated by the black line. MKK6
phosphorylation sites (Ser207 and Thr211 for human) are indicated. The start of the
structure in (b) is indicated. b) Crystal structure of unphosphorylated MKK6 (PDB ID:
3VN9; Matsumoto et al., 2012) rendered as a cartoon in PyMol. The cysteine residues and
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Figure D.1: Prdx1 is required for p38 response in HAP1 cells. Relates to main
Figure 5.6). Full blots for p38 response for H2O2 treatment of HAP1 WT and Prdx1 KO
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Figure D.2: Unspecific bands with p38α antibody and poor Prdx1 over-expression. a) WT
HAP1 cells treated with 100 µM H2O2 for times indicated, lysed with a RIPA buffer,
subjected to western blot and probed for p38α (used at a 1 in 2,000 dilution, Novus
Biologicals, catalogue number: NB100-56665). The predicted size of p38α is indicated. The
samples on this blot are the same as in as in main Figure 5.5. Other experiments gave
similar results. b) StepII-tagged Prdx1, or green fluorescent protein (GFP; in a modified
StrepII-LIC-pcDNA3 vector, see Appendix A.1) was transfected into HAP1 cells (see
Appendix A.2 for method). Cells were lysed in RIPA buffer and resolved by western blot,
probing for Prdx1, StrepII-tag and α-tubulin (loading control). GFP was used as a control






























































Lanes: 1,5 2,6 3,4,7,8
Figure D.3: IAM blocks reduced cysteines. a) Flow diagram for differential protein
labelling with 5-iodoacetamidofluorescein (IAF). Proteins were either not labelled with IAF,
reduced with DTT and labelled with IAF or alkylated (with IAM or NEM), reduced and
labelled with IAF. Alkylation occurred at room temperature for 30 minutes, in the dark.
Reduction occurred at 50 °C for 15 minutes. IAF-labelling occurred at room temperature,
30 minutes in the dark. In between each step, the lysate was precipitated with 10% (v/v)
(as in Methods, 2.11.3.2). b) IAF-labelled protein were visualised with in-gel fluorescence
on a LAS-3000 (FujiFilm), before staining with Coomassie to visualise total protein.
M—protein marker; lanes 1 and 5—no IAF; lanes 2 and 6—total labelling; lanes 3 and
7—pre-blocking with IAM before labelling; lanes 4 and 8—pre-blocking with NEM.
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Figure D.4: Technical replicates of
H2O2 treated, ICAT-labelled WT or
Prdx1 KO HAP1 cells. Relates to 5.5.3.
See main Figure 5.11 for an overview of
the experiment. a) Venn diagrams
showing overlap between the duplicate
LC-MS/MS runs on the same sample.
Only proteins that had a ‘high
confidence’ score in Proteome Discoverer
were carried forward. Numbers in
parenthesis indicate additional proteins
that were found, but were only labelled in
either the heavy or light channel. b)
Standard deviation of the protein ICAT
ratios from duplicate LC-MS/MS runs. c)
Percentage of identified proteins that
were ICAT-labelled. Only proteins found
























































































Figure D.5: ICAT-labelled proteins from either H2O2 treated WT or Prdx1 KO HAP1
cells. a) and b) HAP1 cells were treated with 100 µM H2O2 (or an equal volume of water),
for 2.5 minutes. Cells were lysed and ICAT-labelled as for the untreated WT/Prdx1 KO
pilot trial (see 5.5.2). Graphical display of Tables D.2 and D.4. a) WT HAP1 cells. The
ICAT ratio is heavy (H) (H2O2 treated) over light (L) (untreated). b) Prdx1 KO HAP1
cells. The ICAT ratio is light (L) (H2O2 treated) over heavy (H) (untreated). Note—these

















































































































































































































































































































Prdx1 KO + H2O2
Figure D.5: ICAT-labelled proteins from either H2O2 treated WT or Prdx1 KO HAP1 cells.




























































Figure D.6: ICAT-labelled protein and cysteine origins. Relates to main Figure 5.14. a)
Percentage of total ICAT-labelled protein that originate from disulfide bonds. b) Breakdown of
sub-cellular origins of identified ICAT-labelled proteins. Annotated manually according to UniProt
(www.uniprot.org; The UniProt Consortium, 2017).
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Rep 1 Rep 2 Rep 3
‘Mean’
Run 1 Run 1 Run 2 Run 1 Run 2
GPC3 Glypican-3 P51654 1.65 1.35 0.01 0.01 1.5 349 No
CANX Calnexin P27824 1.16 0.93 100.00 0.83 100.00 0.97 194 Yes (160)
NDUFB10 NADH dehydrogenase 1 beta O96000 0.01 1.30 1.24 0.75 0.79 1.02 119 No
subcomplex subunit 10
TF Serotransferrin P02787 1.52 0.79 0.79 100.00 1.16 1.16 137 Yes (213)
GAPDH Glyceraldehyde-3-phosphate P04406 1.17 0.43 0.70 0.41 0.01 0.72 152 No
dehydrogenase
RPS12 40S ribosomal protein S12 P25398 1.25 0.01 0.01 1.25 106 No
HCCS Cytochrome c-type P53701 1.18 1.07 100.00 1.12 179 No
heme lyase 218 No
TUBA1B Tubulin alpha-1B chain P68363 1.74 0.01 0.01 1.74 315 No
GALNT2 Polypeptide N-acetylgalac- Q10471 1.18 0.29 0.01 0.73 539 Yes (555)
tosaminyltransferase 2
ALB Serum albumin P02768 0.01 0.90 0.77 0.83 0.85 224 Yes (270)
500 Yes (511)
501 Yes (485)
Manually annotated using UniProt (www.uniprot.org; The UniProt Consortium, 2017). ICAT ratio = heavy (Prdx1 KO) / light (WT). If
a peptide was only found in one channel (heavy or light) Proteome Discoverer gives the peptide a value or 100 for the channel identified.
Thereby a value of 100 means a protein was only found in the heavy channel, if it is only found in the light channel the ratio will equal
1/100 (i.e. 0.01). Underlined numbers were used to calculate the ‘mean’.
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CNPY2 Protein canopy homolog 2 Q9Y2B0 0.73 86 Yes (137)
171 Yes (28)
TUBA1B Tubulin alpha-1B chain P68363 0.73 115 No
TXNDC5 Thioredoxin domain-containing protein 5 Q8NBS9 0.77 381 Yes (338)
POFUT1 GDP-fucose protein O-fucosyltransferase 1 Q9H488 0.77 126 Yes (140)
249 Yes (283)
SOD1 Superoxide dismutase P00441 0.83 58 Yes (147)
ALB Serum albumin P02768 0.84 289 Yes (303)
500 Yes (511)
501 Yes (485)
AK2 Adenylate kinase 2 P54819 0.86 42 Yes (92)
92 Yes (42)
UBE2D1 Ubiquitin-conjugating enzyme E2 D1 P51668 0.87 85 No
GAPDH Glyceraldehyde-3-phosphate dehydrogenase P04406 0.89 152 No
SDF2L1 Stromal cell-derived factor 2-like protein 1 Q9HCN8 0.91 92 No
149 No
CHCHD3 MICOS complex subunit MIC19 Q9NX63 0.91 183 Yes (214)
193 Yes (204)
NPTN Neuroplastin Q9Y639 0.93 218 Yes (170)
BSG Basigin P35613 0.93 242 Yes (301)
Continued on next page
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ERP44 Endoplasmic reticulum resident protein 44 Q9BS26 0.94 189 Yes (241)
301 Yes (318)
CTSL Cathepsin L1 P07711 0.95 322 Yes (269)
PPT1 Palmitoyl-protein thioesterase 1 P50897 0.95 128 Yes (96)
PPIA Peptidyl-prolyl cis-trans isomerase A P62937 0.96 62 No
115 No
LMAN2 Vesicular integral-membrane protein VIP36 Q12907 0.96 202 Yes (239)
239 Yes (202)
PRDX4 Peroxiredoxin-4 Q13162 0.97 51 No
LTF Lactotransferrin P02788 0.97 424 Yes (705)
478 Yes (553)
IGF2R Cation-independent mannose-6-phosphate receptor P11717 0.99 731 Yes (760)
F11R Junctional adhesion molecule A Q9Y624 1.00 50 Yes (109)
NDUFA8 NADH dehydrogenase 1 alpha subcomplex subunit 8 P51970 1.02 36 Yes (66)
66 Yes (36)
110 Yes (78)
CALR Calreticulin P27797 1.02 105 Yes (137)
MIF Macrophage migration inhibitory factor P14174 1.02 81 No
LDHB L-lactate dehydrogenase B chain P07195 1.03 164 No
Continued on next page
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ERGIC1 Endoplasmic reticulum-Golgi Q969X5 1.05 116 No
intermediate compartment protein 1
PRKCSH Glucosidase 2 subunit beta P14314 1.05 471 No
AHSG Alpha-2-HS-glycoprotein P02765 1.05 132 Yes (114)
219 Yes (208)
TIMM8A Mitochondrial import inner O60220 1.07 47 Yes (62)
membrane translocase subunit Tim8 A
HCCS Cytochrome c-type heme lyase P53701 1.07 177 No
CANX Calnexin P27824 1.09 194 Yes (C160)
FKBP10 Peptidyl-prolyl cis-trans isomerase FKBP10 Q96AY3 1.09 112 No
212 No
NDUFB10 NADH dehydrogenase 1 O96000 1.10 119 No
beta subcomplex subunit 10
CD276 CD276 antigen Q5ZPR3 1.10 383 Yes (438)
PRCP Lysosomal Pro-X carboxypeptidase P42785 1.10 233 Yes (310)
P4HA2 Prolyl 4-hydroxylase subunit alpha-2 O15460 1.11 504 No
NPC2 Epididymal secretory protein E1 P61916 1.13 99 Yes (93)
LAMP2 Lysosome-associated membrane glycoprotein 2 P13473 1.14 153 Yes (189)
TMED2 Transmembrane emp24 Q15363 1.17 93 Yes (32)
domain-containing protein 2
ACTB Actin, cytoplasmic 1 P60709 1.19 285 No
TIMM13 Mitochondrial import inner Q9Y5L4 1.21 50 Yes (65)
membrane translocase subunit Tim13
CD59 CD59 glycoprotein P13987 1.22 70 Yes (88)
NDUFB7 NADH dehydrogenase 1 P17568 1.32 59 Yes (90)
beta subcomplex subunit 7
Continued on next page
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CMC2 COX assembly mitochondrial protein 2 homolog Q9NRP2 1.36 37 Yes (24)
CCDC58 Coiled-coil domain-containing protein 58 Q4VC31 1.45 53 No
74 No
FAM136A Protein FAM136A Q96C01 1.56 53 No
57 No
UQCRHL Cytochrome b-c1 complex subunit 6-like A0A096LP55 1.68 81 Yes (37)
P4HA1 Prolyl 4-hydroxylase subunit alpha-1 P13674 1.76 503 No
RNASET2 Ribonuclease T2 O00584 1.81 121 Yes (75)
GPC4 Glypican-4 O75487 1.90 30 No
341 No
Annotated manually using UniProt (www.uniprot.org; The UniProt Consortium, 2017). This data is displayed graphically in Appendix
Figure D.5a
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(partner)Run 1 Run 2
FKBP2 Peptidyl-prolyl cis-trans isomerase FKBP2 P26885 100.00 0.01 42 No
TF Serotransferrin P02787 100.00 0.98 137 Yes (213)
469 Yes (542)
GPC3 Glypican-3 P51654 100.00 1.38 349 No
PTK7 Inactive tyrosine-protein kinase 7 Q13308 100.00 100.00 301 Yes (246)
SDF2 Stromal cell-derived factor 2 Q99470 0.92 0.01 80 No
88 No
NDUFS5 NADH dehydrogenase iron-sulfur protein 5 O43920 1.02 0.01 33 Yes (66)
MT1E Metallothionein-1E P04732 1.11 0.01 44 No
TIMM10 Mitochondrial import inner P62072 0.01 1.30 29 Yes (54)
membrane translocase subunit Tim10 50 Yes (33)
Annotated manually using UniProt (www.uniprot.org; The UniProt Consortium, 2017). ICAT ratio = heavy (treated) / light (untreated).
If a peptide was only found in one channel (heavy or light) Proteome discoverer gives the peptide a value or 100 for the channel identified.
Thereby a value of 100 means a protein was only found in the heavy channel, if it is only found in the light channel the ratio will equal
1/100 (i.e. 0.01).
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CMC2 COX assembly mitochondrial protein 2 homolog Q9NRP2 0.52 37 Yes (24)
NDUFB10 NADH dehydrogenase 1 beta subcomplex subunit 10 O96000 0.65 119 No
TIMM10 Mitochondrial import inner P62072 0.66 29 Yes (54)
membrane translocase subunit Tim10 50 Yes (33)
NDUFB7 NADH dehydrogenase 1 beta subcomplex subunit 7 P17568 0.67 59 Yes (90)
90 Yes (59)
NDUFA8 NADH dehydrogenase 1 alpha subcomplex subunit 8 P51970 0.71 36 Yes (66)
66 Yes (36)
110 Yes (78)
P4HA1 Prolyl 4-hydroxylase subunit alpha-1 P13674 0.71 503 No
TIMM13 Mitochondrial import inner Q9Y5L4 0.74 50 Yes (65)
membrane translocase subunit Tim13
KDELC2 KDEL motif-containing protein 2 Q7Z4H8 0.80 459 No
AK2 Adenylate kinase 2 P54819 0.87 42 Yes (92)
92 Yes (42)
SDF2L1 Stromal cell-derived factor 2-like protein 1 Q9HCN8 0.89 50 No
92 No
142 No
CCDC58 Coiled-coil domain-containing protein 58 Q4VC31 0.91 53 No
74 No
CALR Calreticulin P27797 0.93 105 Yes (137)
UBE2D3 Ubiquitin-conjugating enzyme E2 D3 P61077 0.94 84 No
CANX Calnexin P27824 0.95 194 Yes (160)
PRKCSH Glucosidase 2 subunit beta P14314 0.95 472 No
UBE2L3 Ubiquitin-conjugating enzyme E2 L3 P68036 0.95 86 No
Continued on next page
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ERP44 Endoplasmic reticulum resident protein 44 Q9BS26 0.98 189 Yes (241)
301 Yes (318)
CHCHD3 MICOS complex subunit MIC19 Q9NX63 0.98 183 Yes (214)
193 Yes (204)
CD59 CD59 glycoprotein P13987 0.98 70 Yes (88)
LMAN2 Vesicular integral-membrane protein VIP36 P13987 0.99 202 Yes (239)
239 Yes (202)
SOD1 Superoxide dismutase P00441 0.99 58 Yes (147)
TIMM8A Mitochondrial import inner O60220 1.01 47 Yes (62)
membrane translocase subunit Tim8 A
LMAN1 Protein ERGIC-53 P49257 1.06 190 Yes (230)
TOR1AIP2 Torsin-1A-interacting protein 2 Q8NFQ8 1.06 310 Yes (468)
FKBP10 Peptidyl-prolyl cis-trans isomerase FKBP10 Q96AY3 1.07 110 No
222 No
F11R Junctional adhesion molecule A Q9Y624 1.08 50 Yes (109)
MIF Macrophage migration inhibitory factor P14174 1.10 81 No
CNPY2 Protein canopy homolog 2 Q9Y2B0 1.11 86 Yes (137)
171 Yes (28)
GALNT2 Polypeptide N-acetylgalactosaminyltransferase 2 Q10471 1.13 539 Yes (555)
LAMP2 Lysosome-associated membrane glycoprotein 2 P13473 1.13 153 Yes (189)
HCCS Cytochrome c-type heme lyase P53701 1.15 178 No
HLA-A HLA class I histocompatibility antigen, P01891 1.17 283 Yes (227)
A-68 alpha chain
Continued on next page
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GAPDH Glyceraldehyde-3-phosphate dehydrogenase P04406 1.19 152 No
PRDX4 Peroxiredoxin-4 Q13162 1.24 51 Noa
BSG Basigin P35613 1.25 242 Yes (301)
LTF Lactotransferrin P02788 1.28 424 Yes (705)
478 Yes (553)
FAM136A Protein FAM136A Q96C01 1.29 53 No
57 No
ENO1 Alpha-enolase P06733 1.30 399 No
NPTN Neuroplastin Q9Y639 1.32 218 Yes (170)
PPIA Peptidyl-prolyl cis-trans isomerase A P62937 1.33 115 No
LDHA L-lactate dehydrogenase A chain P00338 1.34 163 No
ALDOA Fructose-bisphosphate aldolase A P04075 1.37 202 No
ACTB Actin, cytoplasmic 1 P60709 1.42 285 No
TXNDC5 Thioredoxin domain-containing protein 5 Q8NBS9 1.60 128 Yes (121)
381 Yes (388)
CD276 CD276 antigen Q5ZPR3 1.66 383 Yes (438)
ALB Serum albumin P02768 1.69 500 Yes (511)
501 Yes (485)
AHSG Alpha-2-HS-glycoprotein P02765 1.83 132 Yes (114)
Continued on next page
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GPC4 Glypican-4 O75487 1.89 244 No
341 No
PRDX6 Peroxiredoxin-6 P30041 1.90 47 No
Annotated manually using UniProt (www.uniprot.org; The UniProt Consortium, 2017). a—Prdx4 Cys51 is in the N-terminal signal
peptide. A graph of this data is in Appendix D.5b









(partner)Run 1 Run 2
PTK7 Inactive tyrosine-protein kinase 7 Q13308 100 1.022 301 Yes (246)
GPC3 Glypican-3 P51654 0.785 100 349 No
TF Serotransferrin P02787 100 100 137 Yes (213)
469 Yes (542)
Annotated manually using UniProt (www.uniprot.org; The UniProt Consortium, 2017). ICAT ratio=light (treated)/heavy (untreated). If
a peptide was only found in one channel (heavy or light) Proteome discoverer gives the peptide a value or 100 for the channel identified.
Thereby a ratio value of 100 means a protein was only found in the light channel, if it is only found in the heavy channel the ratio will
equal 1/100 (i.e. 0.01)
265
Table D.6: Non-linear regression output from Prism









ICAT ratio Log2 ICAT ratio ICAT ratio
Amplitude 20.99 24.22 35.73 21.61
Mean 0.94 −0.06 0.02 0.13
SD 0.17 0.29 0.20 0.34
Standard Error
Amplitude 2.40 3.62 3.20 3.45
Mean 0.02 0.05 0.02 0.06
SD 0.02 0.05 0.02 0.06
95% CI (profile likelihood)
Amplitude 15.19–27.67 15.46–34.5 27.84–44.18 13.38–31.59
Mean 0.89-0.99 −0.20–0.06 −0.04–007 −0.03–0.29
SD 0.11-0.26 0.17–0.52 0.15–0.26 0.19–0.62
Goodness of Fit
Degrees of Freedom 9 9 6 8
R square 0.82 0.77 0.94 0.72
Absolute Sum of Squares 103.9 201.4 71.58 188.3
Sy.x 3.40 4.73 3.454 4.85
Constraints
SD SD >0 SD >0 SD >0 SD >0
Number of points analysed
X values 12 12 9 11
Y values 12 12 9 11
Relates to main Figures 5.9 and 5.12.
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Apoptosis signal-regulating kinases (ASK1–3) are apical kinases of
the p38 and JNK MAP kinase pathways. They are activated by di-
verse stress stimuli, including reactive oxygen species, cytokines,
and osmotic stress; however, a molecular understanding of how
ASK proteins are controlled remains obscure. Here, we report a bio-
chemical analysis of the ASK1 kinase domain in conjunction with its
N-terminal thioredoxin-binding domain, along with a central regu-
latory region that links the two. We show that in solution the cen-
tral regulatory region mediates a compact arrangement of the
kinase and thioredoxin-binding domains and the central regulatory
region actively primes MKK6, a key ASK1 substrate, for phosphor-
ylation. The crystal structure of the central regulatory region reveals
an unusually compact tetratricopeptide repeat (TPR) region capped
by a cryptic pleckstrin homology domain. Biochemical assays show
that both a conserved surface on the pleckstrin homology domain
and an intact TPR region are required for ASK1 activity. We propose
a model in which the central regulatory region promotes ASK1 ac-
tivity via its pleckstrin homology domain but also facilitates ASK1
autoinhibition by bringing the thioredoxin-binding and kinase do-
mains into close proximity. Such an architecture provides a mecha-
nism for control of ASK-type kinases by diverse activators and
inhibitors and demonstrates an unexpected level of autoregulatory
scaffolding in mammalian stress-activated MAP kinase signaling.
ASK1 | MAP kinase | scaffolding | signaling | MKK6
Mitogen-activated protein (MAP) kinase cascades transmitsignals from membrane-associated receptors to intracellular
targets to effect changes in cellular behavior. They form a hier-
archical system in which activated upstream kinases (MAP3Ks)
phosphorylate intermediate MAP kinase kinases (MAP2Ks),
which in turn phosphorylate terminal MAP kinases, primarily
ERK, p38, and JNK and their isoforms (1). Extensive studies have
focused on the activation of RAS-RAF-MEK upstream in the
ERK pathway and provided fertile ground for the discovery of
new therapeutics (2). In contrast to the ERK pathway, which
primarily promotes cellular proliferation, JNK and p38 phos-
phorylate a range of substrates to promote inflammation and cell
death (1, 3). In addition, cross-regulation among the p38, JNK,
and ERK pathways is important for the efficacy of various cancer
therapies that are in use or in development (4, 5). Molecular
details on the more diverse upstream regulation of the p38 and
JNK pathways are currently less clear, however.
Apoptosis signal-regulating kinases (ASK1–3) are MAP3Ks
that trigger cellular responses to redox stress and inflammatory
cytokines (6, 7) and play vital roles in innate immunity and viral
infection (8–11). When activated, ASK1–3 activate JNK and p38
via phosphorylation of MAP2Ks (MKK3/4/6/7) (12). The key
initiator role of ASK1–3 in this pathway means that either too
much or too little ASK activity can have pathological effects. For
instance, inhibiting ASK1 is beneficial against gastric cancer (13,
14), but inactivating mutations in ASK1 contribute to the devel-
opment of melanoma (15, 16). In addition, ASK1 inhibitors have
shown promise for treatment in mouse models of amyotrophic
lateral sclerosis, highlighting it as a critical factor modulating
cellular survival (17).
Initiator signaling kinases such as MAP3Ks are often regulated by
oligomerization and regulatory domains, rather than solely by
phosphorylation (18, 19). This is especially true of ASK1–3, which
share a conserved architecture in which the central kinase domain is
flanked on either side by additional domains, and multimeric as-
sociation appears to be crucial to the activity of these domains (Fig.
1A). The active signaling form of ASK1 in cells is thought to be an
oligomer often referred to as the “ASK signalosome,” which also
contains ASK2 and ASK3 (20-22). To the N terminus of the kinase
domain lie several regions with regulatory roles but poorly un-
derstood structures. Separate regions have been proposed to bind to
thioredoxin and TNF receptor-associated factors (TRAFs) (6, 7, 19,
23), which regulate the response of ASK1 to cytokines (Fig. 1A).
The N-terminal region of ASK1 also has been implicated in
binding CIB1 to detect Ca2+-based stress signaling, and in binding
Fbxo21 to trigger innate antiviral signaling, among other protein–
protein interactions (24–26). The region C terminal to the kinase
is less well studied, but contains a 14-3-3 protein-binding site housed
within a predicted disordered sequence (27, 28), followed by a re-
gion proposed to promote constitutive oligomerization of ASK1
(26). This C-terminal oligomerization region of ASK1 also has the
capacity to directly bind to HIV Vif-1 and promote the innate an-
tiviral response by APOBEC3G (8).
The prevailing model of ASK1 regulation is that constitutive
oligomerization through the C terminus works in partnership with
transient protein–protein interactions mediated by regions N ter-
minal to the kinase domain. Regulatory factors, such as thio-
redoxin, associate with the N-terminal thioredoxin-binding domain
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to negatively regulate activity. Under conditions of redox stress,
thioredoxin dissociates with and TRAF proteins associate with the
region between the thioredoxin-binding domain and kinase do-
main, promoting ASK activation and kinase activity (19). There is
some debate about the exact role of thioredoxin in negatively
regulating ASK1 activity, with reports that the ASK–thioredoxin
association is either dependent on or independent of thioredoxin
oxidoreductase activity and disulfide bonds (6, 29–31).
Relatively little is known about the structural basis of ASK1
regulation, and thus previous studies necessarily have relied on
prediction and deletion-based analysis. Although such approaches
have identified various important regions for regulation of ASK
proteins, the lack of atomic resolution data still confounds our
understanding of how ASK proteins respond to diverse stimuli.
For instance, very little is known about how thioredoxin or TRAF
proteins actually might influence the recruitment of substrates to
the ASK signalosome, or control the kinase activity of ASK1 on its
substrate MAP2Ks. Here we present the first structure of a reg-
ulatory domain of ASK1, that of the central region that links the
thioredoxin-binding and kinase domains of ASK1. This so-called
“domain of unknown function” (PFAM domain DUF4071) cor-
responds to the region proposed to associate with TRAF proteins
during ASK1 activation. The crystal structure reveals a surprisingly
compact fold, with core features that are highly conserved in all
human ASK proteins and in ASK orthologs throughout meta-
zoans. Our biochemical and biophysical analyses reveal conserved
residues that regulate ASK1 activity in both positive and negative
manners, and show that the compact fold of the central regulatory
region is crucial for bringing the thioredoxin-binding and kinase
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Fig. 1. N-terminal regulatory domains of ASK1. (A) Schematic representation of ASK1 domains, with functional regions indicated, and previously proposed NCC and
C-terminal coiled-coil regions hatched. Constructs used in this work are indicated below. Example purified proteins from each of these constructs are shown in Fig.
S1A. (B) Phos-tag SDS/PAGE comparing phosphorylation of kinase dead MKK6 by ASK1 kinase domain (669–941), and ASK1(88–941) at matched concentrations.
(C) MKK6 phosphorylation by 0.01 μM ASK1 kinase domain with increasing concentrations of ASK1(269–658) added. MKK6 was held constant (3 μM), and phos-
phorylation was monitored by Western blot analysis. Total protein transferred to membranes visualized by staining membrane with Ponceau S (shown below).
(D) Quantitation of the independent triplicate experiments shown in C. Each band was normalized to the band intensity of the kinase-alone 10-min time point for
that experiment. Mean values are plotted with error bars representing the SEM. (E) MKK6 phosphorylation by 0.01 μM ASK1 kinase domain with increasing concen-
trations of ASK1(88–266) added. MKK6 was held constant (3 μM), and phosphorylation was monitored byWestern blot analysis. Total protein transferred to membranes
visualized by staining membrane with Ponceau S (shown below). (F) Potential model of MKK6 priming. (Left) Crystal structure of unphosphorylated MKK6 (PDB ID code
3VN9), with the αC helix in orange, the activation loop in blue, and buried phosphorylation target residues shown as spheres. (Right) A model of MKK6 based on PDB
3fme, which shows a markedly different αC-helix conformation and has a disordered activation loop. In this figure, the loop was modeled using MODELER (76).
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phosphorylation. This model provides a structural template on
which to interpret various proposed mechanisms of ASK kinase
regulation by different binding partners.
Results
The ASK1 Central Regulatory Region Promotes MKK6 Phosphorylation.
The N-terminal region of ASK1 has been proposed to interact with
various partners to regulate ASK kinase activity (Fig. 1A). To
develop a quantitative system to analyze ASK1 activity, we used in
vitro kinase assays and Phos-tag SDS/PAGE to compare the
phosphorylation of kinase dead MKK6 by either the isolated ASK1
kinase domain or ASK1(88–941), which contains the N-terminal
thioredoxin-binding domain, a central regulatory region, and the
kinase domain (Fig. 1A). In Phos-tag SDS/PAGE, phosphorylated
proteins have reduced mobility compared with unphosphorylated
protein, and thus can be readily visualized (32). In this system, both
the isolated ASK1 kinase domain and ASK1(88–941) were able to
catalyze phosphorylation of MKK6, but activity of ASK1(88–941)
was reduced by at least 10-fold (Fig. 1B). This observation supports
previous reports that the N-terminal region of ASK1 suppresses
kinase activity (19), and shows that a reconstituted in vitro system is
a useful tool for detailed analysis of ASK1 regulation.
To gain greater insight into the role of the N-terminal portions
of ASK1, we designed further constructs based on secondary
structure prediction. These constructs encompassed residues
88–266 (the thioredoxin-binding domain) and residues 269–658
(the central regulatory region) (Fig. 1A). Following expression in
Escherichia coli and purification to homogeneity (Fig. S1A), we
tested how these additional domains affected ASK1 kinase activity
in trans. In these experiments, MKK6 phosphorylation was moni-
tored using Western blot analysis, because phospho-MKK6 comi-
grated with the central regulatory region on Phos-tag SDS/PAGE.
Surprisingly, activity of the wild-type (WT) ASK1 kinase domain
was greatly enhanced by the addition of 30 μM ASK1(269–658)
(Fig. 1 C and D). We did not observe any equivalent enhancement
or inhibition of MKK6 phosphorylation by the thioredoxin-binding
domain of ASK1 when present in similar concentrations (Fig. 1E).
Although these results are consistent with published experiments
showing that ASK1 lacking the thioredoxin-binding domain is more
active than full-length ASK1 in cells (19), it has not previously been
suggested that the central regulatory region is capable of stimulating
ASK1 kinase activity in trans. In our simplified assay system, there
are two potential mechanisms by which the central regulatory re-
gion could enhance MKK6 phosphorylation: allosterically activating
the ASK1 kinase domain or priming the MKK6 substrate for
phosphorylation. At concentrations of the central regulatory region
up to 100-fold greater than ASK1 kinase (0.01 μM) but well below
substrate MKK6 levels (3 μM), there was no significant rate en-
hancement (Fig. S2). Such a dose response where excess levels of
the ASK1 central regulatory region relative to the substrate, rather
than active kinase, are required is most consistent with the idea that
the central regulatory region acts by binding to the substrate,
MKK6. Attempts to investigate activity of the central regulatory
region and kinase domain in one polypeptide, without the thio-
redoxin-binding domain, were hampered by the fact that a construct
comprising residues 269–941 was completely insoluble when
expressed in E. coli.
The foregoing experiments demonstrate two interesting con-
cepts. First, a region outside of the ASK1 kinase domain can as-
sociate with downstream substrate kinases, thereby acting as a
scaffold for substrate recruitment. Second, because rate enhance-
ment occurs when the kinase and central regulatory region are on
separate polypeptides, the central regulatory region actively pro-
motes a state of MKK6 that is primed for phosphorylation. In
offering an explanation of how this might occur, we surveyed the
available structures of MKK6. The three available crystal structures
exhibit three different conformations of the activation loop, and
movement of up to 18 Å in the N-terminal end of the αC helix,
indicating that it is relatively flexible (Fig. S1B). Two of these
structures contain phosphomimetic mutations (PDB ID codes
3FME and 3ENM), but the structure of unphosphorylated MKK6
(PDB ID code 3VN9) shows that the phosphorylation target resi-
dues in the activation loop (Ser207/Thr211) are buried, and that
the activation loop is stabilized by the αC-helix (Fig. 1F) (33).
Structures of MKK6 bearing phosphomimetic activation loop
mutations exhibit notably different positions in the αC-helix (34)
(PDB ID code 3FME), which lead to different conformations of
the activation loop (Fig. S1B). Thus, we propose that by maneu-
vering the αC-helix, it is plausible that ASK1(269–658) could
manipulate access to the phosphorylation target residues and
thereby “prime” MKK6 for phosphorylation (Fig. 1F). This con-
cept provides another layer of complexity to the thoroughly in-
vestigated kinetics of MKK6 dual phosphorylation by ASK1 (35,
36), and raises the question of how the central regulatory region
plays such an active scaffolding role.
Structure of the Central Regulatory Region of ASK1. To gain insight
into how the central regulatory region might prime MKK6 for
phosphorylation, we expressed and purified human ASK1 residues
269–658 from E. coli, crystallized it, and solved its crystal structure
to a resolution of 2.1 Å (Fig. 2A and Table 1). The final structure
contains two molecules in the asymmetric unit, which are essen-
tially identical and share an rmsd of 0.04 Å. Given the various
reports of multimerization in ASK1 regulation, we also tested




















































































Fig. 2. Structure of the ASK1 central regulatory re-
gion. (A) Cartoon representation of the crystal struc-
ture of ASK1(269–658). Individual TPRs are labeled,
and the pleckstrin homology domain is in purple. A
modified domain schematic (used hereinafter) is
shown below. (B) SEC-MALLS of ASK1(269–658), with
theoretical molecular weights of a putative monomer
and dimer species indicated. (C) Overlay of experi-
mental SAXS data (black circles) and scattering profile
calculated using CRYSOL for the crystal structure of
ASK1(269–658). Agreement between the experimen-
tal data and calculated scatter pattern is signified by χ
= 0.379. (Inset) Guinier analysis.















a role in the formation of ASK(269–658) dimers. Neither size
exclusion chromatography (SEC) coupled to both multiple-angle
laser light scattering (SEC-MALLS) nor small-angle X-ray scat-
tering (SEC-SAXS) indicated a tendency of ASK1(269–658) to
form multimers in solution at the concentrations tested (Fig. 2 B
and C and Table 2).
The overall structure of ASK1(269–658) encompasses an ex-
tended series of 14 helices, which form seven tetratricopeptide
repeats (TPRs), followed by a pleckstrin homology domain that
had not previously been predicted within ASK1 (Fig. 2A). To the
best of our knowledge, the overall compact arrangement of TPRs
capped by a pleckstrin homology domain has no close matches to
previously solved structures. In contrast to the extended arrange-
ments observed in many TPR proteins (37), the ASK1 TPR region
progressively folds back on itself and forms a compact arrange-
ment, with a close physical association between residues from
helices that are significantly separated in sequence. Such a stable
globular arrangement is supported by SAXS analyses showing that
the ASK1(269–658) monomer crystal structure is highly repre-
sentative of its solution behavior, with excellent agreement be-
tween the theoretical scatter pattern calculated from the crystal
structure coordinates and the experimental scattering data of (χ =
0.379) (Fig. 2C and Table 2). Close interactions between residues
that are well separated in sequence are centered around the first
helix of TPR 7 (residues 508–524), which makes contact with
constituent residues from helices of TPRs 2–7.
Although sequence-based predictions and experimental evidence
have implicated an N-terminal coiled-coil (NCC) region as re-
sponsible for mediating interactions at the N terminus of ASK, we
observed a surprisingly compact protein. Crucially, the crystallized
ASK1 construct contains the predicted NCC region (residues 297–
324) (19). The structure shows that residues 297–324 reside stably
within TPRs 1 and 2, forming numerous interactions with sur-
rounding TPR helices. Thus, although it is clearly important for
ASK1 structure, the NCC is more accurately described as an in-
tegral part of the TPR domain and seems unlikely to directly me-
diate conventional coiled-coil type oligomerization.
The pleckstrin homology domain of ASK1 adopts the typical
form of two antiparallel β-sheets followed by a C-terminal amphi-
pathic helix, but lacks the tryptophan found within the terminal
helix of most conventional pleckstrin homology domains (38). It is
not uncommon for widely disparate sequences to produce the
pleckstrin homology fold, and in ASK1 the lack of a locking tryp-
tophan residue (which is Phe646 in ASK1) may explain why it had
not been recognized previously. The interface between the base of
the pleckstrin homology domain and the TPR region is highly hy-
drophobic and forms an extensive network of interactions with
helices 12 and 14 from TPRs 6 and 7 (Fig. S3). The complemen-
tarity of these interactions, in conjunction with scattering data de-
scribed above, suggests that the intimate association between the
TPRs and pleckstrin homology domain of ASK1 is the stable form
of ASK1 in solution. In line with this idea, attempts to express
the isolated ASK1 pleckstrin homology domain in the absence of
the TPR region yielded completely insoluble protein, in contrast
to the solubility and stability of ASK1(269–658).
ASK1 Has a Cryptic Pleckstrin Homology Domain That Promotes
Substrate Phosphorylation. The yeast MAPK scaffolding pro-
tein Ste5 contains a pleckstrin homology domain that has been
previously proposed to bind phospholipids, and is crucial for
protecting the yeast MAPK pathway from inappropriate activation
and localizing the activated scaffold to the plasma membrane (39,
40). Interestingly, neither the ASK1 pleckstrin homology domain nor
a model of the equivalent region of ASK2 has a surface patch of
increased positive charge, as is observed in bona fide phosphoinosi-
tide-binding pleckstrin homology domains, such as that from phos-
pholipase C (Fig. 3A). In fact, the ASK1 pleckstrin homology cavity is
notably negatively charged, as is the equivalent region of a homology
model generated for the ASK2 pleckstrin homology domain. This is
in line with genome-wide analysis in yeast showing that the majority
of pleckstrin homology domains do not bind lipid head groups (41),
and since their discovery, pleckstrin homology domains have been
ascribed diverse roles in mediating protein–protein interactions (38).
To identify a function for the ASK1 pleckstrin homology do-
main beyond phospholipid binding, we mapped the conservation
of sequences from ASK1, ASK2, and ASK3 from diverse mam-
malian species, as well as sequences from dASK1 (Drosophila
melanogaster) and NSY1 (Caenorhabditis elegans), onto the crystal
structure of ASK1(269–658) (Fig. 3B and Fig. S4). This analysis
uncovered two regions of high conservation within the central
regulatory region of ASK1: residues at the core of the ASK1
closed TPR repeat region that folds back on itself, and a clear
enrichment of conserved residues on the face of the ASK1
pleckstrin homology domain formed by β5–β7. The reverse side of
the protein shows relatively little conservation (Fig. 3B).
At the heart of the β5–β7 pleckstrin homology surface lie Phe623
from β6 and Asp632 from β7, which are invariant across the ASK
homologs analyzed (Fig. 3B and Fig. S4). To experimentally verify
the importance of these conserved residues, we created mutants in
the ASK1(88–941) construct (Phe623Glu and Asp632Arg; Fig. S1C)
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and analyzed their ability to phosphorylate MKK6 using Phos-tag
kinase assays. We hypothesized that if the conserved surface is im-
portant for autoinhibition (as observed in Fig. 1B), then the activity
of mutants should be increased, whereas if the surface is important
for priming MKK6 (Fig. 1C), then the Phe623Glu and Asp632Arg
mutants should show decreased activity. Both mutants had markedly
lower initial rates of MKK6 phosphorylation (Fig. 3 C and D),
clearly supporting the hypothesis that the conserved pleckstrin ho-
mology surface plays an important positive role in facilitating
MAP2K phosphorylation by ASK1. The position of the ASK1
pleckstrin homology domain directly adjacent to the kinase domain
makes it an ideal location for transient docking of MAP2Ks for both
localization and priming of the activation loop for phosphorylation.
Having established that the conserved pleckstrin homology
surface is important for ASK1 activity on downstream substrates,
we next sought to understand how the remainder of the con-
served closed TPR facilitates signal control and reduced activity
of ASK1(88–941) relative to the isolated kinase domain.
Closed TPR Interactions Facilitate ASK Kinase Regulation. In the
compact arrangement of the central regulatory region, its N and C
termini are separated by only ∼50 Å (Fig. 2A). Based on previous
reports showing that deleting the thioredoxin-binding domain
leads to more active full-length ASK1, we hypothesized that a
major role of the central regulatory region is to bring the thio-
redoxin-binding domain into close proximity to the kinase domain
to inhibit its activity. Other possible effects of such an interaction
may be to protect the β5–β7 pleckstrin homology surface and
impede MAP2K recruitment and priming (Fig. 1).
As described above, stabilizing interactions within the TPR re-
gion are centered around the first helix of TPR 7 (helix 13, residues
508–524), which makes contacts across the TPR fold. The most
long-range of these contacts involve π-cation stacking between
Trp509 from helix 13 and Arg322 in TPR 2 (Fig. 4A). Trp509 is
also one of the most conserved residues across the sequence logo
of diverse occurrences of DUF4071 in PFAM. To investigate the
importance of the closed TPR interactions, we designed two
mutants, one substituting Trp509 with glutamate and the other
replacing Arg395 with glutamate. These mutants serve two dif-
ferent purposes. Trp509Glu could reasonably be expected to form
a salt bridge with Arg322 and maintain the overall TPR archi-
tecture, but to disrupt ASK1 function if the closed TPR interaction
is mobile and Trp509 takes on a different conformation in an
active signaling form. Arg395Glu was designed as a disruptive
mutant to destabilize the compact closed TPR structure. Analyzing
both the time course and initial rates of MKK6 phosphorylation by
these ASK1 variants showed that disruption of the closed TPR by
Arg395Glu markedly reduced ASK1 activity, whereas Trp509Glu
was indistinguishable fromWT protein (Fig. 4 B and C). Based on
these findings, we conclude that the closed TPR must remain in-
tact to allow the full activity of ASK1(88–941).
Trp476 is another notable residue conserved within the ASK1
central domain. Trp476 is one of three invariant residues over
the consensus definition of DUF4071, along with Trp509, and
Trp542 (which is buried at the interface between the TPR region
and the pleckstrin homology domain). In contrast to the latter two
residues, which play clear roles in stabilizing the structure, Trp476 is
unusually surface-exposed. It is located at the N-terminal end of
TPR helix 11 (residues 475–488) and faces toward the center of the
closed TPR region. To ascertain a function of Trp476, we mutated
the residue to serine in the context of ASK1(88–941). Surprisingly,
ASK1 W476S phosphorylated MKK6 more effectively than WT
ASK1, with a roughly twofold higher initial rate (Fig. 4). This finding
is consistent with Trp476 playing a role in stabilizing autoinhibitory
interactions that suppress the activity of the kinase domain.
Interacting closed TPR residues (displayed in Fig. 4A) are re-
markably well conserved among ASK-type kinases (Fig. S4).
Namely, kinases including human ASK1, ASK2, and ASK3; Dro-
sophila ASK1 and NSY1; and the C. elegans ASK homolog all
maintain residues that mediate long-range TPR interactions,
Table 2. SAXS data collection and analysis statistics





Beam geometry 120-μm point source
Wavelength, Å 1.033
Exposure time, s 2
Temperature, K 285
q range, Å−1* 0.0048–0.290 0.0057–0.334 0.0057–0.334 0.0057–0.334
Protein concentration 50 μL of 7.7 mg/mL
protein via inline gel
filtration chromatography
50 μL of 9.7 mg/mL
protein via inline gel
filtration chromatography
50 μL of 9.3 mg/mL
protein via inline gel
filtration chromatography
50 μL of 11.5 mg/mL
protein via inline gel
filtration chromatography
Structural parameters
I(0), cm−1, from P(r) 0.0087 ± 0.0001 0.0274 ± 0.0002 0.0239 ± 0.0001 0.0182 ± 0.0001
Rg, Å, from P(r) 25.46 ± 0.21 32.54 ± 0.19 47.01 ± 0.25 44.68 ± 0.27
Dmax, Å 75 100 145 130
I(0), cm−1, from
Guinier
0.0087 ± 0.0001 0.0273 ± 0.0003 0.0243 ± 0.0002 0.0187 ± 0.0003
Rg, Å, from Guinier 25.10 ± 0.49 32.10 ± 0.53 47.30 ± 0.53 45.9 ± 1.03
Software used
Primary data reduction Scatterbrain
(Australian Synchrotron)









*q is the magnitude of the scattering vector, which is related to the scattering angle (2θ) and the wavelength (λ) as follows: q = (4π/λ)sinθ.















suggesting that this compact fold and function are highly conserved.
Overall, these results, along with previous studies showing that
deletion of residues 297–324 (the NCC) disrupts ASK1 regulation,
show that the integrity of the TPR region is important for both
function and regulation of ASK1 signaling. Whereas conforma-
tional changes cannot be discounted, it appears that a major role of
the central closed TPR of ASK1 is to bring the kinase domain into
relative proximity of the N-terminal (thioredoxin-binding) regula-
tory domain to mediate the regulation of kinase activity.
Architecture of the ASK Autoregulatory Scaffold in Solution. To in-
vestigate how the architecture of the thioredoxin-binding and
central regions of ASK1 may facilitate signal regulation, we turned
to SAXS analysis, first analyzing the ASK1 N-terminal regulatory
region ASK1(88–658) alone (Table 2). Guinier analysis showed
that the sample was monodispersed, and under the reducing SEC-
SAXS conditions when optimal data were collected, we found no
evidence of the dimerization previously shown to occur through
the NCC region of ASK1. Because the structure of the N-terminal
thioredoxin-binding domain has not been solved, we used the Robetta
server to generate a homology model of ASK1(89–266), which pre-
dicted a globular fold based around an α-β sandwich (Fig. S5) (42).
Because our earlier SAXS analysis of the central regulatory
region alone showed a stable fold and limited flexibility, when
analyzing scattering data, we treated residues 89–266 and 272–654
as two separate rigid bodies. Using BUNCH (43), we generated a
model for ASK1(88–658) that provided an excellent fit to the
scattering data (χ = 0.49) (Fig. 5 A and B, Table 2, and Fig. S6A).
In this model, the ASK1 thioredoxin-binding domain sits adjacent
to the N terminus of the central regulatory region, occupying a
position toward the conserved face of the central regulatory region
that contains both W476 and F623/D632 (Fig. 5B).
We next collected scattering data for ASK1(88–941) under
equivalent conditions to ASK1(88–658) (Fig. 5 C and D, Table 2,
Fig. 3. The ASK1 pleckstrin homology domain mediates protein-protein interactions and activity. (A, Left) Superposition of the ASK1 pleckstrin homology domain
(purple) with the canonical pleckstrin homology domain of phospholipase C (PLC, in yellow; PDB ID code 1MAI) (77). (A, Right) Three electrostatic surface repre-
sentations calculated in APBS (78) for the pleckstrin homology domains of PLC bound to Ins(1,4,5)P3, ASK1, and a model of the same region of ASK2 generated using
MODELER. (Conservation betweenASK1 and ASK2 can be viewed in the alignment in Fig. S4.) (B) Surface representation of ASK1(269–658), color-coded according to
the degree of conservation in the alignment in Fig. S4. The least conserved residues are in cyan; the most conserved, in maroon. Areas of high conservation are also
indicated with circles. (Inset) Close-up view of the conserved pleckstrin homology surface. (C) Phos-tag SDS/PAGE monitoring MKK6 (3 μM) phosphorylation by
ASK1(88–941) (1 μM)WT or indicated pleckstrin homology domain mutants. Quantitation of independent triplicate experiments is shown alongside as mean values,
with error bars representing SEM. (D) Rates of MKK6 phosphorylation calculated over the first 5 min from C. Error bars represent the SD of the linear rate fit.
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and Fig. S6B), and derived a model by incorporating the crystal
structure of the isolated ASK1 kinase domain (PDB ID code
2CLQ) into rigid-body (BUNCH) analysis (44). Again, the scat-
tering data suggested a monomeric species, consistent with the
elution profile of ASK1(88–941) when loaded onto size exclusion
chromatography at a high concentration (Fig. S1D). The model
revealed a more compact arrangement of the thioredoxin-binding
domain relative to the central regulatory region, with the thio-
redoxin-binding domain folding toward the conserved surface that
contains W476, bringing it closer to both the pleckstrin homology
and kinase domains (Fig. 5D). We also collected scattering data
from the mutant ASK1(88–941) W476S construct, which displayed
elevated activity (Table 2 and Fig. S6 C–E). Apart from a small
reorientation of the kinase domain, the W476S model did not differ
markedly from WT protein in its overall arrangement. Attempts to
collect data from inhibitory mutants within the pleckstrin homology
domain were hampered by protein instability at high concentrations.
The main conclusion that we draw from these solution studies is
that ASK1(88–941) likely exists in dynamic continuum between an
active open form and a closed conformation in which the thio-
redoxin-binding domain is in close proximity to the ASK kinase
domain. Subtle changes (such as the W476S mutation) can alter
the structural ensemble present in solution, but we are reticent to
propose specific interdomain contacts, given that our modeling
relies on a de novo model of the thioredoxin-binding domain. In
the proposed model, the thioredoxin-binding domain is ideally
placed to inhibit activity of the ASK kinase domain and impede
access to the MKK6 activating surface of the ASK1 pleckstrin ho-
mology domain—in effect acting as a stimulus-responsive toggle to
control ASK1 kinase activity and substrate recruitment and priming.
Discussion
Based on the results of our biochemical, biophysical, and structural
experiments, we are now able to put forward a model to interpret
the regulation of ASK proteins (Fig. 6). The central regulatory
region spans ∼400 residues between the thioredoxin-binding do-
main and the kinase domain. More importantly, it provides a
platform for the recruitment and priming of MAP2K substrates, as
well as a link that brings the N-terminal thioredoxin-binding do-
main and C-terminal kinase domains of ASK1 into proximity for
autoinhibition. Although our experiments have focused on ASK1,
functional residues also are highly conserved in ASK2 and ASK3,
and from mammals to nematodes, and so this architecture is likely
to be functionally conserved throughout ASK-type kinases.
The presence of adjacent pleckstrin homology and kinase do-
mains is reminiscent of the domain architecture of AKT proteins.
This similarity is only superficial, however, given that AKT
pleckstrin homology domains are bona fide binders of phosphoi-

















































































Fig. 4. TPRmutants activate and inhibit ASK1 activity. (A) Detailed view of the
closed TPR region, with residues of interest subjected to mutagenesis shown as
sticks and labeled. (B) Phos-tag SDS/PAGE monitoring MKK6 (3 μM) phos-
phorylation by ASK1(88–941) WT or indicated TPR mutants (1 μM). Quantita-
tion of independent triplicate experiments is shown alongside as mean values,
with error bars representing SEM. (C) Rates of MKK6 phosphorylation calcu-































































































Fig. 5. ASK1 autoregulatory scaffolding in solution.
(A) Overlay of experimental scattering data (black
circles) and a scattering profile calculated using
BUNCH for the model of ASK1(88–658). A Guinier
plot for the dataset is shown below, indicating that
aggregates do not measurably contribute to the
scattering profile. Agreement between the experi-
mental data and calculated scatter pattern is in-
dicated by χ = 0.49. (B) Surface representation of the
BUNCH model of ASK1(88–658), with the thio-
redoxin-binding domain in gray, the TPR region in
yellow, and the pleckstrin homology domain in pur-
ple. Residues that affect activity when mutated are
indicated. (C and D) Experimental scattering data (C)
and BUNCH model (D) for ASK1(88–941). The ASK1
kinase domain (PDB ID code 2CLQ), is colored green.
Agreement between the experimental data and
calculated scatter pattern is indicated by χ = 1.14.















its pleckstrin homology domain and kinase antagonize each other
in a reciprocal manner—the pleckstrin homology domain forces
the kinase into an inactive confirmation, and the kinase domain
blocks the phospholipid binding site of the pleckstrin homology
domain (45, 46). Instead, it appears that the pleckstrin homology
domain plays a positive role in ASK1 activity, closer to that of the
pleckstrin homology domain within the yeast MAP kinase scaffold
Ste5 (40). Ste5 contains a predicted pleckstrin homology domain
that has been shown to bind the MAP3K Ste11 and promote ac-
tivation of the mating pathway (39). In contrast to Ste5, ASK
proteins already contain a MAP3K domain, and use their pleck-
strin homology domain as a recruitment site for their primary
substrate, MAP2Ks, thereby forming their own scaffold.
Whereas some scaffold proteins act passively by colocalizing
participating active signaling proteins, other scaffolds play more
active roles by activating or deactivating participating proteins to
promote signal fidelity (47). For instance, in mammals, KSR1/2
act as scaffolds in the RAF-MEK-ERK MAPK pathway and
promote signaling by forming RAF-KSR pseudokinase hetero-
dimers that activate RAF kinase activity (48, 49). Directly relevant
to our MKK6-ASK1 data, the yeast Ste5 scaffold contains a von
Willebrand type A (VWA) domain that primes the Fus3 MAPK
for phosphorylation by the MAP2K Ste7 (50). We propose that
the ASK pleckstrin homology domain plays a role analogous to
that of the VWA domain of Ste5, promoting a conformation of
MKK6 that is primed for phosphorylation. Beyond the afore-
mentioned Ste5 from yeast, there have been few examples of
substrate priming of MAP2Ks described in metazoan MAPK
pathways. The diversity of the activation loop and αC helix con-
formations observed for various MAP2K proteins suggests that
they may be particularly sensitive to such regulation (33, 34, 51–53).
Previous work has shown the isolated ASK1 kinase domain is
intrinsically active (35, 44). Cell-based studies also have shown that
ASK1 lacking the N-terminal thioredoxin-binding domain is more
active than full-length protein (19), suggesting that it plays an im-
portant role in suppressing ASK1 activity. Our experiments, which
used recombinant proteins in the absence of other possible inter-
actors, show the seemingly contradictory results that ASK1(88–
941) is autoinhibited relative to the kinase domain alone, but that
the central regulatory region promotes MKK6 phosphorylation in
trans. Our point mutants surrounding the closed TPR also show an
interesting dichotomy; disruption at the core of the closed TPR
(R395) abrogates ASK1 activity, whereas mutation of the surface-
exposed W476, which presumably retains the overall structure of
the central regulatory region, appears to disrupt autoinhibition.
This suggests that the overall integrity of the central regulatory
domain is important for activity, but also mediates autoinhibitory
interactions. The results of the SAXS analysis presented here are
entirely consistent with such a role, with the thioredoxin-binding
domain well positioned to restrict access of MAP2K to the
pleckstrin homology docking site and to suppress ASK1 activity.
Our observation that the thioredoxin-binding domain does not
markedly autoinhibit kinase activity in trans (Fig. 1E) reinforces the
idea that the central regulatory domain is vital, but the exact
structural basis of ASK1 kinase autoinhibition remains a key out-
standing question. Similarly, it remains to be determined whether
ASK1 priming is specific to MKK6 or occurs across all MAP2Ks
that are substrates of ASK proteins.
The ASK1 kinase domain has been shown to form a relatively
tight dimer (with a dissociation constant of ∼0.2 μM) (44), and it is
possible that formation of a kinase domain dimer could represent
the activated state of ASK proteins. ASK1(88–941) was monomeric
in solution in our SAXS experiments, in contrast with previous re-
ports regarding the isolated kinase domain (28, 44), which may
provide some insight into a potential activation mechanism. Our
model do not preclude ASK kinase dimer formation, but the
scattering data do suggest that it occurs less readily with longer
proteins than the kinase domain. However, the presence of the
C-erminal region of ASK1, which likely predisposes the protein to
form oligomers, could enable kinase dimerization to predominate
in the context of the full-length protein. In addition, 14-3-3 pro-
teins bind adjacent to the kinase domain and can themselves form
dimers (28). Active kinase dimers also would be analogous to
RAF MAP3Ks, which have been the topic of intense study in the
ERK pathways (54–57). Our functional experiments are consistent
with ASK1 regulation in either a monomer form or a dimer form.
In this regard, one possibility is that MKK6 primed by one
pleckstrin homology domain could be phosphorylated by an ASK
kinase across the kinase dimer interface. There is a wealth of data
suggesting that ASK1 functions as part of an oligomeric multi-
protein complex, and our observation of autoregulatory scaffold-
ing could be amplified or regulated in the presence of ASK1–3
oligomers. No doubt many intriguing questions remain to be
addressed by future biochemical and structural studies in-
vestigating how ASK1–3 oligomerization affects kinase regulation.
The precise molecular basis for manipulation of the autoregulatory
scaffold from ASK-type proteins by various partners is a clear
avenue for future study. For instance, thioredoxin forms both
covalent and noncovalent complexes with the thioredoxin-binding
domain (6, 30), either of which may be capable of interfering with
the regulation of kinase activity in the context of the higher-order
assembly known as the ASK signalosome. Cysteine residues that
are essential for activation of ASK1 by reactive oxygen species are
located very close to the linker between the central and thio-
redoxin-binding domains of ASK1 (31, 58). It is easy to envisage
that disulfide bond formation by these cysteines could restrict
ASK1 dynamics in a conformation that favors MAP2K re-
cruitment and activity. Furthermore, the central regulatory region
is also essential for binding of TRAFs to ASK proteins (7, 10, 59),
which could disrupt the autoinhibitory arrangement between the
ASK1 kinase and thioredoxin-binding domains.
In conclusion, the model provided here for autoregulatory
scaffolding by ASK1 N-terminal regulatory domains is an enticing
framework on which to interpret the various reported stimuli that
control ASK1 activity. In addition, the role of substrate kinase
priming in MAP kinase signaling has been underappreciated, and
it will be intriguing to observe the prevalence of substrate priming
for ASK-type kinases on different substrates, for other MAP3K-
MAP2K phosphorylation events, or for MAP2K-MAPK activity.
Further insight into each of these phenomena will allow a
greater understanding of how ASK-type proteins become dys-
regulated in disease, as well as the fundamental regulation of
kinase signaling networks.
Materials and Methods
Protein Expression and Purification. For biochemical studies and native crys-
tallization, all proteins were expressed in E. coli BL21(DE3). Fragments of the
gene encoding ASK1 were amplified from the MegaMan Human Tran-
scriptome Library (Agilent) and cloned into modified pET-LIC vectors (a kind
gift from the Netherlands Cancer Institute Protein Facility, with funding from
Grant 175.010.2007.012). ASK1(269–658) and ASK1(88–658) were expressed
MAP2K












Fig. 6. Proposed model of ASK1 autoregulatory scaffolding. An autoinhibited
conformation with limited activity is shown on the left. Activity can be induced
by oxidation, thioredoxin dissociation, or TRAF association (among other stim-
uli), at which point the activating pleckstrin homology surface becomes avail-
able for MAP2K association, activation loop priming, and phosphorylation.
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incorporating an N-terminal 6×His tag and 3C protease cleavage site. ASK1(88–
941) was cloned with the same N-terminal 6×His tag and 3C protease cleavage
site, but also with an additional StrepII tag at its C terminus, and coexpressed
with human thioredoxin-1 and lambda protein phosphatase. All mutants were
generated using the QuikChange Mutagenesis Kit (Agilent).
ASK1(269–658) and ASK1(88–658) were initially purified by Ni2+ affinity
chromatography and then purified to homogeneity after cleavage with 3C
protease using anion-exchange chromatography (Resource Q) and size exclu-
sion chromatography (Superdex 200 Increase column; GE Healthcare). Isolated
proteins and complexes were flash-frozen for storage in 10 mM Hepes pH 7.6,
300 mM NaCl, and 2 mM DTT. Selenomethionine-labeled ASK1(269–658) was
produced in the methionine auxotroph E. coli 834(DE3) using SelenoMet
medium (Molecular Dimensions) according to the manufacturer’s instructions.
Purification proceeded as for native proteins.
ASK1(88–941) was purified by Ni2+ affinity chromatography and cleaved
overnight using 3C protease while dialyzing against a buffer consisting of
50 mM Tris pH 8.0, 150 mMNaCl, 1 mM EDTA, and 2 mMDTT. Dialyzed protein
was bound to Strep-Tactin high-capacity or Strep-TactinXT resin, washed with
additional dialysis buffer, and eluted with 5 mM desthiobiotin (for Strep-Tactin
high-capacity) or 5 mM D-Biotin (for Strep-TactinXT) diluted in dialysis buffer.
Eluted proteins were then subsequently dialysed against 50 mM Tris pH 8.0,
150 mM NaCl. Samples for enzymatic assays were used directly, For SAXS
analysis, eluted protein was further purified using size exclusion chromatog-
raphy (Superdex 200 Increase 10/300).
Kinase dead MKK6 (MKK6 K82A) was purified as an N-terminal 6xHis tag
and 3C protease cleavage and further purified by size-exclusion chroma-
tography (Superdex 200 Increase 10/300).
Crystallization and Structure Solution. ASK1(269–658) was initially crystallized
in 0.2 M sodium fluoride and 20% (wt/vol) PEG 3350. Poor initial diffraction was
improved through seeding and additive screening, with final data collected
from crystals grown in 0.1 M sodium fluoride and 10% (wt/vol) PEG 3350 and
frozen with the addition of 20% (vol/vol) glycerol. The structure was solved by
single-wavelength anomalous dispersion, using a 2.9-Å peak dataset created by
merging data from two separate selenomethionine-labeled ASK1 crystals col-
lected at 0.9793 Å. Thirteen of 14 possible selenium sites from two ASK1 mol-
ecules in the asymmetric unit were located using PhenixAutosol (60). An initial
backbone built by Buccaneer (61) was rebuilt manually. The model was further
improved using ArpWarp and finally refined against native data to 2.1 Å using
Refmac and the PDB_REDOweb server, with cycles of manual rebuilding in Coot
(62–65). Analysis of diffraction data by Phenix.Xtriage indicated a large (23%
relative to origin) Patterson Peak consistent with the presence of translational
pseudosymmetry, which contributed to marginally higher refinement statistics
than may be expected at 2.1-Å resolution (Rcryst/Rfree, 0.233/0.267). Nevertheless,
the final model has excellent geometry and, aside from several disordered loops
connecting TPR helices, is clearly defined in both molecules of the asymmetric
unit. Structural figures were generated using UCSF Chimera (66).
SAXS. SAXS data collection was performed at the Australian Synchrotron
SAXS/WAXS beamline using an inline gel filtration chromatography setup (67),
essentially as described previously (68–71). Summary statistics for data collec-
tion and analysis are reported in Table 2. Here 50 μL of purified recombinant
ASK1(269–658) at 7.7 mg/mL, ASK1(88–658) at 9.7 mg/mL, or ASK1(88–941) at
9.3 mg/mL (WT) or 11.5 mg/mL (W476S), were injected onto an inline Superdex
200 5/150 column (GE Healthcare) and eluted at a flow rate of 0.2 mL/min via a
1.5-mm glass capillary positioned in the X-ray beam in 500 mM NaCl, 10 mM
Hepes (pH 7.5), 5% (vol/vol) glycerol, and 0.2 mM TCEP at 12 °C. Coflow SAXS
was used to minimize sample dilution and maximize signal to noise (72).
Scattering data were collected in 2-s exposures over the course of the elution
and2D intensity plotswith consistent scatter intensities fromthepeakof the sizing
exclusion chromatography run were radially averaged, normalized to sample
transmission, and background subtraction performed using Scatterbrain software
(Stephen Mudie, Australian Synchrotron). Background scatter was assessed by
averaging scattering profiles from earlier in the size exclusion chromatography
run, before protein elution. Guinier analysis of each scatter pattern across the
single elution peak showed consistent radius of gyration (Rg) values, and super-
imposable patterns were averaged. Four profiles for ASK1(269–658), eight pro-
files for ASK1(88–658), 21 profiles for ASK1(88–941), and four profiles for ASK1
(88–941)W476S were averaged and background-subtracted using Scatterbrain to
generate the averaged scatter patterns presented in themanuscript. Guinier data
analyses were performed using PRIMUS (73). Indirect Fourier transform with
GNOM (74) was used to obtain the distance distribution function, P(r), and the
maximum dimension, Dmax, of the scattering particle. CRYSOL (75) was used to
calculate theoretical scattering curves from crystal structure atomic coordinates
and compare them with experimental scattering curves.
SEC-MALLS. SEC-MALLS was conducted using a Wyatt Dawn 8+ detector
(Wyatt Technology) coupled to a Superdex 200 10/300 column (GE Health-
care) and a refractive index detector. Samples were run in 10 mM Hepes
(pH 7.6), 500 mM NaCl, 5% (vol/vol) glycerol, and 0.2 mM TCEP and loaded at
2.2 mg/mL. All data were analyzed using ASTRA V software.
Kinase Assays. Each kinase assay was carried out at room temperature with
final concentrations of 25mMHepes pH 7.6, 20mMMgCl2, 2 mMDTT, 100mM
NaCl, and 3 μM kinase dead MKK6, along with 0.01–1 μM kinase and 0.01–
30 μM ASK1 regulatory domains and 50 μM ATP. Assays were set up as master
mixes containing all components except kinase and ATP, to ensure equal
substrate addition to all reactions. For kinase assays, including separate ASK1
regulatory domains, ASK1 kinases was added to the master mix. The master
mix was then aliquoted into eight-well PCR strip tubes to facilitate the use of a
multichannel pipette and simultaneous addition and removal of samples. ASK1
kinases and regulatory domains were diluted in serial dilutions. The reactions
were started by the addition of ATP. At each time point, an aliquot from each
tube was removed in parallel, and the reaction was terminated by immediate
mixing into 4× Laemmli sample buffer [240 mM Tris pH 6.8, 32% (vol/vol)
glycerol, 8% (wt/vol) SDS, and 0.02% (wt/vol) bromophenol blue]. Samples
were briefly spun down and stored at −20 °C until downstream analysis.
For analysis by Phos-tag gels, 15-well, 1-mm-thick Phos-tag analysis gels
were hand-poured to contain final concentration of 20 μM Phos-tag, 100 μM
MnCl2, and 10% (wt/vol) polyacrylamide. Gels were run as conventional SDS/
PAGE gels. Total protein was visualized with Coomassie brilliant blue and
imaged with an Odyssey Fc imaging system (LI-COR) in the 700 channel.
Quantitation was performed by measuring the intensity of both phosphor-
ylated and unphosphorylated MKK6 bands. The intensity of phosphorylated
bands was expressed as a fraction of total intensity, and converted to an
absolute concentration by multiplying the fraction of phosphorylated spe-
cies by the 3 μM total concentration of MKK6 in all assays. Using mass
spectrometry, we confirmed that phosphorylation of MKK6 followed the
precisely ordered phosphorylation events established by Humphreys et al.
(35), with the more rapidly appearing band on Phos-tag SDS/PAGE corre-
sponding to Thr211 of MKK6 (Figs. 3 and 4).
For analysis byWestern blot, samples were run in a conventional manner and
transferred by a semidry method to 0.45 μm nitrocellulose (GE Healthcare).
Total protein transferred to membrane was visualized by staining membrane in
0.5% (wt/vol) Ponceau S solution for 5 min at room temperature. Excess Pon-
ceau S was removed by rinsing in distilled water. Ponceau S-stained blots were
imaged using the Odyssey Fc imaging system in the 800 channel. After imaging,
blots were rinsed further before blocking in 5% (wt/vol) BSA in Tris-buffered
saline (TBS) for 1 h at room temperature. Blots were then incubatedwith rabbit
polyclonal [p-MKK3/6 (Ser187), sc-7994-R; Santa Cruz Biotechnology], diluted
1/2,500 in TBST with 1% (wt/vol) BSA and allowed to bind overnight at 4 °C.
Blots were then washed three times for 5 min each in TBST before incubation
with secondary antibody (goat anti-rabbit IRdye 680LT; LI-COR) diluted
1/20,000 in TBST with 1% (wt/vol) BSA. The secondary antibody was allowed to
bind for 1 h at room temperature before being washed another three times in
TBST. Blots were developed in the Odyssey Fc imaging system. Quantification
of blots and Phos-tag gels was performed using ImageStudioLite (LI-COR).
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Fig. S1. (A) Example purified sample proteins from each of the constructs used in this work. (B) Illustration of MKK6 conformational flexibility. (Left) An
overlay of the three crystal structures of MKK6 currently available in the protein databank. All proteins are colored gray, with respective αC helices in yellow
(2VN9), pink (3ENM), and green (3FME). The distance between the N terminus of the αC helix in 3ENM and 3FME is indicated. An illustrative model was created
using Modeler to model in the disordered activation loop of structure 3FME. (Right) A comparison of 3FME with the Modeler output, with the activation loop
indicated. The Modeler model is shown in Fig. 1F. (C) Purified point mutants of ASK1(88–941) used for the assays shown in Figs. 3C and 4B. A schematic
summarizing the constructs is shown above, indicating that the construct containing only the central regulatory region and kinase was insoluble and so could
not be tested in activity assays. (D) Preparative size-exclusion chromatography of ASK1(88–941) with molecular weight standards indicated. The majority of
ASK1 protein elutes later than the 160-kDa marker, consistent with it behaving as a (∼100-kDa) monomeric species. Peak fractions elute at a concentration of
∼40 μM based on A280.


























Fig. S2. Relates to Fig. 1C. MKK6 phosphorylation by 0.01 μM ASK1 kinase domain with concentrations of ASK1(269–658) substoichiometric to the substrate
(MKK6), but up to 100-fold excess to the ASK1 kinase domain. MKK6 is held constant (3 μM), and phosphorylation is monitored by Western blot analysis.
Quantitation of independent triplicate experiments is shown. Each band was normalized to the band intensity of the kinase alone at the 10-min time point for







Fig. S3. Detailed view of the interface between TPR repeats 6 and 7 and the pleckstrin homology domain. Hydrophobic residues at the core of the interface
are indicated.
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Fig. S4. Sequence alignment of ASK1–3 and orthologs from various species over the central regulatory domain, with the secondary structure indicated. Point
mutants generated in this work are indicated above with a blue circle. The figure was generated using ALINE (79).
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(grey used for BUNCH)
5 Robetta models
B
Fig. S5. (A) BUNCH model of ASK1(88–941) with three closely related Robetta models of the thioredoxin-binding domain overlaid. (B) As for A, but with all
five models output by Robetta shown. The two additional models in B have a similar beta sheet core but differ in their decorating helices.







































































































Fig. S6. (A and B) Interatomic distance distributions of ASK1(88–658) (A) and ASK1(88–941) (B). (C) Overlay of experimental scattering data (black circles) and
scattering profile calculated using BUNCH for the model of ASK1(88–941) W476S. A Guinier plot for the dataset is shown below, indicating that aggregates do
not measurably contribute to the scattering profile. (D) Interatomic distance distributions of ASK1(88–941) W476S. (E) Surface representation of the BUNCH
model of ASK1(88–941) W476S, with the thioredoxin-binding domain in gray, the TPR region in yellow, and the pleckstrin homology domain in purple.
Residues that affect activity when mutated are indicated in red (F623 and D632) and blue (W476). Agreement between the experimental data and the cal-
culated scatter pattern is indicated by χ = 0.55.
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a b s t r a c t
Peroxiredoxin 1 is a member of the ubiquitous peroxiredoxin family of thiol peroxidases that catalyse the
reduction of peroxides. In recent years eukaryotic peroxiredoxins have emerged as a critical component
of cellular redox signalling, particularly in response to alterations in production of hydrogen peroxide.
Peroxiredoxins are exquisitely sensitive to oxidation by hydrogen peroxide making them key peroxide
sensing enzymes within cells. Evidence gathered over the last decade suggests that in addition to sensing
the redox signal, peroxiredoxins have a major role in transducing this signal to downstream signalling
proteins, ultimately contributing to regulation of diverse cellular processes including proliferation, dif-
ferentiation and apoptosis. In this review we present the three current models for the sensing and signal
transducing roles of peroxiredoxins, with a specific focus on mammalian peroxiredoxin 1. The evidence
for each mechanism is discussed and areas for future work are identified.
© 2016 Elsevier Inc. All rights reserved.
Changes in the redox state of cells are intimately involved in
regulating a multitude of cell processes. Key questions revolve
around how changes in the redox state are sensed, and then how
this information is transduced into a specific change in cell func-
tion. A critical molecule in redox signalling is the mild oxidant
hydrogen peroxide (H2O2). H2O2 is a strong candidate for a second
messenger in redox signalling because its production in cells can be
regulated, it is relatively stable compared to many cellular oxidants,
and it has a preference of oxidation of cysteine thiols in proteins
[1e3]. Reversible thiol oxidation has emerged as an important and
widespread mechanism of controlling protein function [4,5]. The
use of thiol labelling combined with quantitative proteomics by
mass spectrometry is leading the way in identifying signalling
proteins with cysteine residues subject to reversible oxidation
[6e9]. However there remains a major gap in our knowledge to
understand how specific protein thiols become preferentially oxi-
dised in the context of a signal transduction pathway. Based purely
on reaction kinetics, H2O2 will be reduced by professional peroxi-
dases and other proteins will not be able to compete with this
interaction [10,11]. Nevertheless, in cells thiol residues in non-
peroxidase proteins do become reversibly oxidised. Thus there
must be regulated and highly specific mechanisms that enable this
to occur, analogous to the multiple layers in regulation of signal
transduction by phosphorylation and dephosphorylation.
When considering the relationship between H2O2-mediated
thiol oxidation, and redox sensing and signalling, members of the
peroxiredoxin enzyme family are key players. These ubiquitous
enzymes are found in almost all forms of life, and use cysteine
thiols to catalyse reduction of peroxides to water. The mammalian
peroxiredoxins were first identified due to their involvement in a
wide range of cellular processes including proliferation, differen-
tiation and inflammation. These enzymes were subsequently found
to be homologues of the yeast thiol specific antioxidant, with a
primary catalytic function of thiol-dependent reduction of perox-
ides. In the ensuing ~20 years since the discovery of peroxiredoxins,
we have gained a detailed understanding of their enzymology and
structure. However despite early indications of the involvement of
peroxiredoxins in signal transduction [12], there is still ongoing
debate regarding the precise role(s) of peroxiredoxins in redox
sensing and signalling.
The enzymology and structural biology of peroxiredoxins has
been extensively studied and recently reviewed [13,14]. Here we
provide a brief overview of this information as it pertains to per-
oxiredoxin 1 (Prdx1), and then present the current understanding
of the role(s) of mammalian Prdx1 in signal transduction and
discuss future research directions. Prdx1, along with other perox-
iredoxins, has been implicated in numerous disease states [15].
Therefore understanding how these enzymes function in both
physiological and pathological settings is of broad interest.
1. Enzymology of peroxiredoxin 1
All peroxiredoxins use thiol residues to reduce peroxides. The
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PeroxiRedoxin classification indEX (PREX) database categorises
peroxiredoxins into six subfamilies [13,16]. In mammalian species
there are six peroxiredoxins, Prdx1-4 (Ahp/Prdx1 subfamily), Prdx5
(Prdx5 subfamily) and Prdx6 (Prdx6 subfamily). Prdx1-4 utilise a
typical 2-Cys mechanism, whereas Prdx5 uses an atypical 2-Cys
mechanism and Prdx6 has a 1-Cys mechanism [17]. These Prdx1
family members differ in subcellular location with Prdx1 and 2
primarily cytosolic, Prdx3 mitochondrial and Prdx4 present in the
endoplasmic reticulum lumen. Expression levels of each vary across
different cell types [17,18].
Mammalian Prdx1 is a typical 2-Cys peroxiredoxin and is esti-
mated to be present at 15e60 mM in the cytosol of mammalian cells
[19,20]. In amechanism common to all 2-Cys peroxiredoxins, Prdx1
functions as a head-to-tail homodimer, with each monomer con-
taining a peroxidatic Cys (CP) and a resolving Cys (CR) (residues 52
and 173 respectively in Fig. 1A&B). The CP thiol has a low pKa and
thus is deprotonated at physiological pH. The thiolate (CPS) reacts
with peroxide to form a sulfenic acid (CPSOH), which condenses
with CRSH on the other monomer to form a disulfide bond (Fig. 1B).
Thus each active homodimer has the capacity to form two disulfide
bonds and reduce 4 molecules of peroxide. The disulfide is then
reduced in a disulfide exchange reaction originally postulated to be
catalysed by thioredoxins [21]. The second order rate constant for
reduction of peroxide has not been reported for a mammalian
Prdx1 but, based on the homology of the active site with other
mammalian 2-Cys peroxiredoxins (Fig. 2), is expected to be in the
range of 107-108 M1 s1 [22,23]. As an alternative to disulfide
formation, the CPSOH can further react with peroxide to form sul-
finic (CPSO2H) and sulfonic (CPSO3H) acids, commonly referred to as
over- or hyper-oxidation [13,24,25]. These forms are catalytically
inactive, with CPSO2H slowly reduced by sulfiredoxin in an ATP-
dependent reaction [26,27] and CPSO3H regarded as irreversible.
An ongoing question in the field has been given an antioxidant role
of peroxiredoxins, why should they be so susceptible to inactivation
by their own substrate?
In addition to inactivation by hyperoxidation, the activity of
Prdx1 is regulated by other post-translational modifications. The
best understood of these is phosphorylation, which can both inhibit
[28e32] and activate [33] the peroxidase activity of Prdx1. Prdx1
activity is also inhibited by S-nitrosylation [34]. Prdx1 can be glu-
tathionylated at three of its cysteine residues: CP52, C83, and CR173
in vitro and in response to H2O2 treatment in cultured cells [35]. The
significance of glutathionylation of Prdx1 in redox signalling is as
yet unknown, but may represent a possible regulatory mechanism
or an alternative recycling mechanism as proposed for Prdx2 [36].
High throughput mass spectrometry approaches as indexed by the
PhosphoSitePlus resource [37] indicate modification of Prdx1 by
ubiquitylation, sumoylation, acetylation and succinylation,
although the physiological roles of these modifications await
further investigation.
2. Tertiary and quaternary structure of peroxiredoxin 1
Structures of five mammalian Prdx1 have been reported; oxi-
dised rat C83S Prdx1 (PDB accession code 1QQ2) [38], rat C52S
Prdx1 (PDB accession code 2Z9S) [39], oxidised human C83S Prdx1
(PDB accession code 4XCS), human C71S, C83E, C173S Prdx1 in
complex with sulfiredoxin (PDB accession code 2RII) [40] and hu-
man C52D, C71S, C83E, A86E, C173S, K185C Prdx1 in complex with
sulfiredoxin, ATP and Mg2þ (PDB accession code 3HY2) [41]. In
commonwith other members of the Ahp/Prdx1 subfamily, reduced
mammalian Prdx1 exists in equilibrium between fully folded (FF)
and locally unfolded (LU) states (Fig. 1A&B). The structure of the
active site pocket in the FF state of the protein optimises H2O2
Fig. 1. Structural features of Prdx1. A. Dimeric rat C52S Prdx1 (PDB accession code 2Z9S). The Prdx1 homodimer contains two centrally located active sites with C83 at the
periphery. The C173 CR (inset) is 13.9 Å from the catalytic mutant CP, S52 that exists in a fully folded (FF) helix. B. Dimeric rat C83S Prdx1 (PDB accession code 1QQ2). The homodimer
exists with active site cysteines oxidised as a disulfide bond (inset), with the CP (C52) now occupying a locally unfolded (LU) loop at the conclusion of the catalytic cycle. C.
Decameric rat C52S Prdx1 (PDB accession code 2Z9S). The decamer exists in a toroidal (a2)5 configuration, with each dimer shown as a blue and green monomer pair. D. C83-C83
disulfide bond at dimer-dimer (DD) interface of decameric rat C52S Prdx1 (PDB accession code 2Z9S). Colouring as in Fig. 1C and disulfide bonding C83 sulfurs shown in yellow.
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binding and oxidation of the CP thiolate to sulfenic acid. However in
the FF state, CR of onemonomer is ~14 Å away from CP of the second
monomer (Fig. 1A), sufficiently slowing condensation of CPSOH
with CRSH so as tomake further oxidation to sulfinic acid kinetically
competitive with disulfide bonding between CP and CR [13,42].
Rearrangement of the active site to the locally unfolded (LU) state
repositions CR to enable disulfide bond formation with CP (Fig. 1B).
The rate of transition from the FF to the LU state is thought to
explain, at least in part, the varying reactivity's of peroxiredoxins to
hyperoxidation [43] although this has not yet been specifically
demonstrated for a mammalian Prdx1.
There is high sequence conservation of Prdx1 across vertebrates
(Fig. S1) with the active site and the residues involved in the
monomer-monomer interface being the most conserved regions
(Fig. 3A). Prdx1 also has high conservation with the other
mammalian 2-cys peroxiredoxins (Fig. S2). The FF rat Prdx1 struc-
ture aligns to human Prdx3 and 4 with root mean standard devi-
ation (RMSD) values of 0.609 Å and 0.390 Å respectively, with the
position of key active site residues and H-bonds conserved (Fig. 2).
An intriguing feature of peroxiredoxins is the assembly of the
dimers into higher order toroidal (a2)5 decamers or (a2)6 dodeca-
mers. Human Prdx1 forms decamers (Fig. 1C) in vitro and in vivo
with the equilibrium between decamer and dimer reported to be
influenced by protein concentration, ionic strength, redox state,
glutathionylation and S-nitrosylation [19,34,39,44]. The critical
transition concentration for reduced human Prdx1 in vitro has been
reported as 1.3 mM [45] suggesting it will exist mainly as the dec-
amer in vivo. In general the equilibrium is pushed towards the
decameric state under reduced and hyperoxidised conditions,
whereas oxidation favours the dimeric form although this has not
yet been formally demonstrated for a mammalian Prdx1. Prdx1 is
unique among the 2-Cys peroxiredoxins in containing a third
cysteine residue (C83 in hPrdx1) that is conserved in all but four
vertebrate Prdx1 and sits at the dimer-dimer interface of the dec-
amer (Fig. 1D). While disulfide bond formation between adjacent
C83 residues of Prdx1 at the dimer-dimer interface was initially
reported to be necessary for formation of the decamer [44], it is
apparent frommutagenesis studies and other crystallographic data
that this feature is not essential for decamerisation and is likely
dependent on the crystallisation conditions used [39]. Instead
decamer formation involves hydrophobic interactions and van der
Waals contacts between adjacent dimers [39]. Overall the dimer-
dimer interface is a region of lower homology (Fig. 3B) and it is
not known if Prdx1 dimers from different species could form
heterodecamers.
Peroxiredoxins also form higher order complexes that are pro-
posed to lose peroxidase activity and gain chaperone activity [46],
and this has been observed for Prdx1 in vitro [44]. Details such as
what functional role if any oligomers play in vivo, as well as how
this process influences signalling functions of peroxiredoxins
remain unclear.
3. Current models of the role of Prdx1 in signal transduction
The role of Prdx1 in redox sensing and transducing is complex.
Here we discuss the three current models for the role of Prdx1 as a
redox sensor and transducer, giving examples that support each
model. These models are not necessarily mutually exclusive, and it
is highly likely that the role of Prdx1 varies with cell type, stimulus
and other factors.
3.1. Prdx1 as the redox sensor and transducer: the signal peroxidase
model
Peroxiredoxins have been proposed to play an active role in
redox signalling whereby they sense the H2O2 signal and transduce
this signal by catalysing disulfide formation in target proteins,
sometimes referred to as a disulfide relay. Early work in yeast
demonstrated the functional importance of formation of an inter-
molecular disulfide between the Schizosaccharomyces pombe per-
oxiredoxin Tpx1 and the p38/JNK homologue Sty1 [47], and
between the Saccharomyces cerevisiae peroxiredoxin Gpx3 and the
AP-1 homologue Yap-1 [48] in response to increasing concentra-
tions of H2O2. This sensor and signalling role is consistent with gene
expression analysis suggesting the main role of peroxiredoxins in
yeast was not as antioxidants but as regulators of gene expression
[49].
The first evidence for the ability of mammalian Prdx1 to catalyse
disulfide formation in a target came from a study of the role of
hPrdx1 in the regulation of apoptosis signalling kinase 1 (ASK1).
ASK1 is a key redox-sensitive protein kinase that activates p38 and
JNK MAP kinase pathways [50]. ASK1 is oxidised upon treatment of
cells with H2O2, with oxidation being necessary for full activation in
response to a redox stress [51,52]. Co-immunoprecipitation ex-
periments demonstrated that Prdx1 forms a transient DTT sensitive
and covalently-linked intermediate with ASK1 in cultured cells
[53]. This result suggested that Prdx1 is able to catalyse oxidation of
ASK1 to a disulfide bond-linked oligomer. In the absence of Prdx1,
Fig. 2. Structural alignment of Prdx1 with Prdx3 and Prdx4. Structures of reduced
human Prdx3 (orange, PDB accession code 5JCG) and human Prdx4 (salmon, PDB
accession code 3KTP) were aligned against rat Prdx1 C52S (green, PDB accession code
2Z9S) using the standard align function in PyMOL (The PyMOL Molecular Graphics
System, v1.5.0.5, Schr€odinger, LLC.). The inset shows the wild-type canonical FF CP
hydrogen bonding network (cyan dashes) for the corresponding residues in the rat
Prdx1 C52S structure. Residue numbering is that of Prdx1.
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H2O2-induced ASK1 oxidation and subsequent p38 phosphoryla-
tionwas inhibited, demonstrating the requirement for the presence
of active Prdx1 for signalling.
These observations led to the proposal of a signal peroxidase
model for control of H2O2 signalling by peroxiredoxins in
mammalian cells (Fig. 4A) [53]. In this model, peroxiredoxins
“sense” the H2O2 by oxidation of CPS to CPOH. The H2O2 signal is
subsequently transduced to target proteins (in yellow in Fig. 4) via
formation of a transient intermolecular disulfide bond between the
peroxiredoxin and the target protein. Supporting data for the signal
peroxidase model of Prdx1 function has come from recent finding
of putative disulfide relays between Prdx2 and both signal trans-
ducer and activation of transcription 3 (STAT3) [54], and DJ-1 [55].
STAT3 undergoes oxidative regulation in response to H2O2 with its
transcriptional activity attenuated upon oxidation [56]. STAT3 and
Prdx2 were found to associate via a mixed disulfide intermediate in
response to both H2O2 and cytokine treatment of cells, and loss of
Prdx2 inhibited STAT3 oxidation. DJ-1 (also known as PARK7) is a
20 kDa, redox sensitive protein with many attributed functions
including peroxidase and cytoprotective properties [57,58]. Prdx2
has been proposed to act as a sensor of H2O2 to facilitate the
dimerization of DJ-1 whereby a disulfide linked species between
Prdx2 and DJ-1 subsequently condenses to produce a DJ-1 disulfide
linked homodimer [55].
Currently it is unclear whether disulfide bond formation in
Prdx1 targets such as ASK1, (or indeed Prdx2 targets STAT3 and DJ-
1) occurs via disulfide exchange (reaction 2 in Fig. 4A), or whether
the peroxiredoxin CPSOH resolves with a cysteine in the target
protein rather thanwith CRSH of the other peroxiredoxin monomer
(reaction 1 in Fig. 4A). Disulfide exchange is characteristically cat-
alysed by thiol oxidoreductases containing a conserved CXXC motif
within a thioredoxin fold [59e61]. This is the mechanism by which
Fig. 3. Homology of vertebrate Peroxiredoxin 1. Homology of Prdx1 was modelled following generation of a multiple alignment file (Fig. S1A) using Clustal Omega [83]. The
ConSurf server [84] was used to generate homology based on Chain A of the dimeric rat Prdx1 (PBD accession code 1QQ2) (Fig. S1B). PyMOL was used to render and overlay the
homology onto the dimeric (A) and decameric (B) forms (PDB accession code 2Z9S). Only one monomer is rendered in colour for clarity. The associated pse file is provided (Fig. S3).
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thioredoxins reduce cytosolic and mitochondrial peroxiredoxins,
and endoplasmic reticulum (ER) oxidoreductases such as protein
disulfide isomerase reduce the ER localised Prdx4 [62,63]. While it
is well established that intramolecular disulfide exchange can occur
in non-thiol oxidoreductases [33,64], there is little direct evidence
for intermolecular disulfide exchange with a non-thiol oxidore-
ductase. There is however direct support in the literature for the
reaction of CPSOH of a 2-Cys peroxiredoxinwith a target thiol group
[65]. This currently seems the most likely mechanism for Prdx1-
catalysed disulfide formation in target proteins. Indeed, the struc-
tural features of 2-Cys peroxiredoxins that delay the reaction of
CRSOH with CPSH may be an adaptation that enables CRSOH to
condense with a thiol in a target protein to transduce the peroxide
signal.
3.2. Prdx1 as the redox sensor: the protein interaction model
A second model for Prdx1 function in H2O2 sensing and
signalling involves non-covalent interaction of Prdx1 with target
proteins (Fig. 4B). Prdx1 has been reported to interact with a wide
range of proteins [66], and the Biogrid interaction database [67]
currently lists 130 unique Prdx1 interactors (http://thebiogrid.
org/111089/table/homo-sapiens/prdx1.html, accessed 22/6/16). A
difference between the binding affinities of reduced, oxidised or
potentially hyperoxidised Prdx1 for the target proteinwould enable
transduction of the redox signal to target proteins that do not
contain redox active cysteine residues. To date the relationship
between interactionwith the target protein and the oxidation state
of Prdx1 has only been considered in a few cases. The dual-
specificity lipid phosphatase and tensin homologue (PTEN) is one
such protein. PTEN is inactivated upon formation of an intra-
molecular disulfide bond following treatment with H2O2 [68] or
growth factors such as epidermal growth factor [68,69], with
reduction catalysed by Trx1 [70]. Prdx1 has been reported to
interact with PTEN, although in one case this interactionwas shown
to protect PTEN from oxidation, with Prdx1 dissociating following
Fig. 4. Models of the redox sensing and signalling function of Prdx1. A. Signal peroxidase model showing two possible mechanisms for formation of disulfide bond formation in
the target protein: 1. Direct reaction of CPOH with the SH in the target or 2. Disulfide exchange reaction. B. Protein interaction model whereby oxidation of Prdx1 results in either
dissociation (top) or association (bottom) of a target protein. C. Peroxiredoxin inactivation model whereby Prdx1 is inactivated by hyperoxidation (left) or another post-translational
modification such as phosphorylation (right) allowing direct oxidation of a target protein. Prdx1 is drawn from the surface model of human C83S Prdx1 (PDB accession code 4XCS).
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H2O2 treatment [71], whereas in another case Prdx1 interacted
more strongly with oxidised than reduced PTEN [72]. This disparity
suggests we still have much to learn regarding the role of Prdx1 in
regulation of PTEN activity. Prdx1 has been also been reported to
interact with non-redox proteins and regulate their activity
without changing their redox state. Prdx1 interacts with mamma-
lian Ste20-like kinase-1 (Mst-1) in an oxidation state- and
oligomerization-dependent manner, stimulating Mst-1 autophos-
phorylation and activation by triggering dissociation of the inhib-
itory C-terminal domain of Mst-1 [73]. The transcription factor c-
Myc has also been identified as a Prdx1 interacting protein, with
Prdx1 inhibiting c-Myc mediated transcription and potentially
acting as a tumour suppressor [74].
Further analysis of Prdx1 interacting partners will be an
important approach for ascertaining the roles of Prdx1 as a signal
transducing molecule in global cellular function. A large number of
these potential interactors have only been identified in high-
throughput mass spectrometric-based methods. The high cellular
expression of Prdx1 makes artefactual identification of interactions
a strong possibility, and thus further validation of much of this data
is required. In addition many studies investigating Prdx1 in-
teractions have used overexpression of tagged Prdx1, however as
the presence of a tag alters peroxiredoxin activity [75] it is unclear if
these results are relevant for endogenous Prdx1.
3.3. Peroxiredoxin inactivation as the redox sensor: the floodgate
model
The quandary between the abundance and high reactivity of
peroxiredoxins with H2O2 on the one hand, and the clear demon-
stration that regulated oxidation of non-peroxidase proteins occurs
in cells on the other, was first addressed in terms of the suscepti-
bility of eukaryotic peroxiredoxins to hyperoxidation [42]. In its
original version the floodgate model proposed that at low con-
centrations, H2O2 is reduced by peroxiredoxins and is not available
as a second messenger for redox signalling (Fig. 4C). As the con-
centration of H2O2 rises, for example as a result of stimulation of
NADPH oxidase activity, the peroxidase function of peroxiredoxins
is inactivated by hyperoxidation, thereby allowing H2O2 to accu-
mulate and oxidise target proteins directly. However there is little
evidence for widespread peroxiredoxin hyperoxidation in response
to H2O2-generating stimuli and it now seems this model as origi-
nally proposed is unlikely to be a major contributor to transduction
of the H2O2 signal. Instead, the concept of localised inactivation of
peroxidase activity by other post-translational modifications is
gaining increasing support (Fig. 4C). In this scenario, localised and
regulated inactivation of peroxiredoxins, for example by phos-
phorylation [28,32], enables localised build-up of H2O2 which can
directly oxidise a target protein in the immediate vicinity. This
mechanism has been suggested to explain the role of Prdx1 in
control of cell cycle progression, whereby inhibitory phosphoryla-
tion of Prdx1 at Thr90 by Cdk1 at the centrosome allows local
accumulation of H2O2 so a centrosome-bound phosphatase can be
directly oxidised and thus inhibited, preventing early degradation
of mitotic activators [28]. However it still remains unclear how
H2O2 can accumulate at the centrosome to enable oxidation of the
phosphatase. Lim et al. [28] suggested that H2O2 is channelled to
the centrosome from its site of production, but there is currently no
mechanistic explanation for this. In addition, even if Prdx1 is
inactive, cytosolic Prdx2, GPx enzymes and even GSH are likely to
outcompete signalling proteins for reaction with H2O2 [11].
An alternative role of peroxiredoxin hyperoxidation in a yeast
cell's response to oxidative stress has recently proposed, whereby
hyperoxidation is a means of removing peroxiredoxin as a substrate
for thioredoxin, thus enabling thioredoxin to reduce other oxidised
proteins [76]. It remains to be determined if this mechanism is
relevant for mammalian peroxiredoxins.
4. Reversing the redox signal e the role of thioredoxins,
thioredoxin reductase and NADPþ/NADPH
The activity of Prdx1 in redox signalling is controlled not only by
variations in H2O2 levels, but also by changes in thioredoxin ac-
tivity, TrxR activity and the NADPþ/NADPH ratio. Thioredoxins have
two potential functions in Prdx1-mediated redox signalling. They
may directly reduce Prdx1, or they may reduce the targets oxidised
by Prdx1, thus providing a reversal of the redox signal. Completion
of the Prdx1 catalytic cycle ultimately requires reducing equiva-
lents derived from NADPH. This links Prdx1 activity to metabolic
events, and implies that Prdx1 activity and thus its role in redox
sensing and transducing will vary even in the absence of endoge-
nous production of H2O2. Indeed the levels of oxidised mitochon-
drial Prdx3 have been found to increase when NADPH levels
decrease in the absence of nicotinamide nucleotide trans-
hydrogenase [77]. The circadian variation in peroxiredoxin oxida-
tion has been linked to an altering NADPþ/NADPH ratio [78].
Similarly, inhibition of thioredoxin reductase causes basal oxida-
tion of cytosolic and mitochondrial peroxiredoxins [79].
5. Future perspectives
In the relatively short time since their initial identification
substantial progress has been made in understanding the basic
enzymology of peroxiredoxins. The next step is to gain a full un-
derstanding of how this enzymology relates to the function of
peroxiredoxins in vivo. Teasing out the specific functions of the
different peroxiredoxins in signal transduction will be experi-
mentally challenging as potential intermediates are formed tran-
siently and are at low levels. Progress in this area will require
development and use of methodologies that allow trapping of in-
termediates. In the short term it is critical to prove the formation of
direct peroxiredoxin-S-S-target linkages in mammalian cells via a
technique such as LC-MS/MS, and to ascertain which of the multi-
tude of peroxiredoxin interactions are specific and modulated by
the redox state of the peroxiredoxin. More information is also
required addressing the role of alterations in the Trx/TrxR/NADPH
system in controlling peroxiredoxin activity. The recent develop-
ment of kinetic models [80e82] attempting to explain H2O2 sig-
nalling is a promising start, and obtaining more information on the
in vivo roles of peroxiredoxin will improve these models so that
they better explain redox signalling on a whole cell basis.
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